Page last updated: 2024-08-24

atorvastatin and Elevated Cholesterol

atorvastatin has been researched along with Elevated Cholesterol in 839 studies

Research

Studies (839)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's47 (5.60)18.2507
2000's462 (55.07)29.6817
2010's294 (35.04)24.3611
2020's36 (4.29)2.80

Authors

AuthorsStudies
Buckett, L; Davidson, R; Holdgate, G; McCormick, A; McTaggart, F; Schneck, D; Smith, G; Warwick, M1
Askew, V; Auerbach, B; Bainbridge, G; Caspers, N; Choi, C; Dillon, L; Hanselman, JC; Harris, MS; Hutchings, R; Kowala, M; Larsen, SD; Lin, Z; Lu, GH; Park, W; Pavlovsky, A; Pfefferkorn, JA; Robertson, A; Sekerke, C; Tait, BD1
Imreh, É; Karádi, I; Karvaly, GB; Neely, MN; Prohászka, Z; Trojnár, E; Vásárhelyi, B; Vincze, I; Zsáry, A1
Duarte, K; Fauler, G; Fellström, B; Girerd, N; Jardine, AG; März, W; Massy, ZA; Rossignol, P; Sadiku, S; Scharnagl, H; Schmieder, RE; Silbernagel, G; Zannad, F1
Leal, K; Paez, I; Prado, Y; Rojas, G; Saavedra, K; Saavedra, N; Salazar, LA; Ubilla, CG1
Borghi, C; Cicero, AFG; D'Addato, S; Fogacci, F; Giovannini, M; Rizzoli, E1
Abolbashari, S; Eid, AH; Karimian, MS; Modaghegh, MHS; Saberianpour, S; Sahebkar, A; Sathyapalan, T1
Chen, J; Ding, C; Ge, J; Li, Z; Liu, Y; Qian, J; Ren, X; Shi, M; Yang, P; Zhang, X1
Al-Ashwal, FY; Halboup, A; Kubas, MA; Sheikh Ghadzi, SM; Sulaiman, SAS1
Çenesiz, M; Çenesiz, S; Çiftci, A; Çiftci, G; Onuk, B; Savaşan, S1
Cai, SY; Gu, X; Jiang, JJ; Jiang, YN; Li, RS; Liu, PJ; Wang, JA; Yao, W; Yin, YH; Yu, B; Yuan, ZY; Zhao, SP1
Kowalcze, K; Krysiak, R; Okopień, B3
Farooq Ur Rehman, RM; Khokhar, SA; Masood, S1
Fu, Y; Liu, S; Wang, H; Zhou, C1
Cho, JM; Choi, JY; Chun, SW; Chung, JW; Hong, SJ; Hong, YJ; Kim, BJ; Kim, CS; Kim, DH; Kim, HS; Kim, KS; Kim, SH; Kim, TN; Lee, CW; Lee, SA; Lee, SH; Lee, SR; Park, HC; Sung, JH; Yoon, SB1
Chen, N; Chen, Y; Geng, D; Li, P; Liang, L; Liu, L; Liu, X; Wang, Z; Xu, J; Yang, H; Zhang, X; Zhao, K1
Guo, JB; He, J; Li, LZ; Peng, SQ; Yu, L; Yuan, XY; Zhang, L; Zhang, TF; Zhao, J; Zhao, ZM1
He, X; Liang, L; Liu, S; Peng, C; Xiao, C; Zhang, G; Zhao, S1
Alaaeddine, R; El-Sabban, ME; El-Yazbi, AF; Elkhatib, MAW; Fouad, H; Mroueh, A; Plane, F; Saad, EI1
Blot, WJ; Gonzales, H; Miller, R; Muñoz, D; Munro, H; Pappalardo, S; Reynolds, C; Song, W; Tousey, P; Uzoije, P; Walkley, D; Wang, TJ; White, C1
Li, Y; Matsuoka, N; Suzuki, A; Teramoto, T; Yokote, K1
Copkiran, Ö; Özdemir, IH; Tıkız, C; Tıkız, H1
Akao, H; Fukizawa, S; Ieiri, I; Iwadare, M; Kajinami, K; Kusuhara, H; Lee, N; Maeda, K; Masauji, T; Niwa, O; Sugiyama, Y; Takeda, K; Tomaru, A; Yamane, N1
Chakrapani, LN; Kalaiselvi, P; Singh, A; Srinivasan, AK1
Kawashiri, MA; Nomura, A; Okada, H; Tada, H; Takamura, M1
Chiba, T; Fujioka, T; Hara, F; Iwasaki, Y; Moroi, M; Nagayama, D; Nishizawa, K; Saiki, A; Sato, N; Shiba, T; Shimizu, K; Shirai, K; Sugi, K; Sugimoto, H; Takahashi, M; Tatsuno, I; Usui, S; Yamamura, S; Yamasaki, J1
Fujisawa, S; Fukatsu, Y; Sugimoto, Y1
Beaufrère, H; Douglas, JM; Graham, JL; Guzman, DS; Havel, PJ; Knych, H; Paul-Murphy, JR; Robertson, JA; Stanhope, KL; Tully, TN1
Ahangari, G; Arshad, M; Babaheidarian, P; Emruzi, Z; Stockinger, H1
El-Gallil, HA; El-Ghaweet, HA; El-Sayyad, HIH1
Bélanger, M; Bouchard, DR; Doiron, MD; Eltonsy, S; Jose, C; LeBlanc, R; Sénéchal, M; Simard, P1
Kang, HT; Kim, HS; Kim, J; Lee, JW; Yang, W1
Chen, MF; Chien, KL; Hsu, HC; Lee, YT; Lin, HJ; Lu, TP; Su, TC; Yu, SL1
Burnett, JR; Dayasiri, K; Hooper, AJ; Majitha, SI; Thadchanamoorthy, V1
Aslan, G; İlhan, N; Sahin, K; Sahna, E; Sezgin, D; Tuzcu, M1
Urquhart, L1
Hüttl, M; Kazdová, L; Malínská, H; Marková, I; Miklánková, D; Oliyarnyk, O; Poruba, M; Rácová, Z; Večeřa, R1
Ahn, SG; Cho, YH; Doh, JH; Kim, JB; Kim, JW; Kim, SJ; Park, JS; Park, YH; Song, WH; Youn, TJ1
Banach, M; Penson, PE1
Hanselman, JC; MacDougall, DE; Nicholls, SJ; Rubino, J; Sterling, LR1
Cha, KS; Chae, SC; Choi, BG; Choi, CU; Choi, JY; Jang, WY; Jeong, MH; Kang, DO; Kim, EJ; Kim, JW; Kim, W; Na, JO; Oh, SK; Park, CG; Park, Y; Rha, SW; Seo, HS; Seong, IW; Yoon, CH1
Bortolin, RH; Cerda, A; Fajardo, CM; Hirata, MH; Hirata, RDC; Manriquez, V; Salazar, L; Zambrano, T1
Abd El-Aal, RA; Abdel-Latif, HA; Abdelkader, NF; Abdulwahab, DK; Ibrahim, WW1
Baralic, I; Ciric, MZ; Djordjevic, BI; Kotur-Stevuljevic, J; Markovic, S; Ostojic, M; Stankovic, I; Zivkovic, S1
Bian, Z; Chen, X; Ding, Y; Liu, N; Lu, F; Wu, H; Yang, D; Zheng, P1
Ahmadi, F; Ahmadi, M; Davoudi, A; Hassantabar, R; Kasgari, HA; Najafi, N; Rabiee, M; Sharifi, A; Tayebi, A1
Baruch, A; Budha, NR; Chiu, CPC; Cowan, KJ; Davis, JC; Kahn, RS; Kirchhofer, D; Leabman, M; Luca, D; Peterson, A; Tingley, WG; Wu, Y1
Bergeron, J; Catapano, AL; Krempf, M; Lee, LV; Louie, MJ; Thompson, D1
Filipiak, KJ; Kapłon-Cieślicka, A; Kołtowski, Ł; Michalak, M1
Collier, T; Collins, R; Dahlof, B; Gupta, A; Poulter, N; Sever, P; Thompson, D; Whitehouse, A1
Hsieh, HC; Hsu, JC; Lu, CY1
Chaudhuri, S; Imai, K; Kanada, S; Matsuoka, N; Matsuoka, O; Sekino, H; Tabira, J; Teramoto, T; Yokote, K1
Baccara-Dinet, MT; Harada-Shiba, M; Ishigaki, Y; Kawabata, Y; Kiyosue, A; Kondo, A; Ozaki, A; Sata, M; Teramoto, T; Tobita, K1
Abidin, IZ; Bewersdorf, JP; Ismail, D; Kofink, D; Loch, A; Veriah, RS1
Cannon, CP; Khan, I; Klimchak, AC; Reynolds, MR; Sanchez, RJ; Sasiela, WJ1
Prado, Y; Salazar, LA; Zambrano, T1
Peng, D; Zhao, S1
Carmichael, AJ; Ghadiri, SJ; Gunputh, P; Poyner, EFM1
Al-Muzafar, HM; Amin, KA1
Baum, CM; Billotte, S; Forgues, P; Garzone, PD; Gumbiner, B; Joh, T; Levisetti, M; Liang, H; Pons, J; Shelton, DL; Vana, AM; Wan, H1
Lv, YZ; Wang, HM; Wang, ZZ; Xiao, W; Zhou, JM1
Berbée, JFP; Boon, MR; Gart, E; Groen, AK; Hoeke, G; Klop, HG; Mol, IM; Pieterman, EH; Princen, HMG; Rensen, PCN; van Dam, AD; van den Berg, SM; Wang, Y1
Arencibia, A; Prado, Y; Salazar, LA; Zambrano, T1
Anzalone, DA; Evans, KA; Johnston, S; Lewis, SJ; Malangone-Monaco, E; Olufade, T1
Ahmed, YM; Baothman, OAS; Khan, I; Khan, TJ; Mehanna, MG; Mohamed, SA; Yasir, M; Zamzami, MA1
Kong, W; Li, Y; Ling, Z; Liu, L; Liu, X; Shu, N; Sun, B; Wang, F; Wu, T; Xu, F; Xu, J; Zhang, M; Zhong, Z; Zhu, L1
Anil, C; Bozkus, Y; Demir, C; Kut, A; Mousa, U; Nar, A; Tutuncu, NB1
Ahmed, YM; Baothman, OAS; Kaleemuddin, M; Khan, I; Khan, TJ; Kuerban, A; Mehanna, MG; Siddiqui, AM; Yasir, M; Zamzami, MA1
Book, G; Dager, AD; Meda, S; Panza, GA; Pearlson, GD; Polk, DM; Stevens, MC; Tartar, S; Taylor, BA; Thompson, PD; White, CM; Zaleski, AL1
Ballantyne, CM; Baum, SJ; Davidson, MH; Koren, A; Langslet, G; Mandel, J; McCullough, PA; Sanganalmath, SK; Shah, PK1
Alvares, J; Bennie, M; de Acurcio, FA; do Nascimento, RCRM; Godman, B; Gomes, IC; Guerra, AA; Kurdi, AB1
Chen, X; Li, Y; Lin, L; Wang, S; Zhang, H1
Volpe, M1
Abbasi, A; Bahrami, M; Farhad, N; Froushani, SMA; Zarei, L1
Krysiak, R; Okopień, B; Szkróbka, W1
Collier, T; Godec, T; Gupta, A; Mackay, J; Pocock, S; Poulter, N; Sever, P; Whitehouse, A1
Drosdzol-Cop, A; Krysiak, R; Okopień, B; Skrzypulec-Plinta, V1
Adam, S; Durrington, PN; Soran, H1
Alía-Ramos, P; Baena-Díez, N; Caixàs-Pedragós, A; Calmarza, P; Candás-Estébanez, B; Güell-Miró, R; Jusmet-Miguel, X; Navarro-Badal, R; Padró-Miquel, A; Pintó-Sala, X; Puzo-Foncilla, JL; Ruiz-Iruela, C1
Ai, C; He, Q; Shi, J; Zhang, S1
Chan, P; Liu, ZM; Shao, L; Tomlinson, B; Zhang, Y1
Ge, J; Jiang, H; Yu, Y; Zhang, L; Zhang, S1
Bai, Y; Chen, K; Clements, TP; Cooke, JP; Diaz, MF; Fang, L; Gu, Q; Kim, JD; Li, W; Lv, J; Meng, S; Miller, YI; Tandon, B; Traver, D; Wagner, DS; Wang, R; Wenzel, PL; Xia, B; Xiong, F; Yang, X; Zhang, J; Zon, LI1
Maghsoomi, Z; Moghadasi, M1
Blé-Castillo, JL; Díaz-Zagoya, JC; Juárez-Rojop, IE; Marín-Medina, A; Ruíz-Hidalgo, G; Zamora, RM; Zetina-Esquivel, AM1
Ihm, SH; Kim, CH; Park, CG; Shin, J1
Chan, P; Liu, Z; Ma, YB; Tomlinson, B; Zhang, Y1
Bednarska-Czerwińska, A; Kowalcze, K; Krysiak, R; Okopień, B1
Hovland, A; Kjellmo, CA; Lappegård, KT; Pop, G1
Cai, Y; Chen, C; Hu, Z; Li, C; Liu, X; Liu, Y; Luo, H; Wang, DZ; Wu, G; Xia, X; Xu, Z; Yang, Y; Yu, J; Zeng, C; Zhang, W; Zhang, X1
Dézsi, CA; Simon, A1
Georgianos, PI; Kanaki, AI; Kanavos, K; Lasaridis, AN; Sarafidis, PA; Tziolas, IM; Zebekakis, PE1
Akin, F; Akin, MN; Ayça, B; Canbek, TD; Güngör, O; Köse, N; Sahin, I1
Hirayama, A; Hiro, T; Honye, J; Kodama, K; Komatsu, S; Li, Y; Nanto, S; Saito, S; Takayama, T; Takazawa, K; Ueda, Y; Yajima, J; Yamaguchi, O1
Arazi, SS; Baudhuin, LM; Bernik, MM; Bertolami, MC; Bryant, SC; Cerda, A; Dorea, EL; Faludi, A; Genvigir, FD; Hirata, MH; Hirata, RD; Largura, A; Rodrigues, AC; Willrich, MA1
Dormuth, CR; Ernst, P; Garg, AX; Hemmelgarn, BR; James, MT; Lafrance, JP; Levy, A; Paterson, JM; Raymond, CB; Teare, GF1
Filipiak, KJ; Mamcarz, A; Naruszewicz, M; Siebert, J; Sliż, D1
Gierman, LM; Huizinga, TW; Kloppenburg, M; Koudijs, A; Kühnast, S; Pieterman, EJ; Princen, HM; Stojanovic-Susulic, V; van Osch, GJ; Zuurmond, AM1
Inazu, T; Kawahara, C; Kawahara, T; Nishikawa, M; Sakai, K; Suzuki, G1
Biwa, T; Kurogi, K; Matsui, K; Nakamura, S; Ogawa, H; Sakamoto, K; Sugiyama, S; Tayama, S1
Bakhoum, SW; Issac, MS; Mishriki, AA; Shabana, MF1
Ozaydin, M; Varol, E1
Choi, YH; DeGorter, MK; Dresser, GK; Hegele, RA; Iwuchukwu, O; Kim, RB; Myers, K; Schwarz, UI; Suskin, N; Tirona, RG; Wei, WQ; Wilke, RA; Zou, G1
Chen, CH; Chu, CS; Dixon, RA; Huang, RY; Lai, WT; Lu, J; Lu, LS; Sawamura, T; Walton, B; Wang, YC; Yilmaz, HR1
Delibas, N; Gocmen, AY; Gumuslu, S; Ocak, GA; Ozbilim, G1
Bertolami, MC; Cavalli, SA; Cerda, A; Faludi, AA; Genvigir, FD; Hirata, MH; Hirata, RD; Issa, MH; Rohde, CB1
Dabrowski, M; Wiliński, J1
Averna, M; Bays, HE; Brudi, P; De Pellegrin, A; Farnier, M; Giezek, H; Lee, R; Lowe, RS; Majul, C; Muller-Wieland, D; Triscari, J1
Catapano, AL; Corrao, G; Ibrahim, B; Mancia, G; Merlino, L; Nicotra, F; Pasini, TS; Zambon, A1
Chen, JW; Chen, JY; Chien, KL; Hsia, CH; Hung, YR; Lin, HJ; Lin, LY; Liu, PY; Wu, TC; Yeh, HI1
Calabria, P; Limbruno, U; Micheli, A; Picchi, A1
Bozbeyoğlu, E; Çanga, Y; Kaya, C; Kul, Ş; Nurkalem, Z; Özcan, KS; Satılmış, S; Yildirimtürk, Ö1
Banach, M; Celecova, Z; Gaspar, L; Hirnerova, E; Huckova, N; Kucera, M; Oravec, S1
Fan, J; Keyamura, Y; Kohashi, M; Koyama, T; Niimi, M; Nozako, M; Yasufuku, R; Yoshikawa, T1
Aksoy, Y; Senen, K; Sivri, N; Tekin, G; Yalta, K; Yetkin, E1
Becker, ML; de Keyser, CE; Hofman, A; Klungel, OH; Maitland-van der Zee, AH; Peters, BJ; Stricker, BH; Uitterlinden, AG; Verstuyft, C; Visser, LE1
Ben-Yehuda, O; Constance, C; Hanson, ME; Lin, J; Lowe, RS; Tershakovec, AM; Wenger, NK; Zieve, F1
Elens, L; Elisaf, M; Kolovou, G; Kolovou, V; Manolopoulos, VG; Ragia, G; Tavridou, A; Tselepis, AD; Van Schaik, RH2
Bermúdez-Ocaña, DY; Díaz-Zagoya, JC; Espinosa-García, MT; Jiménez-Santos, MA; Juárez-Oropeza, MA; Juárez-Rojop, IE; Ramón-Frías, T; Tovilla-Zárate, CA1
Fotiadis, G; Kadoglou, NP; Kapelouzou, A; Liapis, CD; Sailer, N1
Chattopadhyay, S; Dey, S; Mazumder, B1
Lagos, J; Rosales, A; Salazar, LA; Zambrano, T2
Chang, WT; Huang, SK; Liau, I; Yang, YC1
Elisaf, M; Giannakopoulou, E; Kolovou, G; Kolovou, V; Manolopoulos, VG; Ragia, G; Tavridou, A; Tselepis, AD1
Hegele, RA; Joy, TR; Mahon, JL; McDonald, CG; Monjed, A; Zou, GY1
Du, S; Han, YG; Li, L; Luo, P; Wang, GG; Wang, LX; Wu, SL; Zhu, HH1
Belcaro, G; Cornelli, U; Finco, A1
Simonyi, G1
Fialkow, J; Legg, JC; Nedergaard, BS; Nelson, P; Neutel, JM; Ramstad, D; Robinson, JG; Rogers, WJ; Scott, R; Somaratne, R; Wasserman, SM; Weiss, R1
Lozzi, A1
Mokhtari-Dizaji, M; Rahmani-Cherati, T; Rostami, A; Vajhi, A1
Chang, TT; Chen, JS; Chen, JW; Huang, CC; Huang, PH; Leu, HB; Lin, LY; Lin, SJ; Wu, TC1
Ceng, C; Han, W; Huang, C; Liu, Y; Zhan, H; Zheng, D1
Budoff, M; Folse, HJ; Goswami, D; Kahn, R; Rengarajan, B1
Hirayama, A; Nagao, K; Takahashi, A; Tani, S1
Bai, L; Chen, Y; Fan, J; Gao, S; Guan, H; Li, Y; Lin, Y; Liu, E; Wang, Y; Zhao, S; Zhu, N1
Almeida, S; Ferreira, ME; Fiegenbaum, M; Hutz, MH; Lima, LO; Pires, RC; Smiderle, L; Van der Sand, CR; Van der Sand, LC1
Jinnouchi, H; Masuda, I; Matsui, K; Mori, H; Ogawa, H; Saito, Y; Sugawara, M; Sugiyama, S; Waki, M; Watada, H; Yoshiyama, M1
Chang, YP; Mitchell, BD; Montasser, ME; O'Hare, EA; Wang, X; Zaghloul, NA1
Bays, HE; Colhoun, HM; Donahue, S; Du, Y; Hanotin, C; Jones, PH; Robinson, JG1
Li, WS; Li, YX; Lin, CQ; Shi, DY; Zeng, SY1
Ahn, CW; Cha, BS; Cho, Y; Choe, E; Choi, Y; Kang, ES; Lee, HC; Lee, YH; Seo, JW; Wang, HJ; Yun, Y1
Cohen Tervaert, JW; de Jong, HJ; Helle, MJ; Klungel, OH; Meyboom, RH; Niskanen, L1
Krysiak, R; Okopien, B1
Ebisawa, S; Ikeda, U; Izawa, A; Kagoshima, M; Kashima, Y; Kitabayashi, H; Koyama, J; Miura, T; Miyashita, Y; Sakurai, S; Tomita, T; Yamamoto, H1
Canas, JA; Caulfield, MP; Damaso, LC; Gidding, SS; Hossain, J; Mauras, N; Ross, JL; Sikes, KM; Taboada, MV1
Bays, HE; Chen, E; McPeters, G; Polis, AB; Tomassini, JE; Triscari, J1
Berdan, LG; Bessac, L; Bhatt, DL; Bittner, V; Diaz, R; Goodman, SG; Hanotin, C; Harrington, RA; Jukema, JW; Mahaffey, KW; Moryusef, A; Pordy, R; Roe, MT; Rorick, T; Sasiela, WJ; Schwartz, GG; Shirodaria, C; Steg, PG; Szarek, M; Tamby, JF; Tricoci, P; White, H; Zeiher, A1
Chan, LW; Gu, XY; Li, J; Liu, L; Luo, XP; Ni, HC; Qiao, J; Shi, HM; Wen, ZC1
Dohi, T1
Ahmed, A; Hameed, MK; Najam, A; Sheikh, ZA1
Dubrovins'ka, TV; Skrypnyk, IM1
Einecke, D3
Ambegaonkar, BM; Cao, X; Ejzykowicz, F; Mavros, P; Ramey, DR; Sajjan, S; Tunceli, K1
Gilowski, W; Krysiak, R; Okopien, B1
Bacova, BS; Benova, T; Knezl, V; Radosinska, J; Tribulova, N; Viczenczova, C1
de Entrambasaguas, M; Peñaranda, N; Ponz, A; Sánchez-Monzó, P1
Alves, C; Cerda, A; Dorea, EL; Fajardo, CM; Genvigir, FD; Gusukuma, MC; Hirata, MH; Hirata, RD; Pinto, GA; Rodrigues, AC1
Baer, AL; deGoma, EM; Donovan, DS; Dunbar, RL; Ginsberg, HN; Gutstein, DE; Holleran, S; Johnson-Levonas, AO; Jumes, P; Karmally, W; Lassman, ME; Liu, Y; Millar, JS; Obunike, J; Pollan, L; Rader, DJ; Rafeek, H; Ramakrishnan, R; Reyes-Soffer, G; Tohyama, J; Wagner, JA1
AlBacha, Jd; Azar, A; Fajloun, Z; Haddad, K; Hamoui, S; Khoury, M; Makdissy, N; Mouawad, C1
Deng, L; Gong, L; Li, D; Li, Y; Qi, C; Wu, W; Zhang, C; Zhang, Q; Zhang, T; Zhang, Y1
Aguilar-Salinas, C; Arzola-Paniagua, A; Carreón-Torres, E; Flores-Castillo, C; Fragoso, JM; Franco, M; López-Olmos, V; Luna-Luna, M; Pérez-Méndez, Ó; Rodríguez-Pérez, JM; Vargas-Alarcón, G; Zamora-Pérez, JÁ1
Brudi, P; Farnier, M; Giezek, H; Krempf, M; Lee, R; Ramey, DR; Simpson, RJ; Tomassini, JE1
Rajamannan, NM1
Brinkmann, SJ; Buijs, N; Couderc, R; Cynober, L; Richir, M; van Leeuwen, PA; Wörner, EA1
Bai, L; Cheng, D; Cheng, G; Chu, Y; Gao, S; Liu, E; Sun, W; Wang, X; Wang, Y; Zhao, S1
Dippel, DW; Scheele, M; van den Meiracker, AH; Versmissen, J1
Akalin Çiftçi, G; Akalin, A; Alataş, İÖ; Ertorun, İ; Musmul, A1
Atarashi, H; Kohashi, K; Kosugi, M; Kusama, Y; Nakagomi, A; Shibui, T; Shimizu, W1
Gilowski, W; Krysiak, R; Okopien, B; Szkrobka, W1
Bai, L; Chen, Y; Fan, J; Gao, S; Guan, H; Li, Y; Lin, Y; Liu, E; Sun, L; Wang, Y; Zhao, S; Zhu, N1
Al-Badriyeh, D; Al-Khal, A; Alabbadi, I; Fahey, M; Zaidan, M1
Almeida, S; Ferreira, ME; Fiegenbaum, M; Hutz, MH; Pires, RC; Smiderle, L; Van Der Sand, CR; Van Der Sand, LC1
Lagos, J; Prado, Y; Rosales, A; Saavedra, N; Salazar, LA; Zambrano, T1
Ballantyne, CM; Hsueh, WA; Lin, J; Lowe, RS; Rosen, JB; Shah, AK; Tershakovec, AM1
Cuevas, A; Fernández, C; Ferrada, L; Rosales, A; Saavedra, N; Salazar, LA; Zambrano, T1
Sozer, V1
Bertacco, E; Buso, R; Di Virgilio, R; Fadini, GP; Faggin, E; Palmosi, T; Pauletto, P; Plebani, M; Puato, M; Rattazzi, M; Zaninotto, M1
Anzalone, DA; Cain, VA; Friday, KE; Lewis, SJ; Welty, FK1
Banerjee, P; Hamon, S; Hanotin, C; Kereiakes, D; Koren, MJ; McKenney, JM; Pourfarzib, R; Winegar, D1
Bando, Y; Hisada, A; Kanehara, H; Okafuji, K; Tanaka, N; Toya, D; Toyama, H1
Chiang, CE; Ferrières, J; Gotcheva, NN; Henriksson, KM; Hermans, MP; Raal, FJ; Shehab, A; Sung, J1
De Meyer, GR; Martinet, W; Rombouts, M; Roth, L; Schrijvers, DM1
Amuzie, C; Denham, S; Mais, DE; Rogers, CS; Swart, JR; Vihtelic, T1
Ashavaid, TF; Kadam, P; Ponde, CK; Rajani, RM1
Ferenci, T; Simonyi, G1
Scheen, AJ4
Ballantyne, CM; Brennan, DM; Bruckert, E; Ceška, R; Dent-Acosta, RE; Elliott, M; Gouni-Berthold, I; Lehman, SJ; Lepor, N; Nissen, SE; Preiss, D; Rosenson, RS; Sattar, N; Scott, R; Somaratne, R; Stein, EA; Stroes, E; Wasserman, SM1
Crevar-Sakac, M; Ivanisević, J; Jelić-Ivanović, Z; Kotur-Stevuljević, J; Markelić, M; Milenković, M; Vujcić, Z; Vujić, Z1
Sungkanuparph, S; Wangpatharawanit, P1
Wang, M; Zeng, R; Zhang, L1
Barter, PJ; Karlson, BW; Lundman, P; Nicholls, SJ; Palmer, MK; Wiklund, O1
Amento, EP; Bigos, M; Madasamy, S; Shivasubramani, U; Villanueva, J; Wu, AH1
Baccara-Dinet, MT; Bergeron, J; Langslet, G; Manvelian, G; Moriarty, PM; Rader, DJ; Roth, EM; Zhao, J1
Cai, G; Crawford, R; Du, Z; Farnaghi, S; Friis, T; Mao, X; Prasadam, I; Xiao, Y1
Chae, SC; Cho, DG; Chung, MH; Ha, JW; Han, GR; Hyon, MS; Jo, SH; Kim, CH; Kim, DW; Kim, KS; Kim, SH; Kim, YD; Lee, HL; Lee, NH; Lee, SC; Lee, SY; Oh, BH; Park, CG; Ryu, GH; Seung, KB; Yoon, MH1
Al Mamun, A; Hashimoto, M; Hossain, S; Katakura, M; Shido, O; Tanabe, Y; Tsuchikura, S1
Acevedo, M; Contreras, S; González, C; Hidalgo, P; Mezzano, D; Panes, O; Pereira, J; Rigotti, A; Sánchez, X; Valderas, JP1
Ann, SJ; Cheon, DH; Cheon, EJ; Choi, D; Choi, S; Kang, SM; Kim, KY; Lee, CJ; Lee, JE; Lee, SH; Noh, HM; Park, S1
Gromnaky, NI; Mikhin, VP; Zhilyaeva, YA1
Duda, M; Maczewska, J; Maczewski, M1
Baxter, LC; Connor, DJ; Haut, MW; Johnson, SC; Lemieux, SK; Lopez, JE; Sabbagh, MH; Sampath, H; Sparks, DL; Sparks, LM1
Kevelaitiene, S; Slapikas, R1
Hirano, T; Ito, Y; Michishita, I; Nozue, T1
Gokkaya, SC; Guzel, O; Hakan Koyuncu, H; Levent Ozdal, O; Memis, A; Ozden, C1
Ageta, M; Biro, S; Ikeda, Y; Kajiwara, K; Kobori, S; Kono, S; Kuribayashi, T; Otonari, T; Saikawa, T; Sasaki, J; Yamamoto, K1
Ikeda, S; Koga, S; Kohno, S; Miyahara, Y; Oka, H1
Bucci, A; Di Giacomo, S; Fraone, N; Mazza, F; Mazzarella, B; Stefanutti, C; Vivenzio, A1
Beamer, B; Costa-Scharplatz, M; Frial, T; Gandhi, S; Ramanathan, K1
Elsais, A; Kerty, E; Lund, C1
Arazi, SS; Bernik, MM; Bertolami, MC; Dorea, EL; Faludi, AA; Genvigir, FD; Hirata, MH; Hirata, RD; Rebecchi, IM; Rodrigues, AC; Willrich, MA1
Avello L, M; Bravo D, M; Calvo M, C; Mennickent C, S1
Benjanuwatra, T; Boonbaichaiyapruck, S; Buakhamsri, A; Cheepudomwit, S; Moleelerkpoom, W; Panjavenin, P; Sukanandachai, B; Suthichaiyakul, T1
Daubresse, JC; Herregods, MC; Lamotte, M; Michel, G; Vandenhoven, G; Vissers, E1
Agarwal, S; Baruch, L; Eng, C; Gupta, B; Lieberman-Blum, SS1
Amarenco, P; Callahan, A; Goldstein, LB; Hennerici, MG; Messig, M; Sillesen, H; Welch, KM; Zivin, J1
Coimbra, SR; Crisostomo, LM; Favarato, D; Luz, PL; Mendes, CM; Souza, CA1
Kadonosono, K; Takano, T; Tanaka, S; Terauchi, Y; Yamakawa, T1
Calza, L; Chiodo, F; Colangeli, V; Manfredi, R; Pavoni, M; Pocaterra, D1
Korber, KE1
Bays, HE; Bird, SR; Conard, SE; Leiter, LA; Lowe, RS; Rubino, J; Tershakovec, AM; Tomassini, JE1
Bays, H; Bird, S; Conard, S; Hanson, ME; Leiter, LA; Rubino, J; Tershakovec, AM; Tomassini, JE1
Kurabayashi, M; Yamazaki, T1
Smith, M; Sullivan, D; Wlodarczyk, J1
Argyropoulou, MI; Elisaf, M; Kiortsis, DN; Tselepis, AD; Tsouli, SG; Xydis, V1
Fujii, T; Kunita, E; Maeda, K; Sekiguchi, Y; Tasaki, N; Tsujiyama, S; Urabe, Y1
Jiang, GH; Qu, HY; Wang, ZY; Xiao, YW; Zhang, M; Zhang, Y1
Simon, HB1
Habon, T; Horvath, B; Szapary, L; Toth, K1
Glueck, CJ; Goldenberg, N; Khan, NA; Rawal, B; Wang, P; Yeramaneni, S1
Cater, NB; Faergeman, O; Holme, I; Kastelein, JJ; Larsen, ML; Lindahl, C; Olsson, AG; Pedersen, TR; Tikkanen, MJ1
Cable, EE; Chi, B; Erion, MD; Fujitaki, JM; Ito, BR; Linemeyer, DL; MacKenna, DA; Song, X; van Poelje, PD; Wilker, CE; Zhang, BH1
Abramsky, O; Boimel, M; Grigoriadis, N; Lourbopoulos, A; Rosenmann, D; Rosenmann, H; Touloumi, O1
Amarenco, P; Benavente, O; Callahan, A; Gilbert, S; Goldstein, LB; Hennerici, MG; Rudolph, AE; Sillesen, H; Simunovic, L; Welch, KM; Zivin, JA1
Ayaori, M; Fayad, ZA; Kihara, T; Kusuhara, M; Momiyama, Y; Nagata, M; Nakamura, H; Nakaya, K; Ogura, M; Ohmori, R; Ohsuzu, F; Tamai, S; Tanaka, N; Taniguchi, H; Yonemura, A1
Akbay, E; Corapcioglu, D; Emral, R; Gen, R; Sezer, K1
Ikewaki, K; Inoue, Y; Nakada, Y; Ozasa, H; Terao, Y; Tohyama, J; Yoshimura, M1
Goldstein, MR; Mascitelli, L; Pezzetta, F1
Alcudia, JF; Badimon, L; Guadall, A; Martínez-González, J; Raposo, B; Rodríguez, C; Sánchez-Gómez, S1
Altug, T; Aydin, S; Sozer, V; Uzun, H1
Amarenco, P; Callahan, A; Goldstein, LB; Hennerici, MG; Messig, M; O'Neill, BJ; Sillesen, H; Welch, KM; Zivin, JA1
Jeon, TI; Osborne, TF; Seo, YK; Zhu, B1
Goldberg, RB; Guyton, JR; Jensen, E; Mazzone, T; Polis, A; Tershakovec, AM; Tomassini, JE; Weinstock, RS1
Adewale, AJ; Ballantyne, CM; Grundy, SM; Hsueh, WA; Parving, HH; Polis, AB; Robinson, JG; Rosen, JB; Tershakovec, AM; Tomassini, JE1
Bláha, M; Bláha, V; Nováková, L; Sadílek, P; Satínský, D; Solich, P; Solichová, D; Vlcková, H1
Saito, Y; Yokote, K1
Bregar, U; Jug, B; Poredos, P; Sabovic, M; Sebestjen, M1
Abramczyk, P; Bidiuk, J; Ciarka, A; Dobosiewicz, A; Gaciong, Z; Lewandowski, J; Siński, M1
Chen, P; Gan, Y; Li, G; Wu, S; Xing, X; Zhang, J; Zhang, Y; Zhao, S1
Claudel, T; Fauler, G; März, W; Putz-Bankuti, C; Scharnagl, H; Sourij, H; Stauber, RE; Stojakovic, T; Trauner, M; Wagner, M; Wascher, TC; Winkler, K1
Ferdinand, KC; Flack, JM; Jamieson, MJ; Kursun, A; Saunders, E; Shi, H; Victor, R; Watson, K1
Kuriyama, G; Mori, Y; Tajima, N; Tanaka, T1
Raczak, G1
Bailey, KM; Balmforth, AJ; Hall, AS; Romaine, SP1
Mamotte, CD; Pocathikorn, A; Taylor, RR1
Basili, S; Cangemi, R; Carnevale, R; Loffredo, L; Pignatelli, P; Sanguigni, V; Stefanutti, C; Violi, F1
Leekha, S; Lena, YL; Ong, LM; Punithavathi, N1
Arazi, SS; Bernik, MM; Bertolami, MC; Cerda, A; Dorea, EL; Faludi, AA; Genvigir, FD; Hirata, MH; Hirata, RD1
Bays, HE; Carter, RN; Doyle, RT; Maki, KC; McKenney, J; Stein, E1
Goldberg, RB; Guyton, JR; Mazzone, T; Polis, AB; Tershakovec, AM; Tipping, D; Tomassini, JE; Weinstock, RS1
Calciu, CD; Langer, A; Leiter, LA; Rabkin, SW; Ur, E1
Bays, H; Bird, S; Conard, S; Hanson, ME; Leiter, LA; Lin, J; Shah, A; Tershakovec, AM1
Dhumma-Upakorn, R; Putwai, P; Sansanayudh, N; Wongwiwatthananukit, S1
Chae, JK; Choi, JY; Hong, TJ; Jeong, MH; Kim, DS; Kim, KY; Kim, YJ; Kim, YN; Oh, SK; Park, JS; Seong, IW1
Arvanitakis, Z; Knopman, DS1
Shimano, H; Teramoto, T; Urashima, M; Yokote, K1
Al Khadra, A; Erdine, S; Kim, JH; Lopez, AP; Sutradhar, S; Westergaard, M; Yunis, C; Zamorano, J1
King, S; Superko, HR1
Chang, LL; Chen, HW; Cheng, WL; Kuo, CL; Lii, CK; Liu, CS; Su, SL; Tsai, CW1
Han, SH; Kim, SJ; Koh, KK; Lee, Y; Quon, MJ; Shin, EK1
Athyros, VG; Karagiannis, A; Mikhailidis, DP; Tziomalos, K; Wierzbicki, AS1
Benner, JS; Chapman, RH; Foody, JM; Hussein, MA; Joyce, A; Solomon, HA; Tang, SS1
Cipollone, F; Faggin, E; Ganassin, L; Grego, F; Mezzetti, A; Pauletto, P; Plebani, M; Puato, M; Rattazzi, M; Zambon, A1
Chaiyaroj, SC; Chansrichavala, P; Chantharaksri, U; Ngaosuwankul, N; Sritara, P1
Allgar, V; Chipperfield, R; Gaunt, R; Harvey, P; McCormack, T; Robinson, P1
Watson, KE1
Atkin, SL; Kilpatrick, ES; Sathyapalan, T1
Cao, G; Konrad, RJ; Pacanowski, MA; Troutt, JS; Welder, G; Zineh, I1
Derosa, G; Maffioli, P1
Athyros, VG; Karagiannis, A; Mikhailidis, DP; Tziomalos, K1
Peters, GJ; Schneiders, FL; van den Berg, HP; van der Vliet, HJ; Verheul, HM1
Holford, TR; Kane, JP; Kocherla, M; Pullinger, CR; Ruaño, G; Seip, RL; Thompson, PD; Windemuth, A; Wu, AH1
Beadle, K; Gurnsey, C; Hoenig, MR; Johnson, L; Walker, PJ1
Clarkson, PM; Grimaldi, AS; Haller, RG; Hoffman, EP; Levine, BD; Parker, BA; Pescatello, LS; Thompson, PD; White, CM1
Kruger, A; Ostadal, P; Vondrakova, D1
Mehta, JL1
Baer, A; Ky, B; Millar, JS; Pruscino, L; Rader, DJ; Wolfe, ML1
El-Shenawy, SM; ElRokh, el-SM; Ibrahim, BM; Yassin, NA1
Acharjee, S; Cannon, CP1
Bartimoccia, S; Basili, S; Carnevale, R; Di Santo, S; Napoleone, L; Pignatelli, P; Sanguigni, V; Tanzilli, G; Violi, F1
Bays, HE; Bird, SR; Conard, SE; Leiter, LA; Lowe, RS; Tershakovec, AM1
Arazi, SS; Bernik, MM; Cerda, A; Curi, R; Dorea, EL; Genvigir, FD; Hirata, MH; Hirata, RD; Oliveira, R; Rodrigues, AC; Willrich, MA1
Bays, H; Conard, S; Hanson, ME; Leiter, LA; Lin, J; Shah, A; Tershakovec, AM1
Adewale, AJ; Brown, WV; Flaim, D; Foody, JM; Jones-Burton, C; Lowe, RS; Tershakovec, AM; Zieve, F1
Belgamwar, V; Maurya, D; Tekade, A1
Chen, P; Duan, S; Gan, Y; Jiang, LZ; Li, GY; Wu, SJ; Zhang, J; Zhang, Y; Zhao, SP1
Brunet, M; Cofán, F; Cofán, M; Guillén, D; Millán, O; Ros, E1
Auteri, A; Ciabattoni, G; Ciani, F; Davì, G; Ferrante, E; Ghezzi, A; Lattanzio, S; Liani, R; Pasqui, AL; Puccetti, L; Santilli, F; Scarpini, F1
Arranz Martínez, E; Gordillo López, FJ; Hermosa Hernán, JC; Ruiz García, A1
Cho, YS; Hong, SJ; Hyon, MS; Kim, DW; Kim, HS; Kim, SH; Lee, MY; Moon, GW; Park, K; Sung, JD; Yoon, MH1
Sasaki, J1
Blanco-Vaca, F; Chacón, P; Ciudin, A; Francisco, G; Hernández, C; Llaverias, G; Montoro, B; Simó, R1
Cámara, C; Costo, A; Crespo, L; Fernández Pereira, L; Pereira, G; Sánchez Muñoz-Torrero, JF1
Ahmed, K; Ahn, Y; Cho, JG; Cho, SH; Choi, YH; Hachinohe, D; Hong, YJ; Hwang, SH; Jeong, MH; Kang, JC; Kim, JH; Kim, KH; Ko, JS; Lee, MG; Park, HW; Park, JC; Park, KH; Sim, DS; Yoon, HJ; Yoon, NS1
Betteridge, J1
Higa, M; Masuzaki, H; Shimabukuro, M; Shimabukuro, T; Tanaka, H; Yamakawa, K1
Furusawa, T; Inazu, T; Kawahara, T; Nishikawa, M; Suzuki, G1
Choi, D; Chung, N; Jang, Y; Kang, SM; Lee, SH; Park, S1
Babaoglu, MO; Bozkurt, A; Kilicarslan, A; Sain-Guven, G; Yardimci, Y; Yasar, U1
Campo, N; Campo-Bustillo, I; Forteza, A; Gutierrez, J; Haussen, DC; Koch, S; Romano, JG1
Kadonosono, K; Kaneko, T; Kawaguchi, J; Morita, S; Shigematu, E; Terauchi, Y; Yamakawa, T1
Boncler, M; Czyz, M; Luzak, B; Rysz, J; Rywaniak, J; Stanczyk, L; Watala, C; Wilk, R1
Bayés, B; Egido, J; Lauzurica, R; Martínez-Cáceres, E; Mas, S; Navarro-Muñoz, M; Pastor, MC; Pérez, V; Romero, R1
Caretta, G; Dei Cas, L; Della Pina, P; Gorga, E; Madureri, A; Raddino, R1
Berkowitz, DE; Holowatz, LA; Kenney, WL; Santhanam, L; Webb, A1
Noda, K; Saku, K; Zhang, B2
Hirayama, A; Honye, J; Kodama, K; Komatsu, S; Li, Y; Nanto, S; Saito, S; Takayama, T; Takazawa, K; Ueda, Y; Yajima, J; Yamaguchi, O1
Arazi, SS; Bernik, MM; Cerda, Á; Dorea, EL; Genvigir, FD; Hirata, MH; Hirata, RD; Oliveira, Rd; Rodrigues, AC; Willrich, MA1
Ayaori, M; Ikewaki, K1
Anzivino, C; Baldelli, E; Bertolotti, M; Carulli, L; Carulli, N; Corna, F; Del Puppo, M; Gabbi, C; Galli Kienle, M; Loria, P1
Sillence, D; Tchan, M1
Kadoglou, NP; Kapelouzou, A; Kostakis, A; Lampropoulos, S; Liapis, CD; Sailer, N; Vrabas, IS1
Holowatz, LA; Kenney, WL2
Nart, D; Onat, T; Sezer, ED; Sozmen, EY1
Caulfield, M; Chang, CL; Chapman, N; Dahlöf, B; Feder, G; Poulter, NR; Sever, PS1
Chang, CL; Hingorani, A; Hughes, AD; Poulter, NR; Sattar, N; Sever, PS; Thom, SA; Welsh, P1
Chang, CL; Gupta, AK; Poulter, NR; Sever, PS; Whitehouse, A1
Georgianos, PI; Kanaki, AI; Kanavos, K; Lasaridis, AN; Sarafidis, PA; Stafylas, PC; Tziolas, IM1
Chacra, AP; Gagliardi, AC; Krieger, JE; Miname, MH; Pereira, AC; Santos, PC; Santos, RD1
Bang, OY; Huh, W; Kim, HG; Kim, JW; Kim, SR; Ko, JW; Lee, SC; Lee, SY; McLeod, HL; O'Connell, TM; Won, HH1
Tanaka, M1
Arazi, SS; Bernik, MM; Bertolami, MC; Carracedo, A; Dorea, EL; Faludi, AA; Fondevila, M; Freire, A; Genvigir, FD; Hirata, MH; Hirata, RD; Lareu, MV; Luchessi, AD; Perin, PM; Phillips, C; Porras-Hurtado, L; Purim, SG; Rodrigues, AC; Salas, A; Santos, C; Silbiger, VN; Willrich, MA1
Anderson, L; Bhattacharya, S; Bose, N; Fraser, E; Graham, K; Lumsden, G; McClue, L; Robertson, L; Tho, LM; Yosef, H1
Chu, Q; Dunlop, D; Hao, D; Jacobs, CD; Leighl, N; Lopez-Anaya, A; Middleton, G; Ramlau, R; Rodon, J; Rowinsky, EK; Takimoto, CH; Wakelee, HA; Zatloukal, P1
Arazi, SS; Bernik, MM; Bertolami, MC; Cerda, A; Dorea, EL; Faludi, AA; Genvigir, FD; Hirata, MH; Hirata, RD; Willrich, MA1
Bertolami, MC; Cavalli, SA; Cerda, A; Faludi, AA; Genvigir, FD; Hirata, MH; Hirata, RD; Issa, MH1
Leekha, S; Lena, YL; Mahanim, O; Ong, LM; Punithavathi, N1
Alvear, M; Cuevas, A; Rosales, A; Saavedra, N; Salazar, LA; Zambrano, T1
Saito, Y1
Hayashi, K; Ikewaki, K; Inazu, A; Kawashiri, MA; Kobayashi, J; Konno, T; Mabuchi, H; Miwa, K; Nakanishi, C; Noguchi, T; Nohara, A; Tada, H; Takata, M; Terao, Y; Tsuchida, M; Yamagishi, M1
Allahkhah, AA; Enshaei, A; Falahatkar, S; Farhat, B; Heidari Bateni, Z; Khosropanah, D; Khosropanah, I1
Krasznai, Z; Toth, P1
Bao, W; Benessiano, J; Mallat, Z; Olsson, AG; Ryu, SK; Schwartz, GG; Tedgui, A; Tsimikas, S1
Deli, CK; Fatouros, IG; Fotopoulou, N; Jamurtas, AZ; Koutedakis, Y; Nikolaidis, MG; Panayiotou, G; Paschalis, V; Sampanis, M; Theodorou, AA1
Bada, V; Božek, P; Kucharská, J; Šikurová, L; Uličná, O; Vančová, O; Waczulíková, I1
Civeira, F; Dan, AG; De Tilleghem, Cle B; Hanson, ME; Hing Ling, PK; Massaad, R; Milardo, C; Triscari, J1
Hirayama, A; Honye, J; Kodama, K; Komatsu, S; Li, Y; Nanto, S; Okada, K; Saito, S; Takayama, T; Takazawa, K; Ueda, Y; Yajima, J; Yamaguchi, O1
Lee, T1
Choudhury, RP; Iacob, AO1
Du, Y; Gasparino, E; Gutierrez, M; Kranz, T; Lisbon, E; Logan, D; Mellis, S; Smith, WB; Stahl, N; Stein, EA; Swergold, GD; Webb, C; Wu, R; Yancopoulos, GD1
Nachtigal, P; Rathouska, J; Strasky, Z; Zemankova Vecerova, L1
Ferrand, AC; Hanotin, C; Kereiakes, DJ; Koren, MJ; McKenney, JM; Stein, EA1
Vogel, RA1
Davies, GR1
Fenech, ME; Mackay, JW; Myint, KS1
Covelli, D; Crisanti, F; De Vuono, S; Lupattelli, G; Mannarino, E; Pirro, M; Roscini, AR; Siepi, D1
Gugliucci, A; Ishibashi, S; Kotani, K; Miyamoto, M; Taniguchi, N; Yamada, T1
Boussoula, E; Boutsikou, M; Giannakopoulou, V; Katsiki, N; Kollia, A; Kolovou, G; Kolovou, V; Mavrogeni, S; Mihas, C; Vasiliadis, I1
Bartimoccia, S; Basili, S; Cangemi, R; Carnevale, R; Napoleone, L; Nocella, C; Pastori, D; Pignatelli, P; Violi, F1
El-Moselhy, MA; Heeba, GH; Mourad, AA; Taye, A1
Bruckert, E; Dallongeville, J; Rosenbaum, D; Sabouret, P1
Kilpatrick, ES; Narayanan, D1
Bereal-Williams, C; Cannon, RO; Chi, A; Dalby, CK; Hauser, KP; Hunter, CJ; Hunter, L; Kato, GJ; Machado, RF; McGowan, V; Tailor, A1
Ghosh, AK; Kumar, KK; Kumar, KV; Prusty, P1
Chen, P; Chen, XD; Jiang, XY; Li, SY; Lu, M; Wang, GC; Wang, HB; Zhang, NN; Zhang, Q; Zhuang, MQ1
Hirayama, A; Nagao, K; Tani, S1
Gong, FY; Lu, YS; Qu, RB1
Christensen, JH; Lundbye-Christensen, S; Lysgaard, C; Nielsen, MS; Riahi, S; Schmidt, EB1
Adámková, V; Ceška, R; Dlouhá, D; Hubáček, JA; Lánská, V; Prusíková, M; Rynekrová, J; Vrablík, M; Zlatohlávek, L1
Asset, G; Hanotin, C; McKenney, JM; Roth, EM; Stein, EA1
Furutani, N; Ikewaki, K; Ito, K; Kurata, H; Shoda, T; Tada, N; Tsimikas, S; Witztum, JL; Yanai, H; Yoshida, H1
Simoens, S; Sinnaeve, PR1
Ahmed, W; Ali, IS; Ali, SH; Azam, M; Niazi, AK; Niazi, SH; Qamar, R; Riaz, M; Sadeque, A; Younas, A1
Choi, DH; Hong, TJ; Kim, HS; Kim, SH; Seo, MK; Yoon, MH1
Brudi, P; Hanson, ME; Jimenez, JG; Massaad, R; McPeters, G; Pirags, V; Rosen, JB; Triscari, J; Vides, H1
García-Estévez, DA; Navarro, C; San Millán, B; Sogo, T1
Chatlaong, B; Laothavorn, P; Nasawadi, C; Piamsomboon, C; Pongsiri, K; Saguanwong, S; Tanprasert, P1
Aviram, M; Fuhrman, B; Hayek, T; Keidar, S; Koren, L; Volkova, N1
Berra, C; Branchi, A; Colombo, E; Dalla Valle, E; Fiorenza, AM; Muzio, F; Rovellini, A; Sommariva, D; Torri, A2
Velussi, M1
Segal, AS1
González, M; González-Santos, P; Márquez, M; Palacios, R; Ruiz, J; Santos, J; Valdivielso, P1
Cayssials, A; Ferraris, JR; Krmar, RT; Legal, S; Ramirez, JA; Sorroche, P1
Chapman, MJ; Doucet, C; Gonbert, S; Laouenan, H; Malinsky, S; Sposito, AC; Thillet, J1
Dick, JB; Patterson, D; Struthers, AD1
Francis, PJ; Parmar, B; Ragge, NK1
Hin, AT; Lee, YT; Suyono, S; Sy, R; Tanphaichitr, V; Wu, CC1
Mercuro, G; Rosano, GM; Saiu, F; Sarais, C; Zoncu, S1
Deedwania, PC; Matalka, MS; Ravnan, MC1
Altavilla, D; Bonaiuto, M; Campo, S; Castaldo, M; Cinquegrani, M; Maesano, A; Nicocia, G; Saitta, A; Sardo, MA; Spadaro, M; Versace, A1
Ammirati, F; Colivicchi, F; Guido, V; Montefoschi, N; Santini, M; Tubaro, M; Varveri, A1
Shah, PK1
Nordøy, A1
Chmielewski, M; Rutkowski, B; Zdrojewski, Z1
Raison, J; Rudnichi, A; Safar, ME1
Ceska, R; Kasalová, Z; Marinov, I; Stulc, T; Vrablík, M1
Istad, H; Luurila, O; Olsson, AG; Ose, L; Pears, J; Southworth, H; Stender, S; Tuomilehto, J; Wiklund, O; Wilpshaar, JW1
Ostroumova, OD1
At'kov, OIu; Balakhonova, TV; Kobylianskiĭ, AG; Kukharchuk, VV; Kuznetsova, TV; Masenko, VP; Pogorelova, OA; Susekov, AV; Titov, VN; Tvorogova, MG1
Frolkis, JP; Minor, S; Nambi, V; Pearce, GL; Sprecher, DL1
Ballantyne, CM; Chitra, RR; Knopp, RH; McPherson, R; Schneck, DW; Simonson, SG1
Angori, P; Auteri, A; Bova, G; Bruni, F; Cercignani, M; Palazzuoli, A; Pasqui, AL; Pastorelli, M; Puccetti, L1
Derhaschnig, U; Dorner, GT; Jilma, B; Joukhadar, C; Petternel, V; Rassoul, F; Richter, V; Wagner, OF; Wolzt, M1
Chin-Dusting, JP; Kaye, DM; Parnell, MM; Starr, J1
Krane, V; Wanner, C1
Bianchi, S; Bigazzi, R; Caiazza, A; Campese, VM1
Ishii, T; Miyauchi, A; Nagakura, C; Sakurai, S; Tsujibayashi, T; Yoshitomi, Y1
Eriksson, M; Johnson, O; Kjellström, T; Lanke, J; Larsen, ML; Olsson, AG; Pedersen, T; Tikkanen, MJ; Wiklund, O1
Bouzamondo, A; Corvol, JC; Hulot, JS; Lechat, P; Sanchez, P; Sirol, M1
Stein, EA1
Blasetto, JW; Brown, WV; Chitra, R; Raza, A; Stein, EA1
Barter, P; Hunninghake, DB; Hutchinson, HG; McKenney, JM; Shepherd, J1
Caplan, RJ; Davidson, MH; Pears, JS; Rader, DJ1
Fuller, S; Gillen, D; Lacey, L; Marriott, J; Wilson, K1
Buller, N; Casciano, R; Doyle, J; Gillen, D; Wilson, K1
McBurney, CR; Smith, DG1
Bolaman, Z; Kadikoylu, G; Yavasoglu, I; Yukselen, V1
Athyros, VG; Boudoulas, H; Demitriadis, DS; Kontopoulos, AG; Papageorgiou, AA; Pehlivanidis, AN1
Aviles, RJ; Brennan, ML; Fu, X; Gokce, N; Goormastic, M; Hazen, SL; Keaney, JF; Pearce, GL; Penn, MS; Shishehbor, MH; Sprecher, DL; Vita, JA1
Dratwa, M; Lameire, NH; Lins, RL; Matthys, KE; Peeters, PC; Stolear, JC; Verpooten, GA1
Bendahan, D; Bernard, V; Cozzone, PJ; Figarella-Branger, D; Guis, S; Kozak-Ribbens, G; Lando, A; Mattei, JP; Pellissier, JF; Treffouret, S1
Ballantyne, CM; Houri, J; LeBeaut, AP; Lipka, LJ; Melani, L; Notarbartolo, A; Sager, PT; Sun, S; Suresh, R; Veltri, EP1
SoRelle, R1
Gilchrist, JM1
Berry, DA; Berry, SM; McKellar, J; Pearson, TA1
Ahmadi-Kashani, M; Balian, H; Bashir, M; Ebrahimi, R; Jafari, M1
Gill, MJ; Mah Ming, JB1
Aragoncillo, P; Cachofeiro, V; Cediel, E; de las Heras, N; Díaz, C; Hernández, G; Lahera, V; Oubiña, MP; Sanz-Rosa, D1
Bays, HE; Blasetto, JW; Cain, VA; Davidson, MH; Jones, PH; McKenney, JM; Miller, E; Stein, EA1
Ballantyne, CM; Gumbiner, B; Hunninghake, DB; Maccubbin, DL; Mitchel, YB; Shah, AK1
Aviles, RJ; Brennan, ML; Fu, X; Hazen, SL; Penn, MS; Shishehbor, MH; Sprecher, DL1
Hedner, T; Himmelman, A; Kjeldsen, SE1
Averkov, OV; Deev, AD; Gratsianskiĭ, NA; Pokrovskaia, EV; Vaulin, NA1
Ceska, R; Kasalová, Z; Prázný, M; Skrha, J; Stulc, T; Vrablík, M1
Marais, AD; McCrindle, BW; Ose, L1
Annuar, R; Khalid, BA; Nawawi, H; Osman, NS; Yusoff, K1
Malkan, D; McDonnell, CG; Shorten, GD; Van Pelt, FD1
Bax, JJ; Biagini, E; Boersma, E; Bountioukos, M; Kertai, MD; Krenning, BJ; Poldermans, D; Rizzello, V; Roelandt, JR; Schinkel, AF; Vourvouri, EC1
Khalid, BA; Nawawi, H; Osman, NS; Yusoff, K1
Baumbach, A; Fitzke, M; Herdeg, C; Karsch, KR; Oberhoff, M; Schroeder, S1
Zhang, DQ; Zhao, SP2
CarloTonolo, G; Carrozza, C; Lulli, P; Musumeci, S; Santini, SA; Zuppi, C1
Collisson, EA; De, A; Gambhir, SS; Kleer, C; Kolodney, MS; Merajver, SD; Wu, M1
Nasu, M; Tamura, A; Watanabe, T1
Fukuda, N; Nada, T; Sakabe, K; Shinohara, H; Tamura, Y; Wakayama, K3
Aviram, M; Hayek, T; Hussein, K; Rosenblat, M1
Ballantyne, CM; Blazing, MA; Davidson, MH; DeLucca, P; Hunninghake, DB; Hustad, CM; Palmisano, J; Ramsey, KE; Yuan, Z1
Gylling, H; Miettinen, TA1
Bertolami, MC; Cihon, F; Davidson, MH; Dujovne, CA; Escobar, ID; Frohlich, J; Maccubbin, DL; Mercuri, M; Ose, L; Scott, RS1
Ceska, R; Fialová, L; Malbohan, I; Malík, J; Soukupová, J; Stulc, T1
Gupta, S1
Bolaman, Z; Kadikoylu, G1
Antonini-Canterin, F; Cervesato, E; Granata, G; Nicolosi, GL; Pavan, D; Piazza, R; Popescu, BA; Zuppiroli, A1
Alexy, T; Horvath, B; Kesmarky, G; Marton, Z; Szapary, L; Toth, K1
Asai, T; Iguchi, A; Kanda, S; Koike, T; Kuzuya, M; Nakamura, A; Satake, S; Suzuki, Y; Umegaki, H1
Adamczyk, MA; Blasetto, JW; Bryzinski, BS; Cain, VA; Jones, PH; McKenney, JM1
García-Idoate, G; Mora, C; Muros, M; Navarro, JF1
Böhm, M; Faul, A; Laufs, U; Nickenig, G; Ribaudo, N; Wassmann, S1
Brousseau, ME; Kajinami, K; Ordovas, JM; Schaefer, EJ3
Brousseau, ME; Kajinami, K; Nartsupha, C; Ordovas, JM; Schaefer, EJ1
Ayan, F; Curgunlu, A; Ertürk, N; Karter, Y; Mihmanli, I; Vehid, S1
Gershovich, OE; Lyman, AE1
Blasetto, J; Caplan, R; Dane, A; Hutchison, H; Strutt, K1
Bernaud, C; Boutouyrie, P; Christin-Maitre, S; Gompel, A; Jaillon, P; Laurent, S; Simon, T; Thuillez, C; Zannad, F1
Kröger, K; Wittlinger, T1
Edwards, JE; Moore, RA1
Blennow, K; Eikenberg, O; Höglund, K; Vanderstichele, H; Vanmechelen, E; Wiklund, O1
Tellier, P1
Barter, PJ; Bonnet, J; Cheung, RC; Kallend, D; Morrell, JM; Raza, A; Schuster, H; Stender, S; Watkins, C1
Kadioglu, M; Kalyoncu, NI; Kesim, M; Ulku, C; Yaris, E; Yaris, F1
Daida, H; Miyauchi, K; Shimada, K1
Kulbertus, H; Scheen, AJ1
Mason, P1
Auteri, A; Bova, G; Bruni, F; Cercigani, M; Di Renzo, M; Leo, A; Pasqui, AL; Pastorelli, M; Puccetti, L1
Ballantyne, CM; Blazing, MA; Brady, WE; King, TR; Palmisano, J1
Desai, A; Gawde, A; Jain, MM; Jayaram, S; Naikawadi, AA1
Bocksch, W; Fateh-Moghadam, S; Schartl, M1
Guay, AT; Jacobson, J; Saltzman, EA1
Coates, K; DiMauro, S; Naini, A; Rundek, T; Sacco, R1
Bolognese, MA; Caplan, R; Cressman, M; Hutchinson, H; Raza, A; Schwartz, GG; Tremblay, BP1
Nissen, S1
Akin, M; Aliyev, E; Altuglu, I; Ercan, E; Ercan, HE; Sekuri, C; Tengiz, I1
Carlier, M; Claeys, MJ; Cools, F; Cosyns, B; De Meester, A; Dewit, B; Gobin, E; Hoffer, E; Missault, L; Vermeersch, P1
Ceyhan, C; Ercan, E; Onbasili, AO; Tekten, T; Turkoglu, C1
Chen, YF; Hwang, YS; Lin, CC; Lu, YH; Tsai, WC1
Alizadeh, J; Ballantyne, CM; Lipka, LJ; Sager, PT; Strony, J; Suresh, R; Veltri, EP1
Elly, I; Frieman, A; Gavish, D; Hazanov, N; Leibovitz, E1
Levy, Y1
Derosa, G; Fogari, E; Fogari, R; Lazzari, P; Mugellini, A; Rinaldi, A; Zoppi, A1
Lipka, L; Maccubbin, D; Mata, P; Melani, L; Ponsonnet, D; Sager, P; Stein, E; Stender, S; Suresh, R; Veltri, E1
Diz-Lois, F1
Egido, J; Tuñón, J1
Abdalla, DS; Aldrighi, JM; Bertolami, MC; Faludi, AA; Nakamura, Y; Pereira, IR; Ramires, JA; Saleh, MH; Silva, RA; Sousa, JE1
Ascer, E; Bertolami, MC; Buccheri, V; Nicolau, JC; Ramires, JA; Serrano, CV; Souza, J; Venturinelli, ML1
Billiouw, JM; Carpentier, YA; Dratwa, M; Ducobu, J; Dupont, P; Lameire, NH; Lins, RL; Maes, B; Matthys, KE; Peeters, PC; Stolear, JC; Tielemans, C; Verpooten, GA1
Deac, R; Dobreanu, M; Gălăţeanu, C; Simionescu, A1
März, W1
Klose, G1
Blasetto, JW; Caplan, RJ; Ferdinand, KC; Gold, A; Hunninghake, DB; Jones, PH; Stein, EA1
Angelico, F; Arca, M; Burattin, M; Ceci, F; Del Ben, M; Violi, F1
Jorba, O; Ordóñez-Llanos, J; Pérez, A; Wägner, AM1
Laskowitz, DT; Lynch, JR; McGirt, MJ; Woodworth, GF1
Couture, P; Lamarche, B; Mauger, JF; Paradis, ME1
Herman, ZS; Krysiak, R; Okopien, B1
Bäcklund, T; Kahri, J; Kivistö, KT; Valkonen, M; Vuoristo, M1
Hitsumoto, T; Iizuka, T; Nakamura, K; Noike, H; Ohsawa, H; Sakurai, T; Satoh, S; Shimizu, K; Shirai, K; Sugiyama, Y; Takahashi, M; Watanabe, H1
Auteri, A; Bruni, F; Pasqui, AL; Pastorelli, M; Puccetti, L; Sawamura, T1
Feely, J; Sigurdsson, EL; Strandberg, TE1
Endo, K; Ito, Y; Koide, N; Miyashita, Y; Otsuka, M; Oyama, T; Ozaki, H; Saiki, A; Shirai, K1
Aznar, J; Gabriel, F; Guiral, V; Labiós, M; Martínez, E; Martínez, M1
Sawicki, PT; Weizel, A1
Fitchett, DH; Goodman, S; Langer, A; Leiter, LA; Tardif, JC1
Bellia, A; Carnevale, R; Ferro, D; Lauro, R; Lenti, L; Pignatelli, P; Sanguigni, V; Sorge, R; Tesauro, M; Violi, F1
Ganda, OP1
Hirsch, M; Jones, P; O'Donnell, JC1
Chu, CS; Lai, WT; Lee, KT; Sheu, SH; Tsai, LY; Voon, WC; Yen, HW1
Bonow, RH; Bonow, RO; Caira, F; Makkena, B; Rajamannan, NM; Salti, H; Spelsberg, TC; Subramaniam, M; Thennapan, S1
Ahotupa, M; Nuotio, I; Strandberg, T; Tikkanen, MJ; Vanhanen, H; Vasankari, T; Viikari, J; Vuorenmaa, T1
Ayaori, M; Fayad, ZA; Higashi, K; Iwamoto, N; Kihara, T; Kusuhara, M; Momiyama, Y; Nagata, M; Nakamura, H; Ogura, M; Ohmori, R; Ohsuzu, F; Sawada, S; Tamai, S; Taniguchi, H; Yonemura, A1
Geiss, HC; Hund-Wissner, E; Otto, C; Parhofer, KG1
Cheung, RC; Kallend, D; Morrell, JM; Schuster, H; Watkins, C1
Chin, H; Denu-Ciocca, CJ; Dornbrook-Lavender, KA; Hogan, SL; Joy, MS; Pieper, JA1
Delles, C; Jacobi, J; John, S; Schmieder, RE; Schneider, MP1
Barut, A; Sarikaya, S; Tanriverdi, HA1
Almeida, EA; Carneiro, A; Jorge, M; Jorge, PA; Ozaki, MR1
Battisti, WP; Brady, WE; Denke, MA; McBride, PE; Palmisano, J; Pearson, TA1
Braunwald, E; Cannon, CP; Morrow, DA; Ridker, PM; Rifai, N; Rose, LM1
Bonow, RO; Ignatiev, KI; McConnell, JP; Rajamannan, NM; Singh, RJ; Spelsberg, TC; Springett, M; Stock, SR; Stone, NJ; Subramaniam, M1
Berna, C; Calmy, A; Junod, AF; Peytremann-Bridevaux, I1
Bigazzi, F; Bionda, A; Chella, E; Dal Pino, B; Puntoni, MR; Rossi, G; Sampietro, T; Sbrana, F1
Franken, AA; Vincent, HH; Wolffenbuttel, BH1
Adgey, J; Allen, C; Bedarida, GV; Cruz-Fernández, JM; Johnson-Levonas, AO; Massaad, R1
Rosenberg, R1
Higashikata, T; Inazu, A; Katsuda, S; Kawashiri, M; Kobayashi, J; Koizumi, J; Mabuchi, H; Mizuno, M; Nohara, A1
Cannon, CP; Ray, KK1
Barter, P; Kallend, D; Schuster, H; Stender, S; Watkins, C1
Kastelein, JJ; van Leuven, SI1
Jarernsiripornkul, N; Kiatchusakul, S; Ojongpian, S; Srinakarin, J; Tantikosoom, W; Thinkhamrop, B1
Bitto, A; Bonaiuto, A; Bonaiuto, M; Campo, S; Castaldo, M; Cinquegrani, M; Saitta, A; Saitta, C; Sardo, MA; Trimarchi, G1
Cho, KH; Jung, WS; Kang, HS; Moon, SK; Park, SU1
De Paepe, B; Laakso, J; Laaksonen, R; Lehtimäki, T; Lütjohann, D; Mattila, KM; Päivä, H; Smet, J; Thelen, KM; Van Coster, R; von Bergmann, K1
Hirose, T; Kawamori, R; Ohmura, C; Tanaka, Y; Watada, H1
Wu, ZH; Zhao, SP1
Deng, P; Hong, SC; Wu, J; Wu, ZH; Zhao, SP1
Climent, VE; de Teresa, L; García-Herola, A; Lorenzo, S; Marín, F; Roldán, V; Sogorb, F; Tello, A1
Cardona-Muñoz, EG; Fonseca, FA; Fuenmayor, N; Marotti, M; Ruiz, A; Silva, JM1
Courtney, BK; Fitzgerald, PJ; Koizumi, T; Komiyama, N; Komuro, I; Kuriyama, N; Nakayama, T; Nameki, M; Namikawa, S; Yokoyama, M1
Bertolami, MC; Faludi, AA; Hirata, MH; Hirata, RD; Rebecchi, IM; Rodrigues, AC1
Ceska, R; Malik, J; Stulc, T1
Caira, F; Rajamannan, NM; Spelsberg, TC; Stock, SR; Subramaniam, M1
Chiou, KR; Huang, WC; Lin, SL; Liu, CP; Shiang, JC; Wu, SC; Wu, TL1
van Heyningen, C1
Adinaro, J; Beck, R; Doeppenschmidt, D; Henry, JS; Krasuski, RA; Smith, PB; Thompson, CM1
Hirsch, M; O'donnell, J; Olsson, A1
Baldassarre, S; Carpentier, YA; Deckelbaum, RJ; Ducobu, J; Dupont, IE; Scruel, O1
Burnett, JR1
Bays, HE; Davidson, MH; McKenney, JM; Saponaro, J; Thompson, PD1
Juszczyk, MA; Seip, RL; Thompson, PD1
Pai, RG1
Phillips, PS1
Auteri, A; Bruni, F; Ciani, F; Gioffrè, W; Palazzuoli, A; Pasqui, AL; Pastorelli, M; Puccetti, L1
Buchetti, B; Lenti, L; Pignatelli, P; Sanguigni, V; Violi, F1
Bertolami, MC; Cavalli, SA; Forestiero, FJ; Guzmán, EC; Hirata, MH; Hirata, RD; Salazar, LA; Sorkin, SC1
Allen, C; Amabile, N; Barrios, V; Chen, JW; Johnson-Levonas, AO; Massaad, R; Paganelli, F; Vandormael, K1
Bots, AF; Kastelein, JJ1
Nosaka, S; Ueki, M; Ushiroyama, T1
Ahumada, M; Arcas, R; Arribas, JM; Gomez-Plana, J; Marín, F; Martínez, P; Oliver, C; Pascual, DA; Tornel, PL; Valdes, M1
Graselli, U; Joukhadar, C; Kostner, K; Lackner, E; Thallinger, C; Urbauer, E; Wolzt, M1
de Maat, M; Emeis, J; Havekes, L; Jukema, W; Maas, A; Offerman, E; Princen, H; Szalai, A; Trion, A; van der Laarse, A1
Błaszczyk, J; Cegliński, T; Grycewicz, J; Irzmański, R; Kowalczyk, E; Kowalski, J; Liban-Gałka, B; Pawlicki, L1
Broncel, M; Chojnowska-Jezierska, J; Franiak, I; Koter-Michalak, M1
Fukazawa, M; Ishikawa, M; Kubota, T; Moroi, M; Namiki, A; Sugi, K; Yajima, S1
Biggi, A; Chauvie, S; Feola, M; La Scala, E; Papaleo, A; Rolfo, F; Uslenghi, E1
Ebisuno, M; Endo, K; Koide, N; Miyashita, Y; Ohira, M; Oyama, T; Saiki, A; Sasaki, H; Shirai, K; Takeyoshi, M1
Haghfelt, TH1
Badziński, A; Dyrbuś, K; Mercik, G; Nowak, J; Nowalany-Kozielska, E; Poloński, L; Rozek, MM; Szyguła-Jurkiewicz, B; Wilczek, K; Wodniecki, J; Wojnicz, R; Zembala, M1
Balla, J; Dorosz, J; Dulak, J; Jazwa, A; Jozkowicz, A; Loboda, A; Molema, G1
Gregoor, PJ1
Busseuil, D; Collin, B; Cottin, Y; Duvillard, L; Korandji, C; Pitois-Merli, I; Rioufol, G; Rochette, L; Zeller, M1
de Teresa, E; Farsang, C; Gaw, A; Gensini, GF; Langer, A; Leiter, LA; Martineau, P1
Galin, ID; Smith, DA1
Bruckert, E; Carreau, V; Chauvenet, M; Faltaos, DW; Giral, P; Hulot, JS; Lechat, P; Urien, S1
Kimura, M; Okamura, A; Takahashi, M; Takano, T; Yamakawa, T1
Plans-Rubió, P1
Becx, MC; Kuypers, KC; Seldenrijk, CA; Stolk, MF1
Ritsch, A; Tancevski, I1
Allemann, C; Babiychuk, EB; Draeger, A; Hoppeler, H; Mohaupt, M; Monastyrskaya, K; Savolainen, H1
Asai, K; Ito, T; Kosaka, T; Kuhara, Y; Kuroda, Y; Ozaki, Y; Shinjo, H; Takashima, H; Wakita, Y; Waseda, K; Yasukawa, T1
Arteaga Ll, A; Maiz G, A; Rigotti R, A1
Laaksonen, R; Lehtimäki, T; Lütjohann, D; Päivä, H; Thelen, KM1
Bianchi, C; Boodhwani, M; Feng, J; Laham, R; Li, J; Mieno, S; Nakai, Y; Ramlawi, B; Sellke, FW; Voisine, P1
Ayaori, M; Kusuhara, M; Momiyama, Y; Nakamura, H; Ogura, M; Ohmori, R; Ohsuzu, F; Sawada, S; Tanaka, N; Yonemura, A1
Hey-Hadavi, JH; Kuntze, E; Lepetri, B; Luo, D; Pittman, D; Silverman, P1
Chu, CS; Lai, WT; Lee, KT; Lee, MY; Sheu, SH; Su, HM; Voon, WC1
Alemao, E; Attard, C; Bourgault, C; Cook, J; Huse, D; Kohli, M; Lam, A; Marentette, M; Yin, D1
Aizawa, Y; Fukaya, H; Imaki, R; Izumi, T; Kubo, T; Ohtaki, K; Ozaki, K; Ozaki, S; Shinagawa, H1
Bolaman, Z; Kadikoylu, G; Ozgel, N; Yenisey, C1
Davidson, MH; Robinson, JG1
Pogacnik, T; Pretnar-Oblak, J; Sabovic, M; Sebestjen, M; Zaletel, M1
Carod-Artal, FJ1
Knopp, RH; Paramsothy, P1
Abraham, J; Alla, V; Bonkovsky, HL; Chalasani, NP; Raina, D; Siddiqui, J; Wu, GY1
Deig, E; Guelar, A; Guil, J; Pedrol, E; Rodríguez-Martín, M; Soler, A1
Palacios Muñoz, R; Santos González, J1
Haffner, S; Lloret, R; Stein, M; Ycas, J1
Guthrie, RM1
Edwards, C; Gladding, PA; Kerr, A1
Lloyd, K1
Abramowicz, D; Berkenboom, G; Broeders, N; Carpentier, Y; Ghisdal, L; Unger, P; Wissing, KM1
Laaksonen, R; Lehtimäki, T; Luomala, M; Lütjohann, D; Päivä, H; Peltonen, N; Thelen, K1
Auteri, A; Bruni, F; Ciani, F; Ghezzi, A; Palazzuoli, A; Pasqui, AL; Pastorelli, M; Pontani, A; Puccetti, L1
Cubeddu, LX; Cubeddu, RJ; Heimowitz, T; Lamas, GA; Restrepo, B; Weinberg, GB1
Alemao, E; Jousilahti, P; Salomaa, V; Sintonen, H; Yin, D1
Boodhwani, M; Feng, J; Li, J; Mieno, S; Sellke, FW; Sodha, N; Voisine, P1
Agustín Herrero, J; Cámara Hijón, C; Costo Campoamor, A; Crespo Rincón, L; Fernández Pereira, L; Pereira Navarro, G; Sánchez Muñoz-Torrero, JF; Torres Pérez, F1
Checa, JC; Fernández de Bobadilla, J; Navarro Artieda, R; Sicras Mainar, A1
Moriguchi, H; Sato, C; Uemura, T1
Edwards, P; Goldberg, RB; Guyton, JR; Mazzone, T; Polis, A; Tershakovec, AM; Tomassini, JE; Weinstock, RS1
Fukunami, M; Kioka, H; Masuda, M; Mine, T; Morita, T; Node, K; Okuda, K; Tamaki, S; Tsukamoto, Y; Yamada, T1
Fukao, A; Komatsu, Y; Majima, T; Matsumura, T; Nakao, K; Ninomiya, K1
Imaizumi, T; Ishida, S; Jinnouchi, J; Jinnouchi, Y; Takeuchi, M; Yamagishi, S1
Andrys, C; Jamborova, G; Nachtigal, P; Pospechova, K; Pospisilova, N; Semecky, V; Solichova, D; Zdansky, P2
Benndorf, R; Böger, RH; Kom, GD; Maas, R; Schneider, L; Schwedhelm, E1
Kirby, M; Pearmain, H; Ramsbottom, T; Usher-Smith, JA1
Leiter, LA; Miller, P; Palmer, M; Reckless, JP; Rosenson, RS; Schleman, M; Schulte, KL; Sosef, F; Stein, E1
Asztalos, BF; Dallal, GE; Horvath, KV; Jones, PH; Le Maulf, F; McTaggart, F; Schaefer, EJ; Stein, E1
Côté, HC; Frohlich, JJ; Humphries, KH; Laaksonen, R; Lehtimäki, T; Päivä, H; Schick, BA1
Alber, HF; Dichtl, W; Dörler, J; Frick, M; Pachinger, O; Stocker, EM; Süssenbacher, A; Weidinger, F1
Fischer, S; Jaster, M; Martus, P; Morguet, AJ; Piorkowski, M; Rauch, U; Schultheiss, HP; Stellbaum, C1
Gomez, EV; Howey, DC; McErlean, E; Nicholls, SJ; Nissen, SE; Russo, JM; Wang, MD; Wolski, K1
Carnevale, R; Lenti, L; Loffredo, L; Pignatelli, P; Sanguigni, V; Sorge, R; Violi, F1
Couderc, R; Cynober, L; Martin, C; Moinard, C; Rasmusen, C; Tricottet, V1
Fukuda, N; Fukuda, Y; Morishita, S; Nada, T; Sakabe, K; Shinohara, H; Tamura, Y; Wakayama, K2
Blagden, MD; Chipperfield, R1
McMahon, DE1
Abe, M; Hirose, T; Kawamori, R; Mita, T; Nakayama, S; Ogihara, T; Shimizu, T; Uchino, H; Watada, H1
Ceska, R; Kasalová, Z; Marinov, I; Stulc, T; Svobodová, H; Vrablík, M1
Chen, SH; Chu, CS; Kou, HS; Lai, WT; Lee, CJ; Lee, KT; Sheu, SH; Voon, WC1
Vos, E1
von Eckardstein, A2
Chu, CS; Lai, WT; Lee, KT; Lee, ST; Lin, TH; Lu, YH; Sheu, SH; Voon, WC1
Deedwania, PC; Gold, A; Gupta, M; Stein, M; Ycas, J1
Altug, T; Aslan, M; Balci, H; Bolayirli, IM; Hacibekiroglu, M; Seven, A1
Czepluch, FS; Waltenberger, J1
Frial, T; Miller, PS; Tran, YB1
Ballantyne, C; Maccubbin, D; Pearson, T; Shah, A; Sisk, C; Veltri, E1
Gao, RL1
Aznaouridis, K; Dagre, A; Masoura, C; Pitsavos, C; Skoumas, J; Stefanadi, E; Stefanadis, C; Vasiliadou, C; Vlachopoulos, C1
Dande, A; Holford, TR; Kocherla, M; Ruaño, G; Seip, RL; Smith, A; Sorokin, A; Thompson, PD; Windemuth, A; Wu, AH1
Athyros, V; Farsang, C; Gaw, A1
Inazu, A; Katsuda, S; Kawashiri, MA; Kobayashi, J; Koizumi, J; Mabuchi, H; Nohara, A1
Andreasson, A; Andrén, L; Eggertsen, R1
Bolognese, MA; Bone, HG; Kiel, DP; Leary, ET; Lewiecki, EM; Lindsay, RS; Lowe, W; McClung, MR1
Jayaram, S; Langade, DG; Mane, PR; Prasad, HB; Sovani, VB1
George, J; Keren, G; Luboshits, G; Mausner-Fainberg, K; Maysel-Auslender, S; Mor, A; Rubinstein, A1
Cuccurullo, F; Di Febbo, C; Di Nisio, M; Guglielmi, MD; Moretta, V; Porreca, E; Stuppia, L1
Dallinga-Thie, GM; de Haan, W; Havekes, LM; Hoekstra, M; Jukema, JW; Princen, HM; Rensen, PC; Romijn, JA; van der Hoogt, CC; Westerterp, M1
Che, D; Sun, Y; Zhang, D; Zhao, S1
Emanuele, E; Geroldi, D1
Averna, MR; Bucciarelli, L; Cefalù, AB; Ciabattoni, G; Davì, G; Davì, V; Ferrante, E; Noto, D; Pettinella, C; Santilli, F1
Barter, P; Bittner, V; Fruchart, JC; Gotto, AM; Grundy, SM; Kastelein, JJ; LaRosa, JC; Maroni, J; Szarek, M1
Nisanci, Y; Oflaz, H; Pamukcu, B; Tirnaksiz, E1
Betteridge, DJ; Gibson, JM; Sager, PT1
Arnaboldi, L; Corsini, A; Guzzetta, M; Paoletti, R; Pazzucconi, F; Radaelli, G; Sirtori, CR1
Date, AA; Nagarsenker, MS1
Blasetto, J; Gandhi, S; Harley, CR; Heien, H; Nelson, SP; Sasane, R1
Chin, H; Denu-Ciocca, C; Dornbrook-Lavender, KA; Hogan, SL; Joy, MS1
Azuma, A; Matsubara, H; Sasaki, S; Sawada, T; Yamada, T1
Hirata, MH; Hirata, RD; Rodrigues, AC1
Cangemi, R; Carnevale, R; Loffredo, L; Patrizi, MP; Perri, L; Pignatelli, P; Sanguigni, V; Violi, F1
Ghattas, AE; Pimenta, J1
Davidson, MH; Fox, KM; Gandhi, SK; Ohsfeldt, RL1
Ahn, TH; Cha, KS; Choi, SW; Chung, N; Han, SW; Ho Yun, K; Hyon, MS; Kim, CJ; Kim, DI; Kim, HS; Kim, WH; Kwan, J; Lee, SH; Park, SH; Seo, HS; Shim, WJ; Shin, DG; Shin, YW; Yoon, MH1
Acampa, M; Auteri, A; Bruni, F; Ciani, F; Palazzuoli, A; Pasqui, AL; Pastorelli, M; Puccetti, L1
Bruschi, P; Ferdinand, KC; Flack, JM; Jamieson, MJ; Saunders, E; Shi, H; Tarasenko, L; Victor, R; Watson, K1
Beevers, G; Caulfield, M; Collins, R; Dahlof, B; Kjeldsen, SE; Kristinsson, A; McInnes, G; Mehlsen, J; Nieminen, MS; O'Brien, ET; Ostergren, J; Poulter, NR; Sever, PS; Wedel, H1
Lee, YT; Ro, YM; Sim, KH; Sriratanasathavorn, C; Tomlinson, B; Zhu, JR1
Shaley, FM1
Kirby, M; Pearmain, H; Ramsbottom, T; Usher-Smith, J1
Dupliakov, DV1
Athyros, VG; Kakafika, AI; Karagiannis, A; Koumaras, H; Mikhailidis, DP; Tziomalos, K1
Bacarea, A; Dobreanu, D; Dobreanu, M; Fodor, A1
Bolewski, A; Burchardt, P; Lipiecki, J; Plewa, R; Siminiak, T1
Abe, Y; Furukado, S; Hori, M; Hoshi, T; Hougaku, H; Kitagawa, K; Sakaguchi, M; Yamagami, H1
Brenner, H; Hahmann, H; Hoffmann, MM; Rothenbacher, D; Vossen, CY; Wüsten, B1
Chen, YD; Ge, CJ; Hu, SJ; Ji, Y; Lu, SZ; Wu, XF1
Allina, J; Bach, N; Bodenheimer, H; Bodian, C; Odin, JA; Stanca, CM1
Ando, H; Fujimura, A; Kaneko, S; Saito, T; Sugimoto, K; Takamura, T; Tsuruoka, S; Yanagihara, H1
Anagnostis, P; Athyros, VG; Kakafika, AI; Karagiannis, A; Koumaras, C; Mikhailidis, DP; Pagourelias, E; Papageorgiou, AA; Paraskevas, KI; Tziomalos, K1
Asmar, R; Duffield, E; Faergeman, O; Hill, L; Sosef, F; Wiklund, O; Windler, E1
Arazi, SS; Bernik, M; Dorea, EL; Genvigir, FD; Hirata, MH; Hirata, RD; Willrich, MA1
Breazna, A; Deedwania, PC; Kostis, JB; LaRosa, JC1
Gaughan, JP; Klibanov, OM; Tedaldi, EM; van den Berg-Wolf, M1
Bujo, H; Hanaoka, H; Kodama, T; Mikami, K; Miyashita, Y; Nishikawa, T; Saito, Y; Shinomiya, M; Tada, N; Yokote, K1
Fox, KM; Gandhi, SK; McKenney, JM; Ohsfeldt, RL1
Derdak, Z; Harangi, M; Mirdamadi, HZ; Paragh, G; Seres, I; Sztanek, F1
Auerbach, BJ; Bisgaier, CL; Krause, BR; Newton, RS1
Black, DM; Davidson, MH; Haber, HE; Jones, PH; Lupien, PJ; Nawrocki, JW; Schwartz, SL; Sprecher, DL; Weiss, SR1
Ciaravino, V; Hovey, CA; Kropko, ML; Rothwell, CE; Theiss, JC1
Abe, Y; Ballantyne, CM; Dunn, K; Gotto, AM; Hackman, A; Insull, W; Pownall, H; Smith, L1
Krause, BR; Newton, RS1
Bertolini, S; Bon, GB; Campbell, LM; Egros, F; Farnier, M; Fayyad, R; Langan, J; Mahla, G; Nawrocki, JW; Pauciullo, P; Sirtori, C1
Bakker-Arkema, R; Black, D; Davidson, M; Fayyad, R; McKenney, J; Schrott, H; Stein, E1
Best, J; Black, D; Bracs, P; d'Emden, M; Dart, A; Hamilton-Craig, I; Jerums, G; Nicholson, G; Sullivan, D; Tallis, G; West, M1
Alaupovic, P; Black, DM; Heinonen, T; Shurzinske, L1
Calder, RA1
Hunninghake, D; Jones, P; Kafonek, S; Laurora, I1
Celermajer, DS; Simons, J; Simons, LA; Sullivan, D1
Tucker, G1
Black, DM; Mahla, G; Muller, D; Pentrup, A; Wolffenbuttel, BH1
Simons, LA1
Pincus, J1
Ghali, JK1
Fong, NT; Yee, HS1
Malinowski, JM1
Liguori, E; Sarcinella, R1
Geiss, HC; Parhofer, KG; Schwandt, P1
Bakker-Arkema, RG; Black, DM; Davidson, MH; Henley, RW; Hunninghake, DB; Koren, MJ; McKenney, JM; McLain, RW; Schrott, HG; Smith, DG; Tresh, P; Weiss, SR1
Bataille, L; Hamoir, V; Horsmans, Y; Nakad, A; Sempoux, C1
Brown, WV; Eisenberg, D; McCormick, LS; Pitt, B; Schwartz, L; Shurzinske, L; Title, LM; van Boven, AJ; Waters, D1
Kostner, KM1
Alvarez, ML; Ballester, B; Errasti, P; García, I; García, N; Gómez, G; Lavilla, FJ; Purroy, A1
Branchi, A; Fiorenza, AM; Macor, S; Muzio, F; Rovellini, A; Sommariva, D; Torri, A1
Attanasio, E; Badia, X; Russo, P1
Bäumer, AT; Böhm, M; Jockenhövel, F; Kebben, D; Nickenig, G; Temur, Y1
Carpentier, Y; Ducobu, J; Sternon, J1
Cheung, R; Mutus, B; Tannous, M; Vignini, A1
Baim, DS; Carrozza, JP; Cohen, DJ1
Davidson, CJ; Ricciardi, MJ1
Bloom, JM1
Eminton, Z; Fowler, G; Maton, S; Neil, HA; Patel, H1
Furberg, CD; Rodrigues, M; Sinzinger, H1
Crook, MA; Mikhailidis, DP; Nair, DR; Wierzbicki, AS; Winder, AF1
Farnier, M; Maigret, P; Portal, JJ1
Jones, PH1
Bakker-Arkema, RG; Black, DM; Nawrocki, JW1
Barter, PJ; O'Brien, RC1
Kolsky, MP; Laureno, R; Negevesky, GJ; Yau, TH1
Cernigoi, AM; Merni, M; Tortul, C; Velussi, M1
Kastelein, JJ; Smilde, TJ; Stalenhoef, AF; van den Berkmortel, FW; van Langen, H; Wollersheim, H1
Blair, SN; Capuzzi, DM; Cater, NB; Gottlieb, SO; Morgan, JM; Nguyen, T1
Black, DM; Davidson, MH; Hunninghake, D; Isaacsohn, JL; McLain, R; Singer, R1
Calviño, J; Rodriguez, J; Romero, R; Sánchez-Guisande, D1
Candigliota, M; Ceravolo, R; Chello, M; Cloro, C; Maio, R; Mastroroberto, P; Mattioli, PL; Mongiardo, A; Perticone, F; Scozzafava, A1
Acosta, S; Dobs, A; Recto, CS1
Lupattelli, G; Mannarino, E; Marchesi, S; Roscini, AR; Schillaci, G; Siepi, D; Sinzinger, H; Vaudo, G1
Cromwell, WC; Ziajka, PE1
Dotani, MI; Elnicki, DM; Gibson, CM; Jain, AC1
Black, DM1
Strandberg, TE; Tikkanen, MJ; Vanhanen, H1
Dzurick, J; Hiller, D; Peralta, B; Rindone, JP1
Dorner, GT; Joukhadar, C; Klein, N; Prinz, M; Schmetterer, L; Schrolnberger, C; Vukovich, T; Wolzt, M1
Marschall, HU1
Celada Rodríguez, A; Cerdán Oliver, M; de Miguel Clavé, J; Ocaña López, JM; Solera Albero, J; Tárraga López, PJ1
Autin, JM; Bruniquel, F; Colpaert, FC; Degryse, AD; Delhon, A; Junquero, D; N'Guyen, X; Patoiseau, JF1
Agrusta, M; Amodio, M; Corigliano, G; De Simone, G; Gaeta, I; Gentile, S; Guarino, G; Magliano, P; Oliviero, B; Salvatore, T; Sasso, CF; Torella, R; Turco, S1
Arai, Y; Funatsu, T; Kakuta, H; Miyata, K; Suzuki, K; Tanaka, H1
Bairaktari, ET; Chatzidimou, KG; Elisaf, MS; Goudevenos, JA; Mikhailidis, DP; Milionis, HJ1
Allen, SE; Attanasio, E; Russo, P1
Bachmann, GA; Callister, TQ; Davidson, M; Kafonek, S; Laskey, R; Pittman, D; Raggi, P; Scott, R; Welty, FK1
Wierzbicki, AS1
Kajinami, K; Takekoshi, N1
Brohet, C; De Backer, G; Heller, F; Muls, E1
Aragoncillo, P; Cachofeiro, V; Cediel, E; de Las Heras, N; Díaz, C; Hernández, G; Lahera, V; Navarro-Cid, J; Ruilope, LM; Sanz-Rosa, D; Vázquez-Pérez, S1
Angus, C; Genest, J; McPherson, R; Murray, P1
Farnier, M; Mercuri, M; Stein, EA; Waldstreicher, J1
Ito, MK1
Crouse, JR; Davidson, MH; Escobar, ID; Hunninghake, DB; Illingworth, DR; Liu, M; Ma, PT; Melino, MR; Mercuri, M; Mitchel, YB; O'Grady, L; Paragh, G; Stalenhoef, AF1
Athyros, VG; Bouloukos, VJ; Demitriadis, DS; Kontopoulos, AG; Papageorgiou, AA; Pehlivanidis, AN1
Susekov, AV1
Bakker-Arkema, RG; Black, DM; Corella, D; Ordovas, JM; Pedro-Botet, J; Schaefer, EJ; Stein, EM1
McKellar, J; Mizan, J; Olsson, AG; Pears, J; Raza, A1
Davidson, M; Hunninghake, D; Insull, W; Jones, P; Kafonek, S; Knopp, R; Lohrbauer, L1
Akanuma, Y; Kawakami, M; Ohashi, Y; Saito, Y; Tanaka, A; Yamada, N1
Burke, SK; Davidson, D; Donovan, JM; Hunninghake, D; Insull, W; Toth, P1
Hsue, PY; Waters, DD1
Deedwania, P1
Grundy, SM1
Criqui, MH1
Erkelens, DW1
Igel, M; Sudhop, T; von Bergmann, K1
Alfón, J; Badimon, L; Berrozpe, M; Martínez-González, J1
Goa, KL; Malhotra, HS1
Bernini, F; Paoletti, R; Poli, A1
Gavish, D; Hazanov, N; Leibovitz, E; Shargorodsky, M; Zimlichman, R1
Chitra, R; Davidson, M; Gotto, AM; Hutchinson, H; Ma, P; Raza, A; Stein, EA1
Ting, CT; Wang, KY1
Hurt-Camejo, E; Mattsson-Hultén, L; Oscarsson, J; Wiklund, O1
Castro, JG; Gutierrez, L1
Almenar Bonet, L; Arnau Vives, MA; Dicenta Gisbert, F; Martínez-Dolz, L; Osa Sáez, A; Palencia Pérez, M; Rueda Soriano, J1
Caccese, D; Lauro, R; Lenti, L; Magnaterra, R; Martini, F; Pignatelli, P; Pulcinelli, FM; Sanguigni, V; Violi, F1
Bellosta, S; Corsini, A; Paoletti, R1
Bonow, RO; McConnell, JP; Niekrasz, M; Rajamannan, NM; Sebo, TC; Singh, RJ; Spelsberg, TC; Springett, M; Stone, NJ; Subramaniam, M1
Auteri, A; Bova, G; Bruni, F; Cercignani, M; Console, E; Palazzuoli, A; Pasqui, AL; Puccetti, L1
Hinman, J; Scanu, AM1
Gavish, D; Harats, D; Leibovitz, E1
Mikhailidis, DP; Wierzbicki, AS1

Reviews

74 review(s) available for atorvastatin and Elevated Cholesterol

ArticleYear
Therapeutic effects of statins on osteoarthritis: A review.
    Journal of cellular biochemistry, 2022, Volume: 123, Issue:8

    Topics: Atorvastatin; Cholesterol; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Osteoarthritis; Oxidoreductases; Simvastatin

2022
Optimising treatment of hyperlipidaemia: Quantitative evaluation of UK, USA and European guidelines taking account of both LDL cholesterol levels and cardiovascular disease risk.
    Atherosclerosis, 2018, Volume: 278

    Topics: Anticholesteremic Agents; Atorvastatin; Cardiology; Cardiovascular Diseases; Cholesterol, LDL; Europe; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemias; Oxazolidinones; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Risk Factors; United Kingdom; United States

2018
Comparing the combination therapy of ezetimibe and atorvastatin with atorvastatin monotherapy for regulating blood lipids: a systematic review and meta-analyse.
    Lipids in health and disease, 2018, Oct-17, Volume: 17, Issue:1

    Topics: Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hypercholesterolemia; Male; Triglycerides

2018
An evaluation of pitavastatin for the treatment of hypercholesterolemia.
    Expert opinion on pharmacotherapy, 2019, Volume: 20, Issue:1

    Topics: Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Quinolines; Treatment Outcome

2019
Efficacy and safety of rosuvastatin vs. atorvastatin in lowering LDL cholesterol : A meta-analysis of trials with East Asian populations.
    Herz, 2020, Volume: 45, Issue:6

    Topics: Atorvastatin; Cholesterol, LDL; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Rosuvastatin Calcium; Treatment Outcome

2020
Evaluating the efficacy and safety of atorvastatin + ezetimibe in a fixed-dose combination for the treatment of hypercholesterolemia.
    Expert opinion on pharmacotherapy, 2019, Volume: 20, Issue:8

    Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Drug Combinations; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Risk Factors; Simvastatin

2019
Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases.
    BMJ (Clinical research ed.), 2013, Mar-18, Volume: 346

    Topics: Acute Kidney Injury; Adult; Aged; Atorvastatin; British Columbia; Cohort Studies; Confidence Intervals; Databases, Factual; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorobenzenes; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Incidence; Logistic Models; Male; Middle Aged; Odds Ratio; Patient Safety; Pyrimidines; Pyrroles; Retrospective Studies; Risk Assessment; Rosuvastatin Calcium; Simvastatin; Sulfonamides; United Kingdom; United States

2013
Liptruzet: a combination of ezetimibe and atorvastatin.
    The Medical letter on drugs and therapeutics, 2013, Jun-24, Volume: 55, Issue:1419

    Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Drug Combinations; Ezetimibe; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipidemias; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome

2013
The SLCO1B1 c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam Study.
    Pharmacogenetics and genomics, 2014, Volume: 24, Issue:1

    Topics: Aged; Aging; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cytosine; Databases, Factual; Dose-Response Relationship, Drug; Female; Genetic Association Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Organic Anion Transporters; Polymorphism, Single Nucleotide; Prospective Studies; Pyrroles; Risk Factors; Sex Characteristics; Simvastatin; Thymine

2014
[Statins after intracerebral haemorrhage: is this safe?].
    Nederlands tijdschrift voor geneeskunde, 2015, Volume: 159

    Topics: Atorvastatin; Cerebral Hemorrhage; Cholesterol; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Stroke

2015
Variability of low-density lipoprotein cholesterol response with different doses of atorvastatin, rosuvastatin, and simvastatin: results from VOYAGER.
    European heart journal. Cardiovascular pharmacotherapy, 2016, Volume: 2, Issue:4

    Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Dose-Response Relationship, Drug; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins, LDL; Male; Middle Aged; Rosuvastatin Calcium; Simvastatin; Treatment Outcome

2016
[A new approach to the treatment of dyslipidemia].
    Medicina (Kaunas, Lithuania), 2008, Volume: 44, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Diabetes Complications; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Middle Aged; Practice Guidelines as Topic; Prognosis; Pyrroles; Risk Factors

2008
[Pleiotropic effects of statins].
    Revista medica de Chile, 2008, Volume: 136, Issue:6

    Topics: Anticholesteremic Agents; Antioxidants; Atherosclerosis; Atorvastatin; Endothelium, Vascular; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Oxidative Stress; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides

2008
Comparison of benefits and risks of rosuvastatin versus atorvastatin from a meta-analysis of head-to-head randomized controlled trials.
    The American journal of cardiology, 2008, Dec-15, Volume: 102, Issue:12

    Topics: Atorvastatin; Cholesterol, LDL; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Muscular Diseases; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides

2008
The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy.
    The pharmacogenomics journal, 2010, Volume: 10, Issue:1

    Topics: Anticholesteremic Agents; Asian People; Atorvastatin; Fluorobenzenes; Gene Frequency; Haplotypes; HeLa Cells; Hepatocytes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Liver; Liver-Specific Organic Anion Transporter 1; Organic Anion Transporters; Pharmacogenetics; Polymorphism, Single Nucleotide; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides

2010
New evidence on pitavastatin: efficacy and safety in clinical studies.
    Expert opinion on pharmacotherapy, 2010, Volume: 11, Issue:5

    Topics: Animals; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Practice Guidelines as Topic; Pyrroles; Quinolines

2010
Aggressive statin treatment, very low serum cholesterol levels and haemorrhagic stroke: is there an association?
    Current opinion in cardiology, 2010, Volume: 25, Issue:4

    Topics: Anticholesteremic Agents; Atorvastatin; Brain Ischemia; Cholesterol, LDL; Coronary Artery Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Intracranial Hemorrhages; Primary Prevention; Pyrroles; Risk Factors; Secondary Prevention; Stroke

2010
Effects of amlodipine plus atorvastatin association in hypertensive hypercholesterolemic patients.
    Expert review of cardiovascular therapy, 2010, Volume: 8, Issue:6

    Topics: Amlodipine; Antihypertensive Agents; Atorvastatin; Biomarkers; Blood Pressure; Cardiovascular Diseases; Drug Combinations; Drug Therapy, Combination; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Hypolipidemic Agents; Pyrroles

2010
Atorvastatin: safety and tolerability.
    Expert opinion on drug safety, 2010, Volume: 9, Issue:4

    Topics: Atorvastatin; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Meta-Analysis as Topic; Product Surveillance, Postmarketing; Pyrroles; Randomized Controlled Trials as Topic

2010
Office-based global cardiometabolic risk assessment: a simple tool incorporating nontraditional markers.
    Critical pathways in cardiology, 2010, Volume: 9, Issue:3

    Topics: Atorvastatin; Biomarkers; Cardiovascular Diseases; Clinical Trials as Topic; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Male; Obesity; Office Visits; Practice Patterns, Physicians'; Pravastatin; Pyrroles; Risk Assessment; Smoking; United States

2010
Attainment of Canadian and European guidelines' lipid targets with atorvastatin plus ezetimibe vs. doubling the dose of atorvastatin.
    International journal of clinical practice, 2010, Volume: 64, Issue:13

    Topics: Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Azetidines; C-Reactive Protein; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Multicenter Studies as Topic; Practice Guidelines as Topic; Pyrroles; Randomized Controlled Trials as Topic; Triglycerides

2010
Pitavastatin approved for treatment of primary hypercholesterolemia and combined dyslipidemia.
    Vascular health and risk management, 2010, Nov-02, Volume: 6

    Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials, Phase III as Topic; Dyslipidemias; Heptanoic Acids; Humans; Hypercholesterolemia; Pyrroles; Quinolines; Randomized Controlled Trials as Topic; Treatment Outcome

2010
Pitavastatin - results from phase III & IV.
    Atherosclerosis. Supplements, 2010, Volume: 11, Issue:3

    Topics: Atorvastatin; Clinical Trials, Phase III as Topic; Clinical Trials, Phase IV as Topic; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Pyrroles; Quinolines; Simvastatin

2010
[Indications for statin therapy in patients with acute coronary syndrome of ischemic origin].
    Giornale italiano di cardiologia (2006), 2010, Volume: 11, Issue:10 Suppl 1

    Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atorvastatin; Cholesterol; Electrocardiography; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Myocardial Infarction; Practice Guidelines as Topic; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Secondary Prevention

2010
Pitavastatin: an overview.
    Atherosclerosis. Supplements, 2011, Volume: 12, Issue:3

    Topics: Antioxidants; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials, Phase IV as Topic; Endothelium, Vascular; Hepatocytes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Inflammation; Japan; Metabolic Syndrome; Molecular Structure; Multicenter Studies as Topic; Plaque, Atherosclerotic; Pyrroles; Quinolines; Receptors, LDL

2011
Targeting HDL-cholesterol to reduce residual cardiovascular risk.
    Current opinion in lipidology, 2012, Volume: 23, Issue:2

    Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Sulfonamides

2012
The role of endoglin in atherosclerosis.
    Atherosclerosis, 2012, Volume: 224, Issue:1

    Topics: Animals; Antigens, CD; Atherosclerosis; Atorvastatin; Endoglin; Endothelium, Vascular; Heptanoic Acids; Humans; Hypercholesterolemia; Mice; Nitric Oxide Synthase Type III; Plaque, Atherosclerotic; Proteoglycans; Pyrroles; Receptors, Cell Surface; Receptors, Transforming Growth Factor beta; Swine

2012
Generic atorvastatin, the Belgian statin market and the cost-effectiveness of statin therapy.
    Cardiovascular drugs and therapy, 2013, Volume: 27, Issue:1

    Topics: Anticholesteremic Agents; Atorvastatin; Belgium; Cost-Benefit Analysis; Drug Costs; Drugs, Generic; Heptanoic Acids; Humans; Hypercholesterolemia; Marketing of Health Services; Pyrroles

2013
Statins and omega-3 fatty acids in the treatment of dyslipidemia and coronary heart disease.
    Minerva medica, 2002, Volume: 93, Issue:5

    Topics: Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Diet; Docosahexaenoic Acids; Drug Combinations; Eicosapentaenoic Acid; Exercise; Fatty Acids, Omega-3; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipidemias; Hypertriglyceridemia; Hypolipidemic Agents; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin

2002
Benefits and menaces related to the use of statins in patients after renal transplantation.
    Annals of transplantation, 2002, Volume: 7, Issue:2

    Topics: Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Kidney Transplantation; Lovastatin; Postoperative Complications; Pravastatin; Pyrroles; Simvastatin

2002
Non-high-density lipoprotein cholesterol: a target of lipid-lowering in dialysis patients.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2003, Volume: 41, Issue:3 Suppl 1

    Topics: Animals; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Pyrroles; Renal Dialysis; Simvastatin

2003
Differential effects of lipid-lowering therapies on stroke prevention: a meta-analysis of randomized trials.
    Archives of internal medicine, 2003, Mar-24, Volume: 163, Issue:6

    Topics: Anticholesteremic Agents; Atorvastatin; Cholestyramine Resin; Clofibrate; Colestipol; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Myocardial Infarction; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Regression Analysis; Risk Assessment; Risk Factors; Simvastatin; Stroke; Treatment Failure; Treatment Outcome

2003
Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups.
    The American journal of cardiology, 2003, Mar-06, Volume: 91, Issue:5A

    Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Administration Schedule; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Least-Squares Analysis; Male; Middle Aged; Multicenter Studies as Topic; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome

2003
Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals.
    The American journal of cardiology, 2003, Mar-06, Volume: 91, Issue:5A

    Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Administration Schedule; Europe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Multicenter Studies as Topic; Practice Guidelines as Topic; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome

2003
Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin.
    The American journal of cardiology, 2003, Mar-06, Volume: 91, Issue:5A

    Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Europe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Least-Squares Analysis; Lipids; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome

2003
Comparison of the dose-response relationships of 2 lipid-lowering agents: a Bayesian meta-analysis.
    American heart journal, 2003, Volume: 145, Issue:6

    Topics: Anticholesteremic Agents; Atorvastatin; Bayes Theorem; Cholesterol, LDL; Dose-Response Relationship, Drug; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides

2003
Differential effects of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I are consistent across hypercholesterolemic patient subgroups.
    Clinical cardiology, 2003, Volume: 26, Issue:11

    Topics: Apolipoprotein A-I; Atorvastatin; Cholesterol, HDL; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles; Simvastatin

2003
More Western hypercholesterolemic patients achieve Japan Atherosclerosis Society LDL-C goals with rosuvastatin therapy than with atorvastatin, pravastatin, or simvastatin therapy.
    Circulation journal : official journal of the Japanese Circulation Society, 2004, Volume: 68, Issue:2

    Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Drug Evaluation; Europe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Japan; Male; Middle Aged; Multicenter Studies as Topic; Pravastatin; Pyrimidines; Pyrroles; Racial Groups; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; United States

2004
[Role of lipid lowering therapy in patients with peripheral arterial occlusive disease].
    Herz, 2004, Volume: 29, Issue:1

    Topics: Anticholesteremic Agents; Arterial Occlusive Diseases; Atorvastatin; Disease Progression; Exercise Test; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Jejunoileal Bypass; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome

2004
Statins in hypercholesterolaemia: a dose-specific meta-analysis of lipid changes in randomised, double blind trials.
    BMC family practice, 2003, Dec-01, Volume: 4

    Topics: Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Female; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Male; Pravastatin; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Triglycerides

2003
[Ezetimibe: from pharmacology to clinical trials].
    Annales d'endocrinologie, 2003, Volume: 64, Issue:6

    Topics: Animals; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Depression, Chemical; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Hypercholesterolemia; Intestinal Absorption; Liver; Lovastatin; Pravastatin; Pyrroles; Safety; Simvastatin; Treatment Outcome

2003
[The role of intestinal absorption blockade in hypercholesterolemia treatment].
    Revista clinica espanola, 2004, Volume: 204, Issue:10

    Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol; Ezetimibe; Heptanoic Acids; Humans; Hypercholesterolemia; Intestinal Obstruction; Pyrroles

2004
Are Canadian guidelines for cholesterol lowering in high-risk patients optimal?
    The Canadian journal of cardiology, 2005, Volume: 21, Issue:1

    Topics: Atorvastatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hypolipidemic Agents; Male; Maximum Tolerated Dose; Practice Guidelines as Topic; Pravastatin; Prognosis; Pyrroles; Quebec; Randomized Controlled Trials as Topic; Risk Assessment; Sensitivity and Specificity; Severity of Illness Index; Treatment Outcome

2005
The role of lipid management in diabetes.
    Cardiology clinics, 2005, Volume: 23, Issue:2

    Topics: Anticholesteremic Agents; Atorvastatin; Diabetes Mellitus; Diabetic Angiopathies; Gemfibrozil; Heptanoic Acids; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lipoproteins, HDL; Pyrroles; Simvastatin; Triglycerides

2005
["Treating to New Targets": plea for a LDL cholesterol target of or below 75 mg/dl in any patient with coronary heart disease].
    Revue medicale de Liege, 2005, Volume: 60, Issue:4

    Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Heptanoic Acids; Humans; Hypercholesterolemia; Middle Aged; Pyrroles; Randomized Controlled Trials as Topic

2005
Atorvastatin and cardiovascular protection: a review and comparison of recent clinical trials.
    Expert opinion on pharmacotherapy, 2005, Volume: 6, Issue:6

    Topics: Atorvastatin; Cardiovascular Diseases; Clinical Trials as Topic; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Pyrroles

2005
Atorvastatin.
    Expert opinion on pharmacotherapy, 2005, Volume: 6, Issue:7

    Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Carotid Arteries; Cholesterol, LDL; Coronary Artery Disease; Drug Interactions; Endothelium, Vascular; Forecasting; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Leukocytes; Pravastatin; Proportional Hazards Models; Pyrroles; Randomized Controlled Trials as Topic

2005
Statins and aortic stenosis progression: are biologic targets still an option?
    Current cardiology reports, 2005, Volume: 7, Issue:6

    Topics: Aortic Valve Stenosis; Atorvastatin; Disease Progression; Echocardiography, Doppler; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles

2005
[Intensive cholesterol lowering therapy to reduce cardiovascular risk].
    Revista medica de Chile, 2006, Volume: 134, Issue:5

    Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Clofibric Acid; Coronary Artery Disease; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles

2006
Tolerability of atorvastatin in a population aged > or =65 years: a retrospective pooled analysis of results from fifty randomized clinical trials.
    The American journal of geriatric pharmacotherapy, 2006, Volume: 4, Issue:2

    Topics: Aged; Anticholesteremic Agents; Atorvastatin; Chemical and Drug Induced Liver Injury; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Kidney Diseases; Male; Musculoskeletal Diseases; Pyrroles; Randomized Controlled Trials as Topic; Retrospective Studies

2006
Combination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction.
    Expert review of cardiovascular therapy, 2006, Volume: 4, Issue:4

    Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; C-Reactive Protein; Cardiovascular Diseases; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Intestinal Absorption; Lipoproteins, LDL; Phytosterols; Pravastatin; Pyrroles; Simvastatin

2006
How safe is aggressive statin therapy?
    Progress in cardiovascular nursing, 2006,Summer, Volume: 21, Issue:3

    Topics: Atorvastatin; Chemical and Drug Induced Liver Injury; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Muscular Diseases; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides

2006
Comparison of effects of ezetimibe/simvastatin versus simvastatin versus atorvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levels.
    The American journal of cardiology, 2007, Jun-15, Volume: 99, Issue:12

    Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; C-Reactive Protein; Cholesterol, LDL; Double-Blind Method; Drug Combinations; Ezetimibe, Simvastatin Drug Combination; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin

2007
The genetic determinants of atorvastatin response.
    Current opinion in molecular therapeutics, 2007, Volume: 9, Issue:6

    Topics: Animals; Atorvastatin; Cardiovascular Diseases; Cholesterol; Genetic Variation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins, LDL; Muscular Diseases; Pyrroles; Risk Factors

2007
Comparison of low-density lipoprotein cholesterol reduction after switching patients on other statins to rosuvastatin or simvastatin in a real-world clinical practice setting.
    The American journal of managed care, 2007, Volume: 13 Suppl 10

    Topics: Atorvastatin; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Medical Records Systems, Computerized; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome

2007
[Clopidogrel and statins or once more on the danger of direct transfer of results of experimental studies in clinical practice].
    Kardiologiia, 2008, Volume: 48, Issue:2

    Topics: Atorvastatin; Clopidogrel; Coronary Thrombosis; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hypercholesterolemia; Platelet Aggregation Inhibitors; Pyrroles; Ticlopidine

2008
Statins revisited.
    Harvard heart letter : from Harvard Medical School, 1998, Volume: 8, Issue:9

    Topics: Anticholesteremic Agents; Atorvastatin; Coronary Disease; Heptanoic Acids; Humans; Hypercholesterolemia; Myocardial Infarction; Naphthalenes; Pyrroles

1998
Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias.
    The Annals of pharmacotherapy, 1998, Volume: 32, Issue:10

    Topics: Animals; Anticholesteremic Agents; Atorvastatin; Clinical Trials as Topic; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipidemias; Pyrroles; Treatment Outcome

1998
Atorvastatin: a hydroxymethylglutaryl-coenzyme A reductase inhibitor.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 1998, Nov-01, Volume: 55, Issue:21

    Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Drug Interactions; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertriglyceridemia; Pyrroles

1998
[Aggressive therapy and combination therapy in severe hyperlipidemia].
    Wiener medizinische Wochenschrift (1946), 1999, Volume: 149, Issue:5-6

    Topics: Anticholesteremic Agents; Atorvastatin; Blood Component Removal; Cholesterol, LDL; Combined Modality Therapy; Coronary Artery Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles; Simvastatin

1999
[Atorvastatin (Lipitor)].
    Revue medicale de Bruxelles, 1999, Volume: 20, Issue:5

    Topics: Anticholesteremic Agents; Atorvastatin; Belgium; Drug Costs; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Primary Prevention; Pyrroles

1999
Safety profile of atorvastatin-treated patients with low LDL-cholesterol levels.
    Atherosclerosis, 2000, Volume: 149, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipoproteins, LDL; Lovastatin; Male; Middle Aged; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Severity of Illness Index; Simvastatin; Treatment Outcome

2000
Statins in children: what do we know and what do we need to do?
    Current atherosclerosis reports, 2001, Volume: 3, Issue:1

    Topics: Atorvastatin; Bezafibrate; Child; Child Welfare; Cost-Benefit Analysis; Drug Approval; Gemfibrozil; Heptanoic Acids; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lovastatin; Pyridines; Pyrroles; Simvastatin

2001
[Atorvastatin (Lipitor): a review of its pharmacological and clinical profile].
    Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2001, Volume: 117, Issue:1

    Topics: Animals; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemias; Lipoproteins, VLDL; Liver; Pyrroles; Receptors, LDL; Triglycerides

2001
Atorvastatin.
    Expert opinion on pharmacotherapy, 2001, Volume: 2, Issue:5

    Topics: Animals; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Cost-Benefit Analysis; Drug Interactions; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles

2001
[Atorvastatin].
    Nihon rinsho. Japanese journal of clinical medicine, 2001, Volume: 59 Suppl 3

    Topics: Animals; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Cholesterol, LDL; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles; Randomized Controlled Trials as Topic

2001
[Substantiation of increasing doses of statins in clinical practice].
    Terapevticheskii arkhiv, 2001, Volume: 73, Issue:4

    Topics: Adult; Aged; Angiography; Animals; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Clinical Trials as Topic; Colestipol; Coronary Disease; Dogs; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Lipids; Lovastatin; Male; Meta-Analysis as Topic; Middle Aged; Primates; Prospective Studies; Pyrroles; Retrospective Studies; Risk Factors; Simvastatin; Time Factors

2001
What is the role of intensive cholesterol lowering in the treatment of acute coronary syndromes?
    The American journal of cardiology, 2001, Oct-11, Volume: 88, Issue:7B

    Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cholesterol; Clinical Trials as Topic; Coronary Artery Disease; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Myocardial Infarction; Pyrroles; Treatment Outcome

2001
United States Cholesterol Guidelines 2001: expanded scope of intensive low-density lipoprotein-lowering therapy.
    The American journal of cardiology, 2001, Oct-11, Volume: 88, Issue:7B

    Topics: Adult; Anticholesteremic Agents; Atorvastatin; Cholesterol, Dietary; Cholesterol, LDL; Clinical Trials as Topic; Coronary Artery Disease; Heptanoic Acids; Humans; Hypercholesterolemia; Practice Guidelines as Topic; Pyrroles

2001
Systemic atherosclerosis risk and the mandate for intervention in atherosclerotic peripheral arterial disease.
    The American journal of cardiology, 2001, Oct-11, Volume: 88, Issue:7B

    Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Arterial Occlusive Diseases; Arteriosclerosis; Atorvastatin; Cholesterol; Clinical Trials as Topic; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Risk Factors; Survival Rate

2001
Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins).
    European journal of clinical pharmacology, 2001, Volume: 57, Issue:5

    Topics: Atorvastatin; Drug Interactions; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Pravastatin; Pyridines; Pyrroles; Simvastatin

2001
Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia.
    Drugs, 2001, Volume: 61, Issue:12

    Topics: Animals; Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemias; Pyrroles

2001
Safety of HMG-CoA reductase inhibitors: focus on atorvastatin.
    Cardiovascular drugs and therapy, 2001, Volume: 15, Issue:3

    Topics: Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles

2001
Pharmacological interactions of statins.
    Atherosclerosis. Supplements, 2002, Volume: 3, Issue:1

    Topics: Atorvastatin; Cytochrome P-450 Enzyme System; Drug Interactions; Drug Tolerance; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Muscular Diseases; Pyrroles; Rhabdomyolysis

2002

Trials

353 trial(s) available for atorvastatin and Elevated Cholesterol

ArticleYear
High cholesterol absorption is associated with increased cardiovascular risk in haemodialysis patients: insights from the AURORA study.
    European journal of preventive cardiology, 2022, 10-18, Volume: 29, Issue:13

    Topics: Atorvastatin; Cardiovascular Diseases; Cholestanol; Heart Disease Risk Factors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemias; Renal Dialysis; Risk Factors; Rosuvastatin Calcium; Sterols

2022
Efficacy and Tolerability of Ezetimibe/Atorvastatin Fixed-dose Combination Versus Atorvastatin Monotherapy in Hypercholesterolemia: A Phase III, Randomized, Active-controlled Study in Chinese Patients.
    Clinical therapeutics, 2022, Volume: 44, Issue:10

    Topics: Anticholesteremic Agents; Atorvastatin; China; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Treatment Outcome

2022
[Efficacy and safety of various doses of hybutimibe monotherapy or in combination with atorvastatin for primary hypercholesterolemia: a multicenter, randomized, double-blind, double-dummy, parallel-controlled phase Ⅲ clinical trial].
    Zhonghua xin xue guan bing za zhi, 2023, Feb-24, Volume: 51, Issue:2

    Topics: Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Cholesterol, LDL; Double-Blind Method; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Treatment Outcome; Triglycerides

2023
Comparison of efficiency between Rosuvastatin and Atorvastatin in reducing low-density lipoprotein (LDL-C) in patients with diabetes mellitus.
    JPMA. The Journal of the Pakistan Medical Association, 2022, Volume: 72, Issue:11

    Topics: Atorvastatin; Cholesterol, LDL; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome

2022
Effectiveness of low-intensity atorvastatin 5 mg and ezetimibe 10 mg combination therapy compared with moderate-intensity atorvastatin 10 mg monotherapy: A randomized, double-blinded, multi-center, phase III study.
    Medicine, 2023, Nov-24, Volume: 102, Issue:47

    Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles; Treatment Outcome

2023
Polypill for Cardiovascular Disease Prevention in an Underserved Population.
    The New England journal of medicine, 2019, 09-19, Volume: 381, Issue:12

    Topics: Adult; Alabama; Amlodipine; Antihypertensive Agents; Atorvastatin; Cholesterol, LDL; Community Health Centers; Drug Combinations; Female; Humans; Hydrochlorothiazide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Losartan; Male; Medically Underserved Area; Medication Adherence; Middle Aged

2019
Pharmacokinetics and exploratory efficacy biomarkers of bococizumab, an anti-PCSK9 monoclonal antibody, in hypercholesterolemic Japanese subjects
.
    International journal of clinical pharmacology and therapeutics, 2019, Volume: 57, Issue:12

    Topics: Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atorvastatin; Biomarkers; Double-Blind Method; Humans; Hypercholesterolemia; Japan; PCSK9 Inhibitors; Treatment Outcome

2019
Outcome of pitavastatin versus atorvastatin therapy in patients with hypercholesterolemia at high risk for atherosclerotic cardiovascular disease.
    International journal of cardiology, 2020, 04-15, Volume: 305

    Topics: Aged; Atorvastatin; Cardiovascular Diseases; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Pyrroles; Quinolines; Treatment Outcome

2020
Comparing the Effect of Combining Exercise with Rosuvastatin versus Atorvastatin on Lipid Profile and Functional Capacity: A Retrospective Cohort Study.
    BioMed research international, 2020, Volume: 2020

    Topics: Aged; Atorvastatin; Exercise Therapy; Female; Humans; Hypercholesterolemia; Lipids; Male; Middle Aged; Retrospective Studies; Rosuvastatin Calcium

2020
Statin-induced microRNAome alterations modulating inflammation pathways of peripheral blood mononuclear cells in patients with hypercholesterolemia.
    Bioscience reports, 2020, 09-30, Volume: 40, Issue:9

    Topics: Aged; Atorvastatin; Cholesterol, LDL; Female; Gene Expression Profiling; Gene Expression Regulation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Leukocytes, Mononuclear; Male; MicroRNAs; Middle Aged; Plaque, Atherosclerotic; Quinolines; Taiwan

2020
A randomized, open-label, parallel, multi-center Phase IV study to compare the efficacy and safety of atorvastatin 10 and 20 mg in high-risk Asian patients with hypercholesterolemia.
    PloS one, 2021, Volume: 16, Issue:1

    Topics: Anticholesteremic Agents; Asian People; Atorvastatin; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Prognosis; Republic of Korea

2021
Combination of bempedoic acid, ezetimibe, and atorvastatin in patients with hypercholesterolemia: A randomized clinical trial.
    Atherosclerosis, 2021, Volume: 320

    Topics: Anticholesteremic Agents; Atorvastatin; Dicarboxylic Acids; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Fatty Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Middle Aged; Treatment Outcome

2021
Supplementation with Octacosanol Affects the Level of PCSK9 and Restore Its Physiologic Relation with LDL-C in Patients on Chronic Statin Therapy.
    Nutrients, 2021, Mar-10, Volume: 13, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Dietary Supplements; Double-Blind Method; Dyslipidemias; Fatty Alcohols; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Proprotein Convertase 9; Vitamin K 2; Vitamins

2021
A phase 1 study to evaluate the safety and LDL cholesterol-lowering effects of RG7652, a fully human monoclonal antibody against proprotein convertase subtilisin/kexin type 9.
    Clinical cardiology, 2017, Volume: 40, Issue:7

    Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atorvastatin; Biomarkers; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Injections, Subcutaneous; Male; Middle Aged; PCSK9 Inhibitors; Proprotein Convertase 9; Treatment Outcome; Young Adult

2017
Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension p
    Lancet (London, England), 2017, Jun-24, Volume: 389, Issue:10088

    Topics: Adult; Aged; Atorvastatin; Double-Blind Method; Early Termination of Clinical Trials; Female; Hematologic Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Hypolipidemic Agents; Lymphatic Diseases; Male; Middle Aged; Muscular Diseases; Nocebo Effect; Risk Factors; Sleep Wake Disorders; Treatment Outcome

2017
Efficacy and Safety of Bococizumab (RN316/PF-04950615), a Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, in Hypercholesterolemic Japanese Subjects Receiving a Stable Dose of Atorvastatin or Treatment-Naive - Results From a Rand
    Circulation journal : official journal of the Japanese Circulation Society, 2017, Sep-25, Volume: 81, Issue:10

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Asian People; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Proprotein Convertase 9; Treatment Outcome

2017
Efficacy and safety of alirocumab in patients with hypercholesterolemia not adequately controlled with non-statin lipid-lowering therapy or the lowest strength of statin: ODYSSEY NIPPON study design and rationale.
    Lipids in health and disease, 2017, Jun-17, Volume: 16, Issue:1

    Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Atorvastatin; Cholesterol, LDL; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; PCSK9 Inhibitors; Young Adult

2017
Efficacy and safety of rosuvastatin versus atorvastatin in high-risk Chinese patients with hypercholesterolemia: a randomized, double-blind, active-controlled study.
    Current medical research and opinion, 2018, Volume: 34, Issue:2

    Topics: Aged; Asian People; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Drug Monitoring; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Rosuvastatin Calcium; Treatment Outcome

2018
The effects of single- and multiple-dose administration of bococizumab (RN316/PF-04950615), a humanized IgG2Δa monoclonal antibody binding proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects treated with and without atorvastati
    Cardiovascular therapeutics, 2018, Volume: 36, Issue:1

    Topics: Administration, Intravenous; Adult; Aged; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atorvastatin; Biomarkers; Cholesterol, LDL; Down-Regulation; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; PCSK9 Inhibitors; Proprotein Convertase 9; Serine Proteinase Inhibitors; Time Factors; Treatment Outcome

2018
Do Statins Affect Thyroid Volume and Nodule Size in Patients with Hyperlipidemia in a Region with Mild-to-Moderate Iodine Deficiency? A Prospective Study.
    Medical principles and practice : international journal of the Kuwait University, Health Science Centre, 2018, Volume: 27, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Coronary Disease; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Life Style; Lipids; Male; Middle Aged; Prospective Studies; Rosuvastatin Calcium; Thyroid Function Tests; Thyroid Gland; Thyroid Nodule

2018
The effect of high-dose atorvastatin on neural activity and cognitive function.
    American heart journal, 2018, Volume: 197

    Topics: Adult; Atorvastatin; Brain; Cognition; Dose-Response Relationship, Drug; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Magnetic Resonance Imaging; Male; Middle Aged; Neuropsychological Tests; Task Performance and Analysis; Withholding Treatment

2018
Drug effect of atorvastatin on middle cerebral atherosclerotic stenosis and high resolution NMR diagnosis.
    Pakistan journal of pharmaceutical sciences, 2018, Volume: 31, Issue:3(Special)

    Topics: Aged; Atherosclerosis; Atorvastatin; Constriction, Pathologic; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Magnetic Resonance Imaging; Male; Middle Aged; Middle Cerebral Artery; Pravastatin; Rosuvastatin Calcium; Simvastatin

2018
Different Effects of Atorvastatin on Cardiometabolic Risk Factors in Young Women With and Without Hyperprolactinemia.
    Journal of clinical pharmacology, 2019, Volume: 59, Issue:1

    Topics: Adult; Atorvastatin; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Female; Fibrinogen; Homocysteine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperprolactinemia; Lipids; Metabolic Diseases; Middle Aged; Prolactin; Risk Factors

2019
Long-term mortality after blood pressure-lowering and lipid-lowering treatment in patients with hypertension in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow-up results of a randomised factorial trial.
    Lancet (London, England), 2018, 09-29, Volume: 392, Issue:10153

    Topics: Adult; Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atenolol; Atorvastatin; Calcium Channel Blockers; Cardiovascular Diseases; Cause of Death; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Hypertension; Male; Middle Aged; Risk Factors; United Kingdom

2018
Efficacy of a fixed dose combination of irbesartan and atorvastatin (Rovelito
    Drug design, development and therapy, 2019, Volume: 13

    Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Blood Pressure; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Hypercholesterolemia; Hypertension; Male; Middle Aged; Prospective Studies; Surveys and Questionnaires

2019
Intensive lipid lowering therapy reduces large, but not small, dense low-density lipoprotein particles measured by gel electrophoresis, in elderly patients with atrial fibrillation.
    European journal of preventive cardiology, 2019, Volume: 26, Issue:18

    Topics: Age Factors; Aged; Anticholesteremic Agents; Atorvastatin; Atrial Fibrillation; Cholesterol, LDL; Cholesterol, VLDL; Electrophoresis; Humans; Hypercholesterolemia

2019
Effects of low-dose atorvastatin on arterial stiffness and central aortic pressure augmentation in patients with hypertension and hypercholesterolemia.
    American journal of hypertension, 2013, Volume: 26, Issue:5

    Topics: Aged; Anticholesteremic Agents; Aorta; Atorvastatin; Blood Pressure; Comorbidity; Dose-Response Relationship, Drug; Double-Blind Method; Female; Hemodynamics; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Male; Middle Aged; Pulse Wave Analysis; Pyrroles; Treatment Outcome; Vascular Stiffness

2013
Atorvastatin, etidronate, or both in patients at high risk for atherosclerotic aortic plaques: a randomized, controlled trial.
    Circulation, 2013, Jun-11, Volume: 127, Issue:23

    Topics: Adult; Aged; Aged, 80 and over; Aorta, Abdominal; Aorta, Thoracic; Aortic Diseases; Atorvastatin; Bone Density; Calcinosis; Drug Therapy, Combination; Etidronic Acid; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Magnetic Resonance Angiography; Male; Middle Aged; Organ Specificity; Plaque, Atherosclerotic; Prospective Studies; Pyrroles

2013
Comparison of pitavastatin with atorvastatin in increasing HDL-cholesterol and adiponectin in patients with dyslipidemia and coronary artery disease: the COMPACT-CAD study.
    Journal of cardiology, 2013, Volume: 62, Issue:2

    Topics: Adiponectin; Adult; Aged; Aged, 80 and over; Apolipoprotein A-I; Atorvastatin; Cholesterol, HDL; Coronary Artery Disease; Endpoint Determination; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Male; Middle Aged; Pyrroles; Quinolines; Young Adult

2013
Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care.
    Circulation. Cardiovascular genetics, 2013, Volume: 6, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Alleles; Atorvastatin; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cholesterol; Cohort Studies; Cytochrome P-450 CYP3A; Databases, Factual; Female; Fluorobenzenes; Genotype; Heptanoic Acids; Humans; Hydroxycholesterols; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Linear Models; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Neoplasm Proteins; Organic Anion Transporters; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Prospective Studies; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Sulfonamides

2013
Atorvastatin and hormone therapy influence expression of ABCA1, APOA1 and SCARB1 in mononuclear cells from hypercholesterolemic postmenopausal women.
    The Journal of steroid biochemistry and molecular biology, 2013, Volume: 138

    Topics: Anticholesteremic Agents; Apolipoprotein A-I; Atorvastatin; ATP Binding Cassette Transporter 1; Cells, Cultured; Estradiol; Female; Heptanoic Acids; Heterocyclic Compounds; Humans; Hypercholesterolemia; Leukocytes, Mononuclear; Middle Aged; Postmenopause; Pyrroles; Scavenger Receptors, Class B; Transcriptome

2013
Efficacy and safety of ezetimibe added to atorvastatin versus atorvastatin uptitration or switching to rosuvastatin in patients with primary hypercholesterolemia.
    The American journal of cardiology, 2013, Dec-15, Volume: 112, Issue:12

    Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hypercholesterolemia; Logistic Models; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides

2013
Pitavastatin and Atorvastatin double-blind randomized comPArative study among hiGh-risk patients, including thOse with Type 2 diabetes mellitus, in Taiwan (PAPAGO-T Study).
    PloS one, 2013, Volume: 8, Issue:10

    Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Lipoproteins; Male; Middle Aged; Pyrroles; Quinolines; Risk Factors; Treatment Outcome; Triglycerides

2013
Atorvastatin 10 mg plus ezetimibe versus titration to atorvastatin 40 mg: attainment of European and Canadian guideline lipid targets in high-risk subjects ≥65 years.
    Lipids in health and disease, 2014, Jan-13, Volume: 13

    Topics: Aged; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Azetidines; Canada; Cholesterol, LDL; Double-Blind Method; Europe; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Practice Guidelines as Topic; Pyrroles; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Factors; Treatment Outcome

2014
The impact of type 2 diabetes and atorvastatin treatment on serum levels of MMP-7 and MMP-8.
    Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 2014, Volume: 122, Issue:1

    Topics: Aged; Anticholesteremic Agents; Atorvastatin; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Matrix Metalloproteinase 7; Matrix Metalloproteinase 8; Middle Aged; Pyrroles

2014
N-of-1 (single-patient) trials for statin-related myalgia.
    Annals of internal medicine, 2014, Mar-04, Volume: 160, Issue:5

    Topics: Aged; Aged, 80 and over; Atorvastatin; Double-Blind Method; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Myalgia; Pyrimidines; Pyrroles; Research Design; Rosuvastatin Calcium; Sulfonamides

2014
Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.
    JAMA, 2014, May-14, Volume: 311, Issue:18

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atorvastatin; Azetidines; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome

2014
Effects of pitavastatin versus atorvastatin on the peripheral endothelial progenitor cells and vascular endothelial growth factor in high-risk patients: a pilot prospective, double-blind, randomized study.
    Cardiovascular diabetology, 2014, Jul-16, Volume: 13

    Topics: Aged; Atorvastatin; Biomarkers; Diabetes Mellitus, Type 2; Double-Blind Method; Endothelial Progenitor Cells; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pilot Projects; Prospective Studies; Pyrroles; Quinolines; Risk Factors; Treatment Outcome; Vascular Endothelial Growth Factor A

2014
Contribution of apolipoprotein A-I to the reduction in high-sensitivity C-reactive protein levels by different statins: comparative study of pitavastatin and atorvastatin.
    Heart and vessels, 2015, Volume: 30, Issue:6

    Topics: Aged; Anticholesteremic Agents; Apolipoprotein A-I; Atorvastatin; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Japan; Male; Middle Aged; Prospective Studies; Quinolines; Regression Analysis

2015
Differences between rosuvastatin and atorvastatin in lipid-lowering action and effect on glucose metabolism in Japanese hypercholesterolemic patients with concurrent diabetes. Lipid-lowering with highly potent statins in hyperlipidemia with type 2 diabete
    Circulation journal : official journal of the Japanese Circulation Society, 2014, Volume: 78, Issue:10

    Topics: Asian People; Atorvastatin; Blood Glucose; Cholesterol, HDL; Diabetes Mellitus; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Follow-Up Studies; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Japan; Male; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides

2014
Efficacy and safety of alirocumab as add-on therapy in high-cardiovascular-risk patients with hypercholesterolemia not adequately controlled with atorvastatin (20 or 40 mg) or rosuvastatin (10 or 20 mg): design and rationale of the ODYSSEY OPTIONS Studies
    Clinical cardiology, 2014, Volume: 37, Issue:10

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome

2014
Assessment of lipophilic vs. hydrophilic statin therapy in acute myocardial infarction – ALPS-AMI study.
    Circulation journal : official journal of the Japanese Circulation Society, 2015, Volume: 79, Issue:1

    Topics: Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Female; Glycated Hemoglobin; Heart Failure; Hospitalization; Humans; Hydrophobic and Hydrophilic Interactions; Hypercholesterolemia; Japan; Kaplan-Meier Estimate; Lipids; Male; Middle Aged; Mortality; Myocardial Infarction; Myocardial Revascularization; Patient Acceptance of Health Care; Pravastatin; Recurrence; Single-Blind Method; Solubility

2015
A randomized, double blind, placebo-controlled pilot trial of the safety and efficacy of atorvastatin in children with elevated low-density lipoprotein cholesterol (LDL-C) and type 1 diabetes.
    Pediatric diabetes, 2015, Volume: 16, Issue:2

    Topics: Adolescent; Atorvastatin; Child; Cholesterol, LDL; Combined Modality Therapy; Diabetes Mellitus, Type 1; Diet, Diabetic; Diet, Fat-Restricted; Double-Blind Method; Drug Monitoring; Exercise; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Pilot Projects; Pyrroles

2015
Fixed-dose combination ezetimibe+atorvastatin lowers LDL-C equivalent to co-administered components in randomized trials: use of a dose-response model.
    Fundamental & clinical pharmacology, 2015, Volume: 29, Issue:2

    Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hypercholesterolemia; Male; Middle Aged

2015
Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial.
    American heart journal, 2014, Volume: 168, Issue:5

    Topics: Acute Coronary Syndrome; Angina, Unstable; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Fluorobenzenes; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Myocardial Infarction; Proprotein Convertase 9; Proprotein Convertases; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Serine Endopeptidases; Stroke; Sulfonamides; Treatment Outcome

2014
[IMPROVE-IT Study proves effectiveness of ezetimib. The Higgs particle of lipidologists].
    MMW Fortschritte der Medizin, 2014, Dec-15, Volume: 156, Issue:21-22

    Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Pravastatin; Pyrroles; Simvastatin

2014
Modulation of adhesion molecules by cholesterol-lowering therapy in mononuclear cells from hypercholesterolemic patients.
    Cardiovascular therapeutics, 2015, Volume: 33, Issue:4

    Topics: Aged; Atorvastatin; Biomarkers; Cell Adhesion Molecules; Cell Line; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Ezetimibe; Ezetimibe, Simvastatin Drug Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Leukocytes, Mononuclear; Male; Middle Aged; RNA, Messenger; Simvastatin; Treatment Outcome

2015
Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects.
    The Journal of clinical investigation, 2015, Volume: 125, Issue:6

    Topics: Adult; Aged; Anticholesteremic Agents; Apolipoprotein B-100; Atorvastatin; Cholesterol, LDL; Double-Blind Method; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipoproteins, LDL; Male; Middle Aged; Oxazolidinones; Pyrroles; Time Factors; Triglycerides

2015
Patient and physician factors influence decision-making in hypercholesterolemia: a questionnaire-based survey.
    Lipids in health and disease, 2015, May-19, Volume: 14

    Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Patient Care Planning; Practice Patterns, Physicians'; Rosuvastatin Calcium; Surveys and Questionnaires

2015
Differential Effects of Atorvastatin and Pitavastatin on Inflammation, Insulin Resistance, and the Carotid Intima-Media Thickness in Patients with Dyslipidemia.
    Journal of atherosclerosis and thrombosis, 2015, Volume: 22, Issue:11

    Topics: Aged; Atorvastatin; Carotid Artery Diseases; Carotid Intima-Media Thickness; Dyslipidemias; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Inflammation; Insulin Resistance; Male; Prognosis; Prospective Studies; Quinolines

2015
The Effect of Atorvastatin on Cardiometabolic Risk Factors in Bromocriptine-Treated Premenopausal Women with Isolated Hypercholesterolemia.
    Cardiovascular therapeutics, 2015, Volume: 33, Issue:5

    Topics: Adult; Atorvastatin; Bromocriptine; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diet; Dopamine Agonists; Exercise; Female; Fibrinogen; Homocysteine; Humans; Hypercholesterolemia; Hyperprolactinemia; Hypoglycemic Agents; Hypolipidemic Agents; Metformin; Middle Aged; Premenopause; Risk Factors; Uric Acid

2015
Influence of metabolic syndrome factors and insulin resistance on the efficacy of ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome and atherosclerotic coronary heart disease risk.
    Lipids in health and disease, 2015, Sep-04, Volume: 14

    Topics: Aged; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Blood Pressure; C-Reactive Protein; Cholesterol, LDL; Coronary Artery Disease; Coronary Disease; Double-Blind Method; Ezetimibe; Female; Humans; Hypercholesterolemia; Insulin Resistance; Lipoproteins, HDL; Male; Metabolic Syndrome; Middle Aged; Obesity, Abdominal; Risk Factors; Simvastatin; Treatment Outcome; Triglycerides

2015
Atorvastatin Reduces Circulating Osteoprogenitor Cells and T-Cell RANKL Expression in Osteoporotic Women: Implications for the Bone-Vascular Axis.
    Cardiovascular therapeutics, 2016, Volume: 34, Issue:1

    Topics: Aged; Atorvastatin; Biomarkers; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Jurkat Cells; Lipids; Middle Aged; Osteoporosis, Postmenopausal; Osteoprotegerin; RANK Ligand; Stem Cells; T-Lymphocytes; Time Factors; Treatment Outcome

2016
A Comparison of Statin Therapies in Hypercholesterolemia in Women: A Subgroup Analysis of the STELLAR Study.
    Journal of women's health (2002), 2016, Volume: 25, Issue:1

    Topics: Adult; Aged; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Middle Aged; Pravastatin; Rosuvastatin Calcium; Simvastatin; Treatment Outcome; Triglycerides; United States

2016
Effect of PCSK9 Inhibition by Alirocumab on Lipoprotein Particle Concentrations Determined by Nuclear Magnetic Resonance Spectroscopy.
    Journal of the American Heart Association, 2015, Nov-19, Volume: 4, Issue:11

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Atorvastatin; Biomarkers; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Lipoproteins; Lipoproteins, HDL; Lipoproteins, VLDL; Male; Middle Aged; Nuclear Magnetic Resonance, Biomolecular; Particle Size; Proprotein Convertase 9; Proprotein Convertases; Serine Endopeptidases; Serine Proteinase Inhibitors; Treatment Outcome

2015
Switching from atorvastatin to rosuvastatin lowers small, dense low-density lipoprotein cholesterol levels in Japanese hypercholesterolemic patients with type 2 diabetes mellitus.
    Diabetes research and clinical practice, 2016, Volume: 111

    Topics: Adult; Aged; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Down-Regulation; Drug Substitution; Female; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Japan; Male; Middle Aged; Rosuvastatin Calcium; Treatment Outcome

2016
Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial.
    JAMA, 2016, Apr-19, Volume: 315, Issue:15

    Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atorvastatin; Biomarkers; Cholesterol, LDL; Creatine Kinase; Cross-Over Studies; Double-Blind Method; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Muscular Diseases; Myalgia; Myositis; Rhabdomyolysis; Time Factors

2016
Switching Lopinavir/Ritonavir to Atazanavir/Ritonavir vs Adding Atorvastatin in HIV-Infected Patients Receiving Second-Line Antiretroviral Therapy With Hypercholesterolemia: A Randomized Controlled Trial.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2016, 09-15, Volume: 63, Issue:6

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Atorvastatin; Cholesterol; Female; HIV Infections; Humans; Hypercholesterolemia; Lipoproteins, LDL; Lopinavir; Male; Middle Aged; Ritonavir

2016
A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I.
    Atherosclerosis, 2016, Volume: 254

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Genotype; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Proprotein Convertase 9; Simvastatin; Treatment Outcome

2016
Blood Pressure and Cholesterol-lowering Efficacy of a Fixed-dose Combination With Irbesartan and Atorvastatin in Patients With Hypertension and Hypercholesterolemia: A Randomized, Double-blind, Factorial, Multicenter Phase III Study.
    Clinical therapeutics, 2016, Volume: 38, Issue:10

    Topics: Aged; Antihypertensive Agents; Atorvastatin; Biphenyl Compounds; Blood Pressure; Cholesterol; Double-Blind Method; Drug Combinations; Female; Humans; Hypercholesterolemia; Hypertension; Irbesartan; Male; Middle Aged; Risk Factors; Tetrazoles; Time Factors; Treatment Outcome

2016
Platelet tissue factor activity and membrane cholesterol are increased in hypercholesterolemia and normalized by rosuvastatin, but not by atorvastatin.
    Atherosclerosis, 2017, Volume: 257

    Topics: Adult; Aged; Atorvastatin; Biomarkers; Blood Coagulation; Blood Platelets; Cell Membrane; Chile; Cholesterol; Cholesterol, HDL; Factor Xa; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Platelet Aggregation; Platelet Glycoprotein GPIb-IX Complex; Rosuvastatin Calcium; Thromboplastin; Time Factors; Treatment Outcome

2017
Effect of two lipid-lowering strategies on high-density lipoprotein function and some HDL-related proteins: a randomized clinical trial.
    Lipids in health and disease, 2017, Feb-28, Volume: 16, Issue:1

    Topics: Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Cholesterol, HDL; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Treatment Outcome; Vascular Cell Adhesion Molecule-1

2017
Effects of statin on small dense low-density lipoprotein cholesterol and remnant-like particle cholesterol in heterozygous familial hypercholesterolemia.
    Journal of atherosclerosis and thrombosis, 2008, Volume: 15, Issue:3

    Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, LDL; Female; Heptanoic Acids; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins; Male; Middle Aged; Models, Biological; Pyrroles; Quinolines; Regression Analysis; Triglycerides

2008
A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density li
    Clinical therapeutics, 2008, Volume: 30, Issue:6

    Topics: Anticholesteremic Agents; Atorvastatin; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Enzyme Inhibitors; Female; Follow-Up Studies; Glucose Intolerance; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hypercholesterolemia; Japan; Male; Middle Aged; Pyrroles; Quinolines; Time Factors; Treatment Outcome

2008
Atorvastatin induces associated reductions in platelet P-selectin, oxidized low-density lipoprotein, and interleukin-6 in patients with coronary artery diseases.
    Heart and vessels, 2008, Volume: 23, Issue:4

    Topics: Aged; Atorvastatin; Blood Platelets; Cholesterol; Combined Modality Therapy; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Interleukin-6; Lipoproteins, LDL; Male; Malondialdehyde; Middle Aged; P-Selectin; Pyrroles; Time Factors; Treatment Outcome; Triglycerides

2008
Effects of low-dose atorvastatin and rosuvastatin on plasma lipid profiles: a long-term, randomized, open-label study in patients with primary hypercholesterolemia.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2008, Volume: 8, Issue:4

    Topics: Adult; Aged; Atorvastatin; Cholesterol; Cholesterol, LDL; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Triglycerides

2008
Effect of atorvastatin on LDL & hs-CRP in a selected Thai population.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2008, Volume: 91, Issue:8

    Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Risk Factors; Thailand; Treatment Outcome

2008
Discovery Belux: comparison of rosuvastatin with atorvastatin in hypercholesterolaemia.
    Acta cardiologica, 2008, Volume: 63, Issue:4

    Topics: Atorvastatin; Belgium; Cholesterol, LDL; Female; Fluorobenzenes; Health Status Indicators; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Logistic Models; Male; Markov Chains; Middle Aged; Models, Statistical; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides

2008
Ezetimibe 5 and 10 mg for lowering LDL-C: potential billion-dollar savings with improved tolerability.
    The American journal of managed care, 2008, Volume: 14, Issue:10

    Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Dose-Response Relationship, Drug; Ezetimibe; Female; Heptanoic Acids; Hospitals, Veterans; Humans; Hypercholesterolemia; Male; Pyrroles

2008
Vascular and metabolic response to statin in the mildly hypertensive hypercholesterolemic elderly.
    Clinics (Sao Paulo, Brazil), 2008, Volume: 63, Issue:5

    Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Blood Flow Velocity; C-Reactive Protein; Cholesterol, LDL; Double-Blind Method; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Lipids; Male; Pyrroles; Regional Blood Flow; Severity of Illness Index; Vasodilation

2008
Rosuvastatin, pravastatin, and atorvastatin for the treatment of hypercholesterolaemia in HIV-infected patients receiving protease inhibitors.
    Current HIV research, 2008, Volume: 6, Issue:6

    Topics: Adult; Anticholesteremic Agents; Atorvastatin; Cholesterol; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; HIV Infections; HIV Protease Inhibitors; Humans; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Viral Load

2008
Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) versus uptitration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease.
    The American journal of cardiology, 2008, Dec-01, Volume: 102, Issue:11

    Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Logistic Models; Male; Middle Aged; Pyrroles; Risk Assessment; Risk Factors; Treatment Outcome

2008
Efficacy and safety of ezetimibe added on to atorvastatin (40 mg) compared with uptitration of atorvastatin (to 80 mg) in hypercholesterolemic patients at high risk of coronary heart disease.
    The American journal of cardiology, 2008, Dec-01, Volume: 102, Issue:11

    Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Risk Assessment; Treatment Outcome

2008
Superior benefit of aggressive lipid-lowering therapy for high- risk patients using statins: the SUBARU study--more hypercholesterolemic patients achieve Japan Atherosclerosis Society LDL-C goals with rosuvastatin therapy than with atorvastatin therapy.
    Journal of atherosclerosis and thrombosis, 2008, Volume: 15, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Atherosclerosis; Atorvastatin; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Japan; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides

2008
Effect of atorvastatin versus rosuvastatin on levels of serum lipids, inflammatory markers and adiponectin in patients with hypercholesterolemia.
    Pharmaceutical research, 2009, Volume: 26, Issue:4

    Topics: Adiponectin; Adult; Aged; Atorvastatin; Biomarkers; Brachial Artery; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Inflammation Mediators; Lipids; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Time Factors; Treatment Outcome; Vasodilation; Vasodilator Agents

2009
Should high creatine kinase discourage the initiation or continuance of statins for the treatment of hypercholesterolemia?
    Metabolism: clinical and experimental, 2009, Volume: 58, Issue:2

    Topics: Atorvastatin; Cholesterol, LDL; Creatine Kinase; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Rhabdomyolysis; Rosuvastatin Calcium; Simvastatin; Sulfonamides

2009
Lipoprotein predictors of cardiovascular events in statin-treated patients with coronary heart disease. Insights from the Incremental Decrease In End-points Through Aggressive Lipid-lowering Trial (IDEAL).
    Annals of medicine, 2008, Volume: 40, Issue:6

    Topics: Aged; Anticholesteremic Agents; Apolipoprotein A-I; Apolipoproteins B; Atorvastatin; Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Predictive Value of Tests; Pyrroles; Simvastatin; Treatment Outcome

2008
Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial by stroke subtypes.
    Stroke, 2009, Volume: 40, Issue:4

    Topics: Anticholesteremic Agents; Atorvastatin; Brain Ischemia; Cerebral Hemorrhage; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Placebos; Proportional Hazards Models; Pyrroles; Risk Factors; Stroke; Treatment Outcome

2009
Effect of lipid-lowering therapy with atorvastatin on atherosclerotic aortic plaques: a 2-year follow-up by noninvasive MRI.
    European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology, 2009, Volume: 16, Issue:2

    Topics: Aged; Aorta, Abdominal; Aorta, Thoracic; Aortic Diseases; Aortography; Atherosclerosis; Atorvastatin; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Magnetic Resonance Angiography; Male; Middle Aged; Prospective Studies; Pyrroles; Time Factors; Treatment Outcome

2009
Relative and cumulative effects of lipid and blood pressure control in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial.
    Stroke, 2009, Volume: 40, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Blood Pressure; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Ischemic Attack, Transient; Male; Middle Aged; Pyrroles; Risk Factors; Secondary Prevention; Stroke; Treatment Outcome; Triglycerides; Young Adult

2009
Effect of ezetimibe/simvastatin compared with atorvastatin on lipoprotein subclasses in patients with type 2 diabetes and hypercholesterolaemia.
    Diabetes, obesity & metabolism, 2009, Volume: 11, Issue:9

    Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Simvastatin; Young Adult

2009
Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study).
    The American journal of cardiology, 2009, Jun-15, Volume: 103, Issue:12

    Topics: Adolescent; Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Lipids; Male; Metabolic Syndrome; Middle Aged; Pyrroles; Simvastatin; Treatment Outcome; Young Adult

2009
Influence of statins on glucose tolerance in patients with type 2 diabetes mellitus: subanalysis of the collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis prevention (CHIBA study).
    Journal of atherosclerosis and thrombosis, 2009, Volume: 16, Issue:3

    Topics: Atherosclerosis; Atorvastatin; Diabetes Mellitus, Type 2; Glucose Intolerance; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles; Quinolines; Treatment Outcome

2009
The influence of atorvastatin on walking performance in peripheral arterial disease.
    VASA. Zeitschrift fur Gefasskrankheiten, 2009, Volume: 38, Issue:2

    Topics: Aged; Anticholesteremic Agents; Arterial Occlusive Diseases; Atorvastatin; Cholesterol, LDL; Combined Modality Therapy; Diet, Fat-Restricted; Dose-Response Relationship, Drug; Double-Blind Method; Exercise Test; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Intermittent Claudication; Male; Middle Aged; Pyrroles; Statistics, Nonparametric; Walking

2009
Atorvastatin reduces sympathetic activity and increases baroreceptor reflex sensitivity in patients with hypercholesterolaemia and systemic arterial hypertension.
    Kardiologia polska, 2009, Volume: 67, Issue:6

    Topics: Adult; Anticholesteremic Agents; Atorvastatin; Baroreflex; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Male; Pressoreceptors; Pyrroles

2009
Low-dose atorvastatin improves dyslipidemia and vascular function in patients with primary biliary cirrhosis after one year of treatment.
    Atherosclerosis, 2010, Volume: 209, Issue:1

    Topics: Atorvastatin; Blood Vessels; Cardiovascular Diseases; Cholestasis; Cholesterol; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Liver Cirrhosis, Biliary; Male; Middle Aged; Prospective Studies; Pyrroles

2010
Usefulness of aggressive lipid-lowering therapy with rosuvastatin in hypercholesterolemic patients with concomitant type 2 diabetes.
    Endocrine, 2009, Volume: 36, Issue:3

    Topics: Aged; Atorvastatin; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Lipids; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome

2009
Atorvastatin inhibits gp91phox circulating levels in patients with hypercholesterolemia.
    Arteriosclerosis, thrombosis, and vascular biology, 2010, Volume: 30, Issue:2

    Topics: Antioxidants; Atorvastatin; Biomarkers; Blood Platelets; Blotting, Western; Case-Control Studies; Cholesterol; Combined Modality Therapy; Cross-Sectional Studies; Down-Regulation; Enzyme-Linked Immunosorbent Assay; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Immunoprecipitation; Isoprostanes; Leukocytes, Mononuclear; Male; Membrane Glycoproteins; Middle Aged; NADPH Oxidase 2; NADPH Oxidases; Pyrroles; Time Factors; Treatment Outcome

2010
A multicenter study in Malaysia to determine the efficacy and safety of a generic atorvastatin.
    The Medical journal of Malaysia, 2009, Volume: 64, Issue:2

    Topics: Adult; Aged; Atorvastatin; Cholesterol, LDL; Drugs, Generic; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrroles

2009
Effects of prescription omega-3-acid ethyl esters on non--high-density lipoprotein cholesterol when coadministered with escalating doses of atorvastatin.
    Mayo Clinic proceedings, 2010, Volume: 85, Issue:2

    Topics: Analysis of Variance; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Docosahexaenoic Acids; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Drug Prescriptions; Drug Therapy, Combination; Eicosapentaenoic Acid; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertriglyceridemia; Male; Middle Aged; Pyrroles; Treatment Outcome; United States

2010
Relationships between metabolic syndrome and other baseline factors and the efficacy of ezetimibe/simvastatin and atorvastatin in patients with type 2 diabetes and hypercholesterolemia.
    Diabetes care, 2010, Volume: 33, Issue:5

    Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Black People; C-Reactive Protein; Diabetes Mellitus, Type 2; Drug Combinations; Ezetimibe, Simvastatin Drug Combination; Female; Heptanoic Acids; Hispanic or Latino; Humans; Hypercholesterolemia; Male; Metabolic Syndrome; Multivariate Analysis; Predictive Value of Tests; Pyrroles; Risk Factors; Simvastatin

2010
Achieving cholesterol targets by individualizing starting doses of statin according to baseline low-density lipoprotein cholesterol and coronary artery disease risk category: the CANadians Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titr
    The Canadian journal of cardiology, 2010, Volume: 26, Issue:2

    Topics: Adult; Aged; Atorvastatin; Canada; Cholesterol, LDL; Coronary Artery Disease; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Risk Factors; Treatment Outcome

2010
Ezetimibe added to atorvastatin compared with doubling the atorvastatin dose in patients at high risk for coronary heart disease with diabetes mellitus, metabolic syndrome or neither.
    Diabetes, obesity & metabolism, 2010, Volume: 12, Issue:3

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Canada; Coronary Artery Disease; Diabetic Angiopathies; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Metabolic Syndrome; Middle Aged; Pyrroles; Risk Factors; Treatment Outcome; United States; Young Adult

2010
Comparative efficacy and safety of low-dose pitavastatin versus atorvastatin in patients with hypercholesterolemia.
    The Annals of pharmacotherapy, 2010, Volume: 44, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Cholesterol; Cholesterol, LDL; Cost-Benefit Analysis; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Prospective Studies; Pyrroles; Quinolines; Treatment Outcome

2010
Comparative study of low doses of rosuvastatin and atorvastatin on lipid and glycemic control in patients with metabolic syndrome and hypercholesterolemia.
    The Korean journal of internal medicine, 2010, Volume: 25, Issue:1

    Topics: Atorvastatin; Blood Glucose; Cholesterol, LDL; Female; Fluorobenzenes; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperglycemia; Insulin; Male; Metabolic Syndrome; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome

2010
Design and rationale of a real-life study to compare treatment strategies for cardiovascular risk factors: the CRUCIAL study.
    Postgraduate medicine, 2010, Volume: 122, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Calcium Channel Blockers; Cardiovascular Diseases; Cluster Analysis; Drug Combinations; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Internationality; Male; Middle Aged; Primary Prevention; Prospective Studies; Pyrroles; Research Design; Risk Assessment; Risk Factors; Surveys and Questionnaires

2010
Atorvastatin increases blood ratios of vitamin E/low-density lipoprotein cholesterol and coenzyme Q10/low-density lipoprotein cholesterol in hypercholesterolemic patients.
    Nutrition research (New York, N.Y.), 2010, Volume: 30, Issue:2

    Topics: 8-Hydroxy-2'-Deoxyguanosine; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Deoxyguanosine; Erythrocytes; Female; Glutathione; Heptanoic Acids; Humans; Hypercholesterolemia; Lipids; Male; Middle Aged; Oxidative Stress; Pyrroles; Ubiquinone; Vitamin E

2010
Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients.
    Journal of the American College of Cardiology, 2010, Mar-23, Volume: 55, Issue:12

    Topics: Adult; Aged; Atorvastatin; Blood Glucose; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Insulin; Insulin Resistance; Male; Middle Aged; Pyrroles; Treatment Outcome

2010
Atorvastatin reduces macrophage accumulation in atherosclerotic plaques: a comparison of a nonstatin-based regimen in patients undergoing carotid endarterectomy.
    Stroke, 2010, Volume: 41, Issue:6

    Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Cholestyramine Resin; Endarterectomy, Carotid; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lymphocyte Count; Macrophages; Male; Pyrroles; Sitosterols

2010
Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets.
    International journal of clinical practice, 2010, Volume: 64, Issue:8

    Topics: Aged; Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Azetidines; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Fluorobenzenes; General Practice; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Secondary Prevention; Simvastatin; Sulfonamides; Treatment Outcome

2010
High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol.
    Journal of lipid research, 2010, Volume: 51, Issue:9

    Topics: Atorvastatin; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Proprotein Convertase 9; Proprotein Convertases; Pyrroles; Serine Endopeptidases; Triglycerides

2010
Markers of cholesterol absorption and synthesis predict the low-density lipoprotein cholesterol response to atorvastatin.
    Journal of cardiovascular pharmacology, 2010, Volume: 56, Issue:4

    Topics: Absorption; Aged; Atorvastatin; Biomarkers; Cholestanol; Cholesterol; Cholesterol, LDL; Desmosterol; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Prognosis; Prospective Studies; Pyrroles

2010
A randomized clinical trial to assess the effect of statins on skeletal muscle function and performance: rationale and study design.
    Preventive cardiology, 2010,Summer, Volume: 13, Issue:3

    Topics: Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Creatine Kinase; Decision Trees; Double-Blind Method; Exercise Test; Female; Health Status Indicators; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Isometric Contraction; Male; Motor Activity; Muscle Strength; Muscle Strength Dynamometer; Muscle Weakness; Muscle, Skeletal; Physical Endurance; Pyrroles; Research Design; Surveys and Questionnaires

2010
Immediate effect of intensive atorvastatin therapy on lipid parameters in patients with acute coronary syndrome.
    Lipids in health and disease, 2010, Jul-14, Volume: 9

    Topics: Acute Coronary Syndrome; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Male; Middle Aged; Pyrroles; Triglycerides

2010
Short-term treatment with high-dose atorvastatin reduces LDL cholesterol but shows no anti-inflammatory effects in normolipidemic subjects with normal CRP levels.
    Clinical and translational science, 2010, Volume: 3, Issue:4

    Topics: Adult; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Inflammation; Leukocytes; Male; Middle Aged; Pyrroles; Young Adult

2010
Atorvastatin inhibits oxidative stress via adiponectin-mediated NADPH oxidase down-regulation in hypercholesterolemic patients.
    Atherosclerosis, 2010, Volume: 213, Issue:1

    Topics: Adiponectin; Aged; Antioxidants; Atorvastatin; Blood Platelets; Case-Control Studies; Cross-Sectional Studies; Female; Free Radicals; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Membrane Glycoproteins; Middle Aged; NADPH Oxidase 2; NADPH Oxidases; Oxidative Stress; Pyrroles

2010
Influence of age, gender, and race on the efficacy of adding ezetimibe to atorvastatin vs. atorvastatin up-titration in patients at moderately high or high risk for coronary heart disease.
    International journal of cardiology, 2011, Dec-01, Volume: 153, Issue:2

    Topics: Adolescent; Adult; Age Factors; Aged; Atorvastatin; Azetidines; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Racial Groups; Risk Factors; Sex Factors; Treatment Outcome; Young Adult

2011
Safety and efficacy of ezetimibe/simvastatin combination versus atorvastatin alone in adults ≥65 years of age with hypercholesterolemia and with or at moderately high/high risk for coronary heart disease (the VYTELD study).
    The American journal of cardiology, 2010, Nov-01, Volume: 106, Issue:9

    Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Biomarkers; Coronary Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipids; Logistic Models; Male; Pyrroles; Risk Factors; Simvastatin; Treatment Outcome

2010
Biomarker assessment of the immunomodulator effect of atorvastatin in stable renal transplant recipients and hypercholesterolemic patients.
    Molecular diagnosis & therapy, 2010, Dec-01, Volume: 14, Issue:6

    Topics: Adenosine Triphosphate; Adult; Aged; Atorvastatin; Biomarkers; Cell Proliferation; Culture Media, Conditioned; Cytokines; Female; Gene Expression Regulation; Heptanoic Acids; Humans; Hypercholesterolemia; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged; Mycophenolic Acid; Pyrroles; T-Lymphocyte Subsets; T-Lymphocytes, Regulatory; Tacrolimus; Transplantation

2010
Effects of atorvastatin and rosuvastatin on thromboxane-dependent platelet activation and oxidative stress in hypercholesterolemia.
    Atherosclerosis, 2011, Volume: 214, Issue:1

    Topics: 3' Untranslated Regions; Anticholesteremic Agents; Atorvastatin; Blood Platelets; Double-Blind Method; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hypercholesterolemia; Lipids; Male; Middle Aged; Oxidative Stress; Platelet Activation; Polymorphism, Genetic; Prospective Studies; Prostaglandins A; Pyrimidines; Pyrroles; Regression Analysis; Rosuvastatin Calcium; Sulfonamides; Thromboxane B2

2011
Efficacy and tolerability of a generic and a branded formulation of atorvastatin 20 mg/d in hypercholesterolemic Korean adults at high risk for cardiovascular disease: a multicenter, prospective, randomized, double-blind, double-dummy clinical trial.
    Clinical therapeutics, 2010, Volume: 32, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Double-Blind Method; Drugs, Generic; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Korea; Male; Middle Aged; Prospective Studies; Pyrroles; Risk Factors; Therapeutic Equivalency; Treatment Outcome; Young Adult

2010
Effect of atorvastatin on lipoprotein (a) and interleukin-10: a randomized placebo-controlled trial.
    Diabetes & metabolism, 2011, Volume: 37, Issue:2

    Topics: Aged; Anticholesteremic Agents; Atorvastatin; Double-Blind Method; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Interleukin-10; Lipoprotein(a); Male; Middle Aged; Placebos; Pyrroles

2011
Comparison of effects of rosuvastatin and atorvastatin on plaque regression in Korean patients with untreated intermediate coronary stenosis.
    Circulation journal : official journal of the Japanese Circulation Society, 2011, Volume: 75, Issue:2

    Topics: Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Coronary Stenosis; Disease Progression; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Korea; Male; Plaque, Atherosclerotic; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Ultrasonography, Interventional

2011
Distinct effects of pitavastatin and atorvastatin on lipoprotein subclasses in patients with Type 2 diabetes mellitus.
    Diabetic medicine : a journal of the British Diabetic Association, 2011, Volume: 28, Issue:7

    Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipoproteins; Male; Middle Aged; Pyrroles; Quinolines; Treatment Outcome

2011
The effects of statin monotherapy and low-dose statin/ezetimibe on lipoprotein-associated phospholipase A₂.
    Clinical cardiology, 2011, Volume: 34, Issue:2

    Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Biomarkers, Pharmacological; Chemokine CCL2; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Fibrinogen; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Interleukin-6; Male; Middle Aged; Pyrroles; Treatment Outcome; Young Adult

2011
High-dose atorvastatin enhances impaired cerebral vasomotor reactivity.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2012, Volume: 21, Issue:6

    Topics: Aged; Antihypertensive Agents; Atorvastatin; Biomarkers; Blood Flow Velocity; Blood Pressure; Brain Infarction; Cerebrovascular Circulation; Chi-Square Distribution; Cholesterol, LDL; Female; Florida; Hemodynamics; Heptanoic Acids; Hispanic or Latino; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Male; Middle Aged; Middle Cerebral Artery; Prospective Studies; Pyrroles; Time Factors; Treatment Outcome; Ultrasonography, Doppler, Transcranial

2012
The effect of a platelet cholesterol modulation on the acetylsalicylic acid-mediated blood platelet inhibition in hypercholesterolemic patients.
    European journal of pharmacology, 2011, May-11, Volume: 658, Issue:2-3

    Topics: Acetylation; Aspirin; Atorvastatin; Blood Platelets; Blood Proteins; Cholesterol; Drug Interactions; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipoproteins, LDL; Male; Middle Aged; Pyrroles

2011
Proteomic approach to the study of statin pleiotropy in kidney transplant patients.
    Pharmacology, 2011, Volume: 87, Issue:3-4

    Topics: Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Immunoenzyme Techniques; Kidney Function Tests; Kidney Transplantation; Lipids; Male; Middle Aged; Molecular Weight; Peptide Fragments; Prospective Studies; Proteomics; Pyrroles; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Treatment Outcome; Tumor Necrosis Factor-alpha

2011
Oral atorvastatin therapy restores cutaneous microvascular function by decreasing arginase activity in hypercholesterolaemic humans.
    The Journal of physiology, 2011, Apr-15, Volume: 589, Issue:Pt 8

    Topics: Administration, Oral; Adult; Analysis of Variance; Arginase; Arginine; Atorvastatin; Biomarkers; Biopsy; Blood Flow Velocity; Cholesterol; Down-Regulation; Enzyme Inhibitors; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins, LDL; Male; Microcirculation; Microdialysis; Middle Aged; Nitric Oxide; Nitric Oxide Synthase Type III; Pennsylvania; Pyrroles; Regional Blood Flow; Skin; Time Factors; Treatment Outcome; Triglycerides

2011
Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (quantity and quality of LDL): the PATROL trial.
    Circulation journal : official journal of the Japanese Circulation Society, 2011, Volume: 75, Issue:6

    Topics: Aged; Analysis of Variance; Atorvastatin; Biomarkers; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Japan; Male; Middle Aged; Patient Selection; Prospective Studies; Pyrimidines; Pyrroles; Quinolines; Rosuvastatin Calcium; Sulfonamides; Time Factors; Treatment Outcome

2011
Impact of atorvastatin on serum vaspin levels in hypercholesterolemic patients with moderate cardiovascular risk.
    Regulatory peptides, 2011, Oct-10, Volume: 170, Issue:1-3

    Topics: Aged; Anticholesteremic Agents; Atorvastatin; Coronary Artery Disease; Cytokines; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Nicotinamide Phosphoribosyltransferase; Prospective Studies; Pyrroles; Regression Analysis; Risk Factors; Risk Reduction Behavior; Serpins

2011
Oral atorvastatin therapy increases nitric oxide-dependent cutaneous vasodilation in humans by decreasing ascorbate-sensitive oxidants.
    American journal of physiology. Regulatory, integrative and comparative physiology, 2011, Volume: 301, Issue:3

    Topics: Administration, Oral; Adult; Analysis of Variance; Antioxidants; Arginase; Ascorbic Acid; Atorvastatin; Enzyme Inhibitors; Female; Heating; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Microdialysis; Microvessels; Middle Aged; Nitric Oxide; Nitric Oxide Synthase; Oxidative Stress; Pennsylvania; Pyrroles; Skin; Time Factors; Treatment Outcome; Vasodilation; Vasodilator Agents

2011
Ethnic variations in lipid-lowering in response to a statin (EVIREST): a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).
    Ethnicity & disease, 2011,Spring, Volume: 21, Issue:2

    Topics: Aged; Atorvastatin; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Ireland; Male; Middle Aged; Pyrroles; Racial Groups; Treatment Outcome; United Kingdom

2011
Evaluation of C-reactive protein prior to and on-treatment as a predictor of benefit from atorvastatin: observations from the Anglo-Scandinavian Cardiac Outcomes Trial.
    European heart journal, 2012, Volume: 33, Issue:4

    Topics: Aged; Atorvastatin; Biomarkers; C-Reactive Protein; Case-Control Studies; Cholesterol, LDL; Coronary Disease; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Male; Middle Aged; Pyrroles; Risk Assessment; Stroke; Treatment Outcome

2012
Acute localized administration of tetrahydrobiopterin and chronic systemic atorvastatin treatment restore cutaneous microvascular function in hypercholesterolaemic humans.
    The Journal of physiology, 2011, Oct-01, Volume: 589, Issue:Pt 19

    Topics: Anticholesteremic Agents; Arginase; Arginine; Atorvastatin; Biopterins; Cholesterol; Female; Heating; Heptanoic Acids; Humans; Hypercholesterolemia; Lipoproteins, LDL; Male; Microcirculation; Microdialysis; Middle Aged; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase Type III; Pyrroles; Regional Blood Flow; Skin; Vasodilation

2011
The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid-lowering arm in the U.K.
    European heart journal, 2011, Volume: 32, Issue:20

    Topics: Adult; Aged; Atorvastatin; Cause of Death; Coronary Disease; Double-Blind Method; Early Termination of Clinical Trials; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Male; Middle Aged; Prospective Studies; Pyrroles; Treatment Outcome

2011
Low-dose atorvastatin reduces ambulatory blood pressure in patients with mild hypertension and hypercholesterolaemia: a double-blind, randomized, placebo-controlled study.
    Journal of human hypertension, 2012, Volume: 26, Issue:10

    Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Double-Blind Method; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Male; Middle Aged; Pyrroles; Treatment Outcome

2012
The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancer.
    Cancer chemotherapy and pharmacology, 2012, Volume: 69, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Atorvastatin; Bexarotene; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Drug Interactions; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertriglyceridemia; Lung Neoplasms; Male; Metabolic Clearance Rate; Middle Aged; Pyrroles; Tetrahydronaphthalenes; Treatment Outcome

2012
Atorvastatin and hormone therapy effects on APOE mRNA expression in hypercholesterolemic postmenopausal women.
    The Journal of steroid biochemistry and molecular biology, 2012, Volume: 128, Issue:3-5

    Topics: Aged; Amplified Fragment Length Polymorphism Analysis; Apolipoproteins; Apolipoproteins E; Atorvastatin; Brazil; Cholesterol, LDL; Down-Regulation; Drug Therapy, Combination; Estrogen Replacement Therapy; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Leukocytes, Mononuclear; Liver X Receptors; Middle Aged; Orphan Nuclear Receptors; Polymorphism, Single Nucleotide; Postmenopause; Pyrroles; RNA, Messenger

2012
Long-term efficacy and safety of a generic atorvastatin in usual clinical care setting.
    The Medical journal of Malaysia, 2011, Volume: 66, Issue:3

    Topics: Adult; Aged; Atorvastatin; Cholesterol, LDL; Drug Administration Schedule; Drugs, Generic; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrroles

2011
Assessment of atorvastatin effectiveness on serum PSA level in hypercholesterolemic males.
    Acta medica Iranica, 2011, Volume: 49, Issue:12

    Topics: Aged; Atorvastatin; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Prospective Studies; Prostate-Specific Antigen; Pyrroles; Triglycerides

2011
Ezetimibe/simvastatin 10/40 mg versus atorvastatin 40 mg in high cardiovascular risk patients with primary hypercholesterolemia: a randomized, double-blind, active-controlled, multicenter study.
    Lipids in health and disease, 2012, Jan-31, Volume: 11

    Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; C-Reactive Protein; Cardiovascular Diseases; Double-Blind Method; Drug Combinations; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipids; Male; Middle Aged; Pyrroles; Simvastatin; Treatment Outcome

2012
[Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (quantity and quality of LDL): -- the PATROL trial].
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2011, Dec-10, Volume: 100, Issue:12

    Topics: Atorvastatin; Cholesterol, LDL; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrimidines; Pyrroles; Quinolines; Rosuvastatin Calcium; Sulfonamides

2011
Influence of achieved low-density lipoprotein cholesterol level with atorvastatin therapy on stabilization of coronary plaques: sub-analysis of the TWINS study.
    Circulation journal : official journal of the Japanese Circulation Society, 2012, Volume: 76, Issue:5

    Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Coronary Vessels; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Plaque, Atherosclerotic; Pyrroles; Ultrasonography, Interventional

2012
Effect of a monoclonal antibody to PCSK9 on LDL cholesterol.
    The New England journal of medicine, 2012, Mar-22, Volume: 366, Issue:12

    Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Injections, Intravenous; Injections, Subcutaneous; Least-Squares Analysis; Lipoproteins; Male; Middle Aged; Proprotein Convertase 9; Proprotein Convertases; Pyrroles; Receptors, LDL; Serine Endopeptidases

2012
Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy.
    Journal of the American College of Cardiology, 2012, Jun-19, Volume: 59, Issue:25

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Double-Blind Method; Drug Synergism; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Proprotein Convertase 9; Proprotein Convertases; Pyrroles; Serine Endopeptidases; Time Factors; Treatment Outcome

2012
Cholesterol metabolism differs after statin therapy according to the type of hyperlipemia.
    Life sciences, 2012, Jun-06, Volume: 90, Issue:21-22

    Topics: Adult; Aged; Atorvastatin; Cholesterol; Cholesterol, LDL; Female; Gas Chromatography-Mass Spectrometry; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemia, Familial Combined; Hyperlipidemias; Lipids; Male; Middle Aged; Phytosterols; Pyrroles; Simvastatin; Sitosterols

2012
Influence of atorvastatin on serum amyloid A-low density lipoprotein complex in hypercholesterolemic patients.
    Pharmacological reports : PR, 2012, Volume: 64, Issue:1

    Topics: Antioxidants; Atorvastatin; Biomarkers; C-Reactive Protein; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipoproteins, LDL; Male; Middle Aged; Prospective Studies; Pyrroles; Serum Amyloid A Protein

2012
Immediate antioxidant and antiplatelet effect of atorvastatin via inhibition of Nox2.
    Circulation, 2012, Jul-03, Volume: 126, Issue:1

    Topics: Aged; Aged, 80 and over; Antioxidants; Atorvastatin; Combined Modality Therapy; Diet, Mediterranean; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Membrane Glycoproteins; Middle Aged; NADPH Oxidase 2; NADPH Oxidases; Oxidative Stress; Platelet Activation; Pyrroles; Treatment Outcome

2012
Atorvastatin reduces serum cholesterol and triglycerides with limited improvement in vascular function in adults with sickle cell anemia.
    Haematologica, 2012, Volume: 97, Issue:11

    Topics: Adult; Anemia, Sickle Cell; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cohort Studies; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles

2012
Association of cholesteryl ester transfer protein mass with peripheral leukocyte count following statin therapy: a pilot study.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2012, Oct-01, Volume: 12, Issue:5

    Topics: Aged; Atorvastatin; Cholesterol Ester Transfer Proteins; Cholesterol, LDL; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Leukocyte Count; Lipids; Male; Middle Aged; Multivariate Analysis; Pilot Projects; Pravastatin; Pyrroles; Regression Analysis; Risk Factors

2012
No effect of high-dose atorvastatin on leukotriene B₄ formation from neutrophils in patients treated with coronary bypass surgery: a randomized placebo-controlled double-blinded trial with a crossover design.
    Prostaglandins, leukotrienes, and essential fatty acids, 2012, Volume: 87, Issue:6

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Atorvastatin; Calcimycin; Calcium Ionophores; Cholesterol, LDL; Combined Modality Therapy; Coronary Artery Bypass; Coronary Disease; Cross-Over Studies; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Leukotriene B4; Male; Middle Aged; Neutrophil Activation; Neutrophils; Pyrroles

2012
Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia.
    The New England journal of medicine, 2012, Nov-15, Volume: 367, Issue:20

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Atorvastatin; Cholesterol, LDL; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Least-Squares Analysis; Male; Middle Aged; Proprotein Convertase 9; Proprotein Convertases; Pyrroles; Serine Endopeptidases; Treatment Outcome

2012
Effects of pitavastatin and atorvastatin on lipoprotein oxidation biomarkers in patients with dyslipidemia.
    Atherosclerosis, 2013, Volume: 226, Issue:1

    Topics: Atorvastatin; Biomarkers; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins; Male; Middle Aged; Oxidation-Reduction; Prospective Studies; Pyrroles; Quinolines

2013
Assessment of the efficacy and tolerability of 2 formulations of atorvastatin in Korean adults with hypercholesterolemia: a multicenter, prospective, open-label, randomized trial.
    Clinical therapeutics, 2013, Volume: 35, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Apolipoprotein A-I; Apolipoproteins B; Asian People; Atorvastatin; Biomarkers; C-Reactive Protein; Chemistry, Pharmaceutical; Cholesterol, HDL; Cholesterol, LDL; Drugs, Generic; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Prospective Studies; Pyrroles; Republic of Korea; Therapeutic Equivalency; Time Factors; Treatment Outcome; Triglycerides; Young Adult

2013
A comparison of efficacy and safety of an ezetimibe/simvastatin combination compared with other intensified lipid-lowering treatment strategies in diabetic patients with symptomatic cardiovascular disease.
    Diabetes & vascular disease research, 2013, Volume: 10, Issue:3

    Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Complications; Diabetic Angiopathies; Double-Blind Method; Drug Combinations; Drug Monitoring; Ezetimibe, Simvastatin Drug Combination; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hypercholesterolemia; Longitudinal Studies; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Severity of Illness Index; Simvastatin; Sulfonamides

2013
Use of atorvastatin in hyperlipidemic hypertensive renal transplant recipients.
    Pediatric nephrology (Berlin, Germany), 2002, Volume: 17, Issue:7

    Topics: Adolescent; Atorvastatin; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Child; Child, Preschool; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension, Renal; Kidney Transplantation; Male; Prospective Studies; Pyrroles; Treatment Outcome

2002
Atorvastatin lowers lipoprotein(a) but not apolipoprotein(a) fragment levels in hypercholesterolemic subjects at high cardiovascular risk.
    Atherosclerosis, 2002, Volume: 164, Issue:2

    Topics: Adult; Aged; Apolipoproteins A; Atorvastatin; Cardiovascular Diseases; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Lipoprotein(a); Logistic Models; Male; Middle Aged; Probability; Pyrroles; Reference Values; Risk Assessment; Sensitivity and Specificity; Severity of Illness Index; Simvastatin; Statistics, Nonparametric; Treatment Outcome

2002
Comparing the efficacy and safety of atorvastatin and simvastatin in Asians with elevated low-density lipoprotein-cholesterol--a multinational, multicenter, double-blind study.
    Journal of the Formosan Medical Association = Taiwan yi zhi, 2002, Volume: 101, Issue:7

    Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Simvastatin

2002
Effect of atorvastatin on endothelium-dependent vasodilation in postmenopausal women with average serum cholesterol levels.
    The American journal of cardiology, 2002, Oct-01, Volume: 90, Issue:7

    Topics: Acetylcholine; Anticholesteremic Agents; Arginine; Atorvastatin; Brachial Artery; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Double-Blind Method; Endothelium, Vascular; Female; Forearm; Heptanoic Acids; Humans; Hypercholesterolemia; Middle Aged; Nitroprusside; omega-N-Methylarginine; Postmenopause; Pyrroles; Reference Values; Regional Blood Flow; Treatment Outcome; Vasodilation; Vasodilator Agents

2002
Is alternate daily dose of atorvastatin effective in treating patients with hyperlipidemia? The Alternate Day Versus Daily Dosing of Atorvastatin Study (ADDAS).
    American heart journal, 2002, Volume: 144, Issue:4

    Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Double-Blind Method; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pilot Projects; Pyrroles

2002
Effects of atorvastatin treatment on sICAM-1 and plasma nitric oxide levels in hypercholesterolemic subjects.
    Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2002, Volume: 8, Issue:3

    Topics: Adult; Anticholesteremic Agents; Atorvastatin; Cholesterol; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Intercellular Adhesion Molecule-1; Male; Middle Aged; Nitric Oxide; Placebos; Pyrroles; Time Factors

2002
Effects of atorvastatin 80 mg daily early after onset of unstable angina pectoris or non-Q-wave myocardial infarction.
    The American journal of cardiology, 2002, Oct-15, Volume: 90, Issue:8

    Topics: Aged; Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cardiovascular Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Myocardial Infarction; Pyrroles; Recurrence; Survival Rate

2002
Effects of atorvastatin on aortic pulse wave velocity in patients with hypertension and hypercholesterolaemia: a preliminary study.
    Journal of human hypertension, 2002, Volume: 16, Issue:10

    Topics: Adult; Aged; Anticholesteremic Agents; Aorta; Atorvastatin; Blood Pressure; Double-Blind Method; Elasticity; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Male; Middle Aged; Pulse; Pyrroles; Statistics, Nonparametric; Treatment Outcome

2002
Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia.
    American heart journal, 2002, Volume: 144, Issue:6

    Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Double-Blind Method; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides

2002
[Effect of atorvastatin on endothelial function in patients with familial hypercholesterolemia].
    Kardiologiia, 2002, Volume: 42, Issue:1

    Topics: Adult; Anticholesteremic Agents; Atorvastatin; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles

2002
Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease.
    The American journal of cardiology, 2003, Jan-01, Volume: 91, Issue:1

    Topics: Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hypercholesterolemia; Linear Models; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome

2003
Time-dependent effect of statins on platelet function in hypercholesterolaemia.
    European journal of clinical investigation, 2002, Volume: 32, Issue:12

    Topics: Adult; Analysis of Variance; Antiporters; Atorvastatin; Blood Platelets; Case-Control Studies; Cholesterol; Cholesterol, LDL; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Linear Models; Lipoproteins, LDL; Male; Middle Aged; Nitric Oxide Synthase; P-Selectin; Platelet Activation; Pravastatin; Pyrroles; Simvastatin; Time Factors

2002
Levels of adhesion molecules do not decrease after 3 months of statin therapy in moderate hypercholesterolaemia.
    Clinical science (London, England : 1979), 2003, Volume: 104, Issue:2

    Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cell Adhesion Molecules; Cholesterol; Cross-Sectional Studies; Double-Blind Method; E-Selectin; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Intercellular Adhesion Molecule-1; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Vascular Cell Adhesion Molecule-1

2003
Low-dose atorvastatin therapy does not augment endothelial function in active hypercholesterolaemic males.
    British journal of clinical pharmacology, 2003, Volume: 55, Issue:2

    Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, LDL; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrroles

2003
A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2003, Volume: 41, Issue:3

    Topics: Anticholesteremic Agents; Atorvastatin; Chronic Disease; Disease Progression; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Kidney Diseases; Kidney Glomerulus; Male; Middle Aged; Prospective Studies; Proteinuria; Pyrroles

2003
A 52-week, multicenter, randomized, parallel-group, double-blind, double-dummy study to assess the efficacy of atorvastatin and simvastatin in reaching low-density lipoprotein cholesterol and triglyceride targets: the treat-to-target (3T) study.
    Clinical therapeutics, 2003, Volume: 25, Issue:1

    Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Simvastatin; Treatment Outcome; Triglycerides

2003
Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups.
    The American journal of cardiology, 2003, Mar-06, Volume: 91, Issue:5A

    Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Administration Schedule; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Least-Squares Analysis; Male; Middle Aged; Multicenter Studies as Topic; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome

2003
Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals.
    The American journal of cardiology, 2003, Mar-06, Volume: 91, Issue:5A

    Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Administration Schedule; Europe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Multicenter Studies as Topic; Practice Guidelines as Topic; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome

2003
Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin.
    The American journal of cardiology, 2003, Mar-06, Volume: 91, Issue:5A

    Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Europe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Least-Squares Analysis; Lipids; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome

2003
A pharmacoeconomic evaluation of the Myocardial Ischaemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study in the United Kingdom.
    PharmacoEconomics, 2003, Volume: 21 Suppl 1

    Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Cohort Studies; Cost-Benefit Analysis; Double-Blind Method; Endpoint Determination; Health Care Costs; Heptanoic Acids; Hospitalization; Humans; Hypercholesterolemia; Myocardial Ischemia; Pyrroles; Treatment Outcome; United Kingdom

2003
An economic analysis of the Atorvastatin Comparative Cholesterol Efficacy and Safety Study (ACCESS).
    PharmacoEconomics, 2003, Volume: 21 Suppl 1

    Topics: Adult; Aged; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Male; Middle Aged; Pravastatin; Pyrroles; Risk Factors; Simvastatin; Treatment Outcome

2003
Hemostatic effects of atorvastatin versus simvastatin.
    The Annals of pharmacotherapy, 2003, Volume: 37, Issue:4

    Topics: Adult; Aged; Atorvastatin; Cholesterol; Dose-Response Relationship, Drug; Double-Blind Method; Female; Hemostasis; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Simvastatin

2003
Long-term treatment effect of atorvastatin on aortic stiffness in hypercholesterolaemic patients.
    Current medical research and opinion, 2003, Volume: 19, Issue:1

    Topics: Adult; Aged; Anticholesteremic Agents; Aortic Valve; Atorvastatin; Cardiovascular Diseases; Echocardiography; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Placebos; Pyrroles; Time; United States

2003
Pharmacokinetics of atorvastatin and its metabolites after single and multiple dosing in hypercholesterolaemic haemodialysis patients.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2003, Volume: 18, Issue:5

    Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Drug Tolerance; Female; Half-Life; Heptanoic Acids; Humans; Hypercholesterolemia; Kidney Failure, Chronic; Male; Middle Aged; Pyrroles; Renal Dialysis

2003
Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial.
    Circulation, 2003, May-20, Volume: 107, Issue:19

    Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Digestive System; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Musculoskeletal Diseases; Prospective Studies; Pyrroles; Treatment Outcome; Triglycerides

2003
Efficacy of alternate-day dosing versus daily dosing of atorvastatin.
    Journal of cardiovascular pharmacology and therapeutics, 2003, Volume: 8, Issue:2

    Topics: Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Drug Administration Schedule; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Liver Function Tests; Middle Aged; Prospective Studies; Pyrroles; Triglycerides

2003
Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).
    The American journal of cardiology, 2003, Jul-15, Volume: 92, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Time Factors

2003
Comparative effects of simvastatin and atorvastatin in hypercholesterolemic patients with characteristics of metabolic syndrome.
    Clinical therapeutics, 2003, Volume: 25, Issue:6

    Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Metabolic Syndrome; Middle Aged; Pyrroles; Risk Factors; Simvastatin; Time Factors; Triglycerides

2003
Statins promote potent systemic antioxidant effects through specific inflammatory pathways.
    Circulation, 2003, Jul-29, Volume: 108, Issue:4

    Topics: Antioxidants; Arteriosclerosis; Atorvastatin; Biomarkers; C-Reactive Protein; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Inflammation; Lipoproteins; Male; Middle Aged; Oxidation-Reduction; Prospective Studies; Pyrroles; Reactive Oxygen Species; Signal Transduction; Statistics, Nonparametric; Tyrosine

2003
[Markers of inflammation and platelet aggregation in patients with non ST elevation acute coronary syndrome treated with atorvastatin or pravastatin].
    Kardiologiia, 2003, Volume: 43, Issue:1

    Topics: Acute Disease; Adult; Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Coronary Disease; Drug Administration Schedule; Electrocardiography; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Inflammation; Male; Middle Aged; Platelet Aggregation; Pravastatin; Pyrroles; Time Factors

2003
Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial.
    The Journal of pediatrics, 2003, Volume: 143, Issue:1

    Topics: Adolescent; Adult; Apolipoproteins B; Atorvastatin; Child; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipidemias; Hypolipidemic Agents; Male; Pyrroles; Severity of Illness Index; Triglycerides

2003
Soluble intercellular adhesion molecule-1 and interleukin-6 levels reflect endothelial dysfunction in patients with primary hypercholesterolaemia treated with atorvastatin.
    Atherosclerosis, 2003, Volume: 169, Issue:2

    Topics: Anticholesteremic Agents; Atorvastatin; E-Selectin; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Intercellular Adhesion Molecule-1; Interleukin-6; Male; Middle Aged; Multivariate Analysis; Prospective Studies; Pyrroles; Vascular Cell Adhesion Molecule-1; Vasodilation

2003
Elimination of alfentanil delivered by infusion is not altered by the chronic administration of atorvastatin.
    European journal of anaesthesiology, 2003, Volume: 20, Issue:8

    Topics: Adult; Aged; Alfentanil; Analgesics, Opioid; Anticholesteremic Agents; Area Under Curve; Atorvastatin; Chromatography, Gas; Drug Interactions; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Infusions, Intravenous; Male; Middle Aged; Pyrroles; Time Factors

2003
Effect of atorvastatin on myocardial contractile reserve assessed by tissue Doppler imaging in moderately hypercholesterolemic patients without heart disease.
    The American journal of cardiology, 2003, Sep-01, Volume: 92, Issue:5

    Topics: Aged; Atorvastatin; Blood Flow Velocity; Blood Pressure; Cardiotonic Agents; Cholesterol, HDL; Cholesterol, LDL; Diastole; Diet, Fat-Restricted; Dobutamine; Echocardiography, Doppler; Female; Follow-Up Studies; Heart Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Myocardial Contraction; Pyrroles; Stroke Volume; Systole; Treatment Outcome; Triglycerides

2003
Reduction in serum levels of adhesion molecules, interleukin-6 and C-reactive protein following short-term low-dose atorvastatin treatment in patients with non-familial hypercholesterolemia.
    Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2003, Volume: 35, Issue:8

    Topics: Atorvastatin; C-Reactive Protein; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; E-Selectin; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Intercellular Adhesion Molecule-1; Interleukin-6; Lipids; Male; Middle Aged; Multivariate Analysis; Pyrroles; Vascular Cell Adhesion Molecule-1

2003
Atorvastatin treatment does not affect gonadal and adrenal hormones in type 2 diabetes patients with mild to moderate hypercholesterolemia.
    Journal of atherosclerosis and thrombosis, 2003, Volume: 10, Issue:3

    Topics: Adrenal Cortex Hormones; Adrenal Glands; Aged; Atorvastatin; Diabetes Mellitus, Type 2; Female; Gonadal Steroid Hormones; Gonads; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Severity of Illness Index

2003
Effects of atorvastatin and pravastatin on malondialdehyde-modified LDL in hypercholesterolemic patients.
    Circulation journal : official journal of the Japanese Circulation Society, 2003, Volume: 67, Issue:10

    Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cross-Over Studies; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Lipoproteins, LDL; Male; Malondialdehyde; Middle Aged; Oxidation-Reduction; Pravastatin; Pyrroles

2003
Effects of atorvastatin therapy on the low-density lipoprotein subfraction, remnant-like particles cholesterol, and oxidized low-density lipoprotein within 2 weeks in hypercholesterolemic patients.
    Circulation journal : official journal of the Japanese Circulation Society, 2003, Volume: 67, Issue:10

    Topics: Aged; Atorvastatin; Biomarkers; Cholesterol; Female; Fibrinolysis; Heptanoic Acids; Humans; Hypercholesterolemia; Lipids; Lipoproteins, LDL; Male; Middle Aged; Pyrroles; Thiobarbituric Acid Reactive Substances; Time Factors

2003
Effect on high-density lipoprotein cholesterol of maximum dose simvastatin and atorvastatin in patients with hypercholesterolemia: results of the Comparative HDL Efficacy and Safety Study (CHESS).
    American heart journal, 2003, Volume: 146, Issue:5

    Topics: Adult; Aged; Alkaline Phosphatase; Apolipoprotein A-I; Atorvastatin; Cholesterol, HDL; Diarrhea; Double-Blind Method; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Musculoskeletal Diseases; Nausea; Pyrroles; Simvastatin

2003
Differential effects of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I are consistent across hypercholesterolemic patient subgroups.
    Clinical cardiology, 2003, Volume: 26, Issue:11

    Topics: Apolipoprotein A-I; Atorvastatin; Cholesterol, HDL; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles; Simvastatin

2003
Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial.
    Current medical research and opinion, 2003, Volume: 19, Issue:8

    Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; North America; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides

2003
Effect of atorvastatin 80 mg on endothelial cell function (forearm blood flow) in patients with pretreatment serum low-density lipoprotein cholesterol levels <130 mg/dl.
    The American journal of cardiology, 2004, Jan-01, Volume: 93, Issue:1

    Topics: Administration, Oral; Anticholesteremic Agents; Atorvastatin; Blood Flow Velocity; Brachial Artery; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Administration Schedule; Endothelium, Vascular; Female; Forearm; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperemia; Male; Middle Aged; Nitroglycerin; Pulsatile Flow; Pyrroles; Treatment Outcome; Triglycerides; Vasodilation

2004
Effects of low and high doses of atorvastatin on arterial compliance.
    Japanese heart journal, 2003, Volume: 44, Issue:6

    Topics: Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Carotid Artery, Common; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Compliance; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Triglycerides; Ultrasonography, Doppler, Color; Ultrasonography, Interventional

2003
Rationale, design and methods of the CASHMERE study.
    Fundamental & clinical pharmacology, 2004, Volume: 18, Issue:1

    Topics: Aged; Atorvastatin; Blood Pressure; Cardiovascular Diseases; Carotid Arteries; Double-Blind Method; Drug Therapy, Combination; Echocardiography; Endpoint Determination; Estrogen Replacement Therapy; Female; Femoral Artery; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Middle Aged; Prospective Studies; Pyrroles; Research Design; Treatment Outcome

2004
Time course differences for statin-induced pleiotropic effects in hypercholesterolemic patients.
    International journal of cardiology, 2004, Volume: 94, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipoproteins; Male; Middle Aged; Mutation; Phenotype; Pyridines; Pyrroles; Time Factors

2004
Plasma levels of beta-amyloid(1-40), beta-amyloid(1-42), and total beta-amyloid remain unaffected in adult patients with hypercholesterolemia after treatment with statins.
    Archives of neurology, 2004, Volume: 61, Issue:3

    Topics: Adult; Aged; Amyloid beta-Peptides; Anticholesteremic Agents; Atorvastatin; Cross-Over Studies; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipids; Male; Middle Aged; Peptide Fragments; Prospective Studies; Pyrroles; Simvastatin; Time Factors

2004
Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study.
    American heart journal, 2004, Volume: 147, Issue:4

    Topics: Aged; Arteriosclerosis; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Logistic Models; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Triglycerides

2004
[Clinical study of the month. REVERAL and PROVE-IT: confirmation of the concept " the lower, the better" for cholesterol therapy in patients with coronary heart disease].
    Revue medicale de Liege, 2004, Volume: 59, Issue:3

    Topics: Anticholesteremic Agents; Atorvastatin; Coronary Artery Disease; Coronary Disease; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hypercholesterolemia; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic

2004
Effect of atorvastatin on different fibrinolyis mechanisms in hypercholesterolemic subjects.
    International journal of cardiology, 2004, Volume: 95, Issue:2-3

    Topics: Adult; Analysis of Variance; Atorvastatin; Female; Fibrinolysis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Statistics, Nonparametric

2004
Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia.
    The American journal of cardiology, 2004, Jun-15, Volume: 93, Issue:12

    Topics: Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Azetidines; Cholesterol; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Simvastatin; Treatment Outcome

2004
Comparative evaluation of the efficacy, safety, and tolerability of rosuvastatin 10 mg with atorvastatin 10 mg in adult patients with hypercholesterolaemia: the first Indian study.
    Journal of the Indian Medical Association, 2004, Volume: 102, Issue:1

    Topics: Apolipoproteins B; Atorvastatin; Cholesterol; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides

2004
Effects of lipid-lowering therapy on coronary artery remodeling.
    Coronary artery disease, 2004, Volume: 15, Issue:1

    Topics: Aged; Atorvastatin; Biomarkers; Cholesterol, LDL; Coronary Artery Disease; Female; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Longitudinal Studies; Male; Middle Aged; Pyrroles; Statistics as Topic; Treatment Outcome; Ultrasonography, Interventional

2004
Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial.
    American heart journal, 2004, Volume: 148, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Cholesterol; Double-Blind Method; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Least-Squares Analysis; Logistic Models; Male; Middle Aged; Muscular Diseases; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Triglycerides

2004
Atorvastatin treatment decreases inflammatory and proteolytic activity in patients with hypercholesterolemia.
    Kardiologia polska, 2004, Volume: 60, Issue:5

    Topics: Adult; Anticholesteremic Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Inflammation; Male; Matrix Metalloproteinase 9; Middle Aged; Prospective Studies; Pyrroles; Treatment Outcome

2004
Short-term effect of atorvastatin on ischaemic threshold in hypercholesterolaemic patients with stable ischaemic heart disease.
    Acta cardiologica, 2004, Volume: 59, Issue:3

    Topics: Aged; Angina Pectoris; Atorvastatin; Cholesterol, LDL; Disease Progression; Exercise Test; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Myocardial Ischemia; Pyrroles; Time Factors

2004
Long-term safety and tolerability profile of ezetimibe and atorvastatin coadministration therapy in patients with primary hypercholesterolaemia.
    International journal of clinical practice, 2004, Volume: 58, Issue:7

    Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Treatment Outcome

2004
Effect of amlodipine-atorvastatin combination on fibrinolysis in hypertensive hypercholesterolemic patients with insulin resistance.
    American journal of hypertension, 2004, Volume: 17, Issue:9

    Topics: Adult; Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Drug Therapy, Combination; Female; Fibrinolysis; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Insulin Resistance; Male; Middle Aged; Plasminogen Activator Inhibitor 1; Pyrroles; Tissue Plasminogen Activator

2004
Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin.
    American heart journal, 2004, Volume: 148, Issue:3

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Risk Factors; Triglycerides

2004
Progesterone abolishes estrogen and/or atorvastatin endothelium dependent vasodilatory effects.
    Atherosclerosis, 2004, Volume: 177, Issue:1

    Topics: Aged; Atorvastatin; Double-Blind Method; Drug Therapy, Combination; Endothelium, Vascular; Estradiol; Estrogen Antagonists; Estrogens; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Middle Aged; Norethindrone; Progesterone; Pyrroles; Vasodilation

2004
Lipid and apoprotein changes during atorvastatin up-titration in hemodialysis patients with hypercholesterolemia: a placebo-controlled study.
    Clinical nephrology, 2004, Volume: 62, Issue:4

    Topics: Aged; Apolipoproteins B; Atorvastatin; Cholesterol, LDL; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Kidney Failure, Chronic; Male; Middle Aged; Pyrroles; Renal Dialysis; Time Factors; Treatment Outcome

2004
Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
    Clinical therapeutics, 2004, Volume: 26, Issue:9

    Topics: Aged; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome

2004
Predictors of change in low-density lipoprotein size during lipid-lowering treatment in type 2 diabetes.
    Metabolism: clinical and experimental, 2004, Volume: 53, Issue:11

    Topics: Aged; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Gemfibrozil; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pyrroles; Triglycerides

2004
Comparison of the impact of atorvastatin and simvastatin on apoA-I kinetics in men.
    Atherosclerosis, 2005, Volume: 178, Issue:1

    Topics: Apolipoprotein A-I; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Double-Blind Method; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Kinetics; Lipids; Male; Middle Aged; Pyrroles; Simvastatin

2005
Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
    Clinical therapeutics, 2004, Volume: 26, Issue:11

    Topics: Atorvastatin; Cholesterol, LDL; Coronary Disease; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Triglycerides

2004
Atorvastatin and pravastatin elevated pre-heparin lipoprotein lipase mass of type 2 diabetes with hypercholesterolemia.
    Journal of atherosclerosis and thrombosis, 2004, Volume: 11, Issue:6

    Topics: Anticholesteremic Agents; Atorvastatin; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoprotein Lipase; Middle Aged; Pravastatin; Pyrroles

2004
Short-term treatment with atorvastatin reduces platelet CD40 ligand and thrombin generation in hypercholesterolemic patients.
    Circulation, 2005, Feb-01, Volume: 111, Issue:4

    Topics: Adenosine Diphosphate; Atorvastatin; Biomarkers; Blood Coagulation; Blood Platelets; CD40 Ligand; Collagen; Coronary Disease; Female; Fibrinolytic Agents; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Monocytes; Multifactorial Inheritance; Peptide Fragments; Prothrombin; Pyrroles; Solubility; Thrombin; Thromboplastin; Treatment Outcome

2005
Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin, pravastatin and simvastatin: analysis of the STELLAR trial.
    European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology, 2005, Volume: 12, Issue:1

    Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Cost-Benefit Analysis; Drug Costs; Economics, Pharmaceutical; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Sulfonamides

2005
Effects of statin therapy on circulating conjugated dienes, a measure of LDL oxidation.
    Atherosclerosis, 2005, Volume: 179, Issue:1

    Topics: Aged; Atorvastatin; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins, LDL; Male; Middle Aged; Pyrroles; Simvastatin

2005
Effect of lipid-lowering therapy with atorvastatin on atherosclerotic aortic plaques detected by noninvasive magnetic resonance imaging.
    Journal of the American College of Cardiology, 2005, Mar-01, Volume: 45, Issue:5

    Topics: Aged; Anticholesteremic Agents; Aorta, Abdominal; Aorta, Thoracic; Aortic Diseases; Arteriosclerosis; Atorvastatin; Cholesterol, LDL; Disease Progression; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Image Enhancement; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Middle Aged; Pyrroles; Treatment Outcome

2005
Effects of ezetimibe on plasma lipoproteins in severely hypercholesterolemic patients treated with regular LDL-apheresis and statins.
    Atherosclerosis, 2005, Volume: 180, Issue:1

    Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Blood Component Removal; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Combined Modality Therapy; Cross-Over Studies; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins; Male; Middle Aged; Pyrroles; Simvastatin; Triglycerides

2005
Effects of switching statins on lipid and apolipoprotein ratios in the MERCURY I study.
    International journal of cardiology, 2005, Apr-20, Volume: 100, Issue:2

    Topics: Analysis of Variance; Apolipoproteins; Atorvastatin; Coronary Disease; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Risk; Rosuvastatin Calcium; Simvastatin; Sulfonamides

2005
Effects of atorvastatin on low-density lipoprotein cholesterol phenotype and C-reactive protein levels in patients undergoing long-term dialysis.
    Pharmacotherapy, 2005, Volume: 25, Issue:3

    Topics: Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cholesterol; Cholesterol, LDL; Chronic Disease; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Kidney Failure, Chronic; Male; Middle Aged; Particle Size; Phenotype; Pilot Projects; Pyrroles; Renal Dialysis; Risk Factors; Triglycerides

2005
Lipid-independent effects of statins on endothelial function and bioavailability of nitric oxide in hypercholesterolemic patients.
    American heart journal, 2005, Volume: 149, Issue:3

    Topics: Acetylcholine; Adult; Aged; Ascorbic Acid; Atorvastatin; Biological Availability; C-Reactive Protein; Dose-Response Relationship, Drug; Double-Blind Method; Endothelium, Vascular; Female; Forearm; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipid Metabolism; Male; Middle Aged; Nitric Oxide; Nitroprusside; omega-N-Methylarginine; Pyridines; Pyrroles; Regional Blood Flow; Vasodilation

2005
Statins have additive effects to vertebral bone mineral density in combination with risedronate in hypercholesterolemic postmenopausal women.
    European journal of obstetrics, gynecology, and reproductive biology, 2005, May-01, Volume: 120, Issue:1

    Topics: Atorvastatin; Bone Density; Bone Diseases, Metabolic; Cholesterol; Cholesterol, LDL; Drug Therapy, Combination; Etidronic Acid; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Pelvic Bones; Postmenopause; Pyrroles; Risedronic Acid

2005
A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial.
    Mayo Clinic proceedings, 2005, Volume: 80, Issue:5

    Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Male; Middle Aged; Nephelometry and Turbidimetry; Practice Guidelines as Topic; Pravastatin; Pyrroles; Retrospective Studies; Risk Factors; Simvastatin

2005
Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial.
    Journal of the American College of Cardiology, 2005, May-17, Volume: 45, Issue:10

    Topics: Administration, Oral; Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Cohort Studies; Coronary Restenosis; Dose-Response Relationship, Drug; Female; Fluoroquinolones; Follow-Up Studies; Gatifloxacin; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Secondary Prevention; Statistics as Topic; Survival Rate; Treatment Outcome

2005
Cholesterol-lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes -- CORALL study.
    Journal of internal medicine, 2005, Volume: 257, Issue:6

    Topics: Anticholesteremic Agents; Apolipoprotein A-I; Apolipoproteins A; Apolipoproteins B; Atorvastatin; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hypercholesterolemia; Lipids; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides

2005
A promoter polymorphism in cholesterol 7alpha-hydroxylase interacts with apolipoprotein E genotype in the LDL-lowering response to atorvastatin.
    Atherosclerosis, 2005, Volume: 180, Issue:2

    Topics: Aged; Anticholesteremic Agents; Apolipoproteins E; Atorvastatin; Bile Acids and Salts; Cholesterol 7-alpha-Hydroxylase; Cholesterol, LDL; Double-Blind Method; Female; Genotype; Heptanoic Acids; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Placebos; Polymorphism, Genetic; Promoter Regions, Genetic; Pyrroles; Sex Factors; Treatment Outcome

2005
Efficacy and safety of ezetimibe co-administered with ongoing atorvastatin therapy in achieving low-density lipoprotein goal in patients with hypercholesterolemia and coronary heart disease.
    International journal of clinical practice, 2005, Volume: 59, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Safety

2005
Reduction of serum ubiquinol-10 and ubiquinone-10 levels by atorvastatin in hypercholesterolemic patients.
    Journal of atherosclerosis and thrombosis, 2005, Volume: 12, Issue:2

    Topics: Aged; Atorvastatin; Biomarkers; Cholesterol; Coenzymes; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Pyrroles; Risk Factors; Treatment Outcome; Ubiquinone

2005
Randomized trial of atorvastatin in improving endothelial function in diabetics without prior coronary disease and having average cholesterol level.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2005, Volume: 88, Issue:3

    Topics: Atorvastatin; Coronary Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Outpatients; Pyrroles; Vascular Diseases

2005
Antioxidant effect of atorvastatin is independent of PON1 gene T(-107)C, Q192R and L55M polymorphisms in hypercholesterolaemic patients.
    Current medical research and opinion, 2005, Volume: 21, Issue:5

    Topics: Anticholesteremic Agents; Aryldialkylphosphatase; Atorvastatin; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Oxidation-Reduction; Placebos; Polymorphism, Genetic; Promoter Regions, Genetic; Pyrroles; Vitamin E

2005
Efficacy and safety of chunghyul-dan (qingwie-dan) in patients with hypercholesterolemia.
    The American journal of Chinese medicine, 2005, Volume: 33, Issue:2

    Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Drugs, Chinese Herbal; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Placebos; Pyrroles; Treatment Outcome

2005
High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial.
    Clinical pharmacology and therapeutics, 2005, Volume: 78, Issue:1

    Topics: Adult; Age Factors; Aged; Atorvastatin; Biopsy; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Citrate (si)-Synthase; Dose-Response Relationship, Drug; Double-Blind Method; Electron Transport; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Muscles; Patient Selection; Phytosterols; Pyrroles; Sex Factors; Simvastatin; Sitosterols; Succinate Cytochrome c Oxidoreductase; Time Factors; Ubiquinone

2005
The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL-C Value--an Evaluation of Rosuvastatin therapY compared with atorvastatin.
    Current medical research and opinion, 2005, Volume: 21, Issue:8

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Program Evaluation; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Triglycerides

2005
Plasma low-density lipoprotein reduction and structural effects on coronary atherosclerotic plaques by atorvastatin as clinically assessed with intravascular ultrasound radio-frequency signal analysis: a randomized prospective study.
    American heart journal, 2005, Volume: 150, Issue:2

    Topics: Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Atorvastatin; Cardiovascular Agents; Cholesterol, LDL; Comorbidity; Coronary Artery Disease; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Prospective Studies; Pyrroles; Radio Waves; Single-Blind Method; Treatment Outcome; Ultrasonography, Interventional

2005
Efficacy and safety of statins in hypercholesterolemia with emphasis on lipoproteins.
    Heart and vessels, 2005, Volume: 20, Issue:5

    Topics: Adult; Anticholesteremic Agents; Atorvastatin; Cross-Over Studies; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipoproteins; Male; Pyrroles; Simvastatin; Statistics, Nonparametric; Treatment Outcome

2005
Beneficial effects of atorvastatin on sd LDL and LDL phenotype B in statin-naive patients and patients previously treated with simvastatin or pravastatin.
    International journal of cardiology, 2005, Oct-10, Volume: 104, Issue:3

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins, LDL; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrroles; Simvastatin; Treatment Outcome; Triglycerides

2005
Use of a treatment algorithm to achieve NCEP ATP III goals with atorvastatin.
    Journal of cardiovascular pharmacology, 2005, Volume: 46, Issue:5

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Algorithms; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Risk Factors

2005
Lipid-altering efficacy of switching from atorvastatin 10 mg/day to ezetimibe/simvastatin 10/20 mg/day compared to doubling the dose of atorvastatin in hypercholesterolaemic patients with atherosclerosis or coronary heart disease.
    International journal of clinical practice, 2005, Volume: 59, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Apolipoproteins B; Atherosclerosis; Atorvastatin; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Europe; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Simvastatin; Taiwan; Treatment Outcome

2005
Achieving lipid goals in real life: the Dutch DISCOVERY study.
    International journal of clinical practice, 2005, Volume: 59, Issue:12

    Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Netherlands; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; Triglycerides

2005
Short-term effects of low-dose atorvastatin on inflammatory status and lipid profiles in perimenopausal hypercholesterolemic, hypertriglyceridemic women.
    International journal of cardiology, 2006, Oct-26, Volume: 113, Issue:1

    Topics: Adult; Atorvastatin; Blood Coagulation; C-Reactive Protein; Cholesterol; Cholesterol, LDL; Female; Fibrinolysis; Gonadal Steroid Hormones; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertriglyceridemia; Inflammation; Lipids; Lipoproteins; Malondialdehyde; Middle Aged; Plasminogen Activator Inhibitor 1; Postmenopause; Premenopause; Prospective Studies; Pyrroles; Time Factors; Tissue Plasminogen Activator; Triglycerides

2006
Preoperative statin therapy and troponin T predict early complications of coronary artery surgery.
    The Annals of thoracic surgery, 2006, Volume: 81, Issue:1

    Topics: Aged; Atorvastatin; Biomarkers; C-Reactive Protein; Comorbidity; Coronary Artery Bypass; Creatine Kinase, MB Form; Female; Heptanoic Acids; Hospital Mortality; Hospitals, University; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Incidence; Interleukin-6; Lipids; Male; Middle Aged; Myocardial Infarction; Postoperative Complications; Pravastatin; Premedication; Preoperative Care; Prospective Studies; Pyrroles; Risk Assessment; Simvastatin; Systemic Inflammatory Response Syndrome; Troponin T

2006
The ability of statins to protect low density lipoprotein from oxidation in hypercholesterolemic patients.
    International journal of clinical pharmacology and therapeutics, 2005, Volume: 43, Issue:12

    Topics: Anticholesteremic Agents; Atorvastatin; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipid Peroxidation; Lipoproteins, LDL; Male; Middle Aged; Oxidation-Reduction; Pravastatin; Pyrroles; Simvastatin; Thiobarbituric Acid Reactive Substances

2005
[Estimation of antioxidative effect of atorvastatin and fluvastatin used in primary prevention of coronary heart disease--effect on lipid peroxidation].
    Wiadomosci lekarskie (Warsaw, Poland : 1960), 2005, Volume: 58, Issue:7-8

    Topics: Adult; Anticholesteremic Agents; Antioxidants; Atorvastatin; Coronary Artery Disease; Fatty Acids, Monounsaturated; Female; Fluvastatin; Free Radical Scavengers; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lipid Peroxidation; Male; Malondialdehyde; Middle Aged; Primary Prevention; Pyrroles; Treatment Outcome

2005
[Erythrocyte fluidity in patients with hyperlipidemia during statins therapy].
    Polskie Archiwum Medycyny Wewnetrznej, 2005, Volume: 113, Issue:6

    Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Erythrocyte Membrane; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipid Peroxidation; Male; Membrane Fluidity; Membrane Lipids; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Statistics, Nonparametric; Triglycerides

2005
Probucol and atorvastatin decrease urinary 8-hydroxy-2'-deoxyguanosine in patients with diabetes and hypercholesterolemia.
    Journal of atherosclerosis and thrombosis, 2006, Volume: 13, Issue:1

    Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Anticholesteremic Agents; Antioxidants; Atorvastatin; Biomarkers; Deoxyguanosine; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Oxidative Stress; Probucol; Pyrroles; Treatment Outcome

2006
Usefulness of atorvastatin in patients with heart failure due to inflammatory dilated cardiomyopathy and elevated cholesterol levels.
    The American journal of cardiology, 2006, Mar-15, Volume: 97, Issue:6

    Topics: Adult; Atorvastatin; Cardiomyopathy, Dilated; Cholesterol, LDL; Drug Therapy, Combination; Endpoint Determination; Evaluation Studies as Topic; Female; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Immunohistochemistry; Male; Myocardium; Pyrroles; Quality of Life; Treatment Outcome; Ventricular Function, Left

2006
Effect of individualizing starting doses of a statin according to baseline LDL-cholesterol levels on achieving cholesterol targets: the achieve cholesterol targets fast with atorvastatin stratified titration (ACTFAST) study.
    Atherosclerosis, 2007, Volume: 191, Issue:1

    Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Risk Factors; Treatment Outcome

2007
Effects of atorvastatin and atorvastatin withdrawal on soluble CD40L and adipocytokines in patients with hypercholesterolaemia.
    Acta cardiologica, 2006, Volume: 61, Issue:3

    Topics: Adiponectin; Aged; Anticholesteremic Agents; Atorvastatin; CD40 Ligand; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Resistin; Substance Withdrawal Syndrome; Triglycerides

2006
Treatment of hypercholesterolemia in patients with metabolic syndrome: how do different statins compare?
    Nature clinical practice. Endocrinology & metabolism, 2006, Volume: 2, Issue:3

    Topics: Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Metabolic Syndrome; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides

2006
[Effectiveness and tolerance of atorvastatin for antiretroviral therapy-secondary dyslipemia].
    Medicina clinica, 2006, Jul-15, Volume: 127, Issue:7

    Topics: Adult; Aged; Antiretroviral Therapy, Highly Active; Atorvastatin; Female; Heptanoic Acids; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Prospective Studies; Pyrroles

2006
Comparison of rosuvastatin versus atorvastatin in Hispanic-Americans with hypercholesterolemia (from the STARSHIP trial).
    The American journal of cardiology, 2006, Sep-15, Volume: 98, Issue:6

    Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Hispanic or Latino; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides

2006
Effect of atorvastatin therapy and conversion to tacrolimus on hypercholesterolemia and endothelial dysfunction after renal transplantation.
    Transplantation, 2006, Sep-27, Volume: 82, Issue:6

    Topics: Adult; Apolipoproteins; Atorvastatin; Body Mass Index; Creatinine; Cross-Over Studies; Drug Therapy, Combination; Endothelium, Vascular; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Immunosuppressive Agents; Kidney Transplantation; Lipids; Male; Middle Aged; Pyrroles; Tacrolimus; Triglycerides

2006
Plasma-soluble CD40 is related to cholesterol metabolism in patients with moderate hypercholesterolemia.
    Scandinavian cardiovascular journal : SCJ, 2006, Volume: 40, Issue:5

    Topics: Anticholesteremic Agents; Atorvastatin; Biomarkers; CD40 Antigens; Cholesterol; Cholesterol, Dietary; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Pyrroles; Severity of Illness Index; Simvastatin; Solubility

2006
Comparative lipid-lowering effects of policosanol and atorvastatin: a randomized, parallel, double-blind, placebo-controlled trial.
    American heart journal, 2006, Volume: 152, Issue:5

    Topics: Adult; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Fatty Alcohols; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Prospective Studies; Pyrroles; Treatment Outcome

2006
Ezetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study.
    Mayo Clinic proceedings, 2006, Volume: 81, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Simvastatin

2006
Short-term effects of atorvastatin on bone turnover in male patients with hypercholesterolemia.
    Endocrine journal, 2007, Volume: 54, Issue:1

    Topics: Aged; Alkaline Phosphatase; Anticholesteremic Agents; Atorvastatin; Biomarkers; Bone Remodeling; Collagen Type I; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Peptides; Pyrroles; Time Factors

2007
Atorvastatin decreases serum levels of advanced glycation end products (AGEs) in patients with type 2 diabetes.
    Clinical and experimental medicine, 2006, Volume: 6, Issue:4

    Topics: Anticholesteremic Agents; Atorvastatin; Diabetes Mellitus, Type 2; Female; Glycation End Products, Advanced; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Matched-Pair Analysis; Pyrroles

2006
Impact of atorvastatin treatment on platelet-activating factor acetylhydrolase and 15-F(2trans)-isoprostane in hypercholesterolaemic patients.
    British journal of clinical pharmacology, 2007, Volume: 63, Issue:6

    Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adult; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; F2-Isoprostanes; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles

2007
Efficacy and safety of rosuvastatin 40 mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolemia: results of the POLARIS study.
    Atherosclerosis, 2007, Volume: 194, Issue:2

    Topics: Aged; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides

2007
Comparison of the effects of high doses of rosuvastatin versus atorvastatin on the subpopulations of high-density lipoproteins.
    The American journal of cardiology, 2007, Mar-01, Volume: 99, Issue:5

    Topics: Adult; Aged; Apolipoprotein A-I; Atorvastatin; Cholesterol; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins, HDL; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Triglycerides

2007
Decreased skeletal muscle mitochondrial DNA in patients treated with high-dose simvastatin.
    Clinical pharmacology and therapeutics, 2007, Volume: 81, Issue:5

    Topics: Adult; Aged; Atorvastatin; DNA, Mitochondrial; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Longitudinal Studies; Male; Middle Aged; Mitochondria, Muscle; Pyrroles; Retrospective Studies; Simvastatin; Ubiquinone

2007
Effect of atorvastatin on peripheral endothelial function and systemic inflammatory markers in patients with stable coronary artery disease.
    Wiener medizinische Wochenschrift (1946), 2007, Volume: 157, Issue:3-4

    Topics: Anticholesteremic Agents; Atorvastatin; Brachial Artery; C-Reactive Protein; Coronary Disease; Double-Blind Method; E-Selectin; Endothelium, Vascular; Heptanoic Acids; Humans; Hypercholesterolemia; Inflammation Mediators; Intercellular Adhesion Molecule-1; Male; Middle Aged; Pyrroles; Vasodilation

2007
Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone: is sufficient cholesterol-lowering enough to inhibit platelets?
    Journal of the American College of Cardiology, 2007, Mar-13, Volume: 49, Issue:10

    Topics: Atorvastatin; Azetidines; Blood Chemical Analysis; Blood Platelets; Cholesterol, LDL; Coronary Artery Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Probability; Pyrroles; Reference Values; Risk Assessment; Severity of Illness Index; Survival Rate; Treatment Outcome

2007
Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials.
    JAMA, 2007, Mar-28, Volume: 297, Issue:12

    Topics: Atorvastatin; Double-Blind Method; Dyslipidemias; Female; Fenofibrate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Lipids; Male; Middle Aged; PPAR alpha; Propionates; Pyrroles; Triazoles

2007
Oxidative stress-mediated platelet CD40 ligand upregulation in patients with hypercholesterolemia: effect of atorvastatin.
    Journal of thrombosis and haemostasis : JTH, 2007, Volume: 5, Issue:6

    Topics: Atorvastatin; Autoantibodies; Blood Platelets; Case-Control Studies; CD40 Ligand; Enzyme Inhibitors; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; In Vitro Techniques; Male; Middle Aged; NADPH Oxidases; Oxidative Stress; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrroles; Superoxides; Up-Regulation

2007
Comparisons of short- and intermediate-term effects of pitavastatin versus atorvastatin on lipid profiles, fibrinolytic parameter, and endothelial function.
    International journal of cardiology, 2008, Mar-28, Volume: 125, Issue:1

    Topics: Aged; Atorvastatin; Coronary Artery Disease; Endothelium, Vascular; Female; Fibrinolysis; Heptanoic Acids; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lipids; Male; Middle Aged; Prospective Studies; Pyrroles; Quinolines; Time Factors; Vasodilation

2008
Efficacy and safety of ezetimibe co-administered with atorvastatin in untreated patients with primary hypercholesterolaemia and coronary heart disease.
    Current medical research and opinion, 2007, Volume: 23, Issue:4

    Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Placebos; Pyrroles; Treatment Outcome

2007
Preferable effect of pravastatin compared to atorvastatin on beta cell function in Japanese early-state type 2 diabetes with hypercholesterolemia.
    Endocrine journal, 2007, Volume: 54, Issue:3

    Topics: Atorvastatin; Cross-Over Studies; Diabetes Mellitus, Type 2; Glucose Intolerance; Glucose Tolerance Test; Heptanoic Acids; Humans; Hypercholesterolemia; Insulin-Secreting Cells; Japan; Patient Compliance; Pravastatin; Pyrroles

2007
Leukocyte and endothelial adhesion molecules in patients with hypercholesterolemia: the effect of atorvastatin treatment.
    Physiological research, 2008, Volume: 57, Issue:2

    Topics: Adult; Anticholesteremic Agents; Atorvastatin; Cell Adhesion Molecules; E-Selectin; Endothelial Cells; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Integrins; Intercellular Adhesion Molecule-1; L-Selectin; Leukocytes; Male; Matched-Pair Analysis; Middle Aged; Pyrroles; Reference Values; Statistics, Nonparametric; von Willebrand Factor

2008
Comparison of rosuvastatin versus atorvastatin in South-Asian patients at risk of coronary heart disease (from the IRIS Trial).
    The American journal of cardiology, 2007, Jun-01, Volume: 99, Issue:11

    Topics: Adult; Aged; Analysis of Variance; Anticholesteremic Agents; Apolipoprotein A-I; Asian People; Atorvastatin; Biomarkers; Canada; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; United States

2007
Statin's cost-effectiveness: a Canadian analysis of commonly prescribed generic and brand name statins.
    The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique, 2007,Summer, Volume: 14, Issue:2

    Topics: Adult; Atorvastatin; Canada; Cholesterol, LDL; Cost-Benefit Analysis; Drug Costs; Drugs, Generic; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Insurance, Pharmaceutical Services; Male; Models, Economic; Practice Guidelines as Topic; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome

2007
[The efficacy and safety of rosuvastatin on treating patients with hypercholesterolemia in Chinese: a randomized, double-blind, multi-center clinical trial].
    Zhonghua xin xue guan bing za zhi, 2007, Volume: 35, Issue:3

    Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Asian People; Atorvastatin; Double-Blind Method; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hypercholesterolemia; Hypolipidemic Agents; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Young Adult

2007
Protective effect of atorvastatin on acute systemic inflammation-induced endothelial dysfunction in hypercholesterolaemic subjects.
    European heart journal, 2007, Volume: 28, Issue:17

    Topics: Adult; Atorvastatin; Brachial Artery; Double-Blind Method; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Oxidative Stress; Pyrroles; Salmonella typhi; Salmonella Vaccines; Systemic Inflammatory Response Syndrome; Vascular Diseases; Vasodilation

2007
Effects of CoQ10 supplementation on plasma lipoprotein lipid, CoQ10 and liver and muscle enzyme levels in hypercholesterolemic patients treated with atorvastatin: a randomized double-blind study.
    Atherosclerosis, 2007, Volume: 195, Issue:2

    Topics: Aged; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coenzymes; Double-Blind Method; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Liver Function Tests; Male; Middle Aged; Muscles; Myoglobin; Pyrroles; Ubiquinone; Vitamins

2007
Interaction between a commercially available St. John's wort product (Movina) and atorvastatin in patients with hypercholesterolemia.
    European journal of clinical pharmacology, 2007, Volume: 63, Issue:10

    Topics: Aged; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Enzyme Induction; Female; Heptanoic Acids; Herb-Drug Interactions; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypericum; Intestinal Mucosa; Intestines; Liver; Male; Middle Aged; Plant Preparations; Pyrroles; Time Factors; Treatment Outcome; Triglycerides; Up-Regulation

2007
Effects of atorvastatin on bone in postmenopausal women with dyslipidemia: a double-blind, placebo-controlled, dose-ranging trial.
    The Journal of clinical endocrinology and metabolism, 2007, Volume: 92, Issue:12

    Topics: Absorptiometry, Photon; Adult; Aged; Atorvastatin; Biomarkers; Bone and Bones; Bone Density; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Middle Aged; Postmenopause; Pyrroles; Spine

2007
Randomised study to compare the efficacy and safety of isapgol plus atorvastatin versus atorvastatin alone in subjects with hypercholesterolaemia.
    Journal of the Indian Medical Association, 2007, Volume: 105, Issue:3

    Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Psyllium; Pyrroles; Treatment Outcome

2007
Decreased plasma soluble RAGE in patients with hypercholesterolemia: effects of statins.
    Free radical biology & medicine, 2007, Nov-01, Volume: 43, Issue:9

    Topics: Anticholesteremic Agents; Arginine; Atherosclerosis; Atorvastatin; Cross-Sectional Studies; Dinoprost; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Nitric Oxide; Nitric Oxide Synthase; Pravastatin; Pyrroles; Receptor for Advanced Glycation End Products; Receptors, Immunologic

2007
HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events.
    The New England journal of medicine, 2007, Sep-27, Volume: 357, Issue:13

    Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Multivariate Analysis; Pyrroles; Risk

2007
Effect of high dose statin therapy on platelet function; statins reduce aspirin-resistant platelet aggregation in patients with coronary heart disease.
    Journal of thrombosis and thrombolysis, 2009, Volume: 27, Issue:1

    Topics: Adenosine Diphosphate; Adult; Aged; Aspirin; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Collagen; Coronary Disease; Diabetes Complications; Drug Resistance; Epinephrine; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Male; Middle Aged; Platelet Aggregation; Platelet Function Tests; Pyrroles; Smoking

2009
Comparison of effectiveness of rosuvastatin versus atorvastatin on the achievement of combined C-reactive protein (<2 mg/L) and low-density lipoprotein cholesterol (< 70 mg/dl) targets in patients with type 2 diabetes mellitus (from the ANDROMEDA study).
    The American journal of cardiology, 2007, Oct-15, Volume: 100, Issue:8

    Topics: Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; England; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; North Carolina; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome

2007
Serum from hypercholesterolemic patients treated with atorvastatin or simvastatin inhibits cultured human smooth muscle cell proliferation.
    Pharmacological research, 2007, Volume: 56, Issue:6

    Topics: Adult; Aged; Atorvastatin; Cell Line; Cell Proliferation; Cholesterol; Cross-Over Studies; Double-Blind Method; Female; Femoral Artery; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Myocytes, Smooth Muscle; Pyrroles; Serum; Simvastatin

2007
Effects of atorvastatin on Lp(a) and lipoprotein profiles in hemodialysis patients.
    The Annals of pharmacotherapy, 2008, Volume: 42, Issue:1

    Topics: Aged; Anticholesteremic Agents; Apolipoprotein A-I; Apolipoproteins B; Atorvastatin; C-Reactive Protein; Cholesterol; Cholesterol, LDL; Dose-Response Relationship, Drug; Female; Fibrinogen; Heptanoic Acids; Humans; Hypercholesterolemia; Lipoprotein(a); Lipoproteins; Male; Middle Aged; Pyrroles; Renal Dialysis; Serum Albumin

2008
Randomized evaluation of atorvastatin in patients with coronary heart disease: a serial intravascular ultrasound study.
    Circulation journal : official journal of the Japanese Circulation Society, 2007, Volume: 71, Issue:12

    Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Coronary Disease; Coronary Vessels; Disease Progression; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Ultrasonography, Interventional

2007
Early decrease of oxidative stress by atorvastatin in hypercholesterolaemic patients: effect on circulating vitamin E.
    European heart journal, 2008, Volume: 29, Issue:1

    Topics: Anticholesteremic Agents; Atorvastatin; Blood Platelets; Cholesterol, LDL; Cross-Sectional Studies; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Isoprostanes; Male; Middle Aged; NADPH Oxidases; Oxidative Stress; Pyrroles; Superoxides; Vitamin E

2008
Efficacy of atorvastatin when not administered daily.
    Arquivos brasileiros de cardiologia, 2007, Volume: 89, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Cost-Benefit Analysis; Drug Administration Schedule; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Prospective Studies; Pyrroles; Treatment Outcome; Triglycerides

2007
Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia.
    Clinical therapeutics, 2007, Volume: 29, Issue:11

    Topics: Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Korea; Male; Middle Aged; Pyrroles; Quinolines; Triglycerides

2007
Genetic influence in antithrombotic actions of atorvastatin in hypercholesterolaemia.
    European journal of clinical investigation, 2008, Volume: 38, Issue:1

    Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Coronary Artery Disease; Female; Fibrinolytic Agents; Heptanoic Acids; Humans; Hypercholesterolemia; Lipoproteins, LDL; Male; Middle Aged; Nitric Oxide Synthase; Polymorphism, Genetic; Pyrroles; Scavenger Receptors, Class E

2008
Improved attainment of blood pressure and cholesterol goals using single-pill amlodipine/atorvastatin in African Americans: the CAPABLE trial.
    Mayo Clinic proceedings, 2008, Volume: 83, Issue:1

    Topics: Adult; Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Black or African American; Drug Combinations; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Male; Middle Aged; Pyrroles; Treatment Outcome

2008
The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closure.
    European heart journal, 2008, Volume: 29, Issue:4

    Topics: Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Coronary Disease; Epidemiologic Methods; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Male; Middle Aged; Myocardial Infarction; Pyrroles; Stroke

2008
A randomised study comparing the efficacy and safety of rosuvastatin with atorvastatin for achieving lipid goals in clinical practice in Asian patients at high risk of cardiovascular disease (DISCOVERY-Asia study).
    Current medical research and opinion, 2007, Volume: 23, Issue:12

    Topics: Anticholesteremic Agents; Asia; Atorvastatin; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Sulfonamides

2007
Effectiveness of ezetimibe alone or in combination with twice a week Atorvastatin (10 mg) for statin intolerant high-risk patients.
    The American journal of cardiology, 2008, Feb-15, Volume: 101, Issue:4

    Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Creatinine; Diabetes Mellitus; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Peripheral Vascular Diseases; Prospective Studies; Pyrroles; Stroke

2008
Flexible initial dosing of atorvastatin based upon initial low-density lipoprotein cholesterol levels in type 2 diabetic patients.
    The Korean journal of internal medicine, 2008, Volume: 23, Issue:1

    Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Brachial Artery; Cholesterol, LDL; Diabetes Mellitus, Type 2; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Plasminogen Activator Inhibitor 1; Prospective Studies; Pyrroles; Regional Blood Flow; Time Factors; Treatment Outcome

2008
Statin therapy increases carotid plaque echogenicity in hypercholesterolemic patients.
    Ultrasound in medicine & biology, 2008, Volume: 34, Issue:9

    Topics: Aged; Atorvastatin; Biomarkers; C-Reactive Protein; Carotid Arteries; Carotid Stenosis; Cholesterol; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Interleukin-18; Interleukin-6; Male; Middle Aged; Pravastatin; Probability; Prospective Studies; Pyrroles; Simvastatin; Triglycerides; Tunica Intima; Ultrasonography

2008
Synergistic effect of amlodipine and atorvastatin on blood pressure, left ventricular remodeling, and C-reactive protein in hypertensive patients with primary hypercholesterolemia.
    Heart and vessels, 2008, Volume: 23, Issue:2

    Topics: Aged; Amlodipine; Antihypertensive Agents; Atorvastatin; Blood Pressure; C-Reactive Protein; Drug Synergism; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Hypertrophy, Left Ventricular; Lipids; Male; Middle Aged; Pyrroles; Time Factors; Treatment Outcome; Uric Acid; Ventricular Remodeling

2008
Effects of atorvastatin and pravastatin on glucose tolerance, adipokine levels and inflammatory markers in hypercholesterolaemic patients.
    Clinical and experimental pharmacology & physiology, 2008, Volume: 35, Issue:9

    Topics: Adipokines; Aged; Anticholesteremic Agents; Atorvastatin; Biomarkers; Blood Glucose; Cross-Over Studies; Female; Glucose Intolerance; Heptanoic Acids; Humans; Hypercholesterolemia; Inflammation; Male; Middle Aged; Pravastatin; Pyrroles

2008
Effects of statin treatment in men and women with stable coronary heart disease: a subgroup analysis of the GREACE Study.
    Current medical research and opinion, 2008, Volume: 24, Issue:6

    Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Outcome Assessment, Health Care; Pyrroles; Sex Factors

2008
Efficacy and tolerability of rosuvastatin and atorvastatin when force-titrated in patients with primary hypercholesterolemia: results from the ECLIPSE study.
    Cardiology, 2008, Volume: 111, Issue:4

    Topics: Aged; Atorvastatin; Canada; Cholesterol, LDL; Coronary Disease; European Union; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Pyrroles; Risk Assessment; Risk Factors; Rosuvastatin Calcium; Sulfonamides

2008
The benefits of intensive lipid lowering in patients with stable coronary heart disease with normal or high systolic blood pressure: an analysis of the Treating to New Targets (TNT) study.
    Journal of clinical hypertension (Greenwich, Conn.), 2008, Volume: 10, Issue:5

    Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Blood Pressure; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Male; Middle Aged; Pyrroles; Systole; Time Factors; Treatment Outcome

2008
Multicenter collaborative randomized parallel group comparative study of pitavastatin and atorvastatin in Japanese hypercholesterolemic patients: collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis preventi
    Atherosclerosis, 2008, Volume: 201, Issue:2

    Topics: Aged; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Body Mass Index; Body Weight; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Japan; Male; Middle Aged; Pyrroles; Quinolines; Waist Circumference

2008
Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor.
    Arteriosclerosis, thrombosis, and vascular biology, 1995, Volume: 15, Issue:5

    Topics: Adolescent; Adult; Aged; Apolipoproteins; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Lipoproteins; Middle Aged; Pyrroles

1995
Atorvastatin--a new lipid-lowering drug.
    The Medical letter on drugs and therapeutics, 1997, Mar-28, Volume: 39, Issue:997

    Topics: Anti-Bacterial Agents; Anticholesteremic Agents; Antifungal Agents; Atorvastatin; Dose-Response Relationship, Drug; Drug Interactions; Erythromycin; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipidemias; Ketoconazole; Pyrroles

1997
Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia.
    Atherosclerosis, 1997, Volume: 130, Issue:1-2

    Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, LDL; Double-Blind Method; Enzyme Inhibitors; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Pyrroles; Triglycerides

1997
Efficacy of atorvastatin in primary hypercholesterolemia. Japan Cholesterol Lowering Atorvastatin Study (J-CLAS) Group.
    The American journal of cardiology, 1997, May-01, Volume: 79, Issue:9

    Topics: Aged; Apolipoproteins; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Administration Schedule; Enzyme Inhibitors; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Triglycerides

1997
Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I.
    The American journal of cardiology, 1997, Jun-01, Volume: 79, Issue:11

    Topics: Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Cholesterol; Double-Blind Method; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Pyrroles; Treatment Outcome

1997
A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia.
    The American journal of cardiology, 1997, Jul-01, Volume: 80, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Apolipoproteins B; Arthralgia; Atorvastatin; Cholesterol; Cholesterol, Dietary; Cholesterol, LDL; Double-Blind Method; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperhidrosis; Hyperlipidemias; Lovastatin; Male; Middle Aged; Patient Education as Topic; Pyrroles; Simvastatin; Triglycerides

1997
Effect of a new HMG-CoA reductase inhibitor, atorvastatin, on lipids, apolipoproteins and lipoprotein particles in patients with elevated serum cholesterol and triglyceride levels.
    Atherosclerosis, 1997, Volume: 133, Issue:1

    Topics: Adolescent; Aged; Aged, 80 and over; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Enzyme Inhibitors; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertriglyceridemia; Lipids; Lipoproteins; Male; Middle Aged; Pyrroles

1997
Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)
    The American journal of cardiology, 1998, Mar-01, Volume: 81, Issue:5

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Treatment Outcome

1998
Effects of atorvastatin monotherapy and simvastatin plus cholestyramine on arterial endothelial function in patients with severe primary hypercholesterolaemia.
    Atherosclerosis, 1998, Volume: 137, Issue:1

    Topics: Adult; Anticholesteremic Agents; Arthralgia; Atorvastatin; Brachial Artery; Cholestyramine Resin; Drug Therapy, Combination; Endothelium, Vascular; Exanthema; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipids; Lipoproteins; Male; Middle Aged; Pyrroles; Simvastatin; Treatment Outcome; Ultrasonography

1998
Efficacy and safety of a new cholesterol synthesis inhibitor, atorvastatin, in comparison with simvastatin and pravastatin, in subjects with hypercholesterolemia.
    The Netherlands journal of medicine, 1998, Volume: 52, Issue:4

    Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Cholesterol; Cholesterol, LDL; Cross-Over Studies; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Treatment Outcome; Triglycerides

1998
Comparison of atorvastatin alone versus simvastatin +/- cholestyramine in the management of severe primary hypercholesterolaemia (the six cities study).
    Australian and New Zealand journal of medicine, 1998, Volume: 28, Issue:3

    Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Combined Modality Therapy; Diet, Fat-Restricted; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Simvastatin; Treatment Outcome; Triglycerides

1998
Rationale and design of the Myocardial Ischemia Reduction With Aggressive Cholesterol lowering (MIRACL) Study that evaluates atorvastatin in unstable angina pectoris and in non-Q-wave acute myocardial infarction.
    The American journal of cardiology, 1998, Sep-01, Volume: 82, Issue:5

    Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cholesterol; Coronary Disease; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hypercholesterolemia; Myocardial Infarction; Pyrroles; Research Design

1998
Atorvastatin compared with simvastatin in patients with severe LDL hypercholesterolaemia treated by regular LDL apheresis.
    Journal of internal medicine, 1999, Volume: 245, Issue:1

    Topics: Anticholesteremic Agents; Atorvastatin; Blood Component Removal; Cholesterol, LDL; Combined Modality Therapy; Coronary Disease; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins; Male; Pyrroles; Simvastatin; Treatment Outcome

1999
The cost of reaching National Cholesterol Education Program (NCEP) goals in hypercholesterolaemic patients. A comparison of atorvastatin, simvastatin, lovastatin and fluvastatin.
    PharmacoEconomics, 1998, Volume: 14, Issue:1

    Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cost-Benefit Analysis; Fatty Acids, Monounsaturated; Female; Fluvastatin; Health Policy; Heptanoic Acids; Humans; Hypercholesterolemia; Indoles; Lovastatin; Male; Middle Aged; Pyrroles; Simvastatin; United States

1998
[Fluvastatin in a comparative study. Are there substance-specific differences between various CSE-inhibitors?].
    Der Internist, 1999, Volume: 40, Issue:3 Suppl Gi

    Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipidemias; Hypertriglyceridemia; Indoles; Pyrroles

1999
[AVERT study (Atorvastatin Versus Revascularization Treatment). Clinical advantage of aggressive lipid lowering].
    Zeitschrift fur Kardiologie, 1999, Volume: 88, Issue:3 Suppl

    Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins, LDL; Male; Middle Aged; Pyrroles

1999
Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators.
    The New England journal of medicine, 1999, Jul-08, Volume: 341, Issue:2

    Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Myocardial Ischemia; Pyrroles; Quality of Life; Risk; Treatment Outcome

1999
Effect of atorvastatin of the treatment of hypercholesterolemia after renal transplantation.
    Transplantation proceedings, 1999, Volume: 31, Issue:6

    Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Kidney Transplantation; Male; Middle Aged; Postoperative Complications; Pyrroles; Time Factors; Triglycerides

1999
Lowering effects of four different statins on serum triglyceride level.
    European journal of clinical pharmacology, 1999, Volume: 55, Issue:7

    Topics: Adult; Aged; Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hypercholesterolemia; Indoles; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Treatment Outcome; Triglycerides

1999
A comparative economic analysis of simvastatin versus atorvastatin: results of the Surrogate Marker Cost-Efficacy (SMaC) study.
    Clinical therapeutics, 1999, Volume: 21, Issue:10

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cost-Benefit Analysis; Double-Blind Method; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Simvastatin

1999
Atorvastatin increases ecNOS levels in human platelets of hyperlipidemic subjects.
    Thrombosis and haemostasis, 1999, Volume: 82, Issue:5

    Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Blood Platelets; Blood Proteins; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Double-Blind Method; Enzyme Induction; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertriglyceridemia; Male; Middle Aged; Nitrates; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Oxidation-Reduction; Pyrroles; Treatment Outcome; Triglycerides; Tyrosine; Vasodilation

1999
An assessment of the efficacy of atorvastatin in achieving LDL cholesterol target levels in patients with coronary heart disease: a general practice study.
    International journal of clinical practice, 1999, Volume: 53, Issue:6

    Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Family Practice; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Patient Compliance; Pyrroles; Treatment Outcome

1999
Dosing of atorvastatin and increases in fibrinogen level.
    Atherosclerosis, 1999, Volume: 147, Issue:2

    Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fibrinogen; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Reference Values; Treatment Outcome

1999
Efficacy of atorvastatin compared with simvastatin in patients with hypercholesterolemia.
    Journal of cardiovascular pharmacology and therapeutics, 2000, Volume: 5, Issue:1

    Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Prospective Studies; Pyrroles; Simvastatin; Single-Blind Method

2000
Achievement of target plasma cholesterol levels in hypercholesterolaemic patients being treated in general practice.
    Atherosclerosis, 2000, Volume: 149, Issue:1

    Topics: Administration, Oral; Adolescent; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholestyramine Resin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Family Practice; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Linear Models; Logistic Models; Male; Middle Aged; Pyrroles; Simvastatin; Treatment Outcome

2000
Atorvastatin for the management of Type 2 diabetic patients with dyslipidaemia. A mid-term (9 months) treatment experience.
    Diabetes, nutrition & metabolism, 1999, Volume: 12, Issue:6

    Topics: Aged; Anticholesteremic Agents; Atorvastatin; Body Mass Index; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipidemias; Male; Middle Aged; Pyrroles; Triglycerides

1999
The effect of cholesterol lowering on carotid and femoral artery wall stiffness and thickness in patients with familial hypercholesterolaemia.
    European journal of clinical investigation, 2000, Volume: 30, Issue:6

    Topics: Adult; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Blood Pressure; Carotid Arteries; Cholesterol, HDL; Cholesterol, LDL; Elasticity; Family Health; Female; Femoral Artery; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Simvastatin; Triglycerides; Tunica Intima

2000
Incremental reduction of serum total cholesterol and low-density lipoprotein cholesterol with the addition of plant stanol ester-containing spread to statin therapy.
    The American journal of cardiology, 2000, Jul-01, Volume: 86, Issue:1

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Atorvastatin; Biomarkers; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Male; Margarine; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Sitosterols; Treatment Outcome; Triglycerides

2000
Effects of atorvastatin and vitamin C on endothelial function of hypercholesterolemic patients.
    Atherosclerosis, 2000, Volume: 152, Issue:2

    Topics: Acetylcholine; Adult; Anticholesteremic Agents; Antioxidants; Ascorbic Acid; Atorvastatin; Blood Flow Velocity; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Endothelium, Vascular; Female; Forearm; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Infusions, Intra-Arterial; Male; Middle Aged; Nitroprusside; omega-N-Methylarginine; Plethysmography; Pyrroles; Vasodilation; Vasodilator Agents

2000
Comparison of the efficacy and tolerability of simvastatin and atorvastatin in the treatment of hypercholesterolemia.
    Clinical cardiology, 2000, Volume: 23, Issue:9

    Topics: Adult; Aged; Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Cross-Over Studies; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Lipoproteins; Male; Middle Aged; Pyrroles; Simvastatin; Statistics, Nonparametric

2000
Short-term atorvastatin treatment improves endothelial function in hypercholesterolemic women.
    Journal of cardiovascular pharmacology, 2000, Volume: 36, Issue:5

    Topics: Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Cholesterol; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipoproteins; Middle Aged; Postmenopause; Pyrroles; Vasodilation

2000
Associations between change in C-reactive protein and serum lipids during statin treatment.
    Annals of medicine, 2000, Volume: 32, Issue:8

    Topics: Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Male; Middle Aged; Pyrroles; Simvastatin; Time Factors

2000
Similar effects of atorvastatin, simvastatin and pravastatin on thrombogenic and inflammatory parameters in patients with hypercholesterolemia.
    Thrombosis and haemostasis, 2001, Volume: 85, Issue:1

    Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Inflammation; Lipids; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Therapeutic Equivalency; Thrombophilia; Treatment Outcome

2001
[Cost-effectiveness of atorvastatin against simvastatin as hypolipemic treatment in hypercholesterolemic patients in primary care].
    Atencion primaria, 2001, Volume: 27, Issue:1

    Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cost-Benefit Analysis; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Prospective Studies; Pyrroles; Simvastatin; Triglycerides

2001
Comparative efficacy study of atorvastatin vs simvastatin, pravastatin, lovastatin and placebo in type 2 diabetic patients with hypercholesterolaemia.
    Diabetes, obesity & metabolism, 2000, Volume: 2, Issue:6

    Topics: Aged; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Insulin; Lovastatin; Male; Middle Aged; Placebos; Pravastatin; Pyrroles; Simvastatin; Triglycerides

2000
The effect of atorvastatin on serum lipids, lipoprotein(a) and plasma fibrinogen levels in primary dyslipidaemia--a pilot study involving serial sampling.
    Current medical research and opinion, 2001, Volume: 16, Issue:4

    Topics: Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Drug Monitoring; Fasting; Female; Fibrinogen; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipoproteinemia Type V; Lipids; Lipoprotein(a); Male; Middle Aged; Pilot Projects; Prospective Studies; Pyrroles; Treatment Outcome

2001
Cost-minimization analysis of simvastatin versus atorvastatin for maintenance therapy in patients with coronary or peripheral vascular disease.
    Clinical therapeutics, 2001, Volume: 23, Issue:2

    Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Cost Control; Drug Costs; Europe; Heptanoic Acids; Humans; Hypercholesterolemia; Peripheral Vascular Diseases; Pyrroles; Simvastatin

2001
Aggressive versus moderate lipid-lowering therapy in postmenopausal women with hypercholesterolemia: Rationale and design of the Beyond Endorsed Lipid Lowering with EBT Scanning (BELLES) trial.
    American heart journal, 2001, Volume: 141, Issue:5

    Topics: Aged; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Cholesterol, LDL; Coronary Vessels; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Middle Aged; Postmenopause; Pravastatin; Prognosis; Prospective Studies; Pyrroles; Reproducibility of Results; Safety; Tomography, X-Ray Computed

2001
The efficacy of atorvastatin in treating patients with hypercholesterolaemia to target LDL-cholesterol goals: the LIPI-GOAL trial.
    Acta cardiologica, 2001, Volume: 56, Issue:2

    Topics: Aged; Atorvastatin; Cholesterol, LDL; Coronary Disease; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrroles

2001
Efficacy of atorvastatin in achieving National Cholesterol Education Program low-density lipoprotein targets in women with severe dyslipidemia and cardiovascular disease or risk factors for cardiovascular disease: The Women's Atorvastatin Trial on Cholest
    American heart journal, 2001, Volume: 141, Issue:6

    Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Canada; Cardiovascular Diseases; Cholesterol, LDL; Female; Health Education; Heptanoic Acids; Humans; Hypercholesterolemia; Middle Aged; Practice Guidelines as Topic; Pyrroles; Risk Factors; Women's Health

2001
Effects of statins on biomarkers of bone metabolism: a randomised trial.
    Nutrition, metabolism, and cardiovascular diseases : NMCD, 2001, Volume: 11, Issue:2

    Topics: Adult; Aged; Alkaline Phosphatase; Anticholesteremic Agents; Atorvastatin; Biomarkers; Bone and Bones; Bone Development; Bone Resorption; Collagen; Collagen Type I; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Peptides; Pyrroles; Simvastatin

2001
Effects of low doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol levels in patients with hypercholesterolemia.
    Clinical therapeutics, 2001, Volume: 23, Issue:6

    Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipids; Male; Middle Aged; Pyrroles; Simvastatin

2001
The effects of converting from simvastatin to atorvastatin on plasminogen activator inhibitor type-1.
    Journal of clinical pharmacology, 2001, Volume: 41, Issue:7

    Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Plasminogen Activator Inhibitor 1; Pyrroles; Serine Proteinase Inhibitors; Simvastatin

2001
A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial.
    Current medical research and opinion, 2001, Volume: 17, Issue:1

    Topics: Adult; Aged; Anticholesteremic Agents; Apolipoprotein A-I; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Male; Middle Aged; Pyrroles; Simvastatin; Treatment Outcome; United States

2001
Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner.
    Atherosclerosis, 2001, Volume: 158, Issue:1

    Topics: Anticholesteremic Agents; Apolipoproteins E; Atorvastatin; Double-Blind Method; Female; Genotype; Heptanoic Acids; Heterozygote; Homozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Lipoproteins; Lovastatin; Male; Middle Aged; Pyrroles; Sex Factors

2001
Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia.
    The American journal of cardiology, 2001, Sep-01, Volume: 88, Issue:5

    Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Pyrroles; Reference Values; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome

2001
Comparison of the efficacy of atorvastatin versus cerivastatin in primary hypercholesterolemia.
    The American journal of cardiology, 2001, Sep-15, Volume: 88, Issue:6

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Prospective Studies; Pyridines; Pyrroles; Treatment Outcome; Triglycerides; United States

2001
A double-blind trial on the effects of atorvastatin on glycemic control in Japanese diabetic patients with hypercholesterolemia.
    Clinica chimica acta; international journal of clinical chemistry, 2001, Volume: 312, Issue:1-2

    Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Blood Glucose; Cholesterol; Deoxyglucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Fructosamine; Glycated Hemoglobin; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles

2001
Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively.
    Atherosclerosis, 2001, Volume: 158, Issue:2

    Topics: Adult; Aged; Allylamine; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Colesevelam Hydrochloride; Double-Blind Method; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Triglycerides

2001
Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia.
    The American journal of cardiology, 2002, Feb-01, Volume: 89, Issue:3

    Topics: Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Canada; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diet; Double-Blind Method; Drug Administration Schedule; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Triglycerides; United States

2002
A randomized, double-blind, placebo-controlled, 8-week study to evaluate the efficacy and safety of once daily atorvastatin (10 mg) in patients with elevated LDL-cholesterol.
    Japanese heart journal, 2001, Volume: 42, Issue:6

    Topics: Aged; Anticholesteremic Agents; Apolipoprotein B-100; Apolipoproteins B; Atorvastatin; Cholesterol; Cholesterol, LDL; Double-Blind Method; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Triglycerides

2001
Effects of simvastatin and atorvastatin on inflammation markers in plasma.
    Journal of internal medicine, 2002, Volume: 251, Issue:4

    Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Inflammation; Intercellular Adhesion Molecule-1; Interleukin-6; Male; Middle Aged; Pyrroles; Simvastatin

2002
Lipid-lowering effect of atorvastatin in heart transplantation.
    Transplantation proceedings, 2002, Volume: 34, Issue:1

    Topics: Adult; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Follow-Up Studies; Heart Transplantation; Heptanoic Acids; Humans; Hypercholesterolemia; Hypolipidemic Agents; Male; Middle Aged; Postoperative Complications; Pyrroles; Time Factors

2002
Effect of diet and treatment with statins on platelet-dependent thrombin generation in hypercholesterolemic subjects.
    Nutrition, metabolism, and cardiovascular diseases : NMCD, 2001, Volume: 11, Issue:6

    Topics: Adult; Anticholesteremic Agents; Atorvastatin; Blood Platelets; Cholesterol; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hypercholesterolemia; Indoles; Male; Middle Aged; Pravastatin; Pyridines; Pyrroles; Simvastatin; Thrombin; Treatment Outcome

2001
Issues concerning the monitoring of statin therapy in hypercholesterolemic subjects with high plasma lipoprotein(a) levels.
    Lipids, 2002, Volume: 37, Issue:5

    Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Enzyme-Linked Immunosorbent Assay; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipoprotein(a); Lipoproteins, LDL; Male; Middle Aged; Pravastatin; Pyridines; Pyrroles; Simvastatin

2002

Other Studies

416 other study(ies) available for atorvastatin and Elevated Cholesterol

ArticleYear
Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.
    The American journal of cardiology, 2001, Mar-08, Volume: 87, Issue:5A

    Topics: Animals; Arteriosclerosis; Cholesterol, LDL; Clinical Trials as Topic; Drug Evaluation, Preclinical; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Molecular Structure; Pyrimidines; Rosuvastatin Calcium; Sulfonamides

2001
Substituted pyrazoles as hepatoselective HMG-CoA reductase inhibitors: discovery of (3R,5R)-7-[2-(4-fluoro-phenyl)-4-isopropyl-5-(4-methyl-benzylcarbamoyl)-2H-pyrazol-3-yl]-3,5-dihydroxyheptanoic acid (PF-3052334) as a candidate for the treatment of hyper
    Journal of medicinal chemistry, 2008, Jan-10, Volume: 51, Issue:1

    Topics: Animals; Cholesterol, LDL; Cricetinae; Guinea Pigs; Hepatocytes; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; In Vitro Techniques; Liver; Male; Mesocricetus; Muscle Cells; Pyrazoles; Rats; Stereoisomerism; Structure-Activity Relationship

2008
A pharmacokinetics-based approach to the monitoring of patient adherence to atorvastatin therapy.
    Pharmacology research & perspectives, 2021, Volume: 9, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Cholesterol, LDL; Drug Monitoring; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Medication Adherence; Middle Aged; Monte Carlo Method

2021
MicroRNA-20a-5p Downregulation by Atorvastatin: A Potential Mechanism Involved in Lipid-Lowering Therapy.
    International journal of molecular sciences, 2022, Apr-30, Volume: 23, Issue:9

    Topics: Atorvastatin; Down-Regulation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; MicroRNAs

2022
Impact of simultaneous management of hypertension and hypercholesterolemia with ACE inhibitors and statins on cardiovascular outcomes in the Brisighella Heart Study: A 8-year follow-up.
    Nutrition, metabolism, and cardiovascular diseases : NMCD, 2022, Volume: 32, Issue:9

    Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atorvastatin; Blood Pressure; Calcium; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Perindopril

2022
Physicians and pharmacists' clinical knowledge of statin therapy and monitoring parameters, and the barriers to guideline implementation in clinical practice.
    PloS one, 2023, Volume: 18, Issue:1

    Topics: Atorvastatin; Cholesterol; Guideline Adherence; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pharmacists

2023
Investigation of the effects of atorvastatin and Lactobacillus acidophilus on some hormones and oxidative stress in experimental hypercholesterolemia.
    Prostaglandins & other lipid mediators, 2023, Volume: 165

    Topics: Animals; Antioxidants; Atorvastatin; Cholesterol; Ghrelin; Hypercholesterolemia; Insulins; Lactobacillus acidophilus; Leptin; Oxidative Stress; Probiotics; Rats; Serotonin

2023
Cardiometabolic Risk Factors in Atorvastatin-Treated Women with Euthyroid Autoimmune Thyroiditis.
    Pharmacology, 2023, Volume: 108, Issue:3

    Topics: Atorvastatin; C-Reactive Protein; Cardiometabolic Risk Factors; Cardiovascular Diseases; Cholesterol; Female; Fibrinogen; Hashimoto Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Risk Factors; Thyroiditis, Autoimmune; Uric Acid

2023
Fatal hepatic failure following atorvastatin treatment: A case report.
    Medicine, 2023, May-12, Volume: 102, Issue:19

    Topics: Atorvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Liver Failure; Male; Middle Aged

2023
Prediction of Atorvastatin Pharmacokinetics in High-Fat Diet and Low-Dose Streptozotocin-Induced Diabetic Rats Using a Semiphysiologically Based Pharmacokinetic Model Involving Both Enzymes and Transporters.
    Drug metabolism and disposition: the biological fate of chemicals, 2019, Volume: 47, Issue:10

    Topics: Animals; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; Cells, Cultured; Cytochrome P-450 CYP3A; Diabetes Mellitus, Experimental; Diet, High-Fat; Hepatocytes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Intestinal Mucosa; Male; Microsomes, Liver; Models, Biological; Primary Cell Culture; Rats; Solute Carrier Organic Anion Transporter Family Member 1B3; Streptozocin

2019
Impact of Macroprolactinemia on Cardiometabolic Effects of Atorvastatin in Women With Hypercholesterolemia.
    The American journal of cardiology, 2019, 10-15, Volume: 124, Issue:8

    Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Biomarkers; Cardiovascular Diseases; Cholesterol, LDL; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Hyperprolactinemia; Incidence; Insulin Resistance; Middle Aged; Poland; Prolactin; Risk Factors

2019
Atorvastatin induces mitochondrial dysfunction and cell apoptosis in HepG2 cells via inhibition of the Nrf2 pathway.
    Journal of applied toxicology : JAT, 2019, Volume: 39, Issue:10

    Topics: Apoptosis; Atorvastatin; Hep G2 Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Mitochondria; NF-E2-Related Factor 2

2019
Probiotic strains improve high-fat diet-induced hypercholesterolemia through modulating gut microbiota in ways different from atorvastatin.
    Food & function, 2019, Sep-18, Volume: 10, Issue:9

    Topics: Animals; Anticholesteremic Agents; Atorvastatin; Bacteria; Cricetinae; Cytokines; Diet, High-Fat; Dysbiosis; Feces; Gastrointestinal Microbiome; Glucose; Hypercholesterolemia; Lactobacillus plantarum; Male; Mesocricetus; Pediococcus; Pediococcus acidilactici; Pediococcus pentosaceus; Probiotics; Weight Gain

2019
Impaired Endothelium-Dependent Hyperpolarization Underlies Endothelial Dysfunction during Early Metabolic Challenge: Increased ROS Generation and Possible Interference with NO Function.
    The Journal of pharmacology and experimental therapeutics, 2019, Volume: 371, Issue:3

    Topics: Animals; Atorvastatin; Endothelium, Vascular; Energy Intake; Gap Junctions; Hypercholesterolemia; Hyperinsulinism; Male; Nitric Oxide; Potassium Channels, Inwardly Rectifying; Proto-Oncogene Proteins c-akt; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Vasodilation

2019
Peripheral polyneuropathy in patients receiving long-term statin therapy.
    Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir, 2019, Volume: 47, Issue:7

    Topics: Atorvastatin; Case-Control Studies; Drug Administration Schedule; Electromyography; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Incidence; Male; Middle Aged; Peripheral Nervous System Diseases; Risk Factors; Rosuvastatin Calcium; Turkey

2019
Microdosing clinical study to clarify pharmacokinetic and pharmacogenetic characteristics of atorvastatin in Japanese hypercholesterolemic patients.
    Drug metabolism and pharmacokinetics, 2019, Volume: 34, Issue:6

    Topics: Aged; Anticholesteremic Agents; Atorvastatin; ATP Binding Cassette Transporter, Subfamily G, Member 2; Female; Humans; Hypercholesterolemia; Japan; Liver-Specific Organic Anion Transporter 1; Male; Neoplasm Proteins; Pharmacogenetics; Polymorphism, Single Nucleotide

2019
LOX-1, the Common Therapeutic Target in Hypercholesterolemia: A New Perspective of Antiatherosclerotic Action of Aegeline.
    Oxidative medicine and cellular longevity, 2019, Volume: 2019

    Topics: Amides; Animals; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cell Line; Diet, High-Fat; Disease Models, Animal; Humans; Hypercholesterolemia; Lipoproteins, LDL; Macrophages; Male; Mice; Molecular Targeted Therapy; Rats; Rats, Wistar; Scavenger Receptors, Class E

2019
Beneficial effect of ezetimibe-atorvastatin combination therapy in patients with a mutation in ABCG5 or ABCG8 gene.
    Lipids in health and disease, 2020, Jan-04, Volume: 19, Issue:1

    Topics: Aged; Atorvastatin; ATP Binding Cassette Transporter, Subfamily G, Member 5; ATP Binding Cassette Transporter, Subfamily G, Member 8; Cholesterol, LDL; Drug Combinations; Ezetimibe; Female; Humans; Hypercholesterolemia; Lipoproteins; Male; Middle Aged; Mutation

2020
[Atorvastatin-induced anemia accompanied by elevated serum LDH levels].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2020, Volume: 61, Issue:1

    Topics: Aged; Anemia; Atorvastatin; Cholesterol, LDL; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Simvastatin

2020
Evaluation of Orally Administered Atorvastatin on Plasma Lipid and Biochemistry Profiles in Hypercholesterolemic Hispaniolan Amazon Parrots (
    Journal of avian medicine and surgery, 2020, Mar-29, Volume: 34, Issue:1

    Topics: Administration, Oral; Amazona; Animals; Atorvastatin; Bird Diseases; Cholesterol; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male

2020
Immune Modulatory Effects of Hypercholesterolemia: Can Atorvastatin Convert the Detrimental Effect of Hypercholesterolemia on the Immune System?
    Iranian journal of allergy, asthma, and immunology, 2019, Oct-23, Volume: 18, Issue:5

    Topics: Adult; Antigens, CD; Atorvastatin; Cholesterol; Cytokines; Female; Humans; Hypercholesterolemia; Immunologic Factors; Killer Cells, Natural; Leukocytes, Mononuclear; Lymphocyte Activation; Male; Middle Aged; Th1 Cells; Th2 Cells

2019
Synergistic effects of pomegranate juice and atorvastatin for improving cerebellar structure and function of breast-feeding rats maternally fed on a high cholesterol diet.
    Journal of chemical neuroanatomy, 2020, Volume: 107

    Topics: Animals; Atorvastatin; Caspase 3; Cerebellum; Cholesterol; Diet, High-Fat; Drug Synergism; Female; Fruit and Vegetable Juices; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lactation; Oxidative Stress; Pomegranate; Pregnancy; Rats; Rats, Wistar

2020
Primary Prevention of Cardiocerebrovascular Diseases and Related Deaths According to Statin Type.
    International journal of environmental research and public health, 2020, 08-30, Volume: 17, Issue:17

    Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cerebrovascular Disorders; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Primary Prevention; Pyrroles; Quinolines; Retrospective Studies; Rosuvastatin Calcium; Simvastatin

2020
Homozygous autosomal recessive hypercholesterolaemia in a South Asian child presenting with multiple cutaneous xanthomata.
    Annals of clinical biochemistry, 2021, Volume: 58, Issue:2

    Topics: Adaptor Proteins, Signal Transducing; Asia, Southeastern; Atorvastatin; Child; Cholesterol, LDL; Elbow; Female; Frameshift Mutation; Genetic Testing; Homozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipoproteinemia Type III; Knee; Receptors, LDL; Skin; Treatment Outcome; Xanthomatosis

2021
The effects of melatonin against atherosclerosis-induced endothelial dysfunction and inflammation in hypercholesterolemic rats.
    Archives of physiology and biochemistry, 2023, Volume: 129, Issue:2

    Topics: Animals; Atherosclerosis; Atorvastatin; Hypercholesterolemia; Hyperlipidemias; Inflammation; Melatonin; Nicotinamide Phosphoribosyltransferase; Nitric Oxide; Rats

2023
Top product forecasts for 2021.
    Nature reviews. Drug discovery, 2021, Volume: 20, Issue:1

    Topics: Anticholesteremic Agents; Atorvastatin; Forecasting; Humans; Hypercholesterolemia

2021
The combination of atorvastatin with silymarin enhances hypolipidemic, antioxidant and anti-inflammatory effects in a rat model of metabolic syndrome.
    Physiological research, 2021, 03-17, Volume: 70, Issue:1

    Topics: Animals; Anticholesteremic Agents; Antioxidants; Atorvastatin; Diabetes Mellitus, Type 2; Disease Models, Animal; Drug Therapy, Combination; Hypercholesterolemia; Hyperlipidemias; Inflammation; Male; Metabolic Syndrome; Oxidative Stress; Rats; Silymarin; Triglycerides

2021
Lipid-lowering therapies: Better together.
    Atherosclerosis, 2021, Volume: 320

    Topics: Atorvastatin; Dicarboxylic Acids; Ezetimibe; Fatty Acids; Humans; Hypercholesterolemia

2021
New onset diabetes mellitus and cardiovascular events in Korean patients with acute myocardial infarction receiving high-intensity statins.
    BMC pharmacology & toxicology, 2021, 02-04, Volume: 22, Issue:1

    Topics: Aged; Asian People; Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Registries; Republic of Korea; Rosuvastatin Calcium; Secondary Prevention; Treatment Outcome

2021
Effect of statins on lipid metabolism-related microRNA expression in HepG2 cells.
    Pharmacological reports : PR, 2021, Volume: 73, Issue:3

    Topics: Anticholesteremic Agents; Atorvastatin; Cell Differentiation; Cell Line, Tumor; Down-Regulation; Hep G2 Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipid Metabolism; Liver; MicroRNAs; RNA, Messenger; Simvastatin; Up-Regulation

2021
Grape seed extract improved the fertility-enhancing effect of atorvastatin in high-fat diet-induced testicular injury in rats: involvement of antioxidant and anti-apoptotic effects.
    The Journal of pharmacy and pharmacology, 2021, Mar-06, Volume: 73, Issue:3

    Topics: Animals; Anticholesteremic Agents; Antioxidants; Apoptosis; Atorvastatin; Diet, High-Fat; Disease Models, Animal; Drug Therapy, Combination; Grape Seed Extract; Hypercholesterolemia; Infertility, Male; Male; Random Allocation; Rats; Rats, Sprague-Dawley; Testis

2021
The impact of hypotestosteronemia on cardiometabolic effects of atorvastatin in men with hypercholesterolemia: a pilot study.
    Coronary artery disease, 2021, 12-01, Volume: 32, Issue:8

    Topics: Adult; Anticholesteremic Agents; Atorvastatin; Humans; Hypercholesterolemia; Male; Metabolic Syndrome; Middle Aged; Pilot Projects; Risk Factors; Testosterone

2021
Atorvastatin reverses high cholesterol-induced cardiac remodelling and regulates mitochondrial quality-control in a cholesterol-independent manner: An experimental study.
    Clinical and experimental pharmacology & physiology, 2021, Volume: 48, Issue:8

    Topics: Animals; Atorvastatin; Diet, High-Fat; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Mice; Mice, Inbred C57BL; Ventricular Remodeling

2021
Studying the Effect of Taking Statins before Infection in the Severity Reduction of COVID-19 with Machine Learning.
    BioMed research international, 2021, Volume: 2021

    Topics: Aged; Algorithms; Atorvastatin; COVID-19; Drug Prescriptions; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Iran; Machine Learning; Male; Middle Aged; Retrospective Studies; Rosuvastatin Calcium; Severity of Illness Index; Simvastatin

2021
Efficacy of alirocumab according to background statin type and dose: pooled analysis of 8 ODYSSEY Phase 3 clinical trials.
    Scientific reports, 2017, 04-04, Volume: 7

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Proprotein Convertase 9; Rosuvastatin Calcium; Simvastatin

2017
How has the treatment of hypercholesterolemia in Poland changed over the last six years?
    Cardiology journal, 2017, Volume: 24, Issue:3

    Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Incidence; Lipoproteins, LDL; Male; Middle Aged; Patient Compliance; Poland; Registries; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Surveys and Questionnaires; Time Factors

2017
10-year trends in statin utilization in Taiwan: a retrospective study using Taiwan's National Health Insurance Research Database.
    BMJ open, 2017, 05-17, Volume: 7, Issue:5

    Topics: Aged; Atorvastatin; Cardiovascular Diseases; Drug Utilization; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; National Health Programs; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Taiwan

2017
Generic atorvastatin is as effective as the brand-name drug (LIPITOR
    BMC research notes, 2017, Jul-17, Volume: 10, Issue:1

    Topics: Aged; Atorvastatin; Cholesterol, LDL; Cross-Sectional Studies; Drugs, Generic; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Retrospective Studies; Triglycerides

2017
Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease.
    JAMA cardiology, 2017, 09-01, Volume: 2, Issue:9

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cholesterol, LDL; Cohort Studies; Computer Simulation; Databases, Factual; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Monte Carlo Method; Patient Care Planning; PCSK9 Inhibitors

2017
Transporter genes ABCG2 rs2231142 and ABCB1 rs1128503 polymorphisms and atorvastatin response in Chilean subjects.
    Journal of clinical pharmacy and therapeutics, 2018, Volume: 43, Issue:1

    Topics: Atorvastatin; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; Cholesterol, LDL; Female; Gene Frequency; Genotype; Humans; Hypercholesterolemia; Lipids; Male; Middle Aged; Neoplasm Proteins; Polymorphism, Single Nucleotide; Triglycerides

2018
Complete resolution of extensive xanthomas associated with primary sclerosing cholangitis following liver transplantation.
    Clinical and experimental dermatology, 2017, Volume: 42, Issue:8

    Topics: Atorvastatin; Cholangitis, Sclerosing; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Liver Transplantation; Male; Treatment Outcome; Xanthomatosis; Young Adult

2017
Efficacy of functional foods mixture in improving hypercholesterolemia, inflammatory and endothelial dysfunction biomarkers-induced by high cholesterol diet.
    Lipids in health and disease, 2017, Oct-06, Volume: 16, Issue:1

    Topics: Animals; Atorvastatin; Cholesterol; Creatine Kinase; Diet, High-Fat; Dietary Fats; Drug Administration Schedule; Functional Food; Homocysteine; Hypercholesterolemia; L-Lactate Dehydrogenase; Male; Nitric Oxide Synthase Type III; Rats; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1

2017
Anti-atherosclerotic effect of Longxuetongluo Capsule in high cholesterol diet induced atherosclerosis model rats.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2018, Volume: 97

    Topics: Animals; Anti-Inflammatory Agents; Anticholesteremic Agents; Aorta; Atherosclerosis; Atorvastatin; Diet, High-Fat; Disease Models, Animal; Drugs, Chinese Herbal; Hypercholesterolemia; Inflammation; Lipid Metabolism; Lipids; Male; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; NF-kappa B; Plaque, Atherosclerotic; Rats; Rats, Sprague-Dawley

2018
Atorvastatin accelerates clearance of lipoprotein remnants generated by activated brown fat to further reduce hypercholesterolemia and atherosclerosis.
    Atherosclerosis, 2017, Volume: 267

    Topics: Adipose Tissue; Adipose Tissue, Brown; Animals; Atherosclerosis; Atorvastatin; Calorimetry, Indirect; Cholesterol Ester Transfer Proteins; Female; Gene Expression Profiling; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemias; Lipids; Lipoproteins; Liver; Mice; Mice, Knockout, ApoE; Proprotein Convertase 9; Receptors, Adrenergic, beta-3; Triglycerides

2017
Gender-Specific Association Between ABCC2 -24C>T SNP and Reduction in Triglycerides in Chilean Patients Treated With Atorvastatin.
    Basic & clinical pharmacology & toxicology, 2018, Volume: 122, Issue:5

    Topics: Adult; Aged; Atorvastatin; Biomarkers; Chile; Cholesterol; Down-Regulation; Female; Genotype; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Pharmacogenetics; Pharmacogenomic Variants; Phenotype; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Sex Factors; Time Factors; Treatment Outcome; Triglycerides

2018
LDL cholesterol levels after switch from atorvastatin to rosuvastatin.
    Current medical research and opinion, 2018, Volume: 34, Issue:10

    Topics: Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Drug Monitoring; Drug Substitution; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipid Metabolism; Male; Middle Aged; Retrospective Studies; Risk Factors; Rosuvastatin Calcium; United States

2018
Effect of atorvastatin on the gut microbiota of high fat diet-induced hypercholesterolemic rats.
    Scientific reports, 2018, 01-12, Volume: 8, Issue:1

    Topics: Animals; Anticholesteremic Agents; Atorvastatin; Bacteria; Diet, High-Fat; Disease Models, Animal; DNA, Bacterial; DNA, Ribosomal; Gastrointestinal Microbiome; Hypercholesterolemia; Male; Phylogeny; Rats; RNA, Ribosomal, 16S; Sequence Analysis, DNA

2018
Atorvastatin impaired glucose metabolism in C2C12 cells partly via inhibiting cholesterol-dependent glucose transporter 4 translocation.
    Biochemical pharmacology, 2018, Volume: 150

    Topics: Animals; Anticholesteremic Agents; Atorvastatin; Cell Line; Cholesterol; Diet, High-Fat; Dose-Response Relationship, Drug; Glucose; Glucose Transporter Type 4; Hypercholesterolemia; Male; Mice; Mice, Inbred C57BL; Muscle, Skeletal

2018
Atorvastatin Treatment Modulates the Gut Microbiota of the Hypercholesterolemic Patients.
    Omics : a journal of integrative biology, 2018, Volume: 22, Issue:2

    Topics: Adolescent; Adult; Anticholesteremic Agents; Atorvastatin; Bacteria; Cholesterol; Female; Gastrointestinal Microbiome; Humans; Hypercholesterolemia; Inflammation; Lipid Metabolism; Male; Middle Aged; RNA, Ribosomal, 16S; Young Adult

2018
Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials).
    The American journal of cardiology, 2018, 04-15, Volume: 121, Issue:8

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cholesterol, LDL; Clinical Trials, Phase III as Topic; Coronary Disease; Drug Therapy, Combination; Female; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipoproteinemia Type II; Male; Maximum Tolerated Dose; Middle Aged; PCSK9 Inhibitors; Peripheral Arterial Disease; Risk; Rosuvastatin Calcium; Simvastatin; Stroke; Treatment Outcome

2018
Statin use in Brazil: findings and implications.
    Current medical research and opinion, 2018, Volume: 34, Issue:10

    Topics: Adult; Aged; Atorvastatin; Brazil; Cardiovascular Diseases; Cross-Sectional Studies; Drug Utilization Review; Female; Health Equity; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Medication Adherence; Middle Aged; Primary Health Care; Rosuvastatin Calcium; Simvastatin

2018
What is the role of PCSK9 inhibitors in treating hypercholesterolemia?
    JAAPA : official journal of the American Academy of Physician Assistants, 2018, Volume: 31, Issue:6

    Topics: Anticholesteremic Agents; Atorvastatin; Humans; Hypercholesterolemia; Male; Middle Aged; PCSK9 Inhibitors

2018
All-trans retinoic acid effectively reduces atheroma plaque size in a rabbit model of high-fat-induced atherosclerosis.
    Advances in clinical and experimental medicine : official organ Wroclaw Medical University, 2018, Volume: 27, Issue:12

    Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Diet, High-Fat; Hypercholesterolemia; Lipids; Plaque, Atherosclerotic; Rabbits; Random Allocation; Tretinoin; Tunica Intima

2018
The effect of atorvastatin on sexual function and depressive symptoms in young women with elevated cholesterol levels - a pilot study.
    Endokrynologia Polska, 2018, Volume: 69, Issue:6

    Topics: Adult; Anticholesteremic Agents; Atorvastatin; Depression; Female; Humans; Hypercholesterolemia; Pilot Projects; Sexual Dysfunction, Physiological; Surveys and Questionnaires

2018
KIF6 gene as a pharmacogenetic marker for lipid-lowering effect in statin treatment.
    PloS one, 2018, Volume: 13, Issue:10

    Topics: Anticholesteremic Agents; Atorvastatin; Biomarkers, Pharmacological; Cholesterol, LDL; DNA; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Kinesins; Male; Middle Aged; Mutation, Missense; Pharmacogenomic Testing; Prospective Studies; Rosuvastatin Calcium; Simvastatin

2018
AIBP-mediated cholesterol efflux instructs hematopoietic stem and progenitor cell fate.
    Science (New York, N.Y.), 2019, 03-08, Volume: 363, Issue:6431

    Topics: Animals; Anticholesteremic Agents; Atorvastatin; Base Sequence; Cholesterol; Chromatin Immunoprecipitation; Coronary Artery Disease; Gene Expression Regulation; Hematopoiesis; Hematopoietic Stem Cells; Hypercholesterolemia; Racemases and Epimerases; Receptors, Notch; Sterol Regulatory Element Binding Protein 2; Zebrafish; Zebrafish Proteins

2019
Statins Can Lead to Acute Hemolysis.
    Cardiovascular & hematological agents in medicinal chemistry, 2018, Volume: 16, Issue:2

    Topics: Adult; Anemia, Hemolytic; Atorvastatin; Female; Hemolysis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Rosuvastatin Calcium

2018
Combined Effect of Diosgenin Along with Ezetimibe or Atorvastatin on the Fate of Labelled Bile Acid and Cholesterol in Hypercholesterolemic Rats.
    International journal of environmental research and public health, 2019, 02-20, Volume: 16, Issue:4

    Topics: Animals; Anticholesteremic Agents; Atorvastatin; Bile Acids and Salts; Cholesterol; Diosgenin; Ezetimibe; Hypercholesterolemia; Liver; Male; Rats; Rats, Wistar

2019
The effect of atorvastatin on cardiometabolic risk factors in women with non-classic congenital adrenal hyperplasia: A pilot study.
    Pharmacological reports : PR, 2019, Volume: 71, Issue:3

    Topics: Adrenal Hyperplasia, Congenital; Adult; Androgens; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Dehydroepiandrosterone Sulfate; Female; Fibrinogen; Homocysteine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pilot Projects; Risk Factors; Testosterone; Uric Acid; Vitamin D

2019
Regulation of Cholesterol Homeostasis by a Novel Long Non-coding RNA LASER.
    Scientific reports, 2019, 05-22, Volume: 9, Issue:1

    Topics: Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Benzoates; Benzylamines; Berberine; Cholesterol; Chromosomes, Human, Pair 11; Coronary Disease; Gene Expression Regulation; Genome-Wide Association Study; Hep G2 Cells; Hepatocyte Nuclear Factor 1-alpha; Hepatocytes; Histone Code; Histone Demethylases; Homeostasis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Leukocytes, Mononuclear; Proprotein Convertase 9; Protein Binding; Protein Interaction Mapping; RNA Interference; RNA, Long Noncoding; RNA, Small Interfering

2019
Treatment of Hypertensive and Hypercholesterolaemic Patients with the Triple Fixed Combination of Atorvastatin, Perindopril and Amlodipine: The Results of the CORAL Study.
    Advances in therapy, 2019, Volume: 36, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Animals; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Comorbidity; Drug Combinations; Female; Humans; Hypercholesterolemia; Hypertension; Male; Middle Aged; Perindopril; Prospective Studies

2019
Effect of atorvastatin on hematologic parameters in patients with hypercholesterolemia.
    Angiology, 2013, Volume: 64, Issue:8

    Topics: Aged; Anticholesteremic Agents; Atorvastatin; Blood Cell Count; Erythrocyte Indices; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Leukocyte Count; Male; Middle Aged; Platelet Activation; Pyrroles

2013
Plaque stabilization by intensive LDL-cholesterol lowering therapy with atorvastatin is delayed in type 2 diabetic patients with coronary artery disease-Serial angioscopic and intravascular ultrasound analysis.
    Journal of cardiology, 2013, Volume: 61, Issue:6

    Topics: Aged; Angioscopy; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Plaque, Atherosclerotic; Pyrroles; Risk Factors; Time Factors; Ultrasonography, Interventional

2013
Effects of atorvastatin on CYP3A4 and CYP3A5 mRNA expression in mononuclear cells and CYP3A activity in hypercholeresterolemic patients.
    Clinica chimica acta; international journal of clinical chemistry, 2013, Jun-05, Volume: 421

    Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Case-Control Studies; Cholesterol, LDL; Cytochrome P-450 CYP3A; Drug Administration Schedule; Female; Gene Expression; Genetic Heterogeneity; Haplotypes; Heptanoic Acids; Humans; Hypercholesterolemia; Leukocytes, Mononuclear; Male; Middle Aged; Phenotype; Pyrroles; RNA, Messenger

2013
Standards of statin usage in Poland in high-risk patients: 3ST-POL study results.
    Kardiologia polska, 2013, Volume: 71, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Anticholesteremic Agents; Atorvastatin; Cardiology; Cardiovascular Diseases; Cohort Studies; Comorbidity; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Drug Utilization; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Outpatients; Patient Compliance; Poland; Population Surveillance; Primary Health Care; Pyrroles; Simvastatin; Surveys and Questionnaires; Treatment Failure

2013
Osteoarthritis development is induced by increased dietary cholesterol and can be inhibited by atorvastatin in APOE*3Leiden.CETP mice--a translational model for atherosclerosis.
    Annals of the rheumatic diseases, 2014, Volume: 73, Issue:5

    Topics: Animals; Anticholesteremic Agents; Apolipoprotein E3; Atherosclerosis; Atorvastatin; Cholesterol Ester Transfer Proteins; Cholesterol, Dietary; Disease Models, Animal; Heptanoic Acids; Humans; Hypercholesterolemia; Mice; Mice, Transgenic; Osteoarthritis; Pyrroles

2014
Do MDR1 and SLCO1B1 polymorphisms influence the therapeutic response to atorvastatin? A study on a cohort of Egyptian patients with hypercholesterolemia.
    Molecular diagnosis & therapy, 2013, Volume: 17, Issue:5

    Topics: Anticholesteremic Agents; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cholesterol, HDL; Cholesterol, LDL; Egypt; Female; Genetic Variation; Heptanoic Acids; Humans; Hypercholesterolemia; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Organic Anion Transporters; Polymorphism, Genetic; Pyrroles; Risk Factors; Sex Characteristics; Triglycerides

2013
Mean platelet volume measurement in patients with hypercholesterolemia: a methodological issue.
    Angiology, 2013, Volume: 64, Issue:8

    Topics: Anticholesteremic Agents; Atorvastatin; Erythrocyte Indices; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Pyrroles

2013
Electronegative low-density lipoprotein increases C-reactive protein expression in vascular endothelial cells through the LOX-1 receptor.
    PloS one, 2013, Volume: 8, Issue:8

    Topics: Adult; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cells, Cultured; Endothelial Cells; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipoproteins, LDL; Male; Middle Aged; Pyrroles; Reactive Oxygen Species; Scavenger Receptors, Class E

2013
Effect of atorvastatin on atherosclerotic plaque formation and platelet activation in hypercholesterolemic rats.
    Canadian journal of physiology and pharmacology, 2013, Volume: 91, Issue:9

    Topics: Animals; Aorta; Aortic Diseases; Atherosclerosis; Atorvastatin; Biomarkers; CD40 Antigens; CD40 Ligand; Cholesterol, Dietary; Disease Models, Animal; Disease Progression; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Interleukin-6; Lipids; Male; P-Selectin; Plaque, Atherosclerotic; Platelet Activation; Platelet Factor 4; Pyrroles; Rats; Rats, Wistar

2013
Safety and tolerability of the use of atorvastatin 40 mg in common daily practice in short-term observation in 3,227 patients.
    Przeglad lekarski, 2013, Volume: 70, Issue:6

    Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Drug Administration Schedule; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Longitudinal Studies; Male; Middle Aged; Muscular Diseases; Observation; Prospective Studies; Pyrroles; Surveys and Questionnaires

2013
Long-term use of statins reduces the risk of hospitalization for dementia.
    Atherosclerosis, 2013, Volume: 230, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Case-Control Studies; Dementia; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Italy; Logistic Models; Male; Middle Aged; Pravastatin; Pyrroles; Risk; Simvastatin; Time Factors

2013
[A multi-device approach to an unusual case of left main thrombosis: when manual thrombectomy is not enough].
    Giornale italiano di cardiologia (2006), 2013, Volume: 14, Issue:10

    Topics: Abciximab; Acute Coronary Syndrome; Antibodies, Monoclonal; Anticoagulants; Atorvastatin; Combined Modality Therapy; Coronary Angiography; Coronary Thrombosis; Coronary Vessels; Embolic Protection Devices; Embolism; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Immunoglobulin Fab Fragments; Infusions, Intra-Arterial; Male; Middle Aged; Platelet Aggregation Inhibitors; Pyrroles; Suction; Thrombectomy; Tomography, Optical Coherence

2013
The effect of rosuvastatin and atorvastatin on erectile dysfunction in hypercholesterolaemic patients.
    Kardiologia polska, 2014, Volume: 72, Issue:3

    Topics: Adult; Anticholesteremic Agents; Atorvastatin; Erectile Dysfunction; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Prospective Studies; Rosuvastatin Calcium

2014
Effect of atorvastatin on low-density lipoprotein subpopulations and comparison between indicators of plasma atherogenicity: a pilot study.
    Angiology, 2014, Volume: 65, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Apolipoproteins B; Atherosclerosis; Atorvastatin; Biomarkers; Cholesterol; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipoproteinemias; Lipoproteins, LDL; Male; Middle Aged; Pilot Projects; Pyrroles; Time Factors; Treatment Outcome; Triglycerides

2014
Probucol inhibits the initiation of atherosclerosis in cholesterol-fed rabbits.
    Lipids in health and disease, 2013, Nov-04, Volume: 12

    Topics: Animals; Anticholesteremic Agents; Aorta; Atherosclerosis; Atorvastatin; Cell Adhesion; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Dietary Fats; Endothelial Cells; Heptanoic Acids; Hypercholesterolemia; Macrophages; Male; Monocytes; Plaque, Atherosclerotic; Probucol; Pyrroles; Rabbits; Triglycerides; Tunica Intima

2013
Statins decrease mean platelet volume irrespective of cholesterol lowering effect.
    Kardiologia polska, 2013, Volume: 71, Issue:10

    Topics: Adult; Atorvastatin; Cholesterol, LDL; Comorbidity; Coronary Disease; Diabetes Mellitus; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Male; Mean Platelet Volume; Middle Aged; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Sulfonamides

2013
Lack of association of the p450 oxidoreductase *28 single nucleotide polymorphism with the lipid-lowering effect of statins in hypercholesterolemic patients.
    Molecular diagnosis & therapy, 2014, Volume: 18, Issue:3

    Topics: Adult; Aged; Atorvastatin; Cholesterol; Cohort Studies; Cytochrome P-450 CYP3A; Female; Gene Frequency; Genetic Association Studies; Genotype; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; NADPH-Ferrihemoprotein Reductase; Polymorphism, Single Nucleotide; Pyrroles; Simvastatin

2014
Coenzyme Q10 supplementation improves metabolic parameters, liver function and mitochondrial respiration in rats with high doses of atorvastatin and a cholesterol-rich diet.
    Lipids in health and disease, 2014, Jan-25, Volume: 13

    Topics: Animals; Atorvastatin; Cell Respiration; Cholesterol, Dietary; Cholesterol, HDL; Diet, High-Fat; Dietary Supplements; Drug Evaluation, Preclinical; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Liver; Male; Mitochondria, Liver; Pyrroles; Rats; Rats, Wistar; Triglycerides; Ubiquinone

2014
Formulation and evaluation of fixed-dose combination of bilayer gastroretentive matrix tablet containing atorvastatin as fast-release and atenolol as sustained-release.
    BioMed research international, 2014, Volume: 2014

    Topics: Administration, Oral; Atenolol; Atorvastatin; Chemistry, Pharmaceutical; Delayed-Action Preparations; Drug Combinations; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Pyrroles; Solubility

2014
Influence of SREBP-2 and SCAP gene polymorphisms on lipid-lowering response to atorvastatin in a cohort of Chilean subjects with Amerindian background.
    Molecular diagnosis & therapy, 2014, Volume: 18, Issue:4

    Topics: Atorvastatin; Cholesterol, LDL; Female; Haplotypes; Heptanoic Acids; Humans; Hypercholesterolemia; Intracellular Signaling Peptides and Proteins; Male; Membrane Proteins; Polymorphism, Genetic; Polymorphism, Restriction Fragment Length; Polymorphism, Single Nucleotide; Pyrroles; Sterol Regulatory Element Binding Protein 2

2014
Characterization of the pharmaceutical effect of drugs on atherosclerotic lesions in vivo using integrated fluorescence imaging and Raman spectral measurements.
    Analytical chemistry, 2014, Apr-15, Volume: 86, Issue:8

    Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Azetidines; Blood Vessels; Ezetimibe; Heptanoic Acids; Hypercholesterolemia; Lipid Metabolism; Lipids; Microscopy, Confocal; Pyrroles; Spectrum Analysis, Raman; Zebrafish

2014
No impact of SLCO1B1 521T>C, 388A>G and 411G>A polymorphisms on response to statin therapy in the Greek population.
    Molecular biology reports, 2014, Volume: 41, Issue:7

    Topics: Adult; Aged; Alleles; Atorvastatin; Cholesterol, LDL; Drug Administration Schedule; Female; Gene Frequency; Gene-Environment Interaction; Haplotypes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Organic Anion Transporters; Polymorphism, Restriction Fragment Length; Polymorphism, Single Nucleotide; Pyrroles; Simvastatin

2014
Summaries for patients. Treatment trials to determine whether statins are the cause of a patient's discomfort.
    Annals of internal medicine, 2014, Mar-04, Volume: 160, Issue:5

    Topics: Aged; Aged, 80 and over; Atorvastatin; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Myalgia; Pyrimidines; Pyrroles; Research Design; Rosuvastatin Calcium; Sulfonamides

2014
Effects of atorvastatin in combination with ezetimibe on carotid atherosclerosis in elderly patients with hypercholesterolemia.
    Genetics and molecular research : GMR, 2014, Apr-03, Volume: 13, Issue:2

    Topics: Aged; Atorvastatin; Azetidines; C-Reactive Protein; Carotid Artery Diseases; Carotid Intima-Media Thickness; Cholesterol, LDL; Drug Combinations; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Pyrroles

2014
The Carotid intima-media thickness modification following atorvastatin is bound to the modification of the oxidative balance.
    Journal of cardiovascular pharmacology and therapeutics, 2014, Volume: 19, Issue:5

    Topics: Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Carotid Arteries; Cholesterol; Heptanoic Acids; Humans; Hypercholesterolemia; Italy; Male; Middle Aged; Oxidative Stress; Pyrroles; Registries; Treatment Outcome

2014
[Lipid-lowering therapy and patient adherence in the MULTI GAP 2013 trial].
    Orvosi hetilap, 2014, Apr-27, Volume: 155, Issue:17

    Topics: Adult; Aged; Atherosclerosis; Atorvastatin; Cholesterol, LDL; Databases, Factual; Drug Prescriptions; Drug Therapy, Combination; Female; Fluorobenzenes; Guideline Adherence; Heptanoic Acids; Humans; Hungary; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Insurance, Health; Male; Middle Aged; Patient Compliance; Practice Guidelines as Topic; Practice Patterns, Physicians'; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Surveys and Questionnaires; Treatment Outcome

2014
Overview on pharmacological and nutraceutical strategies for treatment of borderline dyslipidemia.
    Minerva cardioangiologica, 2014, Volume: 62, Issue:3

    Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Clinical Trials as Topic; Dietary Supplements; Fatty Acids; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Italy; Male; Pyrroles; Risk Factors; Treatment Outcome

2014
Evaluation of statin therapy on endothelial function in hypercholesterolemic rabbits by automatic measurement of arterial wall movement using ultrasound images.
    Ultrasound in medicine & biology, 2014, Volume: 40, Issue:10

    Topics: Algorithms; Animals; Atorvastatin; Blood Flow Velocity; Disease Models, Animal; Endothelium, Vascular; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Image Processing, Computer-Assisted; Male; Pyrroles; Rabbits; Ultrasonography, Doppler; Vasodilator Agents

2014
Metformin enhances nitric oxide production and diminishes Rho kinase activity in rats with hyperlipidemia.
    Lipids in health and disease, 2014, Jul-15, Volume: 13

    Topics: Animals; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Drug Evaluation, Preclinical; Heptanoic Acids; Hypercholesterolemia; Male; Metformin; Nitric Oxide; Pyrroles; Rats, Sprague-Dawley; rho-Associated Kinases

2014
Clinical- and cost-effectiveness of LDL particle-guided statin therapy: a simulation study.
    Atherosclerosis, 2014, Volume: 236, Issue:1

    Topics: Adult; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Comorbidity; Computer Simulation; Cost Savings; Cost-Benefit Analysis; Diabetes Mellitus; Drug Costs; Drug Substitution; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Life Style; Lipoproteins, LDL; Medicare; Models, Cardiovascular; Nuclear Magnetic Resonance, Biomolecular; Pyrroles; Quality-Adjusted Life Years; Risk; Risk Reduction Behavior; Simvastatin; Treatment Outcome; United States

2014
Demonstration of an add-on effect of probucol and cilostazol on the statin-induced anti-atherogenic effects.
    Histology and histopathology, 2014, Volume: 29, Issue:12

    Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cilostazol; Drug Therapy, Combination; Heptanoic Acids; Hypercholesterolemia; Immunohistochemistry; Lipids; Probucol; Pyrroles; Rabbits; Tetrazoles

2014
Evaluation of sexual dimorphism in the efficacy and safety of simvastatin/atorvastatin therapy in a southern Brazilian cohort.
    Arquivos brasileiros de cardiologia, 2014, Volume: 103, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Brazil; Cholesterol; Creatine Kinase; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Myalgia; Prospective Studies; Pyrroles; Sex Factors; Simvastatin

2014
Disruption of ldlr causes increased LDL-c and vascular lipid accumulation in a zebrafish model of hypercholesterolemia.
    Journal of lipid research, 2014, Volume: 55, Issue:11

    Topics: Animals; Atorvastatin; Base Sequence; Blood Vessels; Cholesterol, LDL; Disease Models, Animal; Embryo, Nonmammalian; Gene Expression Regulation; Gene Knockdown Techniques; Hepatomegaly; Heptanoic Acids; Hypercholesterolemia; Liver; Molecular Sequence Data; Morpholinos; Oxidation-Reduction; Pyrroles; Receptors, LDL; Veins; Zebrafish

2014
No effect of CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) on lipid-lowering response to statins in Greek patients with primary hypercholesterolemia.
    Drug metabolism and personalized therapy, 2015, Volume: 30, Issue:1

    Topics: Atorvastatin; Cholesterol; Cholesterol, LDL; Cohort Studies; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Female; Gene Frequency; Greece; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Introns; Male; Middle Aged; Polymorphism, Genetic; Simvastatin; Treatment Outcome

2015
Upregulated expression of human alpha-defensins 1, 2 and 3 in hypercholesteremia and its relationship with serum lipid levels.
    Human immunology, 2014, Volume: 75, Issue:11

    Topics: Aged; alpha-Defensins; Anticholesteremic Agents; Atorvastatin; Case-Control Studies; Cholesterol; Cholesterol, LDL; Female; Gene Expression Regulation; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Neutrophils; Pyrroles

2014
Risk of diabetes in patients treated with HMG-CoA reductase inhibitors.
    Metabolism: clinical and experimental, 2015, Volume: 64, Issue:4

    Topics: Aged; Atorvastatin; Diabetes Mellitus; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Quinolines; Retrospective Studies; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides

2015
Giant cell arteritis and polymyalgia rheumatica after reexposure to a statin: a case report.
    Annals of internal medicine, 2014, Oct-21, Volume: 161, Issue:8

    Topics: Aged; Atorvastatin; Female; Fluorobenzenes; Giant Cell Arteritis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Polymyalgia Rheumatica; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides

2014
The effect of atorvastatin and atorvastatin-ezetimibe combination therapy on androgen production in hyperandrogenic women with elevated cholesterol levels.
    Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 2015, Volume: 123, Issue:2

    Topics: Adult; Androgens; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hyperandrogenism; Hypercholesterolemia; Middle Aged; Pyrroles; Sex Hormone-Binding Globulin; Treatment Outcome; Young Adult

2015
High levels of LDL-C combined with low levels of HDL-C further increase platelet activation in hypercholesterolemic patients.
    Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas, 2015, Volume: 48, Issue:2

    Topics: Aged; Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Female; Flow Cytometry; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; P-Selectin; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrroles; Statistics, Nonparametric

2015
Do statins have a specific drug effect beyond low-density lipoprotein-cholesterol-lowering in the secondary prevention of coronary artery disease?
    Circulation journal : official journal of the Japanese Circulation Society, 2015, Volume: 79, Issue:1

    Topics: Atorvastatin; Cardiovascular Diseases; Female; Humans; Hypercholesterolemia; Male; Myocardial Infarction; Pravastatin

2015
Atorvastatin in the management of tinnitus with hyperlipidemias.
    Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2014, Volume: 24, Issue:12

    Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Female; Hearing Loss, Noise-Induced; Humans; Hypercholesterolemia; Hyperlipidemias; Male; Middle Aged; Prospective Studies; Severity of Illness Index; Surveys and Questionnaires; Tinnitus

2014
[Negative effects of termination statinotherapy in patients after acute coronary event with concominent non-alcoholic steatohepatitis].
    Likars'ka sprava, 2014, Issue:11

    Topics: Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Drug Administration Schedule; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Myocardial Infarction; Non-alcoholic Fatty Liver Disease; Pyrimidines; Pyrroles; Recurrence; Rosuvastatin Calcium; Sulfonamides; Triglycerides

2014
Impact of Switching From High-Efficacy Lipid-Lowering Therapies to Generic Simvastatin on LDL-C Levels and LDL-C Goal Attainment Among High-Risk Primary and Secondary Prevention Populations in the United Kingdom.
    Clinical therapeutics, 2015, Apr-01, Volume: 37, Issue:4

    Topics: Aged; Aged, 80 and over; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Cohort Studies; Drugs, Generic; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Retrospective Studies; Risk Factors; Rosuvastatin Calcium; Secondary Prevention; Simvastatin; United Kingdom

2015
Different effects of atorvastatin on metabolic and cardiovascular risk factors in hypercholesterolemic women with normal thyroid function and subclinical hypothyroidism.
    Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 2015, Volume: 123, Issue:3

    Topics: Adult; Atorvastatin; Cardiovascular Diseases; Comorbidity; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypothyroidism; Middle Aged; Risk Factors; Treatment Outcome

2015
Acute anti-fibrillating and defibrillating potential of atorvastatin, melatonin, eicosapentaenoic acid and docosahexaenoic acid demonstrated in isolated heart model.
    Journal of physiology and pharmacology : an official journal of the Polish Physiological Society, 2015, Volume: 66, Issue:1

    Topics: Animals; Anti-Arrhythmia Agents; Atorvastatin; Cardiac Pacing, Artificial; Docosahexaenoic Acids; Eicosapentaenoic Acid; Female; Guinea Pigs; Heart Rate; Hypercholesterolemia; Isolated Heart Preparation; Male; Melatonin; Rats; Time Factors; Ventricular Fibrillation

2015
[Fasciculations, cramps, and statins].
    Revista de neurologia, 2015, Apr-16, Volume: 60, Issue:8

    Topics: Atorvastatin; Drug Substitution; Electromyography; Fasciculation; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Leg; Middle Aged; Muscle Cramp; Phytosterols; Quinolines; Rosuvastatin Calcium; Toes

2015
APOE polymorphisms contribute to reduced atorvastatin response in Chilean Amerindian subjects.
    International journal of molecular sciences, 2015, Apr-09, Volume: 16, Issue:4

    Topics: Apolipoproteins E; Atorvastatin; Chile; DNA, Mitochondrial; Female; Haplotypes; Humans; Hypercholesterolemia; Male; Middle Aged; Polymorphism, Single Nucleotide; Receptors, LDL

2015
High Incidence of ACE/PAI-1 in Association to a Spectrum of Other Polymorphic Cardiovascular Genes Involving PBMCs Proinflammatory Cytokines in Hypertensive Hypercholesterolemic Patients: Reversibility with a Combination of ACE Inhibitor and Statin.
    PloS one, 2015, Volume: 10, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Atorvastatin; Cytokines; Female; Genetic Association Studies; Genetic Predisposition to Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Lebanon; Male; Middle Aged; Peptidyl-Dipeptidase A; Plasminogen Activator Inhibitor 1; Polymorphism, Single Nucleotide; Ramipril; Treatment Outcome; Young Adult

2015
Identifying Vulnerable Atherosclerotic Plaque in Rabbits Using DMSA-USPIO Enhanced Magnetic Resonance Imaging to Investigate the Effect of Atorvastatin.
    PloS one, 2015, Volume: 10, Issue:5

    Topics: Animals; Anticholesteremic Agents; Aorta, Abdominal; Atherosclerosis; Atorvastatin; CD40 Ligand; Cholesterol; Contrast Media; Dextrans; Diet, High-Fat; Disease Models, Animal; Gene Expression; Hypercholesterolemia; Magnetic Resonance Imaging; Magnetite Nanoparticles; Male; Matrix Metalloproteinase 9; Plaque, Atherosclerotic; Rabbits; Succimer; Transgenes; Tumor Suppressor Protein p53

2015
Atorvastatin and fenofibrate combination induces the predominance of the large HDL subclasses and increased apo AI fractional catabolic rates in New Zealand white rabbits with exogenous hypercholesterolemia.
    Fundamental & clinical pharmacology, 2015, Volume: 29, Issue:4

    Topics: Animals; Apolipoprotein A-I; Aryldialkylphosphatase; Atorvastatin; Blood Glucose; Cholesterol, HDL; Drug Synergism; Fenofibrate; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Kinetics; Lipids; Male; Rabbits

2015
Atorvastatin Attenuates Bone Loss and Aortic Valve Atheroma in LDLR Mice.
    Cardiology, 2015, Volume: 132, Issue:1

    Topics: Animals; Anticholesteremic Agents; Aortic Valve; Aortic Valve Stenosis; Atherosclerosis; Atorvastatin; Calcinosis; Cholesterol, Dietary; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Macrophages; Mice; Osteogenesis; Osteoporosis; Plaque, Atherosclerotic; X-Ray Microtomography

2015
The Arginine/ADMA Ratio Is Related to the Prevention of Atherosclerotic Plaques in Hypercholesterolemic Rabbits When Giving a Combined Therapy with Atorvastatine and Arginine.
    International journal of molecular sciences, 2015, May-29, Volume: 16, Issue:6

    Topics: Animals; Anticholesteremic Agents; Arginine; Atorvastatin; Cholesterol; Dietary Supplements; Hypercholesterolemia; Nitric Oxide; Nitric Oxide Synthase; Plaque, Atherosclerotic; Rabbits

2015
Atorvastatin delays the glucose clearance rate in hypercholesterolemic rabbits.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2015, Volume: 72

    Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Atorvastatin; Blood Glucose; Diet; Feeding Behavior; Glucose; Glucose Tolerance Test; Hypercholesterolemia; Insulin; Lipids; Male; Organ Size; Rabbits

2015
The effects of atorvastatin on antioxidant/antiinflammatory properties of HDLs in hypercholesterolemics.
    Turkish journal of medical sciences, 2015, Volume: 45, Issue:2

    Topics: Adult; Anticholesteremic Agents; Arginine; Atorvastatin; Drug Monitoring; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Inflammation; Lipoproteins, HDL; Male; Malondialdehyde; Middle Aged; Nitric Oxide; Oxidative Stress; Pyrroles; Treatment Outcome

2015
Combined use of probucol and cilostazol with atorvastatin attenuates atherosclerosis in moderately hypercholesterolemic rabbits.
    Lipids in health and disease, 2015, Jul-29, Volume: 14

    Topics: Animals; Aorta; Atherosclerosis; Atorvastatin; Biomarkers; Cilostazol; Drug Therapy, Combination; Hypercholesterolemia; Inflammation; Lipids; Male; Oxidation-Reduction; Oxidative Stress; Probucol; Rabbits; Tetrazoles

2015
Statin Selection in Qatar Based on Multi-indication Pharmacotherapeutic Multi-criteria Scoring Model, and Clinician Preference.
    Clinical therapeutics, 2015, Dec-01, Volume: 37, Issue:12

    Topics: Atorvastatin; C-Reactive Protein; Cholesterol; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Practice Patterns, Physicians'; Pravastatin; Qatar

2015
ESR1 polymorphisms and statin therapy: a sex-specific approach.
    The pharmacogenomics journal, 2016, Volume: 16, Issue:6

    Topics: Aged; Atorvastatin; Biomarkers; Brazil; Estrogen Receptor alpha; Female; Gene Frequency; Haplotypes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Linkage Disequilibrium; Lipids; Male; Middle Aged; Pharmacogenetics; Pharmacogenomic Variants; Phenotype; Polymorphism, Single Nucleotide; Prospective Studies; Sex Factors; Simvastatin; Treatment Outcome

2016
SLCO1B1 c.388A>G Polymorphism Is Associated with HDL-C Levels in Response to Atorvastatin in Chilean Individuals.
    International journal of molecular sciences, 2015, Aug-31, Volume: 16, Issue:9

    Topics: Aged; Atorvastatin; Chile; Cholesterol, HDL; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Organic Anion Transporters; Pharmacogenetics; Polymorphism, Single Nucleotide; Public Health Surveillance; Treatment Outcome

2015
HMGCR rs17671591 SNP Determines Lower Plasma LDL-C after Atorvastatin Therapy in Chilean Individuals.
    Basic & clinical pharmacology & toxicology, 2016, Volume: 118, Issue:4

    Topics: Anticholesteremic Agents; Atorvastatin; Chile; Cholesterol, LDL; Female; Genome-Wide Association Study; Humans; Hydroxymethylglutaryl CoA Reductases; Hypercholesterolemia; Male; Middle Aged; Polymorphism, Single Nucleotide; Proprotein Convertase 9; Treatment Outcome

2016
Ameliorative effect of statin therapy on oxidative damage in heart tissue of hypercholesterolemic rabbits.
    Fundamental & clinical pharmacology, 2015, Volume: 29, Issue:6

    Topics: Animals; Anticholesteremic Agents; Antioxidants; Aryldialkylphosphatase; Atherosclerosis; Atorvastatin; Cholesterol, LDL; Diet; Heart; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Malondialdehyde; Nitric Oxide; Oxidation-Reduction; Oxidative Stress; Rabbits; Superoxide Dismutase

2015
Suboptimal Control of Lipid Levels: Results from 29 Countries Participating in the Centralized Pan-Regional Surveys on the Undertreatment of Hypercholesterolaemia (CEPHEUS).
    Journal of atherosclerosis and thrombosis, 2016, May-02, Volume: 23, Issue:5

    Topics: Adult; Aged; Atorvastatin; Blood Glucose; Cholesterol, LDL; Cross-Sectional Studies; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Internationality; Lipids; Male; Middle Aged; Prospective Studies; Regression Analysis; Risk; Risk Factors; Rosuvastatin Calcium; Simvastatin

2016
Cholesterol-independent effects of atorvastatin prevent cardiovascular morbidity and mortality in a mouse model of atherosclerotic plaque rupture.
    Vascular pharmacology, 2016, Volume: 80

    Topics: Animal Feed; Animals; Anticholesteremic Agents; Apolipoproteins E; Atorvastatin; Cholesterol; Disease Models, Animal; Female; Fibrillin-1; Hypercholesterolemia; Kaplan-Meier Estimate; Mice, Knockout; Plaque, Atherosclerotic; Survival Analysis

2016
A Translational Model for Diet-related Atherosclerosis: Effect of Statins on Hypercholesterolemia and Atherosclerosis in a Minipig.
    Toxicologic pathology, 2016, Volume: 44, Issue:3

    Topics: Animals; Animals, Genetically Modified; Aorta; Atherosclerosis; Atorvastatin; Diet, High-Fat; Disease Models, Animal; Femoral Artery; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Receptors, LDL; Swine; Swine, Miniature; Translational Research, Biomedical

2016
Genetic determinants of lipid-lowering response to atorvastatin therapy in an Indian population.
    Journal of clinical pharmacy and therapeutics, 2016, Volume: 41, Issue:3

    Topics: Aged; Alleles; Atorvastatin; Cholesterol, LDL; Female; Genetic Variation; Genotype; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; India; Male; Middle Aged; Pharmacogenetics; Polymorphism, Single Nucleotide; Treatment Outcome

2016
[One year persistence of atorvastatin and amlodipine fixed dose combination versus atorvastatin therapy].
    Orvosi hetilap, 2016, Mar-13, Volume: 157, Issue:11

    Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Atorvastatin; Blood Pressure; Cholesterol, LDL; Drug Combinations; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Linear Models; Male; Medication Adherence; Middle Aged; Pyrroles; Retrospective Studies; Treatment Outcome

2016
[FIXED COMBINATION ATORVASTATIN-EZETIMIBE (ATOZET®)].
    Revue medicale de Liege, 2016, Volume: 71, Issue:1

    Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Drug Combinations; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Risk Factors

2016
Effects of atorvastatin and artichoke leaf tincture on oxidative stress in hypercholesterolemic rats.
    Vojnosanitetski pregled, 2016, Volume: 73, Issue:2

    Topics: Animals; Anticholesteremic Agents; Antioxidants; Atorvastatin; Cynara scolymus; Disease Models, Animal; Drug Monitoring; Drug Synergism; Herb-Drug Interactions; Hypercholesterolemia; Oxidative Stress; Phytotherapy; Plant Extracts; Plant Leaves; Rats; Treatment Outcome

2016
Is Time an Important Problem in Management of Hypertension and Hypercholesterolemia by Using an Amlodipine-Atorvastatin Single Pill Combination?
    Medical science monitor : international medical journal of experimental and clinical research, 2016, Jul-26, Volume: 22

    Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Atorvastatin; Blood Pressure; Case-Control Studies; Disease Management; Drug Administration Schedule; Drug Combinations; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Male; Middle Aged; Patient Compliance; Pyrroles

2016
Nonenzymatic Mechanism of Statins in Modulating Cholesterol Particles Formation.
    The American journal of cardiology, 2016, Oct-15, Volume: 118, Issue:8

    Topics: Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Flow Cytometry; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; In Vitro Techniques; Lovastatin; Pilot Projects; Prodrugs; Simvastatin

2016
Protective effects of mitochondria-targeted antioxidants and statins on cholesterol-induced osteoarthritis.
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2017, Volume: 31, Issue:1

    Topics: Animals; Anticholesteremic Agents; Antioxidants; Apolipoproteins E; Atorvastatin; Bone Remodeling; Cholesterol; Chondrocytes; Dietary Fats; Hypercholesterolemia; Male; Mice; Mice, Knockout; Mitochondria; Osteoarthritis; Rats; Rats, Wistar

2017
Effect of dietary n-3 fatty acids supplementation on fatty acid metabolism in atorvastatin-administered SHR.Cg-Lepr
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2017, Volume: 85

    Topics: Animals; Anticholesteremic Agents; Atorvastatin; Dietary Fats; Dietary Supplements; Docosahexaenoic Acids; Drug Combinations; Eicosapentaenoic Acid; Food-Drug Interactions; Gene Expression Regulation; Hypercholesterolemia; Male; Metabolic Syndrome; Rats; Rats, Inbred Strains

2017
[Pleotropic Effects of Atorvastatin in Patients With Chronic Ischemic Heart Disease].
    Kardiologiia, 2016, Volume: 56, Issue:5

    Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Middle Aged; Myocardial Ischemia; Pyrroles

2016
Hypercholesterolaemia exacerbates ventricular remodelling after myocardial infarction in the rat: role of angiotensin II type 1 receptors.
    British journal of pharmacology, 2008, Volume: 154, Issue:8

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Anticholesteremic Agents; Atorvastatin; Drug Therapy, Combination; Echocardiography; Heptanoic Acids; Hypercholesterolemia; Losartan; Male; Myocardial Infarction; Pyrroles; Rats; Rats, Inbred WKY; Receptor, Angiotensin, Type 1; Up-Regulation; Ventricular Dysfunction, Left; Ventricular Remodeling

2008
Hippocampal volume change in the Alzheimer Disease Cholesterol-Lowering Treatment trial.
    Cleveland Clinic journal of medicine, 2008, Volume: 75 Suppl 2

    Topics: Aged; Aged, 80 and over; Alzheimer Disease; Anticholesteremic Agents; Atorvastatin; Cognition; Diagnostic Techniques, Neurological; Female; Heptanoic Acids; Hippocampus; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Pilot Projects; Psychological Tests; Psychophysiology; Pyrroles; Risk Factors

2008
[Dual cholesterol inhibition. More high risk patients achieve LDL cholesterol values below 100 mg/dl].
    MMW Fortschritte der Medizin, 2008, Jun-05, Volume: 150, Issue:23

    Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Disease; Diabetic Angiopathies; Drug Therapy, Combination; Ezetimibe; Germany; Heptanoic Acids; Humans; Hypercholesterolemia; Multicenter Studies as Topic; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin

2008
Effect of correcting serum cholesterol levels on erectile function in patients with vasculogenic erectile dysfunction.
    Scandinavian journal of urology and nephrology, 2008, Volume: 42, Issue:5

    Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Heptanoic Acids; Humans; Hypercholesterolemia; Impotence, Vasculogenic; Male; Middle Aged; Penile Erection; Phosphodiesterase Inhibitors; Piperazines; Purines; Pyrroles; Sildenafil Citrate; Sulfones; Ultrasonography, Doppler, Duplex

2008
Cost-effectiveness analysis of rosuvastatin versus atorvastatin, simvastatin, and pravastatin from a Canadian health system perspective.
    Clinical therapeutics, 2008, Volume: 30, Issue:7

    Topics: Adult; Apolipoprotein A-I; Apolipoproteins B; Atorvastatin; British Columbia; Cholesterol, HDL; Cholesterol, LDL; Cost-Benefit Analysis; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Triglycerides

2008
Ptosis, diplopia and statins: an association?
    European journal of neurology, 2008, Volume: 15, Issue:10

    Topics: Adult; Atorvastatin; Autoantibodies; Autoimmune Diseases of the Nervous System; Azetidines; Blepharoptosis; Diabetes Complications; Diagnostic Errors; Diplopia; Eyelid Diseases; Ezetimibe; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Myasthenia Gravis; Myocardial Infarction; Pain; Pravastatin; Pyrroles; Receptors, Cholinergic; Recurrence; Strabismus

2008
CYP3A53A allele is associated with reduced lowering-lipid response to atorvastatin in individuals with hypercholesterolemia.
    Clinica chimica acta; international journal of clinical chemistry, 2008, Volume: 398, Issue:1-2

    Topics: Aged; Alleles; Atorvastatin; Black People; Body Mass Index; Brazil; Cholesterol, LDL; Cytochrome P-450 CYP3A; DNA; DNA Primers; Female; Gene Frequency; Genotype; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Polymorphism, Restriction Fragment Length; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction

2008
Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis: a secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
    Stroke, 2008, Volume: 39, Issue:12

    Topics: Aged; Atorvastatin; Brain Ischemia; Carotid Stenosis; Cerebral Hemorrhage; Cholesterol, LDL; Coronary Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Ischemic Attack, Transient; Male; Middle Aged; Pyrroles; Randomized Controlled Trials as Topic; Recurrence; Risk; Treatment Outcome

2008
Influence of pitavastatin on glucose tolerance in patients with type 2 diabetes mellitus.
    Journal of atherosclerosis and thrombosis, 2008, Volume: 15, Issue:5

    Topics: Atorvastatin; Blood Glucose; Diabetes Mellitus, Type 2; Drug Evaluation; Glucose Intolerance; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Pyrroles; Quinolines; Retrospective Studies

2008
Statin therapy works for patients who have type 2 diabetes.
    JAAPA : official journal of the American Academy of Physician Assistants, 2008, Volume: 21, Issue:10

    Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Male; Middle Aged; Pyrroles

2008
Regression of Achilles tendon thickness after statin treatment in patients with familial hypercholesterolemia: an ultrasonographic study.
    Atherosclerosis, 2009, Volume: 205, Issue:1

    Topics: Achilles Tendon; Adult; Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Risk; Ultrasonography; Xanthomatosis

2009
Coronary plaque stabilization followed by Color Code Plaque analysis with 64-slice multidetector row computed tomography.
    Circulation journal : official journal of the Japanese Circulation Society, 2009, Volume: 73, Issue:4

    Topics: Anticholesteremic Agents; Atorvastatin; Coronary Angiography; Coronary Stenosis; Coronary Vasospasm; Diabetes Complications; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Middle Aged; Pyrroles; Tomography, X-Ray Computed; Ultrasonography

2009
On call. I am pretty healthy for a 73-year-old, but my cholesterol is 280, and my doctor wants me to take Lipitor. I'm willing to do so, but I need to know what tests I should have to be sure I'm not getting side effects. What do you suggest?
    Harvard men's health watch, 2008, Volume: 13, Issue:5

    Topics: Aged; Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; Humans; Hypercholesterolemia; Liver; Male; Pyrroles

2008
[High dosage stain protects heart and brain from recurrence].
    MMW Fortschritte der Medizin, 2008, Nov-27, Volume: 150, Issue:48

    Topics: Anticholesteremic Agents; Atorvastatin; Cerebral Infarction; Cholesterol, LDL; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Myocardial Infarction; Pyrroles; Randomized Controlled Trials as Topic; Secondary Prevention

2008
Short-term effects of atorvastatin on hemorheologic parameters and endothelial dysfunction in patients with hypercholesterolemia. Lower is better?
    Clinical hemorheology and microcirculation, 2008, Volume: 40, Issue:4

    Topics: Adult; Anticholesteremic Agents; Atorvastatin; Cohort Studies; Dose-Response Relationship, Drug; Endothelium, Vascular; Erythrocyte Deformability; Heptanoic Acids; Humans; Hypercholesterolemia; Middle Aged; Platelet Aggregation; Pyrroles; von Willebrand Factor

2008
Thyroid hormone beta receptor activation has additive cholesterol lowering activity in combination with atorvastatin in rabbits, dogs and monkeys.
    British journal of pharmacology, 2009, Volume: 156, Issue:3

    Topics: Animals; Anticholesteremic Agents; Atorvastatin; Cholesterol; Dogs; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Female; Heptanoic Acids; Hypercholesterolemia; Macaca fascicularis; Male; Organophosphonates; Phenols; Prodrugs; Pyrroles; Rabbits; Thyroid Hormone Receptors beta

2009
Statins reduce the neurofibrillary tangle burden in a mouse model of tauopathy.
    Journal of neuropathology and experimental neurology, 2009, Volume: 68, Issue:3

    Topics: Animals; Atorvastatin; Azetidines; Brain; Capillary Permeability; Diet; Disease Models, Animal; Ezetimibe; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Immunohistochemistry; Maze Learning; Mice; Mice, Transgenic; Neurofibrillary Tangles; Pyrroles; Simvastatin; Spinal Cord; Tauopathies

2009
Effect of very low LDL-cholesterol on cortisol synthesis.
    Journal of endocrinological investigation, 2008, Volume: 31, Issue:12

    Topics: Adrenocorticotropic Hormone; Adult; Anticholesteremic Agents; Atorvastatin; Case-Control Studies; Cholesterol, LDL; Dose-Response Relationship, Drug; Endocrine System Diseases; Female; Heptanoic Acids; Humans; Hydrocortisone; Hypercholesterolemia; Male; Middle Aged; Pituitary-Adrenal Function Tests; Pyrroles

2008
Effects of atorvastatin on nuclear magnetic resonance-defined lipoprotein subclasses and inflammatory markers in patients with hypercholesterolemia.
    Journal of atherosclerosis and thrombosis, 2009, Volume: 16, Issue:1

    Topics: Atorvastatin; C-Reactive Protein; Chemokine CCL2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Interleukin-6; Lipoproteins; Magnetic Resonance Spectroscopy; Male; Middle Aged; Pyrroles

2009
Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study.
    Neurology, 2009, Apr-21, Volume: 72, Issue:16

    Topics: Age Factors; Aged; Atorvastatin; Causality; Cerebral Hemorrhage; Clinical Trials as Topic; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Iatrogenic Disease; Intracranial Arteriosclerosis; Male; Pyrroles; Sex Factors

2009
Statins normalize vascular lysyl oxidase down-regulation induced by proatherogenic risk factors.
    Cardiovascular research, 2009, Aug-01, Volume: 83, Issue:3

    Topics: Animals; Atherosclerosis; Atorvastatin; Capillary Permeability; Cattle; Cells, Cultured; Disease Models, Animal; Diterpenes; Dose-Response Relationship, Drug; Down-Regulation; Endothelial Cells; Farnesol; Female; Gene Expression Regulation, Enzymologic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins, LDL; Protein Kinase C; Protein Kinase Inhibitors; Protein-Lysine 6-Oxidase; Pyrroles; rho-Associated Kinases; rhoA GTP-Binding Protein; Risk Factors; RNA, Messenger; Simvastatin; Swine; Transfection; Tumor Necrosis Factor-alpha

2009
Effects of atorvastatin therapy on protein oxidation and oxidative DNA damage in hypercholesterolemic rabbits.
    Pharmacological research, 2009, Volume: 59, Issue:4

    Topics: 8-Hydroxy-2'-Deoxyguanosine; Animals; Anticholesteremic Agents; Atorvastatin; Deoxyguanosine; DNA Damage; Glutathione; Heptanoic Acids; Hypercholesterolemia; Lipid Peroxidation; Liver; Male; Malondialdehyde; Oxidation-Reduction; Oxidative Stress; Protein Carbonylation; Pyrroles; Rabbits; Random Allocation; Sulfhydryl Compounds

2009
Regulation of steroid 5-alpha reductase type 2 (Srd5a2) by sterol regulatory element binding proteins and statin.
    Experimental cell research, 2009, Nov-01, Volume: 315, Issue:18

    Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Animals; Atorvastatin; Azetidines; Cell Line, Tumor; Ezetimibe; Gene Expression Regulation, Enzymologic; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Hypercholesterolemia; Liver; Lovastatin; Male; Mice; Promoter Regions, Genetic; Prostate; Prostatic Neoplasms; Pyrroles; Sterol Regulatory Element Binding Protein 2; Transfection

2009
Ultra high performance liquid chromatography tandem mass spectrometric detection in clinical analysis of simvastatin and atorvastatin.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2009, Jul-15, Volume: 877, Issue:22

    Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Chromatography, High Pressure Liquid; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Sensitivity and Specificity; Simvastatin; Tandem Mass Spectrometry

2009
[Effect of atorvastatin on inflammatory infiltration in the lung of rabbits with hypercholesterolemia].
    Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences, 2009, Volume: 34, Issue:7

    Topics: Animals; Atorvastatin; Bronchoalveolar Lavage; Heptanoic Acids; Hypercholesterolemia; Inflammation; Lung; Macrophages, Alveolar; Male; NF-kappa B; Pyrroles; Rabbits; Random Allocation

2009
Amlodipine/Atorvastatin single-pill therapy for blood pressure and lipid goals in African Americans: influence of the metabolic syndrome and type 2 diabetes mellitus.
    Journal of clinical hypertension (Greenwich, Conn.), 2009, Volume: 11, Issue:10

    Topics: Adult; Aged; Amlodipine; Anticholesteremic Agents; Atorvastatin; Black or African American; Blood Pressure; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Combinations; Drug Tolerance; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Lipids; Male; Metabolic Syndrome; Middle Aged; Pyrroles; Retrospective Studies; Treatment Outcome

2009
[Atorvastatin dreduces sympathetic activity and improves baroreceptor reflex sensitivity in patients with hypercholesterolemia and hypertension].
    Kardiologia polska, 2009, Volume: 67, Issue:6

    Topics: Adult; Anticholesteremic Agents; Atorvastatin; Baroreflex; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Male; Pressoreceptors; Pyrroles

2009
Atorvastatin increases expression of low-density lipoprotein receptor mRNA in human circulating mononuclear cells.
    Clinical and experimental pharmacology & physiology, 2010, Volume: 37, Issue:4

    Topics: Adult; Atorvastatin; Cholesterol; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; LDL-Receptor Related Proteins; Leukocytes, Mononuclear; Male; Middle Aged; Pyrroles; Receptors, LDL; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Up-Regulation

2010
Influence of SCARB1 polymorphisms on serum lipids of hypercholesterolemic individuals treated with atorvastatin.
    Clinica chimica acta; international journal of clinical chemistry, 2010, May-02, Volume: 411, Issue:9-10

    Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Apolipoprotein A-I; Apolipoproteins B; Atorvastatin; Blood; Brazil; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Gene Frequency; Genotype; Haplotypes; Heptanoic Acids; Humans; Hypercholesterolemia; Linkage Disequilibrium; Lipid Metabolism; Lipids; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrroles; Scavenger Receptors, Class B; Triglycerides

2010
Clinical trial efforts in Alzheimer disease: why test statins?
    Neurology, 2010, Mar-23, Volume: 74, Issue:12

    Topics: Alzheimer Disease; Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles; Randomized Controlled Trials as Topic

2010
Letter by Superko and King regarding article, "Lipid Treatment Assessment Project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals".
    Circulation, 2010, Mar-09, Volume: 121, Issue:9

    Topics: Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Female; Genetic Predisposition to Disease; Goals; Guideline Adherence; Health Care Surveys; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Kinesins; Male; Middle Aged; Mutation, Missense; Patient Selection; Pravastatin; Pyrroles; Risk

2010
Does a single-pill antihypertensive/lipid-lowering regimen improve adherence in US managed care enrolees? A non-randomized, observational, retrospective study.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2010, Volume: 10, Issue:3

    Topics: Adult; Aged; Amlodipine; Atorvastatin; Calcium Channel Blockers; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Male; Managed Care Programs; Medication Adherence; Middle Aged; Odds Ratio; Pyrroles; Retrospective Studies

2010
Atorvastatin affects TLR4 clustering via lipid raft modulation.
    International immunopharmacology, 2010, Volume: 10, Issue:8

    Topics: Animals; Anti-Inflammatory Agents; Antibodies, Blocking; Atorvastatin; Cell Line; Heptanoic Acids; Humans; Hypercholesterolemia; Lipopolysaccharides; Membrane Microdomains; Mevalonic Acid; Mice; Precursor Cells, B-Lymphoid; Protein Transport; Pyrroles; Receptor Aggregation; Toll-Like Receptor 4

2010
Pitavastatin: the newest HMG-CoA reductase inhibitor.
    Reviews in cardiovascular medicine, 2010,Winter, Volume: 11, Issue:1

    Topics: Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Product Surveillance, Postmarketing; Pyrroles; Quinolines; Simvastatin

2010
Low density lipoprotein-cholesterol variability in patients with type 2 diabetes taking atorvastatin compared to simvastatin: justification for direct measurement?
    Diabetes, obesity & metabolism, 2010, Volume: 12, Issue:6

    Topics: Aged; Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Half-Life; Heptanoic Acids; Humans; Hypercholesterolemia; Lipid Metabolism; Male; Middle Aged; Pyrroles; Simvastatin; Treatment Outcome

2010
Severe toxicity of capecitabine following uncomplicated treatment with 5-fluorouracil/leucovorin.
    Medical oncology (Northwood, London, England), 2011, Volume: 28, Issue:4

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Atorvastatin; Bisoprolol; Bone Neoplasms; Capecitabine; Colic; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Heptanoic Acids; Humans; Hypercholesterolemia; Ileus; Leucovorin; Lymphatic Metastasis; Middle Aged; Nausea; Pyrroles; Ventricular Premature Complexes; Vomiting

2011
Physiogenomic analysis of statin-treated patients: domain-specific counter effects within the ACACB gene on low-density lipoprotein cholesterol?
    Pharmacogenomics, 2010, Volume: 11, Issue:7

    Topics: Acetyl-CoA Carboxylase; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, LDL; Cross-Sectional Studies; Female; Fluorobenzenes; Genotype; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides

2010
Statins and altered glucose metabolism: a laboratory curiosity or a new disease?
    Journal of the American College of Cardiology, 2010, Aug-17, Volume: 56, Issue:8

    Topics: Atorvastatin; Blood Glucose; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Insulin; Male; Middle Aged; Pyrroles

2010
Antihypercholesterolaemic effect of ginger rhizome (Zingiber officinale) in rats.
    Inflammopharmacology, 2010, Volume: 18, Issue:6

    Topics: Administration, Oral; Animals; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Dietary Fats; Dose-Response Relationship, Drug; Heptanoic Acids; Hypercholesterolemia; Hypolipidemic Agents; Phytotherapy; Plant Preparations; Pyrroles; Rats; Rats, Sprague-Dawley; Rhizome; Triglycerides; Zingiber officinale

2010
Effects of lipid-lowering drugs on reverse cholesterol transport gene expressions in peripheral blood mononuclear and HepG2 cells.
    Pharmacogenomics, 2010, Volume: 11, Issue:9

    Topics: Absorption; Anticholesteremic Agents; Atorvastatin; ATP-Binding Cassette Transporters; Azetidines; Biological Transport; Cholesterol; Dose-Response Relationship, Drug; Down-Regulation; Drug Therapy, Combination; Ezetimibe; Female; Gene Expression; Hep G2 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Leukocytes, Mononuclear; Lipid Metabolism; Male; Middle Aged; Orphan Nuclear Receptors; Pyrroles; RNA, Messenger; Simvastatin; Up-Regulation

2010
Microwave induced solubility enhancement of poorly water soluble atorvastatin calcium.
    The Journal of pharmacy and pharmacology, 2010, Volume: 62, Issue:11

    Topics: Animals; Anticholesteremic Agents; Atorvastatin; Biological Availability; Calcium; Chemistry, Pharmaceutical; Crystallization; Disease Models, Animal; Dosage Forms; Heptanoic Acids; Hypercholesterolemia; Male; Microwaves; Polyethylene Glycols; Polymers; Pyrroles; Rats; Rats, Wistar; Solubility

2010
Atorvastatin attenuates inflammatory infiltration and vascular remodeling in lung of hypercholesterolemia rabbits.
    Experimental lung research, 2010, Volume: 36, Issue:10

    Topics: Animals; Atorvastatin; Body Weight; Bronchoalveolar Lavage Fluid; Cell Proliferation; Drug Evaluation, Preclinical; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Interleukin-6; Lipids; Lung; Lung Diseases; Macrophages, Alveolar; Male; NF-kappa B; Proliferating Cell Nuclear Antigen; Pulmonary Artery; Pyrroles; Rabbits; Random Allocation

2010
[Pharmaco-economic optimization of cholesterol-lowering treatment with statins].
    Medicina clinica, 2011, Jun-25, Volume: 137, Issue:3

    Topics: Atorvastatin; Cholesterol, LDL; Cost-Benefit Analysis; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Goals; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Practice Guidelines as Topic; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Spain; Sulfonamides

2011
[Atorvastatin and oxidized low density lipoprotein antibody. Relationship to age].
    Medicina clinica, 2011, Feb-26, Volume: 136, Issue:5

    Topics: Adult; Age Factors; Aged; Atherosclerosis; Atorvastatin; Autoantibodies; Autoantigens; Blood Glucose; C-Reactive Protein; Creatinine; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Inflammation; Lipid Peroxidation; Lipids; Lipoproteins, LDL; Male; Middle Aged; Pyrroles; Risk Factors; Waist Circumference

2011
Effect of atorvastatin and etidronate combination therapy on regression of aortic atherosclerotic plaques evaluated by magnetic resonance imaging.
    Journal of atherosclerosis and thrombosis, 2011, Volume: 18, Issue:5

    Topics: Aorta; Atorvastatin; Bone Density Conservation Agents; Drug Therapy, Combination; Etidronic Acid; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Magnetic Resonance Imaging; Male; Middle Aged; Plaque, Atherosclerotic; Pyrroles; Treatment Outcome

2011
Effect of atorvastatin on CYP2C9 metabolic activity as measured by the formation rate of losartan metabolite in hypercholesterolaemic patients.
    Basic & clinical pharmacology & toxicology, 2011, Volume: 109, Issue:2

    Topics: Aryl Hydrocarbon Hydroxylases; Atorvastatin; Cytochrome P-450 CYP2C9; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Losartan; Male; Middle Aged; Pyrroles; Retrospective Studies

2011
Glucose-lowering effect of colestimide is associated with baseline HbA1c in type 2 diabetic patients with hypercholesterolemia.
    Endocrine journal, 2011, Volume: 58, Issue:3

    Topics: Aged; Atorvastatin; Blood Glucose; Comorbidity; Diabetes Mellitus, Type 2; Epichlorohydrin; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Hypercholesterolemia; Hypoglycemic Agents; Imidazoles; Lipids; Male; Middle Aged; Multivariate Analysis; Pravastatin; Pyrroles; Quinolines; Resins, Synthetic; Retrospective Studies; Treatment Outcome

2011
Plaque-stabilizing effect of atorvastatin is stronger for plaques evaluated as more unstable by angioscopy and intravenous ultrasound.
    Circulation journal : official journal of the Japanese Circulation Society, 2011, Volume: 75, Issue:6

    Topics: Analysis of Variance; Angioscopy; Atorvastatin; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Male; Middle Aged; Plaque, Atherosclerotic; Predictive Value of Tests; Pyrroles; Rupture, Spontaneous; Severity of Illness Index; Time Factors; Treatment Outcome; Ultrasonography, Interventional

2011
Influence of polymorphisms and cholesterol-lowering treatment on SCARB1 mRNA expression.
    Journal of atherosclerosis and thrombosis, 2011, Volume: 18, Issue:8

    Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Caco-2 Cells; DNA; Ezetimibe; Female; Hep G2 Cells; Heptanoic Acids; Humans; Hypercholesterolemia; Leukocytes, Mononuclear; Lipids; Male; Middle Aged; Polymorphism, Genetic; Pyrroles; RNA, Messenger; Scavenger Receptors, Class B; Simvastatin

2011
Strong statins as the major players for dyslipidemia in high-risk patients: are they all the same or not?
    Circulation journal : official journal of the Japanese Circulation Society, 2011, Volume: 75, Issue:6

    Topics: Analysis of Variance; Atorvastatin; Biomarkers; Cholesterol, LDL; Evidence-Based Medicine; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Patient Selection; Pyrimidines; Pyrroles; Quinolines; Rosuvastatin Calcium; Sulfonamides; Time Factors; Treatment Outcome

2011
Increased appearance rate of 27-hydroxycholesterol in vivo in hypercholesterolemia: a possible compensatory mechanism.
    Nutrition, metabolism, and cardiovascular diseases : NMCD, 2012, Volume: 22, Issue:10

    Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Case-Control Studies; Cholesterol; Female; Fluorobenzenes; Gas Chromatography-Mass Spectrometry; Heptanoic Acids; Humans; Hydroxycholesterols; Hydroxylation; Hypercholesterolemia; Hyperlipidemia, Familial Combined; Hyperlipoproteinemia Type II; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides

2012
Fabry disease and Factor V Leiden: a potent vascular risk combination.
    Internal medicine journal, 2011, Volume: 41, Issue:5

    Topics: Activated Protein C Resistance; alpha-Galactosidase; Aspirin; Atorvastatin; Coronary Stenosis; Defibrillators, Implantable; Drug Therapy, Combination; Enzyme Replacement Therapy; Fabry Disease; Factor V; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Metoprolol; Middle Aged; Perindopril; Pyrroles; Quality of Life; Recurrence; Sequence Deletion; Stents; Stroke; Stroke Rehabilitation; Thrombophilia; Warfarin

2011
Effect of atorvastatin therapy on oxidant-antioxidant status and atherosclerotic plaque formation.
    Vascular health and risk management, 2011, Volume: 7

    Topics: Animals; Antioxidants; Aorta; Aortic Diseases; Aryldialkylphosphatase; Atherosclerosis; Atorvastatin; Catalase; Disease Models, Animal; Erythrocytes; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipid Peroxidation; Lipoproteins, LDL; Male; Oxidation-Reduction; Plaque, Atherosclerotic; Pyrroles; Rabbits; Superoxide Dismutase; Thiobarbituric Acid Reactive Substances; Time Factors

2011
SLCO1B1 haplotypes are not associated with atorvastatin-induced myalgia in Brazilian patients with familial hypercholesterolemia.
    European journal of clinical pharmacology, 2012, Volume: 68, Issue:3

    Topics: Adult; Aged; Atorvastatin; Brazil; Female; Genetic Diseases, Inborn; Haplotypes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Muscular Diseases; Organic Anion Transporters; Pyrroles

2012
Differentially expressed genes in human peripheral blood as potential markers for statin response.
    Journal of molecular medicine (Berlin, Germany), 2012, Volume: 90, Issue:2

    Topics: Adult; Atorvastatin; Biomarkers, Pharmacological; Cholesterol; Gene Expression; Gene Expression Profiling; Genes, MHC Class II; Genome, Human; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Pyrroles

2012
Beneficial effect of atorvastatin on renal function in patients with type 2 diabetes.
    The Journal of international medical research, 2011, Volume: 39, Issue:4

    Topics: Aged; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glycated Hemoglobin; Glycemic Index; Heptanoic Acids; Humans; Hypercholesterolemia; Kidney Function Tests; Male; Middle Aged; Prognosis; Prospective Studies; Pyrroles; Retrospective Studies; Risk Factors; Triglycerides

2011
Pharmacogenetics of OATP transporters reveals that SLCO1B1 c.388A>G variant is determinant of increased atorvastatin response.
    International journal of molecular sciences, 2011, Volume: 12, Issue:9

    Topics: Aged; Anticholesteremic Agents; Atorvastatin; Female; Gene Frequency; Genotype; Haplotypes; Heptanoic Acids; Humans; Hypercholesterolemia; Linkage Disequilibrium; Liver-Specific Organic Anion Transporter 1; Logistic Models; Male; Middle Aged; Multivariate Analysis; Organic Anion Transporters; Pharmacogenetics; Polymorphism, Single Nucleotide; Pyrroles; Treatment Outcome

2011
Trastuzumab-related palmar plantar erythrodysaesthesia.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 2012, Volume: 24, Issue:1

    Topics: Aged; Amlodipine; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Antihypertensive Agents; Antineoplastic Agents; Atorvastatin; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Foot Dermatoses; Hand Dermatoses; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Pyrroles; Trastuzumab

2012
Apolipoprotein E mRNA expression in mononuclear cells from normolipidemic and hypercholesterolemic individuals treated with atorvastatin.
    Lipids in health and disease, 2011, Nov-10, Volume: 10

    Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins E; Atorvastatin; Case-Control Studies; Female; Gene Expression; Genetic Association Studies; Genotype; Heptanoic Acids; Humans; Hypercholesterolemia; Leukocytes, Mononuclear; Lipids; Male; Middle Aged; Polymorphism, Genetic; Pyrroles; RNA, Messenger

2011
Identification of pharmacogenetic predictors of lipid-lowering response to atorvastatin in Chilean subjects with hypercholesterolemia.
    Clinica chimica acta; international journal of clinical chemistry, 2012, Feb-18, Volume: 413, Issue:3-4

    Topics: Anticholesteremic Agents; Atorvastatin; Chile; Cytochrome P-450 CYP3A; Female; Genotype; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pharmacogenetics; Polymorphism, Single Nucleotide; Pyrroles; Treatment Outcome

2012
Altered metabolism of low-density lipoprotein and very-low-density lipoprotein remnant in autosomal recessive hypercholesterolemia: results from stable isotope kinetic study in vivo.
    Circulation. Cardiovascular genetics, 2012, Feb-01, Volume: 5, Issue:1

    Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Gas Chromatography-Mass Spectrometry; Heptanoic Acids; Humans; Hypercholesterolemia; Isotope Labeling; Kinetics; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Middle Aged; Pedigree; Pyrroles

2012
Myocardial infarction in an young patient associated with oral contraceptive, smoking and elevated cholesterol level.
    Archives of gynecology and obstetrics, 2012, Volume: 285, Issue:6

    Topics: Abortion, Induced; Adult; Anticholesteremic Agents; Anticoagulants; Atorvastatin; Clopidogrel; Contraceptives, Oral; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Myocardial Infarction; Pregnancy; Pyrroles; Smoking; Ticlopidine

2012
Phospholipase A2 enzymes, high-dose atorvastatin, and prediction of ischemic events after acute coronary syndromes.
    Circulation, 2012, Feb-14, Volume: 125, Issue:6

    Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Acute Coronary Syndrome; Aged; Atherosclerosis; Atorvastatin; Biomarkers; C-Reactive Protein; Double-Blind Method; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Inflammation; Lipoproteins; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Ischemia; Oxidation-Reduction; Phospholipases A2, Secretory; Pyrroles; Randomized Controlled Trials as Topic; Retrospective Studies; Risk; Risk Factors; Survival Analysis

2012
No adverse effects of statins on muscle function and health-related parameters in the elderly: an exercise study.
    Scandinavian journal of medicine & science in sports, 2013, Volume: 23, Issue:5

    Topics: Adipose Tissue; Aged; Atorvastatin; Body Constitution; Body Mass Index; Case-Control Studies; Diet Records; Energy Metabolism; Exercise; Exercise Test; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Maximal Voluntary Ventilation; Muscle, Skeletal; Pyrroles

2013
Liver mitochondrial respiratory function and coenzyme Q content in rats on a hypercholesterolemic diet treated with atorvastatin.
    Physiological research, 2012, Volume: 61, Issue:2

    Topics: Animals; Atorvastatin; Cholesterol; Diet; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Liver; Male; Micronutrients; Mitochondria, Liver; Pyrroles; Rats; Ubiquinone

2012
Ask the doctor. After a heart attack six years ago, I went on Lipitor (atorvastatin) because my doctor said it was proven to reduce the risk of a second heart attack in high-risk people like me. Three years ago, I switched to a generic (simvastatin) to sa
    Harvard heart letter : from Harvard Medical School, 2012, Volume: 22, Issue:5

    Topics: Atorvastatin; Drugs, Generic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Myocardial Infarction; Pyrroles

2012
PCSK9 inhibition: the next statin?
    Journal of the American College of Cardiology, 2012, Jun-19, Volume: 59, Issue:25

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Proprotein Convertase 9; Proprotein Convertases; Pyrroles; Serine Endopeptidases

2012
Reversible dysphasia and statins.
    Journal of Korean medical science, 2012, Volume: 27, Issue:4

    Topics: Anticholesteremic Agents; Antihypertensive Agents; Anxiety; Aphasia; Atorvastatin; Cytochrome P-450 Enzyme System; Depression; Drug Interactions; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hypercholesterolemia; Indapamide; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides

2012
Acute rhabdomyolysis caused by combination therapy with atorvastatin and warfarin.
    British journal of hospital medicine (London, England : 2005), 2012, Volume: 73, Issue:2

    Topics: Acute Disease; Aged; Anticholesteremic Agents; Anticoagulants; Atorvastatin; Atrial Fibrillation; Drug Interactions; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Pyrroles; Rhabdomyolysis; Warfarin

2012
[In addition to atorvastatin. Innovative antibody lowers LDL around 72%].
    MMW Fortschritte der Medizin, 2012, Apr-19, Volume: 154, Issue:7

    Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Clinical Trials, Phase II as Topic; Coronary Artery Disease; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Proprotein Convertase 9; Proprotein Convertases; Pyrroles; Serine Endopeptidases

2012
Cholesteryl ester transfer protein and ATP-binding cassette transporter A1 genotype alter the atorvastatin and simvastatin efficacy: time for genotype-guided therapy?
    Angiology, 2013, Volume: 64, Issue:4

    Topics: Aged; Atorvastatin; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Biomarkers; Cholesterol; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Female; Gene Frequency; Genotype; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Patient Selection; Phenotype; Polymorphism, Genetic; Precision Medicine; Pyrroles; Simvastatin; Treatment Outcome

2013
Comparative study between atorvastatin and losartan on high fat diet-induced type 2 diabetes mellitus in rats.
    Fundamental & clinical pharmacology, 2013, Volume: 27, Issue:5

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diet, High-Fat; Drug Therapy, Combination; Heptanoic Acids; Hypercholesterolemia; Hyperglycemia; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Losartan; Male; Obesity; Pioglitazone; Pyrroles; Random Allocation; Rats; Rats, Sprague-Dawley; Thiazolidinediones; Tumor Necrosis Factor-alpha

2013
Discontinuation of statin therapy due to muscular side effects: a survey in real life.
    Nutrition, metabolism, and cardiovascular diseases : NMCD, 2013, Volume: 23, Issue:9

    Topics: Adult; Aged; Atorvastatin; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Motor Activity; Muscle Cramp; Muscle Weakness; Muscle, Skeletal; Musculoskeletal Diseases; Pain; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Surveys and Questionnaires; Treatment Outcome

2013
Atorvastatin-related thrombocytopenic purpura.
    BMJ case reports, 2010, May-19, Volume: 2010

    Topics: Adult; Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Purpura, Thrombocytopenic; Pyrroles

2010
Tendinous xanthoma.
    The Journal of the Association of Physicians of India, 2012, Volume: 60

    Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Coronary Angiography; Coronary Stenosis; Echocardiography; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Middle Aged; Pyrroles; Stents; Tendons; Treatment Outcome; Xanthomatosis

2012
CYP7A1 polymorphism influences the LDL cholesterol-lowering response to atorvastatin.
    Journal of clinical pharmacy and therapeutics, 2012, Volume: 37, Issue:6

    Topics: Aged; Atorvastatin; ATP Binding Cassette Transporter, Subfamily G, Member 8; ATP-Binding Cassette Transporters; China; Cholesterol 7-alpha-Hydroxylase; Cholesterol, LDL; Cytochrome P-450 CYP3A; Female; Genetic Variation; Genotype; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrroles

2012
[Effects of atorvastatin and CoQ(10) on myocardial energy metabolism in rabbits with hypercholesterolemia].
    Zhonghua yi xue za zhi, 2012, Jul-10, Volume: 92, Issue:26

    Topics: Animals; Atorvastatin; Energy Metabolism; Heptanoic Acids; Hypercholesterolemia; Male; Mitochondria, Heart; Myocardium; Pyrroles; Rabbits; Ubiquinone

2012
Impact of variants within seven candidate genes on statin treatment efficacy.
    Physiological research, 2012, Volume: 61, Issue:6

    Topics: Aged; Alleles; Anticholesteremic Agents; Apolipoproteins E; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Dyslipidemias; Female; Genetic Variation; Genome, Human; Genotype; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrroles; Treatment Outcome

2012
Association of ANRIL polymorphism (rs1333049:C>G) with myocardial infarction and its pharmacogenomic role in hypercholesterolemia.
    Gene, 2013, Feb-25, Volume: 515, Issue:2

    Topics: Adult; Anticholesteremic Agents; Atorvastatin; Case-Control Studies; Cholesterol; Drug Resistance; Female; Gene Frequency; Genetic Association Studies; Genetic Predisposition to Disease; Heptanoic Acids; Humans; Hypercholesterolemia; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Myocardial Infarction; Pakistan; Polymorphism, Single Nucleotide; Pyrroles; Risk; RNA, Long Noncoding; Sequence Analysis, DNA; Triglycerides

2013
[Myopathy due to deficiency of desaminase myoadenilate induced by atorvastatine].
    Medicina clinica, 2013, Jun-18, Volume: 140, Issue:12

    Topics: Aged; Amino Acid Substitution; AMP Deaminase; Atorvastatin; Biopsy; Causality; Creatine Kinase, MM Form; Exercise Tolerance; Female; Heptanoic Acids; Homozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Liver-Specific Organic Anion Transporter 1; Mitochondria, Muscle; Models, Genetic; Muscle, Skeletal; Mutation, Missense; Myalgia; Organic Anion Transporters; Parkinsonian Disorders; Point Mutation; Polymorphism, Single Nucleotide; Purine-Pyrimidine Metabolism, Inborn Errors; Pyrroles; Ubiquinone

2013
Efficacy and safety of atorvastatin 10 mg every other day in hypercholesterolemia.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2002, Volume: 85, Issue:3

    Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles

2002
Atorvastatin therapy in hypercholesterolemic patients suppresses cellular uptake of oxidized-LDL by differentiating monocytes.
    Atherosclerosis, 2002, Volume: 164, Issue:1

    Topics: Adult; Atorvastatin; CD36 Antigens; Gene Expression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins, LDL; Macrophages; Male; Middle Aged; Monocytes; Oxidation-Reduction; Pyrroles; Receptors, Immunologic; Receptors, Scavenger; RNA

2002
Atorvastatin increases HDL cholesterol in hypercholesterolemic patients. Evidence of a relationship with baseline HDL cholesterol.
    Nutrition, metabolism, and cardiovascular diseases : NMCD, 2002, Volume: 12, Issue:1

    Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Coronary Disease; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Regression Analysis; Triglycerides

2002
Long-term (18-month) efficacy of atorvastatin therapy in type 2 diabetics at cardiovascular risk.
    Nutrition, metabolism, and cardiovascular diseases : NMCD, 2002, Volume: 12, Issue:1

    Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Cohort Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipidemias; Longitudinal Studies; Male; Middle Aged; Pyrroles; Risk Factors; Treatment Outcome; Triglycerides

2002
Alopecia associated with atorvastatin.
    The American journal of medicine, 2002, Aug-01, Volume: 113, Issue:2

    Topics: Adult; Alopecia; Atorvastatin; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles; Risk Assessment

2002
Efficacy and safety of atorvastatin in the treatment of hypercholesterolemia associated with antiretroviral therapy.
    Journal of acquired immune deficiency syndromes (1999), 2002, Aug-15, Volume: 30, Issue:5

    Topics: Adult; Aged; Anticholesteremic Agents; Antiretroviral Therapy, Highly Active; Atorvastatin; Female; Heptanoic Acids; HIV Infections; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles

2002
[Absolutely essential in cardiovascular high risk patients. Statins--more than only anticholesteremic drugs].
    MMW Fortschritte der Medizin, 2002, Jun-27, Volume: 144, Issue:26

    Topics: Atorvastatin; Cardiovascular Diseases; Clinical Trials as Topic; Germany; Heptanoic Acids; Humans; Hypercholesterolemia; Pyrroles; Risk; Survival Rate

2002
Intensive statin treatment improves baroreflex sensitivity: another cardioprotective mechanism for statins?
    Heart (British Cardiac Society), 2002, Volume: 88, Issue:4

    Topics: Anticholesteremic Agents; Atorvastatin; Baroreflex; Blood Pressure; Cholestyramine Resin; Heart Rate; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Norepinephrine; Pyrroles; Sympathomimetics

2002
Statins, fibrates, and ocular myasthenia.
    Lancet (London, England), 2002, Aug-31, Volume: 360, Issue:9334

    Topics: Aged; Anticholesteremic Agents; Atorvastatin; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Myasthenia Gravis; Pyrroles

2002
Low-density lipoprotein lowering and atherosclerosis progression: does more mean less?
    Circulation, 2002, Oct-15, Volume: 106, Issue:16

    Topics: Arteriosclerosis; Atorvastatin; Carotid Arteries; Cholesterol; Cholesterol, LDL; Disease Progression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Pravastatin; Pyrroles; Ultrasonography

2002
[Stable angina pectoris. PTCA improves symptoms, but not prognosis].
    MMW Fortschritte der Medizin, 2002, Sep-26, Volume: 144, Issue:39

    Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Atorvastatin; Combined Modality Therapy; Heptanoic Acids; Humans; Hypercholesterolemia; Prognosis; Pyrroles; Recurrence; Risk Factors; Stents; Treatment Outcome

2002
Atorvastatin reduces expression of leukocyte adhesion molecules in patients with hypercholesterolemia.
    Atherosclerosis, 2003, Volume: 166, Issue:1

    Topics: Atorvastatin; Cell Adhesion Molecules; Cholesterol, LDL; Clinical Trials as Topic; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrroles

2003
[Some new data concerning effectiveness of amlodipine, atorvastatine and quinaprile for heart diseases].
    Kardiologiia, 2002, Volume: 42, Issue:3

    Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Atorvastatin; Calcium Channel Blockers; Cardiovascular Diseases; Heptanoic Acids; Humans; Hypercholesterolemia; Isoquinolines; Pyrroles; Quinapril; Tetrahydroisoquinolines

2002
Statins do not meet expectations for lowering low-density lipoprotein cholesterol levels when used in clinical practice.
    The American journal of medicine, 2002, Dec-01, Volume: 113, Issue:8

    Topics: Aged; Atorvastatin; Cardiology; Cholesterol, LDL; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Observer Variation; Patient Compliance; Pravastatin; Probability; Prospective Studies; Pyrroles; Reference Values; Simvastatin; Treatment Failure; Treatment Outcome

2002
[Ezetimib plus statin combination. A strong duo].
    MMW Fortschritte der Medizin, 2002, Nov-28, Volume: 144, Issue:48

    Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles; Risk Factors; Simvastatin

2002
Related factors of meeting National Cholesterol Education Program-recommended goals with atorvastatin.
    Journal of atherosclerosis and thrombosis, 2003, Volume: 10, Issue:1

    Topics: Aged; Atorvastatin; Body Mass Index; Cholesterol; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; National Health Programs; Pyrroles; Risk Factors; Safety

2003
Introduction: rosuvastatin--an efficacy assessment based on pooled trial data.
    The American journal of cardiology, 2003, Mar-06, Volume: 91, Issue:5A

    Topics: Atorvastatin; Clinical Trials as Topic; Coronary Artery Disease; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Meta-Analysis as Topic; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides

2003
A model to assess the cost effectiveness of statins in achieving the UK National Service Framework target cholesterol levels.
    PharmacoEconomics, 2003, Volume: 21 Suppl 1

    Topics: Atorvastatin; Cholesterol; Clinical Trials as Topic; Cost-Benefit Analysis; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Models, Economic; Pravastatin; Pyrroles; Simvastatin; United Kingdom

2003
Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy.
    JAMA, 2003, Apr-02, Volume: 289, Issue:13

    Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Case-Control Studies; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins; Male; Middle Aged; Prospective Studies; Pyrroles; Risk Factors; Tyrosine

2003
Rhabdomyolysis and myalgia associated with anticholesterolemic treatment as potential signs of malignant hyperthermia susceptibility.
    Arthritis and rheumatism, 2003, Apr-15, Volume: 49, Issue:2

    Topics: Atorvastatin; Cholinesterase Inhibitors; Disease Susceptibility; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Malignant Hyperthermia; Middle Aged; Pain; Pyrroles; Rhabdomyolysis

2003
New lipid-lowering combo proves successful.
    Circulation, 2003, May-20, Volume: 107, Issue:19

    Topics: Atorvastatin; Attitude to Health; Azetidines; Drug Synergism; Drug Therapy, Combination; Europe; Ezetimibe; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Pyrroles; Stroke; Treatment Outcome

2003
Time course of serum CK immediately before and after a single muscle cramp.
    Muscle & nerve, 2003, Volume: 27, Issue:6

    Topics: Amyotrophic Lateral Sclerosis; Atorvastatin; Creatine Kinase; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Muscle Cramp; Muscle, Skeletal; Pyrroles; Time Factors; Up-Regulation

2003
Drug-induced rhabdomyolysis after concomitant use of clarithromycin, atorvastatin, and lopinavir/ritonavir in a patient with HIV.
    AIDS patient care and STDs, 2003, Volume: 17, Issue:5

    Topics: Adult; Anti-Bacterial Agents; Atorvastatin; Clarithromycin; Drug Interactions; Drug Therapy, Combination; Heptanoic Acids; HIV Infections; HIV Protease Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lopinavir; Male; Pyrimidinones; Pyrroles; Rhabdomyolysis; Ritonavir

2003
Synergistic effect of angiotensin-converting enzyme (ACE) and 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibition on inflammatory markers in atherosclerotic rabbits.
    Clinical science (London, England : 1979), 2003, Volume: 105, Issue:6

    Topics: Acyl Coenzyme A; Angiotensin-Converting Enzyme Inhibitors; Animals; Aorta, Thoracic; Arteriosclerosis; Atorvastatin; Blood Pressure; Drug Synergism; Drug Therapy, Combination; Enzyme Inhibitors; Fibrinolysis; Heptanoic Acids; Hypercholesterolemia; In Vitro Techniques; Inflammation Mediators; Male; Pyrroles; Quinapril; Rabbits; Tetrahydroisoquinolines; Tunica Intima; Vasodilation

2003
In light of ALLHAT and ASCOT: are there benefits of statins as add-on treatment in hypertensives?
    Blood pressure, 2003, Volume: 12, Issue:3

    Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Middle Aged; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome

2003
Microvascular reactivity in patients with hypercholesterolemia: effect of lipid lowering treatment.
    Physiological research, 2003, Volume: 52, Issue:4

    Topics: Adult; Anticholesteremic Agents; Atorvastatin; Blood Component Removal; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperemia; Laser-Doppler Flowmetry; Male; Microcirculation; Middle Aged; Pilot Projects; Pyrroles; Skin

2003
Effects of atorvastatin on in-stent stenosis in normo- and hypercholesterolemic rabbits.
    International journal of cardiology, 2003, Volume: 91, Issue:1

    Topics: Animals; Atorvastatin; Cholinergic Antagonists; Constriction, Pathologic; Femoral Artery; Heptanoic Acids; Hypercholesterolemia; Muscle, Smooth, Vascular; Pyrroles; Rabbits; Stents

2003
Atorvastatin reduces interleukin-6 plasma concentration and adipocyte secretion of hypercholesterolemic rabbits.
    Clinica chimica acta; international journal of clinical chemistry, 2003, Volume: 336, Issue:1-2

    Topics: Adipocytes; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Atorvastatin; Cells, Cultured; Cholesterol, Dietary; Gene Expression; Heptanoic Acids; Hypercholesterolemia; Interleukin-6; Male; Pyrroles; Rabbits; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Transcription Factors

2003
Atorvastatin prevents RhoC isoprenylation, invasion, and metastasis in human melanoma cells.
    Molecular cancer therapeutics, 2003, Volume: 2, Issue:10

    Topics: Animals; Atorvastatin; Cell Movement; Green Fluorescent Proteins; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Immunoblotting; Immunohistochemistry; Luciferases; Luminescent Proteins; Melanoma; Mice; Mice, SCID; Microscopy, Fluorescence; Neoplasm Invasiveness; Neoplasm Metastasis; Plasmids; Protein Processing, Post-Translational; Pyrroles; ras Proteins; rho GTP-Binding Proteins; rhoC GTP-Binding Protein; Serum Response Factor; Subcellular Fractions; Time Factors; Tumor Cells, Cultured

2003
Decreased macrophage paraoxonase 2 expression in patients with hypercholesterolemia is the result of their increased cellular cholesterol content: effect of atorvastatin therapy.
    Arteriosclerosis, thrombosis, and vascular biology, 2004, Volume: 24, Issue:1

    Topics: Adult; Aryldialkylphosphatase; Atorvastatin; Cholesterol; Enzyme Induction; Foam Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Macrophages; Male; Middle Aged; Oxidative Stress; Pyrroles

2004
Synthesis and absorption markers of cholesterol in serum and lipoproteins during a large dose of statin treatment.
    European journal of clinical investigation, 2003, Volume: 33, Issue:11

    Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, LDL; Diabetes Mellitus, Type 2; Feces; Heptanoic Acids; Humans; Hypercholesterolemia; Intestinal Absorption; Lipids; Lipoproteins; Liver; Male; Middle Aged; Phytosterols; Pyrroles; Squalene

2003
Increased levels of pregnancy-associated plasma protein-A in patients with hypercholesterolemia: the effect of atorvastatin treatment.
    American heart journal, 2003, Volume: 146, Issue:6

    Topics: Anticholesteremic Agents; Atorvastatin; Biomarkers; Case-Control Studies; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pregnancy-Associated Plasma Protein-A; Pyrroles

2003
Statin face-off. Surprises from the first head-to-head comparison.
    Time, 2003, Nov-24, Volume: 162, Issue:21

    Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Pyrroles; Treatment Outcome; United States

2003
Effects of simvastatin and atorvastatin in hypercholesterolemic patients.
    Clinical therapeutics, 2003, Volume: 25, Issue:10

    Topics: Anticholesteremic Agents; Apolipoproteins A; Apolipoproteins B; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Heptanoic Acids; Humans; Hypercholesterolemia; Pyrroles; Simvastatin; Triglycerides

2003
Effect of statins on the progression of bioprosthetic aortic valve degeneration.
    The American journal of cardiology, 2003, Dec-15, Volume: 92, Issue:12

    Topics: Aged; Aortic Valve; Aortic Valve Insufficiency; Aortic Valve Stenosis; Atorvastatin; Bioprosthesis; Coronary Artery Bypass; Coronary Artery Disease; Female; Heart Valve Prosthesis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Pravastatin; Prosthesis Failure; Pyrroles; Retrospective Studies; Simvastatin; Treatment Outcome; Ultrasonography

2003
Short-term effects of atorvastatin on haemorheologic parameters, platelet aggregation and endothelium dysfunction in patients with hypercholesterolaemia.
    European heart journal, 2004, Volume: 25, Issue:1

    Topics: Anticholesteremic Agents; Antigens; Atorvastatin; Cholesterol; Heptanoic Acids; Humans; Hypercholesterolemia; Middle Aged; Platelet Aggregation; Pyrroles; von Willebrand Factor

2004
Atorvastatin, 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, reduces bone resorption in the elderly.
    Journal of the American Geriatrics Society, 2003, Volume: 51, Issue:11

    Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Atorvastatin; Biomarkers; Bone Density; Bone Resorption; Case-Control Studies; Collagen; Collagen Type I; Creatinine; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Peptides; Prospective Studies; Pyrroles; Treatment Outcome

2003
Atorvastatin enhances cellular uptake of oxidized LDL in adipocytes from hypercholesterolemic rabbits.
    Clinica chimica acta; international journal of clinical chemistry, 2004, Volume: 339, Issue:1-2

    Topics: Adipocytes; Animals; Anticholesteremic Agents; Atorvastatin; CD36 Antigens; Heptanoic Acids; Hypercholesterolemia; Iodine Radioisotopes; Lipoproteins, LDL; Pyrroles; Rabbits; Receptors, Cytoplasmic and Nuclear; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Transcription Factors

2004
Effects of atorvastatin on lipid profile and non-traditional cardiovascular risk factors in diabetic patients on hemodialysis.
    Nephron. Clinical practice, 2003, Volume: 95, Issue:4

    Topics: Adult; Aged; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Homocysteine; Humans; Hypercholesterolemia; Kidney Failure, Chronic; Lipid Metabolism; Lipids; Lipoproteins, LDL; Male; Middle Aged; Oxidative Stress; Prospective Studies; Pyrroles; Renal Dialysis; Risk Factors

2003
CYP3A4 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin in primary hypercholesterolemia.
    The American journal of cardiology, 2004, Jan-01, Volume: 93, Issue:1

    Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Female; Genetic Variation; Genotype; Heptanoic Acids; Humans; Hypercholesterolemia; Lipoproteins; Male; Middle Aged; Pyrroles; Triglycerides

2004
ATP binding cassette transporter G5 and G8 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin.
    Journal of lipid research, 2004, Volume: 45, Issue:4

    Topics: Aged; Anticholesteremic Agents; Atorvastatin; ATP-Binding Cassette Transporters; Drug Resistance; Female; Gene Frequency; Genotype; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Linkage Disequilibrium; Lipoproteins; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrroles

2004
Liver function test abnormalities and pruritus in a patient treated with atorvastatin: case report and review of the literature.
    Pharmacotherapy, 2004, Volume: 24, Issue:1

    Topics: Administration, Oral; Aged; Alanine Transaminase; Atorvastatin; Drug Monitoring; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Liver; Liver Function Tests; Pruritus; Pyrroles

2004
Normal pregnancy outcome following inadvertent exposure to rosiglitazone, gliclazide, and atorvastatin in a diabetic and hypertensive woman.
    Reproductive toxicology (Elmsford, N.Y.), 2004, Volume: 18, Issue:4

    Topics: Adult; Anxiety Disorders; Apgar Score; Atorvastatin; Chronic Disease; Diabetes Complications; Epilepsy; Female; Gliclazide; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Hypoglycemic Agents; Infant, Newborn; Obesity, Morbid; Pregnancy; Pregnancy Complications, Cardiovascular; Pregnancy Outcome; Pyrroles; Rosiglitazone; Thiazolidinediones

2004
Early intervention with atorvastatin modulates TH1/TH2 imbalance in patients with acute coronary syndrome: from bedside to bench.
    Circulation, 2004, May-11, Volume: 109, Issue:18

    Topics: Acute Disease; Angina Pectoris; Angina, Unstable; Anion Exchange Resins; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Atorvastatin; CD4 Lymphocyte Count; Coronary Disease; Epichlorohydrin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Imidazoles; Immunophenotyping; Male; Prospective Studies; Pyrroles; Resins, Synthetic; Th1 Cells; Th2 Cells

2004
Update on statins.
    Journal of vascular nursing : official publication of the Society for Peripheral Vascular Nursing, 2004, Volume: 22, Issue:2

    Topics: Atorvastatin; Coronary Disease; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides

2004
Improvement in erectile function in men with organic erectile dysfunction by correction of elevated cholesterol levels: a clinical observation.
    The Journal of urology, 2004, Volume: 172, Issue:1

    Topics: Adult; Atorvastatin; Comorbidity; Erectile Dysfunction; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Penile Erection; Pyrroles

2004
Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and stroke.
    Archives of neurology, 2004, Volume: 61, Issue:6

    Topics: Aged; Analysis of Variance; Atorvastatin; Cardiovascular Diseases; Coenzymes; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Longitudinal Studies; Male; Middle Aged; Prospective Studies; Pyrroles; Risk Factors; Stroke; Ubiquinone

2004
[Lower, lower, lower. The LDL goal value of 200 mg/dl is still much too high].
    MMW Fortschritte der Medizin, 2004, Mar-25, Volume: 146, Issue:13

    Topics: Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Coronary Artery Disease; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Myocardial Infarction; Pravastatin; Pyrroles; Reference Values; Risk; Survival Analysis; Survival Rate

2004
[Results of randomized study: intensive lipid lowering treatment stops coronary atherosclerosis].
    MMW Fortschritte der Medizin, 2004, Mar-25, Volume: 146, Issue:13

    Topics: Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Coronary Artery Disease; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome; Ultrasonography, Interventional

2004
[Regarding LDL cholesterol: the lower, the better (interview by Dr. Dirk Einecke)].
    MMW Fortschritte der Medizin, 2004, Mar-25, Volume: 146, Issue:13

    Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hypercholesterolemia; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome

2004
The effect of atorvastatin on platelet function in patients with coronary artery disease.
    Acta cardiologica, 2004, Volume: 59, Issue:3

    Topics: Atorvastatin; Blood Platelets; Case-Control Studies; Coronary Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Platelet Aggregation; Prospective Studies; Pyrroles

2004
Interactions between common genetic polymorphisms in ABCG5/G8 and CYP7A1 on LDL cholesterol-lowering response to atorvastatin.
    Atherosclerosis, 2004, Volume: 175, Issue:2

    Topics: Aged; Atorvastatin; ATP Binding Cassette Transporter, Subfamily G, Member 5; ATP Binding Cassette Transporter, Subfamily G, Member 8; ATP-Binding Cassette Transporters; Cholesterol 7-alpha-Hydroxylase; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins; Male; Middle Aged; Polymorphism, Genetic; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome

2004
Effect of atorvastatin on the expression of CD40 ligand and P-selectin on platelets in patients with hypercholesterolemia.
    The American journal of cardiology, 2004, Aug-01, Volume: 94, Issue:3

    Topics: Adult; Atorvastatin; Biomarkers; Case-Control Studies; CD40 Ligand; Cohort Studies; Dose-Response Relationship, Drug; Down-Regulation; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; P-Selectin; Probability; Prognosis; Pyrroles; Reference Values; Sensitivity and Specificity; Severity of Illness Index

2004
Lipid-altering changes and pleiotropic effects of atorvastatin in patients with hypercholesterolemia.
    The American journal of cardiology, 2004, Aug-15, Volume: 94, Issue:4

    Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Basilar Artery; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Endothelium, Vascular; Female; Fibrinolysis; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Long-Term Care; Male; Middle Aged; Plasminogen Activator Inhibitor 1; Prospective Studies; Pyrroles; Thiobarbituric Acid Reactive Substances; Treatment Outcome; Triglycerides; Vasodilation

2004
Atorvastatin reduces fibrinogen levels in patients with severe hypercholesterolemia: additional evidence to support the anti-inflammatory effects of statins.
    The Israel Medical Association journal : IMAJ, 2004, Volume: 6, Issue:8

    Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Female; Fibrinogen; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Risk Factors; Severity of Illness Index

2004
Beyond cholesterol lowering: effect of statins on markers of cardiovascular disease.
    The Israel Medical Association journal : IMAJ, 2004, Volume: 6, Issue:8

    Topics: Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; C-Reactive Protein; Fibrinogen; Heptanoic Acids; Humans; Hypercholesterolemia; Pyrroles; Risk Factors

2004
[Endothelial dysfunction, inflammation and statins: new evidences].
    Revista espanola de cardiologia, 2004, Volume: 57, Issue:10

    Topics: Animals; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Coronary Circulation; Endothelium, Vascular; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Inflammation; Interleukin-6; Pravastatin; Pyrroles; Rabbits; Time Factors

2004
Atorvastatin reduces proinflammatory markers in hypercholesterolemic patients.
    Atherosclerosis, 2004, Volume: 177, Issue:1

    Topics: Adolescent; Adult; Aged; Atorvastatin; Biomarkers; C-Reactive Protein; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Intercellular Adhesion Molecule-1; Interleukin-1; Interleukin-6; Male; Middle Aged; Pyrroles; Tumor Necrosis Factor-alpha

2004
Effects of Atorvastatin on some inflammatory parameters in severe primary hypercholesterolemia.
    Romanian journal of internal medicine = Revue roumaine de medecine interne, 2002, Volume: 40, Issue:1-4

    Topics: Adult; Atorvastatin; Biomarkers; Coronary Stenosis; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrroles

2002
[Decreasing LDL level moderately or drastically. Is differential therapy with statins available? (interview by Dirk Einecke)].
    MMW Fortschritte der Medizin, 2004, Jul-08, Volume: 146, Issue:27-28

    Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Drug Approval; Drugs, Generic; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Pyrroles

2004
[Sequelae of the CARDS Study. LDL of 110 mg/dl still too high?].
    MMW Fortschritte der Medizin, 2004, Jun-24, Volume: 146, Issue:26

    Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Long-Term Care; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome

2004
Treatment of severe hypercholesterolemia with atorvastatin in congenital analbuminemia.
    The American journal of medicine, 2004, Nov-15, Volume: 117, Issue:10

    Topics: Adult; Albumins; Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; Humans; Hypercholesterolemia; Hypoproteinemia; Male; Pyrroles

2004
[Target values are more often attainable. Almost doubly so many patients with values under 100mg/dl].
    MMW Fortschritte der Medizin, 2004, Oct-28, Volume: 146, Issue:44

    Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Humans; Hypercholesterolemia; Pyrroles; Randomized Controlled Trials as Topic; Reference Values; Simvastatin; Time Factors

2004
Synthes Award for Resident Research in Spinal Cord & Spinal Column Injury: Statins for the treatment of neurological injury: a role beyond cholesterol lowering.
    Clinical neurosurgery, 2004, Volume: 51

    Topics: Animals; Anticholesteremic Agents; Atorvastatin; Awards and Prizes; Brain Injuries; Heptanoic Acids; Hypercholesterolemia; Immunoblotting; Interleukin-6; Internship and Residency; Mice; Pyrroles; Research; RNA, Messenger; Simvastatin; Spinal Cord Injuries; Subarachnoid Hemorrhage

2004
Effect of monthly atorvastatin treatment on hemostasis.
    International journal of clinical pharmacology and therapeutics, 2004, Volume: 42, Issue:11

    Topics: Adult; Aged; Atorvastatin; Blood Coagulation Factors; Case-Control Studies; Female; Hemostasis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Risk Factors

2004
Rhabdomyolysis in a patient receiving atorvastatin and fluconazole.
    European journal of clinical pharmacology, 2005, Volume: 60, Issue:12

    Topics: Antifungal Agents; Atorvastatin; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Drug Synergism; Fatal Outcome; Fluconazole; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Mycoses; Pyrroles; Rhabdomyolysis

2005
[A relationship between insulin resistance and reduction in oxidative stress in vivo by atorvastatin].
    Journal of cardiology, 2004, Volume: 44, Issue:6

    Topics: Aged; Atorvastatin; Dinoprost; Female; Heptanoic Acids; Homeostasis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Insulin Resistance; Lipids; Male; Middle Aged; Oxidative Stress; Pyrroles

2004
Atorvastatin reduces platelet-oxidized-LDL receptor expression in hypercholesterolaemic patients.
    European journal of clinical investigation, 2005, Volume: 35, Issue:1

    Topics: Adult; Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Blood Platelets; CD36 Antigens; Citrulline; Female; Flow Cytometry; Heptanoic Acids; Humans; Hypercholesterolemia; Lipoproteins, LDL; Male; Middle Aged; Nitric Oxide Synthase; P-Selectin; Platelet Activation; Pyrroles; Receptors, LDL; Receptors, Oxidized LDL; Scavenger Receptors, Class E

2005
Effect of atorvastatin upon platelet activation in hypercholesterolemia, evaluated by flow cytometry.
    Thrombosis research, 2005, Volume: 115, Issue:4

    Topics: Adenosine Diphosphate; Adult; Aged; Atorvastatin; Blood Platelets; Case-Control Studies; Cholesterol; Cholesterol, LDL; Female; Flow Cytometry; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; In Vitro Techniques; Male; Middle Aged; P-Selectin; Platelet Activation; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrroles; Risk Factors; Thrombin; Thrombosis

2005
[Coronary heart disease patient reaches LDL level of 100 mg/dl with atorvastatin: how do you continue treatment next year?].
    MMW Fortschritte der Medizin, 2004, Dec-16, Volume: 146, Issue:51-52

    Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Cost Control; Drug Costs; Ezetimibe; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Insurance Coverage; Male; Middle Aged; National Health Programs; Pyrroles; Simvastatin

2004
Influence of withdrawal of statin treatment on proinflammatory response and fibrinolytic activity in humans: an effect independent on cholesterol elevation.
    International journal of cardiology, 2005, Feb-28, Volume: 98, Issue:3

    Topics: Aged; Atorvastatin; Cholesterol; Cholesterol, LDL; Female; Fibrinolysis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Tissue Plasminogen Activator; Vascular Cell Adhesion Molecule-1

2005
Atorvastatin decreases cellular proliferation and bone matrix expression in the hypercholesterolemic mitral valve.
    Journal of the American College of Cardiology, 2005, Feb-15, Volume: 45, Issue:4

    Topics: Animals; Anticholesteremic Agents; Atorvastatin; Bone Matrix; Calcinosis; Cell Division; Heart Valve Diseases; Heptanoic Acids; Hypercholesterolemia; Male; Mitral Valve; Pyrroles; Rabbits

2005
[Effects of atorvastatin, fluvastatin, pravastatin, and simvastatin on endothelial function, lipid peroxidation, and aortic atherosclerosis in hypercholesterolemic rabbits].
    Arquivos brasileiros de cardiologia, 2005, Volume: 84, Issue:4

    Topics: Animals; Anticholesteremic Agents; Aortic Diseases; Arteriosclerosis; Atorvastatin; Cholesterol; Cholesterol, LDL; Endothelium, Vascular; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Hypercholesterolemia; Indoles; Lipid Peroxidation; Male; Malondialdehyde; Pravastatin; Pyrroles; Rabbits; Simvastatin

2005
Atorvastatin inhibits calcification and enhances nitric oxide synthase production in the hypercholesterolaemic aortic valve.
    Heart (British Cardiac Society), 2005, Volume: 91, Issue:6

    Topics: Animals; Anticholesteremic Agents; Aortic Valve; Atorvastatin; Blotting, Western; C-Reactive Protein; Calcinosis; Cholesterol; Heart Valve Diseases; Heptanoic Acids; Hypercholesterolemia; Male; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Nitrites; Pyrroles; Rabbits; Tomography, X-Ray Computed

2005
[The PROVE IT-TIMI-22 study or the biter being bit].
    Revue medicale suisse, 2005, Apr-06, Volume: 1, Issue:14

    Topics: Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; Humans; Hypercholesterolemia; Pravastatin; Pyrroles

2005
Upregulation of the immune system in primary hypercholesterolaemia: effect of atorvastatin therapy.
    Journal of internal medicine, 2005, Volume: 257, Issue:6

    Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Biomarkers; Complement C3; Complement C4; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Immunity, Cellular; Intercellular Adhesion Molecule-1; Lipids; Male; Middle Aged; Pyrroles; Up-Regulation

2005
Images in clinical medicine. A medical mystery--bradycardia.
    The New England journal of medicine, 2005, Jun-02, Volume: 352, Issue:22

    Topics: Atorvastatin; Bradycardia; Electrocardiography; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrroles

2005
Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial.
    Diabetes, obesity & metabolism, 2005, Volume: 7, Issue:4

    Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Metabolic Syndrome; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; Triglycerides

2005
Acute onset and worsening of diabetes concurrent with administration of statins.
    Endocrine journal, 2005, Volume: 52, Issue:3

    Topics: Anticholesteremic Agents; Atorvastatin; Blood Glucose; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Pyrroles

2005
Atorvastatin reduces serum leptin concentration in hypercholesterolemic rabbits.
    Clinica chimica acta; international journal of clinical chemistry, 2005, Volume: 360, Issue:1-2

    Topics: Adipocytes; Adipose Tissue; Animals; Atorvastatin; Cholesterol; Drug Evaluation, Preclinical; Heptanoic Acids; Hypercholesterolemia; Leptin; Pyrroles; Rabbits; RNA, Messenger

2005
Effect of atorvastatin on tumor necrosis factor alpha serum concentration and mRNA expression of adipose in hypercholesterolemic rabbits.
    Journal of cardiovascular pharmacology, 2005, Volume: 46, Issue:2

    Topics: Adipose Tissue; Animals; Anticholesteremic Agents; Atorvastatin; Body Weight; Cholesterol; Cholesterol, LDL; Disease Models, Animal; Heptanoic Acids; Hypercholesterolemia; Male; Pyrroles; Rabbits; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Necrosis Factor-alpha

2005
[Effect of maximum dose of atorvastatin on inflammation, thrombogenesis and fibrinolysis in high-risk patients with ischemic heart disease].
    Revista espanola de cardiologia, 2005, Volume: 58, Issue:8

    Topics: Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cholesterol; Coronary Disease; Data Interpretation, Statistical; Enzyme-Linked Immunosorbent Assay; Female; Fibrinolysis; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Immunochemistry; Lipids; Male; Middle Aged; Prothrombin; Pyrroles; Risk Factors; Time Factors

2005
High baseline serum total and LDL cholesterol levels are associated with MDR1 haplotypes in Brazilian hypercholesterolemic individuals of European descent.
    Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas, 2005, Volume: 38, Issue:9

    Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Brazil; Cholesterol, LDL; Female; Gene Frequency; Genes, MDR; Haplotypes; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Polymerase Chain Reaction; Polymorphism, Genetic; Polymorphism, Restriction Fragment Length; Polymorphism, Single Nucleotide; Pyrroles; White People

2005
[Intensive LDL lowering to under 80 mg/dl: hypercholesteremia patients with stable coronary disease and diabetes profit especially significantly].
    MMW Fortschritte der Medizin, 2005, Aug-18, Volume: 147, Issue:33-34

    Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Diabetes Complications; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Life Expectancy; Pravastatin; Pyrroles; Risk; Risk Factors; Time Factors

2005
Matrix metalloproteinases in isolated hypercholesterolemia.
    International angiology : a journal of the International Union of Angiology, 2005, Volume: 24, Issue:3

    Topics: Atherosclerosis; Atorvastatin; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Matrix Metalloproteinases; Middle Aged; Pyrroles; Tissue Inhibitor of Metalloproteinase-1; Tissue Inhibitor of Metalloproteinases

2005
Atorvastatin inhibits hypercholesterolemia-induced calcification in the aortic valves via the Lrp5 receptor pathway.
    Circulation, 2005, Aug-30, Volume: 112, Issue:9 Suppl

    Topics: Animals; Animals, Inbred Strains; Aortic Valve Stenosis; Atorvastatin; beta Catenin; Calcinosis; Cell Division; Cells, Cultured; Cholesterol, Dietary; Diet, Atherogenic; Fibroblasts; Gene Expression Regulation; Heptanoic Acids; Hypercholesterolemia; LDL-Receptor Related Proteins; Lipoproteins, LDL; Low Density Lipoprotein Receptor-Related Protein-5; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Myocytes, Cardiac; Ossification, Heterotopic; Osteopontin; Pyrroles; Rabbits; Sialoglycoproteins; Sus scrofa

2005
Drug-induced acute autoimmune hepatitis during combination therapy with atorvastatin and ezetimibe.
    Annals of clinical biochemistry, 2005, Volume: 42, Issue:Pt 5

    Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Drug Therapy, Combination; Ezetimibe; Female; Hepatitis, Autoimmune; Heptanoic Acids; Humans; Hypercholesterolemia; Liver Function Tests; Middle Aged; Pyrroles

2005
Conversion to atorvastatin in patients intolerant or refractory to simvastatin therapy: the CAPISH study.
    Mayo Clinic proceedings, 2005, Volume: 80, Issue:9

    Topics: Aged; Atorvastatin; Cholesterol; Cohort Studies; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Prospective Studies; Pyrroles; Retrospective Studies; Simvastatin; Treatment Failure; Triglycerides

2005
Rosuvastatin is cost-effective compared with atorvastatin in reaching cholesterol goals.
    International journal of cardiology, 2005, Oct-10, Volume: 104, Issue:3

    Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Cost-Benefit Analysis; Double-Blind Method; Europe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; North America; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Triglycerides

2005
Torcetrapib + atorvastatin (Pfizer).
    Current opinion in investigational drugs (London, England : 2000), 2005, Volume: 6, Issue:9

    Topics: Animals; Atherosclerosis; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Drug Combinations; Heptanoic Acids; Humans; Hypercholesterolemia; Pyrroles; Quinolines

2005
Decreasing LDL cholesterol and medication cost with every-other-day statin therapy.
    Preventive cardiology, 2005,Fall, Volume: 8, Issue:4

    Topics: Atorvastatin; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Sulfonamides

2005
How common is rhabdomyolysis in patients receiving lipid-lowering therapy?
    Nature clinical practice. Cardiovascular medicine, 2005, Volume: 2, Issue:3

    Topics: Aged; Anticholesteremic Agents; Atorvastatin; Biomarkers; Creatine Kinase; Drug Therapy, Combination; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Incidence; Middle Aged; Pravastatin; Pyrroles; Retrospective Studies; Rhabdomyolysis; Risk Factors; Simvastatin; United States

2005
3'UTR/T polymorphism of lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) is associated with modified anti-platelet activity of atorvastatin in hypercholesterolemic subjects.
    Atherosclerosis, 2005, Volume: 183, Issue:2

    Topics: Adult; Alleles; Anticholesteremic Agents; Atorvastatin; Blood Platelets; Chromatography, High Pressure Liquid; Citrulline; DNA; Female; Genotype; Heptanoic Acids; Humans; Hypercholesterolemia; Intracellular Fluid; Male; Middle Aged; Nitric Oxide Synthase; P-Selectin; Platelet Activation; Polymerase Chain Reaction; Polymorphism, Genetic; Pyrroles; Scavenger Receptors, Class E

2005
Early anticoagulant effect of atorvastatin.
    Arteriosclerosis, thrombosis, and vascular biology, 2005, Volume: 25, Issue:12

    Topics: Anticholesteremic Agents; Anticoagulants; Atorvastatin; Heptanoic Acids; Humans; Hypercholesterolemia; Pyrroles

2005
APOA1 polymorphisms are associated with variations in serum triglyceride concentrations in hypercholesterolemic individuals.
    Clinical chemistry and laboratory medicine, 2005, Volume: 43, Issue:12

    Topics: Apolipoprotein A-I; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Female; Genetic Variation; Genomics; Haplotypes; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Polymorphism, Genetic; Pyrroles; Sex Factors; Treatment Outcome; Triglycerides

2005
Anti-atherosclerotic effect of amlodipine, alone and in combination with atorvastatin, in APOE*3-Leiden/hCRP transgenic mice.
    Journal of cardiovascular pharmacology, 2006, Volume: 47, Issue:1

    Topics: Amlodipine; Animals; Apolipoprotein E3; Apolipoproteins E; Atherosclerosis; Atorvastatin; Blood Pressure; C-Reactive Protein; Cholesterol; Disease Models, Animal; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Mice; Mice, Transgenic; Pyrroles; Serum Amyloid A Protein; von Willebrand Factor

2006
Effect of pravastatin and atorvastatin on glucose metabolism in nondiabetic patients with hypercholesterolemia.
    Internal medicine (Tokyo, Japan), 2006, Volume: 45, Issue:2

    Topics: Aged; Anticholesteremic Agents; Atorvastatin; Carbohydrate Metabolism; Diabetes Mellitus; Female; Glucose; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipid Metabolism; Male; Pravastatin; Pyrroles; Retrospective Studies; Treatment Outcome

2006
Atorvastatin improves myocardial perfusion in a patient with hypercholesterolemia and single-vessel coronary disease.
    Clinical nuclear medicine, 2006, Volume: 31, Issue:3

    Topics: Anticholesteremic Agents; Atorvastatin; Coronary Artery Disease; Coronary Circulation; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Organophosphorus Compounds; Organotechnetium Compounds; Pyrroles; Radionuclide Imaging; Radiopharmaceuticals; Treatment Outcome

2006
[Treatment of hypercholesterolemia--lower is better].
    Ugeskrift for laeger, 2006, Feb-27, Volume: 168, Issue:9

    Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Evidence-Based Medicine; Heptanoic Acids; Humans; Hypercholesterolemia; Pyrroles; Simvastatin

2006
Atorvastatin prevents hypoxia-induced inhibition of endothelial nitric oxide synthase expression but does not affect heme oxygenase-1 in human microvascular endothelial cells.
    Atherosclerosis, 2006, Volume: 187, Issue:1

    Topics: Atherosclerosis; Atorvastatin; Blotting, Western; Cells, Cultured; Endothelium, Vascular; Gene Expression Regulation, Enzymologic; Heme Oxygenase-1; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypoxia; Microcirculation; Nitric Oxide Synthase Type III; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction

2006
Atorvastatin may cause nightmares.
    BMJ (Clinical research ed.), 2006, Apr-22, Volume: 332, Issue:7547

    Topics: Aged; Anticholesteremic Agents; Atorvastatin; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Night Terrors; Pyrroles

2006
Short-term atorvastatin treatment does not modify neointimal morphology but reduces MMP-2 expression in normocholesterolemic rabbit stented arteries.
    Journal of cardiovascular pharmacology, 2006, Volume: 47, Issue:3

    Topics: Animals; Atorvastatin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Iliac Artery; Immunohistochemistry; Male; Matrix Metalloproteinase 2; Muscle, Smooth, Vascular; Pyrroles; Rabbits; Stents; Tissue Inhibitor of Metalloproteinase-2; Tunica Intima

2006
Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) Study.
    American heart journal, 2006, Volume: 151, Issue:5

    Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; C-Reactive Protein; Dose-Response Relationship, Drug; Drug Combinations; Ezetimibe, Simvastatin Drug Combination; Heptanoic Acids; Humans; Hypercholesterolemia; Pyrroles; Simvastatin

2006
Use of an indirect effect model to describe the LDL cholesterol-lowering effect by statins in hypercholesterolaemic patients.
    Fundamental & clinical pharmacology, 2006, Volume: 20, Issue:3

    Topics: Adolescent; Adult; Aged; Atorvastatin; Child; Cholesterol, LDL; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Male; Middle Aged; Models, Biological; Pyrroles; Retrospective Studies; Simvastatin

2006
Influences of statins on glucose tolerance in patients with type 2 diabetes mellitus.
    Journal of atherosclerosis and thrombosis, 2006, Volume: 13, Issue:2

    Topics: Aged; Atorvastatin; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glucose Tolerance Test; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypoglycemic Agents; Male; Middle Aged; Pravastatin; Pyrroles; Retrospective Studies

2006
Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2006, Volume: 6, Issue:3

    Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Cholestyramine Resin; Clinical Trials as Topic; Coronary Disease; Cost-Benefit Analysis; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Meta-Analysis as Topic; Pravastatin; Pyrroles; Risk Factors; Simvastatin; Spain

2006
Severe hepatic side effects of ezetimibe.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2006, Volume: 4, Issue:7

    Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Liver Diseases; Male; Middle Aged; Pyrroles; Transaminases

2006
Comment on 'Effect of atorvastatin on SR-BI expression and HDL-induced cholesterol efflux in adipocytes of hypercholesterolemic rabbits' by Zhao et al. (Clin Chim Acta 2006; 365: 119-24).
    Clinica chimica acta; international journal of clinical chemistry, 2006, Volume: 373, Issue:1-2

    Topics: Adipocytes; Animals; Anticholesteremic Agents; Atorvastatin; CD36 Antigens; Cholesterol; Gene Expression Regulation; Heptanoic Acids; Hypercholesterolemia; Lipoproteins, HDL; Pyrroles; Rabbits; RNA, Messenger

2006
Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia.
    The Journal of pathology, 2006, Volume: 210, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Animals; Annexins; Anticholesteremic Agents; Atorvastatin; Biomarkers; Calcium Channels, L-Type; Cholesterol; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Immunohistochemistry; Male; Mice; Mice, Inbred C57BL; Microscopy, Electron; Middle Aged; Muscle Fibers, Skeletal; Muscle, Skeletal; Pravastatin; Pyrroles; Receptors, LDL; Simvastatin

2006
[Regression of a large lipid-rich pool in the coronary artery during treatment with statin detected by intravascular ultrasound: a case report].
    Journal of cardiology, 2006, Volume: 47, Issue:6

    Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Coronary Angiography; Coronary Disease; Coronary Vessels; Heptanoic Acids; Humans; Hypercholesterolemia; Lipids; Male; Middle Aged; Pyrroles; Stents; Ultrasonography, Interventional

2006
High-dose statin treatment does not alter plasma marker for brain cholesterol metabolism in patients with moderately elevated plasma cholesterol levels.
    Journal of clinical pharmacology, 2006, Volume: 46, Issue:7

    Topics: Adult; Aged; Atorvastatin; Biomarkers; Brain; Cholesterol; Female; Heptanoic Acids; Humans; Hydroxycholesterols; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin

2006
High-dose atorvastatin improves hypercholesterolemic coronary endothelial dysfunction without improving the angiogenic response.
    Circulation, 2006, Jul-04, Volume: 114, Issue:1 Suppl

    Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Adenosine Diphosphate; Angiostatins; Animals; Apoptosis; Apoptosis Inducing Factor; Arterioles; Atorvastatin; Caspase 3; Caspases; Cholesterol; Coronary Circulation; Coronary Vessels; Drug Evaluation, Preclinical; Endostatins; Endothelium, Vascular; Female; Fibroblast Growth Factor 2; Gene Expression Regulation; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Matrix Metalloproteinase 9; Myocardial Ischemia; Neovascularization, Physiologic; Nitric Oxide; Nitric Oxide Synthase Type III; Nitroprusside; Phosphorylation; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Receptor, TIE-2; Swine; Swine, Miniature; Vascular Endothelial Growth Factor A; Vasodilation

2006
Effect of atorvastatin on plasma osteopontin levels in patients with hypercholesterolemia.
    Arteriosclerosis, thrombosis, and vascular biology, 2006, Volume: 26, Issue:8

    Topics: Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; Humans; Hypercholesterolemia; Osteopontin; Pyrroles; Sialoglycoproteins

2006
Cost effectiveness of adding ezetimibe to atorvastatin therapy in patients not at cholesterol treatment goal in Canada.
    PharmacoEconomics, 2006, Volume: 24, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Cost-Benefit Analysis; Drug Costs; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles

2006
The anti-atherosclerotic effects of lipid lowering with atorvastatin in patients with hypercholesterolemia.
    Journal of atherosclerosis and thrombosis, 2006, Volume: 13, Issue:4

    Topics: Aged; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; C-Reactive Protein; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Inflammation; Lipids; Male; Middle Aged; Pyrroles; Time Factors; Tunica Intima; Tunica Media

2006
Effects of atorvastatin on coagulation parameters and homocysteine in patients with primary hypercholesterolemia.
    Journal of the National Medical Association, 2006, Volume: 98, Issue:8

    Topics: Adult; Aged; Atorvastatin; Biomarkers; Blood Coagulation; Coronary Disease; Female; Fibrinogen; Follow-Up Studies; Heptanoic Acids; Homocysteine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Prospective Studies; Pyrroles; Treatment Outcome

2006
High-dose statins for diabetes.
    Health news (Waltham, Mass.), 2006, Volume: 12, Issue:8

    Topics: Atorvastatin; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles

2006
Influence of atorvastatin treatment on L-arginine cerebrovascular reactivity and flow-mediated dilatation in patients with lacunar infarctions.
    Stroke, 2006, Volume: 37, Issue:10

    Topics: Aged; Anticholesteremic Agents; Arginine; Atorvastatin; Blood Pressure; Carbon Dioxide; Cerebral Infarction; Cerebrovascular Circulation; Comorbidity; Endothelium, Vascular; Female; Follow-Up Studies; Heart Rate; Hemorheology; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Risk Factors; Single-Blind Method; Ultrasonography, Doppler, Transcranial; Vasodilation; Vasodilator Agents

2006
Statins and cerebral vasomotor reactivity: implications for a new therapy?
    Stroke, 2006, Volume: 37, Issue:10

    Topics: Adult; Animals; Arginine; Atorvastatin; Brain Ischemia; Cerebrovascular Circulation; Clinical Trials, Phase II as Topic; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Intracranial Aneurysm; Mice; Middle Cerebral Artery; Nitric Oxide; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Research Design; Risk Factors; Simvastatin; Stroke; Subarachnoid Hemorrhage; Ultrasonography, Doppler, Transcranial; Vasodilation; Vasomotor System; Vasospasm, Intracranial

2006
Autoimmune hepatitis triggered by statins.
    Journal of clinical gastroenterology, 2006, Volume: 40, Issue:8

    Topics: Atorvastatin; Female; Hepatitis, Autoimmune; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pyrroles; Simvastatin

2006
[HIV infection: from Pneumocystis to statins].
    Medicina clinica, 2006, Jul-15, Volume: 127, Issue:7

    Topics: AIDS-Related Opportunistic Infections; Antiretroviral Therapy, Highly Active; Atorvastatin; Cardiovascular Diseases; Heptanoic Acids; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pneumocystis Infections; Pyrroles; Risk Factors

2006
Media report of rare rhabdomyolysis cases seems to have triggered reluctance among some New Zealanders to use statins.
    The New Zealand medical journal, 2006, Sep-08, Volume: 119, Issue:1241

    Topics: Anticholesteremic Agents; Atorvastatin; Health Education; Health Knowledge, Attitudes, Practice; Heptanoic Acids; Humans; Hypercholesterolemia; Mass Media; New Zealand; Pyrroles; Rhabdomyolysis; Simvastatin

2006
More on switching statins: comments from Pfizer.
    BMJ (Clinical research ed.), 2006, Sep-23, Volume: 333, Issue:7569

    Topics: Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles; Simvastatin

2006
Lectin-like oxidized-LDL receptor-1 (LOX-1) polymorphisms influence cardiovascular events rate during statin treatment.
    International journal of cardiology, 2007, Jun-25, Volume: 119, Issue:1

    Topics: Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Coronary Artery Disease; Drug Resistance; Female; Heptanoic Acids; Heterozygote; Humans; Hypercholesterolemia; Male; Middle Aged; Polymorphism, Genetic; Pyrroles; Retrospective Studies; Risk Factors; Scavenger Receptors, Class E; Simvastatin; Thrombosis

2007
Evaluation of lipid-lowering therapy and cholesterol goal attainment in Finland: the National FINRISK Study.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2006, Volume: 6, Issue:5

    Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cohort Studies; Coronary Disease; Female; Finland; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Risk Factors; Simvastatin; Surveys and Questionnaires; Treatment Outcome

2006
High-dose atorvastatin is associated with impaired myocardial angiogenesis in response to vascular endothelial growth factor in hypercholesterolemic swine.
    The Journal of thoracic and cardiovascular surgery, 2006, Volume: 132, Issue:6

    Topics: Animals; Anticholesteremic Agents; Atorvastatin; Coronary Vessels; Female; Heptanoic Acids; Hypercholesterolemia; Male; Neovascularization, Physiologic; Pyrroles; Swine; Swine, Miniature; Vascular Endothelial Growth Factor A

2006
[Effects of atorvastatin in N-terminal pro-brain natriuretic peptide plasma levels in hypercholesterolemic patients with or without hypertension].
    Medicina clinica, 2006, Oct-14, Volume: 127, Issue:14

    Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Prospective Studies; Pyrroles

2006
[Effectiveness of atorvastatin compared to other statins of usual clinical practice in primary care].
    Medicina clinica, 2006, Oct-14, Volume: 127, Issue:14

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Primary Health Care; Pyrroles; Retrospective Studies; Treatment Outcome

2006
Cholesterol: the good, the bad, and the stopped trials.
    Lancet (London, England), 2006, Dec-09, Volume: 368, Issue:9552

    Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol Ester Transfer Proteins; Clinical Trials, Phase III as Topic; Heptanoic Acids; Humans; Hypercholesterolemia; Pyrroles; Quinolines; Treatment Failure

2006
The MEGA study.
    Lancet (London, England), 2006, Dec-09, Volume: 368, Issue:9552

    Topics: Atorvastatin; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hypercholesterolemia; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome

2006
Atorvastatin therapy associated with improvement in left ventricular remodeling in a case of idiopathic dilated cardiomyopathy.
    The American journal of the medical sciences, 2006, Volume: 332, Issue:6

    Topics: Adult; Anticholesteremic Agents; Atorvastatin; Cardiomyopathy, Dilated; Cardiovascular Agents; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Pyrroles; Ventricular Remodeling

2006
Endoglin expression in hyper-cholesterolemia and after atorvastatin treatment in apoE-deficient mice.
    Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques, 2006, Volume: 9, Issue:3

    Topics: Animals; Apolipoproteins E; Atorvastatin; Diet, Atherogenic; Endoglin; Gene Expression Regulation; Heptanoic Acids; Hypercholesterolemia; Intracellular Signaling Peptides and Proteins; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Pyrroles

2006
Evaluation of the cost savings and clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a Primary Care setting.
    International journal of clinical practice, 2007, Volume: 61, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Benzimidazoles; Biphenyl Compounds; Cost Savings; Cost-Benefit Analysis; Drug Costs; Drugs, Generic; Family Practice; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Losartan; Male; Middle Aged; Patient Satisfaction; Pyrroles; Simvastatin; Tetrazoles; Treatment Outcome

2007
L-arginine plus atorvastatin for prevention of atheroma formation in genetically hypercholesterolaemic rabbits.
    The British journal of nutrition, 2007, Volume: 97, Issue:6

    Topics: Animals; Arginine; Atherosclerosis; Atorvastatin; Cholesterol; Combined Modality Therapy; Dietary Supplements; Eating; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Nitric Oxide; Pyrroles; Rabbits

2007
Gender differences in short-term effects of atorvastatin on lipid profile, fibrinolytic parameters, and endothelial function.
    Nutrition, metabolism, and cardiovascular diseases : NMCD, 2008, Volume: 18, Issue:3

    Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipid Peroxidation; Lipids; Lipoproteins, LDL; Male; Middle Aged; Prospective Studies; Pyrroles; Regional Blood Flow; Sex Factors; Thiobarbituric Acid Reactive Substances; Treatment Outcome

2008
Did a flawed study design affect the results of the VYTAL study?
    Mayo Clinic proceedings, 2007, Volume: 82, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Diabetes Mellitus, Type 2; Drug Combinations; Ezetimibe, Simvastatin Drug Combination; Heptanoic Acids; Humans; Hypercholesterolemia; Middle Aged; Multicenter Studies as Topic; Pyrroles; Random Allocation; Research Design; Simvastatin

2007
Effect of atorvastatin withdrawal on circulating coenzyme Q10 concentration in patients with hypercholesterolemia.
    BioFactors (Oxford, England), 2006, Volume: 28, Issue:3-4

    Topics: Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coenzymes; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Substance Withdrawal Syndrome; Triglycerides; Ubiquinone

2006
Lower is better: implications of the Treating to New Targets (TNT) study for Canadian patients.
    The Canadian journal of cardiology, 2007, Volume: 23, Issue:5

    Topics: Atorvastatin; Canada; Cholesterol, LDL; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles

2007
[CME-Lab 2/Solution. Hypercholesteremia and therapy control].
    Praxis, 2007, Apr-25, Volume: 96, Issue:17

    Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Drug Interactions; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Hypericum; Male; Middle Aged; Patient Compliance; Pyrroles; Triglycerides

2007
[Hypercholesterolemia and control with therapy].
    Praxis, 2007, Apr-11, Volume: 96, Issue:15

    Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diagnosis, Differential; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Myocardial Infarction; Predictive Value of Tests; Pyrroles; Treatment Refusal; Triglycerides

2007
Effects of atorvastatin on ventricular late potentials and repolarization dispersion in patients with hypercholesterolemia.
    The Kaohsiung journal of medical sciences, 2007, Volume: 23, Issue:5

    Topics: Adult; Aged; Atorvastatin; Cholesterol, LDL; Electrocardiography; Female; Heart Ventricles; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrroles

2007
Effects of atorvastatin therapy on hypercholesterolemic rabbits with respect to oxidative stress, nitric oxide pathway and homocysteine.
    Life sciences, 2007, Jun-20, Volume: 81, Issue:2

    Topics: Animals; Arginine; Aryldialkylphosphatase; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Diet; Heptanoic Acids; Homocysteine; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipid Peroxidation; Male; Nitric Oxide; Nitric Oxide Synthase; Oxidative Stress; Pyrroles; Rabbits; Thiobarbituric Acid Reactive Substances; Triglycerides

2007
High-dose atorvastatin is associated with impaired myocardial angiogenesis in response to vascular endothelial growth factor in hypercholesterolemic swine: relevance to the human situation?
    The Journal of thoracic and cardiovascular surgery, 2007, Volume: 133, Issue:6

    Topics: Animals; Anticholesteremic Agents; Atorvastatin; Coronary Vessels; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Neovascularization, Physiologic; Pyrroles; Swine; Swine, Miniature; Vascular Endothelial Growth Factor A

2007
Physiogenomic association of statin-related myalgia to serotonin receptors.
    Muscle & nerve, 2007, Volume: 36, Issue:3

    Topics: Aged; Aged, 80 and over; Atorvastatin; Female; Genomics; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Muscular Diseases; Pain; Polymorphism, Single Nucleotide; Pravastatin; Pyrroles; Receptors, Serotonin; Simvastatin

2007
A multicentre, open study to assess the effect of individualizing starting doses of atorvastatin according to baseline LDL-C levels on achieving cholesterol targets: the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST-2) s
    Current medical research and opinion, 2007, Volume: 23, Issue:8

    Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Dyslipidemias; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Prospective Studies; Pyrroles

2007
The effect of HMG-CoA reductase inhibitors on naturally occurring CD4+CD25+ T cells.
    Atherosclerosis, 2008, Volume: 197, Issue:2

    Topics: Adult; Animals; Atorvastatin; Forkhead Transcription Factors; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Mice; Mice, Inbred C57BL; Pravastatin; Pyrroles; T-Lymphocytes, Regulatory; Up-Regulation

2008
Effects of toll-like receptor-4 gene polymorphisms on soluble P-selectin and von Willebrand factor levels in hypercholesterolemic patients.
    Thrombosis and haemostasis, 2007, Volume: 98, Issue:3

    Topics: Adult; Aged; Atherosclerosis; Atorvastatin; Case-Control Studies; Cohort Studies; Cross-Sectional Studies; Female; Gene Frequency; Genetic Predisposition to Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Male; Middle Aged; P-Selectin; Phenotype; Polymorphism, Genetic; Pyrroles; Risk Factors; Toll-Like Receptor 4; Treatment Outcome; von Willebrand Factor

2007
Atorvastatin increases HDL cholesterol by reducing CETP expression in cholesterol-fed APOE*3-Leiden.CETP mice.
    Atherosclerosis, 2008, Volume: 197, Issue:1

    Topics: Animals; Apolipoprotein E3; Atorvastatin; Cholesterol Ester Transfer Proteins; Cholesterol, Dietary; Cholesterol, HDL; Cholesterol, VLDL; Dose-Response Relationship, Drug; Female; Gene Expression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Pyrroles; RNA, Messenger

2008
Effects of atorvastatin on C-reactive protein secretions by adipocytes in hypercholesterolemic rabbits.
    Journal of cardiovascular pharmacology, 2007, Volume: 50, Issue:3

    Topics: Adipocytes; Animals; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Heptanoic Acids; Hypercholesterolemia; Male; Nephelometry and Turbidimetry; PPAR gamma; Pyrroles; Rabbits; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Up-Regulation

2007
A novel mechanism of action of atorvastatin against cardiovascular risk: a commentary on "decreased plasma soluble RAGE in patients with hypercholesterolemia: effects of statins".
    Free radical biology & medicine, 2007, Nov-01, Volume: 43, Issue:9

    Topics: Atorvastatin; Cardiovascular Diseases; Heptanoic Acids; Humans; Hypercholesterolemia; Pyrroles; Receptor for Advanced Glycation End Products; Receptors, Immunologic

2007
Endothelial expression of endoglin in normocholesterolemic and hypercholesterolemic C57BL/6J mice before and after atorvastatin treatment.
    Canadian journal of physiology and pharmacology, 2007, Volume: 85, Issue:8

    Topics: Animals; Atorvastatin; Endoglin; Endothelium, Vascular; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Immunohistochemistry; Intracellular Signaling Peptides and Proteins; Male; Mice; Mice, Inbred C57BL; Nitric Oxide; Platelet Endothelial Cell Adhesion Molecule-1; Pyrroles; Transforming Growth Factor beta

2007
Novel delivery systems of atorvastatin should be evaluated for pharmacodynamics instead of pharmacokinetics.
    The Journal of pharmacy and pharmacology, 2007, Volume: 59, Issue:11

    Topics: Administration, Oral; Animals; Atorvastatin; Disease Models, Animal; Drug Delivery Systems; Emulsions; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Liver; Pyrroles; Tissue Distribution

2007
Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    The American journal of geriatric pharmacotherapy, 2007, Volume: 5, Issue:3

    Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Cohort Studies; Coronary Disease; Databases, Factual; Fatty Acids, Monounsaturated; Female; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Male; Managed Care Programs; Odds Ratio; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome

2007
Lowering LDL-C for optimal protection in high-risk patients.
    The American journal of managed care, 2008, Volume: 14, Issue:1

    Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus; Guideline Adherence; Heptanoic Acids; Humans; Hypercholesterolemia; Practice Guidelines as Topic; Pravastatin; Pyrroles; Risk Assessment

2008
Evaluation of the clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting: 2 years on.
    International journal of clinical practice, 2008, Volume: 62, Issue:3

    Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Cholesterol; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Losartan; Male; Pyrroles; Retrospective Studies; Simvastatin; Tetrazoles; Therapeutic Equivalency; Treatment Outcome

2008
Integrin expression on monocytes and lymphocytes in unstable angina short term effects of atorvastatin.
    Romanian journal of internal medicine = Revue roumaine de medecine interne, 2007, Volume: 45, Issue:2

    Topics: Adult; Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Case-Control Studies; Cohort Studies; Coronary Artery Disease; Female; Flow Cytometry; Heptanoic Acids; Humans; Hypercholesterolemia; Integrin alpha Chains; Lymphocyte Activation; Male; Middle Aged; Monocytes; Pyrroles; T-Lymphocytes

2007
The effect of atorvastatin treatment on lipid profile and adhesion molecule levels in hypercholesterolemic patients: relation to low-density lipoprotein receptor gene polymorphism.
    Cardiology, 2008, Volume: 111, Issue:2

    Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Drug Administration Schedule; E-Selectin; Female; Follow-Up Studies; Gene Expression Regulation; Heptanoic Acids; Humans; Hypercholesterolemia; Inflammation Mediators; Intercellular Adhesion Molecule-1; Male; Middle Aged; Polymorphism, Genetic; Probability; Prospective Studies; Pyrroles; Receptors, LDL; Reference Values; Severity of Illness Index; Treatment Outcome

2008
Effect of APOE genotype on lipid levels in patients with coronary heart disease during a 3-week inpatient rehabilitation program.
    Clinical pharmacology and therapeutics, 2008, Volume: 84, Issue:2

    Topics: Adult; Aged; Alleles; Apolipoprotein E2; Apolipoprotein E3; Apolipoprotein E4; Apolipoproteins E; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Decision Making; Fatty Acids, Monounsaturated; Female; Fluvastatin; Genotype; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Inpatients; Linear Models; Lovastatin; Male; Middle Aged; Multivariate Analysis; Pravastatin; Predictive Value of Tests; Pyridines; Pyrroles; Simvastatin; Triglycerides

2008
Atorvastatin does not improve liver biochemistries or Mayo Risk Score in primary biliary cirrhosis.
    Digestive diseases and sciences, 2008, Volume: 53, Issue:7

    Topics: Aged; Anticholesteremic Agents; Atorvastatin; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipids; Liver Cirrhosis, Biliary; Liver Function Tests; Male; Middle Aged; Pyrroles; Quality of Life; Retrospective Studies; Treatment Outcome

2008
Atorvastatin effects on SREBF1a and SCAP gene expression in mononuclear cells and its relation with lowering-lipids response.
    Clinica chimica acta; international journal of clinical chemistry, 2008, Jul-17, Volume: 393, Issue:2

    Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Base Sequence; DNA Primers; Female; Gene Expression Regulation; Heptanoic Acids; Humans; Hypercholesterolemia; Intracellular Signaling Peptides and Proteins; Lipids; Male; Membrane Proteins; Middle Aged; Polymerase Chain Reaction; Pyrroles; Sterol Regulatory Element Binding Protein 1

2008
Ezetimibe combined with low-dose statin effectively lowers LDL in protease inhibitor treated patients.
    AIDS patient care and STDs, 2008, Volume: 22, Issue:6

    Topics: Adult; Anticholesteremic Agents; Antiretroviral Therapy, Highly Active; Atorvastatin; Azetidines; Cholesterol, LDL; Drug Administration Schedule; Ezetimibe; Female; Follow-Up Studies; Heptanoic Acids; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Hypercholesterolemia; Lopinavir; Male; Middle Aged; Pilot Projects; Pravastatin; Prospective Studies; Pyrroles; Ritonavir; Treatment Outcome

2008
Statin cost-effectiveness comparisons using real-world effectiveness data: formulary implications.
    Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 2008, Volume: 11, Issue:7

    Topics: Aged; Atorvastatin; Cholesterol, LDL; Cost-Benefit Analysis; Drugs, Generic; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Sulfonamides

2008
The human paraoxonase-1 phenotype modifies the effect of statins on paraoxonase activity and lipid parameters.
    British journal of clinical pharmacology, 2008, Volume: 66, Issue:3

    Topics: Aryldialkylphosphatase; Atorvastatin; Cholesterol, LDL; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lipids; Male; Middle Aged; Phenotype; Polymorphism, Genetic; Pyrroles; Simvastatin

2008
Comparative effects of HMG-CoA reductase inhibitors on apo B production in the casein-fed rabbit: atorvastatin versus lovastatin.
    Atherosclerosis, 1995, Volume: 115, Issue:2

    Topics: Analysis of Variance; Animals; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Caseins; Cholesterol; Diet; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Iodine Radioisotopes; Lipoproteins, LDL; Lovastatin; Male; Pyrroles; Rabbits; Random Allocation

1995
The genotoxicity profile of atorvastatin, a new drug in the treatment of hypercholesterolemia.
    Mutation research, 1995, Volume: 343, Issue:2-3

    Topics: Animals; Anticholesteremic Agents; Atorvastatin; Cricetinae; Cricetulus; Escherichia coli; Female; Fibroblasts; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypoxanthine Phosphoribosyltransferase; Lung; Male; Mice; Micronucleus Tests; Mutagenicity Tests; Pyrroles; Salmonella typhimurium

1995
Levels of soluble cell adhesion molecules in patients with dyslipidemia.
    Circulation, 1996, Apr-01, Volume: 93, Issue:7

    Topics: Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Cell Adhesion Molecules; Colestipol; Drug Therapy, Combination; E-Selectin; Endothelium, Vascular; Enzyme Inhibitors; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertriglyceridemia; Hypolipidemic Agents; Intercellular Adhesion Molecule-1; Lovastatin; Male; Middle Aged; Pyrroles; Risk Factors; Simvastatin; Solubility; Vascular Cell Adhesion Molecule-1

1996
Lipid-lowering activity of atorvastatin and lovastatin in rodent species: triglyceride-lowering in rats correlates with efficacy in LDL animal models.
    Atherosclerosis, 1995, Volume: 117, Issue:2

    Topics: Animals; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Cholesterol, LDL; Guinea Pigs; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertriglyceridemia; Liver; Lovastatin; Male; Pyrroles; Rabbits; Rats; Rats, Sprague-Dawley; Triglycerides

1995
[Lowering cholesterol. New concepts with atorvastatin].
    Der Internist, 1997, Volume: 38, Issue:1 Suppl

    Topics: Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Cholesterol; Clinical Trials as Topic; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Lipids; Pyrroles; Treatment Outcome

1997
[What is new? Therapy with lipid lowering agents].
    Der Internist, 1997, Volume: 38, Issue:11 Suppl T

    Topics: Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipidemias; Pyrroles

1997
[Effective cholesterol and triglyceride lowering with atorvastatin].
    Der Internist, 1996, Volume: 37, Issue:8 Suppl Ef

    Topics: Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertriglyceridemia; Pyrroles

1996
Atorvastatin versus simvastatin.
    The American journal of cardiology, 1997, Dec-15, Volume: 80, Issue:12

    Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Heptanoic Acids; Humans; Hypercholesterolemia; Pyrroles; Simvastatin

1997
[Prevention of cardiovascular diseases: Value of CSE inhibitors in the management of lipid metabolism disorders].
    Zeitschrift fur Kardiologie, 1998, Volume: 87, Issue:4 Suppl St

    Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipidemias; Pyrroles

1998
Atorvastatin (Lipitor).
    Connecticut medicine, 1998, Volume: 62, Issue:5

    Topics: Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles; Randomized Controlled Trials as Topic

1998
Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)
    The American journal of cardiology, 1998, Aug-01, Volume: 82, Issue:3

    Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hypercholesterolemia; Indoles; Lovastatin; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome

1998
[Drug clinics. Drug of the month. Atorvastatin (Lipitor)].
    Revue medicale de Liege, 1998, Volume: 53, Issue:6

    Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Diet, Fat-Restricted; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemias; Hypolipidemic Agents; Liver; Pyrroles; Receptors, LDL; Tablets; Triglycerides

1998
[Evaluation of the efficacy of statin therapy in dyslipidemic diseases such as combined hypercholesterolemia IIA and hyperlipidemia].
    Minerva cardioangiologica, 1998, Volume: 46, Issue:9

    Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemias; Male; Middle Aged; Pyrroles; Time Factors

1998
Atorvastatin-induced acute hepatitis with absence of cross-toxicity with simvastatin.
    Lancet (London, England), 1999, May-22, Volume: 353, Issue:9166

    Topics: Aged; Anticholesteremic Agents; Atorvastatin; Chemical and Drug Induced Liver Injury; Drug Interactions; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Pyrroles; Simvastatin

1999
Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men.
    Circulation, 1999, Nov-23, Volume: 100, Issue:21

    Topics: Adult; Angiotensin Receptor Antagonists; Atorvastatin; Blood Pressure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins, LDL; Male; Middle Aged; Pyrroles; Reactive Oxygen Species; Receptors, Angiotensin; Simvastatin

1999
Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease.
    The New England journal of medicine, 1999, Dec-09, Volume: 341, Issue:24

    Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Heptanoic Acids; Humans; Hypercholesterolemia; Myocardial Ischemia; Pyrroles; Recurrence

1999
Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease.
    The New England journal of medicine, 1999, Dec-09, Volume: 341, Issue:24

    Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Heptanoic Acids; Humans; Hypercholesterolemia; Pyrroles; Stents

1999
Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease.
    The New England journal of medicine, 1999, Dec-09, Volume: 341, Issue:24

    Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Platelet Aggregation Inhibitors; Pyrroles

1999
More on the effect of atorvastatin on plasma fibrinogen levels in primary hypercholesterolaemia.
    Atherosclerosis, 2000, Volume: 148, Issue:1

    Topics: Anticholesteremic Agents; Atorvastatin; Fibrinogen; Heptanoic Acids; Humans; Hypercholesterolemia; Pyrroles

2000
The nature of the statins.
    Circulation, 2000, Feb-29, Volume: 101, Issue:8

    Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles

2000
Reversible atorvastatin-associated external ophthalmoplegia, anti-acetylcholine receptor antibodies, and ataxia.
    Archives of ophthalmology (Chicago, Ill. : 1960), 2000, Volume: 118, Issue:3

    Topics: Ataxia; Atorvastatin; Autoantibodies; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Middle Aged; Ophthalmoplegia; Pyrroles; Receptors, Cholinergic; Visual Acuity

2000
Aggressive Lipid-Lowering Initiation Abates New Cardiac Events (ALLIANCE)-rationale and design of atorvastatin versus usual care in hypercholesterolemic patients with coronary artery disease.
    The American journal of cardiology, 2000, Jul-15, Volume: 86, Issue:2

    Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Randomized Controlled Trials as Topic

2000
Short-term effect of atorvastatin in hypercholesterolaemic renal-transplant patients unresponsive to other statins.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2000, Volume: 15, Issue:9

    Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Drug Resistance; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Kidney Transplantation; Male; Middle Aged; Pyrroles; Retreatment; Time Factors; Treatment Outcome; Triglycerides

2000
Development of tachyphylaxis among patients taking HMG CoA reductase inhibitors.
    The American journal of cardiology, 2000, Nov-15, Volume: 86, Issue:10

    Topics: Atorvastatin; Cholesterol, LDL; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Least-Squares Analysis; Linear Models; Lovastatin; Nonlinear Dynamics; Pravastatin; Pyrroles; Retrospective Studies; Simvastatin; Tachyphylaxis; Time Factors

2000
Effect of preoperative statin therapy and cardiac outcomes after coronary artery bypass grafting.
    The American journal of cardiology, 2000, Nov-15, Volume: 86, Issue:10

    Topics: Aged; Anticholesteremic Agents; Arrhythmias, Cardiac; Atorvastatin; Cause of Death; Coronary Artery Bypass; Coronary Disease; Female; Heart Failure; Heptanoic Acids; Humans; Hypercholesterolemia; Incidence; Lovastatin; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Preoperative Care; Pyrroles; Recurrence; Retrospective Studies; Risk Factors; Simvastatin; Stroke; Treatment Outcome

2000
Effect of atorvastatin 15 mg/week on serum lipids in patients with hypercholesterolemia.
    The American journal of cardiology, 2001, Feb-01, Volume: 87, Issue:3

    Topics: Aged; Atorvastatin; Cholesterol; Coronary Disease; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipids; Male; Middle Aged; Pyrroles

2001
[Meeting report. "MIRACL" study of "Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering"].
    Revue medicale de Liege, 2000, Volume: 55, Issue:12

    Topics: Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; Humans; Hypercholesterolemia; Myocardial Ischemia; Patient Selection; Pyrroles; Treatment Outcome

2000
[Disturbances in cholesterol metabolism].
    Deutsche medizinische Wochenschrift (1946), 2001, Jan-19, Volume: 126, Issue:3

    Topics: Adult; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Coronary Disease; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Pyrroles; Triglycerides

2001
F 12511, a novel ACAT inhibitor, and atorvastatin regulate endogenous hypercholesterolemia in a synergistic manner in New Zealand rabbits fed a casein-enriched diet.
    Atherosclerosis, 2001, Volume: 155, Issue:1

    Topics: Adrenal Glands; Anilides; Animals; Anticholesteremic Agents; Apolipoprotein B-100; Apolipoproteins B; Atorvastatin; Caseins; Cholesterol; Cholesterol, LDL; Cholesterol, VLDL; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Liver; Male; Pyrroles; Rabbits; Sterol O-Acyltransferase

2001
Atorvastatin prevents glomerulosclerosis and renal endothelial dysfunction in hypercholesterolaemic rabbits.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2001, Volume: 16 Suppl 1

    Topics: Acetylcholine; Animals; Anticholesteremic Agents; Atorvastatin; Bridged Bicyclo Compounds, Heterocyclic; Cholesterol, Dietary; Disease Models, Animal; Endothelium, Vascular; Glomerulosclerosis, Focal Segmental; Heptanoic Acids; Hypercholesterolemia; Kidney; Male; Nitroprusside; Oxazoles; Phenylephrine; Platelet Aggregation Inhibitors; Pyrroles; Rabbits; Renal Circulation; Vasodilation

2001
Heart rate variability after long-term treatment with atorvastatin in hypercholesterolaemic patients with or without coronary artery disease.
    Atherosclerosis, 2001, Volume: 157, Issue:2

    Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Blood Pressure; Coronary Disease; Exercise Test; Female; Heart Rate; Heptanoic Acids; Humans; Hypercholesterolemia; Lipids; Male; Middle Aged; Pyrroles; Time Factors

2001
Global risk assessment in the presymptomatic patient.
    The American journal of cardiology, 2001, Oct-11, Volume: 88, Issue:7B

    Topics: Anticholesteremic Agents; Atorvastatin; Coronary Artery Disease; Critical Pathways; Family Practice; Heptanoic Acids; Humans; Hypercholesterolemia; Life Style; Mass Screening; Pyrroles; Risk Assessment

2001
Insulin resistance syndrome and type 2 diabetes mellitus.
    The American journal of cardiology, 2001, Oct-11, Volume: 88, Issue:7B

    Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Clinical Trials as Topic; Coronary Artery Disease; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hypercholesterolemia; Lipoproteins; Metabolic Syndrome; Pyrroles; Risk Factors; Survival Rate

2001
HMG-CoA reductase inhibitors reduce vascular monocyte chemotactic protein-1 expression in early lesions from hypercholesterolemic swine independently of their effect on plasma cholesterol levels.
    Atherosclerosis, 2001, Volume: 159, Issue:1

    Topics: Animals; Aorta; Arteries; Arteriosclerosis; Atorvastatin; Carotid Arteries; Chemokine CCL2; Cholesterol; Coronary Vessels; Down-Regulation; Femoral Artery; Gene Expression; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Iliac Artery; Immunohistochemistry; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Pravastatin; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Swine

2001
Treatment with atorvastatin improves small artery compliance in patients with severe hypercholesterolemia.
    American journal of hypertension, 2001, Volume: 14, Issue:11 Pt 1

    Topics: Adult; Aged; Anticholesteremic Agents; Arteries; Atorvastatin; Compliance; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Male; Middle Aged; Pyrroles; Severity of Illness Index; Treatment Outcome

2001
Rhabdomyolysis with acute renal failure probably related to the interaction of atorvastatin and delavirdine.
    The American journal of medicine, 2002, Apr-15, Volume: 112, Issue:6

    Topics: Acute Kidney Injury; Anti-HIV Agents; Anticholesteremic Agents; Atorvastatin; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Delavirdine; Drug Interactions; Heptanoic Acids; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Mixed Function Oxygenases; Pyrroles; Rhabdomyolysis

2002
Increased superoxide anion production by platelets in hypercholesterolemic patients.
    Thrombosis and haemostasis, 2002, Volume: 87, Issue:5

    Topics: Anticholesteremic Agents; Arachidonic Acid; Atorvastatin; Blood Platelets; Cholesterol; Cholesterol, LDL; Cross-Sectional Studies; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Superoxides; Triglycerides

2002
Atorvastatin inhibits hypercholesterolemia-induced cellular proliferation and bone matrix production in the rabbit aortic valve.
    Circulation, 2002, Jun-04, Volume: 105, Issue:22

    Topics: Alkaline Phosphatase; Animals; Anticholesteremic Agents; Aortic Valve; Atorvastatin; Biomarkers; C-Reactive Protein; Calcinosis; Cell Division; Cholesterol; Cholesterol, Dietary; Disease Models, Animal; Heart Valve Diseases; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Immunohistochemistry; Macrophages; Male; Microscopy, Immunoelectron; Osteoblasts; Osteopontin; Proliferating Cell Nuclear Antigen; Pyrroles; Rabbits; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sialoglycoproteins

2002
Efficacy of atorvastatin in treating high risk patients to reach low density lipoprotein-cholesterol goals: the Treat to Target (TTT-Israel) Study.
    The Israel Medical Association journal : IMAJ, 2002, Volume: 4, Issue:6

    Topics: Adult; Anticholesteremic Agents; Atorvastatin; Chi-Square Distribution; Cholesterol, LDL; Coronary Disease; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Israel; Male; Middle Aged; Primary Prevention; Prospective Studies; Pyrroles; Risk Factors; Treatment Outcome

2002
Dose-response effects of atorvastatin and simvastatin on high-density lipoprotein cholesterol in hypercholesterolaemic patients: a review of five comparative studies.
    International journal of cardiology, 2002, Volume: 84, Issue:1

    Topics: Anticholesteremic Agents; Apolipoprotein A-I; Atorvastatin; Cholesterol, HDL; Clinical Trials as Topic; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Middle Aged; Multicenter Studies as Topic; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin

2002